{"docstore/data": {"f8be2f47-1816-414e-ac75-f27d3d25d1d1": {"__data__": {"id_": "f8be2f47-1816-414e-ac75-f27d3d25d1d1", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded. ", "original_text": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c057e0c-565a-40a8-b28b-c265be499c15", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "original_text": "Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  "}, "hash": "317fb66b128153e7a214edfb659be5d0bf45f51a92c723ffa3a85579d5fd99e7", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c057e0c-565a-40a8-b28b-c265be499c15": {"__data__": {"id_": "3c057e0c-565a-40a8-b28b-c265be499c15", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "original_text": "Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8be2f47-1816-414e-ac75-f27d3d25d1d1", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded. ", "original_text": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f62f1e7d020956eda78612b9040b1bdfc6e1cf3edec96168afc78c41a0b2c17b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d56136e-972c-4797-975a-d7d13926d78f", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n", "original_text": "First Quarter Fiscal Year 2022 \nEarnings Conference Call. "}, "hash": "5c8ca2d8aa5e30a52b1021c314273f3f1a5dea0f027e7229cd495fb11969d0a7", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  ", "start_char_idx": 48, "end_char_idx": 178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d56136e-972c-4797-975a-d7d13926d78f": {"__data__": {"id_": "6d56136e-972c-4797-975a-d7d13926d78f", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n", "original_text": "First Quarter Fiscal Year 2022 \nEarnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c057e0c-565a-40a8-b28b-c265be499c15", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "original_text": "Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2c6bde3f78377ffa46780892355180e056a0776e5ec22163f20feddb4f438ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b714e93-c618-4c48-b41e-9d1f90bdd661", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome. ", "original_text": "Today's conference is being recorded. "}, "hash": "e723a6d13fa686f4fd5d0a9756e125dc107478e8b3051a2f1175f0f10640f2e7", "class_name": "RelatedNodeInfo"}}, "text": "First Quarter Fiscal Year 2022 \nEarnings Conference Call. ", "start_char_idx": 178, "end_char_idx": 236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b714e93-c618-4c48-b41e-9d1f90bdd661": {"__data__": {"id_": "1b714e93-c618-4c48-b41e-9d1f90bdd661", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome. ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d56136e-972c-4797-975a-d7d13926d78f", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n", "original_text": "First Quarter Fiscal Year 2022 \nEarnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a49eb664fcf6daf1cc04264a59492e5b9617d9f32607da956f5d2cdc01f3e09f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcf02825-daab-41d5-9467-a086b729efcf", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results. ", "original_text": "At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. "}, "hash": "54edd45a1b280a48368cda5887c7a76b77048b0d25b8573efb78d603755756c4", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 236, "end_char_idx": 274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcf02825-daab-41d5-9467-a086b729efcf": {"__data__": {"id_": "dcf02825-daab-41d5-9467-a086b729efcf", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results. ", "original_text": "At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b714e93-c618-4c48-b41e-9d1f90bdd661", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome. ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1fd400f3bc9b31e1ed5458959761d4e0b5737570f02ebc7bc0434f004d713a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18dc4bd9-473b-4549-9890-ff2ad3357164", "node_type": "1", "metadata": {"window": "First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.  ", "original_text": "Please go ahead.  \n \n"}, "hash": "019f7568690b4808760fcf2ab93a517e932df06151032a5d0a1b9d9c73ab4ad5", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "start_char_idx": 274, "end_char_idx": 384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18dc4bd9-473b-4549-9890-ff2ad3357164": {"__data__": {"id_": "18dc4bd9-473b-4549-9890-ff2ad3357164", "embedding": null, "metadata": {"window": "First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.  ", "original_text": "Please go ahead.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcf02825-daab-41d5-9467-a086b729efcf", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results. ", "original_text": "At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "927910611736537dc11689581c60593545e3186021776f2af097776c73e87f67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fec8e4ab-6ec3-4bbd-b1d6-9f7e2007e6ea", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n", "original_text": "Kevin Moran:  Good morning, and w elcome. "}, "hash": "d46658a62cad2c26bd55b79881fdee2c934ea56adbfbf50a96dac7a5f518e382", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 384, "end_char_idx": 405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fec8e4ab-6ec3-4bbd-b1d6-9f7e2007e6ea": {"__data__": {"id_": "fec8e4ab-6ec3-4bbd-b1d6-9f7e2007e6ea", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n", "original_text": "Kevin Moran:  Good morning, and w elcome. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18dc4bd9-473b-4549-9890-ff2ad3357164", "node_type": "1", "metadata": {"window": "First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.  ", "original_text": "Please go ahead.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06175810b2504b6fe0a037721463c7cd8a87ce281068fe865a32599a7be114a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bea57437-c45c-4873-af12-7b66f6a49ac8", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.  ", "original_text": "Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results. "}, "hash": "b8628dbb5889101f313fd919de87889a0b3cfb23a2fd3443d5f9c76dbc2f86c2", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Good morning, and w elcome. ", "start_char_idx": 405, "end_char_idx": 447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bea57437-c45c-4873-af12-7b66f6a49ac8": {"__data__": {"id_": "bea57437-c45c-4873-af12-7b66f6a49ac8", "embedding": null, "metadata": {"window": "At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.  ", "original_text": "Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fec8e4ab-6ec3-4bbd-b1d6-9f7e2007e6ea", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n", "original_text": "Kevin Moran:  Good morning, and w elcome. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b96d4d392b661b12814d86281a035890aad5286fb344259ce2fc90fa111553", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8acd3d2-d179-48e6-9143-503f3ab1f628", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.  ", "original_text": "You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.  "}, "hash": "3432baf2021d9199fb69fc27cf00cf675235c074800a990efa920aa55392368d", "class_name": "RelatedNodeInfo"}}, "text": "Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results. ", "start_char_idx": 447, "end_char_idx": 524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8acd3d2-d179-48e6-9143-503f3ab1f628": {"__data__": {"id_": "f8acd3d2-d179-48e6-9143-503f3ab1f628", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.  ", "original_text": "You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bea57437-c45c-4873-af12-7b66f6a49ac8", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.  ", "original_text": "Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9daae0ff44f50288715edb49dd019385afe5fda331a8643ac9ade441127fd2f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9917a0ac-b6fa-4d50-9f11-46e87be9e29c", "node_type": "1", "metadata": {"window": "Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n"}, "hash": "3ec116b9c4276a773f33dec793c27c62ced0c353acfb3e394e635da99859b78e", "class_name": "RelatedNodeInfo"}}, "text": "You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.  ", "start_char_idx": 524, "end_char_idx": 637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9917a0ac-b6fa-4d50-9f11-46e87be9e29c": {"__data__": {"id_": "9917a0ac-b6fa-4d50-9f11-46e87be9e29c", "embedding": null, "metadata": {"window": "Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8acd3d2-d179-48e6-9143-503f3ab1f628", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.  ", "original_text": "You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "993ff6105e9f55b8d96ef338bdfd44b4d7e362781f184f8c3ff54ecb03d1203f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08f868bb-9703-4559-abc8-ed6d99d0280f", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  "}, "hash": "f48c456dfd702c588e748d8481113c50866becaf8da6e3201c1b770488223583", "class_name": "RelatedNodeInfo"}}, "text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n", "start_char_idx": 637, "end_char_idx": 747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08f868bb-9703-4559-abc8-ed6d99d0280f": {"__data__": {"id_": "08f868bb-9703-4559-abc8-ed6d99d0280f", "embedding": null, "metadata": {"window": "Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9917a0ac-b6fa-4d50-9f11-46e87be9e29c", "node_type": "1", "metadata": {"window": "Kevin Moran:  Good morning, and w elcome.  Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8dd29235be97281e8df75a308de26f17844a13202f2e4b8d29f1dbaf3f2a99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8057e9b8-c2a9-4bdc-88a5-c71ec088357c", "node_type": "1", "metadata": {"window": "You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.  "}, "hash": "4cfe2496d4642e141d77618fba1d6030f80ce33e229da0a12d679124da9f9c3b", "class_name": "RelatedNodeInfo"}}, "text": "During the call, we will be making forward -looking statements.  ", "start_char_idx": 747, "end_char_idx": 812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8057e9b8-c2a9-4bdc-88a5-c71ec088357c": {"__data__": {"id_": "8057e9b8-c2a9-4bdc-88a5-c71ec088357c", "embedding": null, "metadata": {"window": "You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08f868bb-9703-4559-abc8-ed6d99d0280f", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health's First Quarter \nFiscal 2022 results.  You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0eea394eb96d1a263930186257116cc59b8b34bd30a15a97cdd0bfb6e030881d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "004a8dcd-4ea3-4861-a921-fffbd5c0a6e7", "node_type": "1", "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n"}, "hash": "2228da4a42c7b52353ae29c9b135395ea2c0fdb75a2565ca6c591f2c8a337326", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.  ", "start_char_idx": 812, "end_char_idx": 985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "004a8dcd-4ea3-4861-a921-fffbd5c0a6e7": {"__data__": {"id_": "004a8dcd-4ea3-4861-a921-fffbd5c0a6e7", "embedding": null, "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8057e9b8-c2a9-4bdc-88a5-c71ec088357c", "node_type": "1", "metadata": {"window": "You can find today's press release and presentation on the IR section of our \nWebsite at ir.cardinalhealth.com.   Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2216b6f68151bd347936e56cd0f59b260a06b833944ef5785a3f8451afffaf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e63949f-837a-44d7-95b7-9c008cceb30f", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.  "}, "hash": "83bf0c61398a75492a09ae3a77fb97f2205ee815361e8029c0d766190106a584", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n", "start_char_idx": 985, "end_char_idx": 1152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e63949f-837a-44d7-95b7-9c008cceb30f": {"__data__": {"id_": "4e63949f-837a-44d7-95b7-9c008cceb30f", "embedding": null, "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "004a8dcd-4ea3-4861-a921-fffbd5c0a6e7", "node_type": "1", "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer; and \nJason Hollar, Chief Financial Officer.   \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f3a1affa8f230b8132b906d726809d57aace19d7a7d40e0cba3bded94d94feb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0256b854-944a-4fe0-8080-30c74772e76c", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n"}, "hash": "a048596f23b4a6a994dab80cf76f29554f54df2b0060e804517eec6cb59a5e3e", "class_name": "RelatedNodeInfo"}}, "text": "Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.  ", "start_char_idx": 1152, "end_char_idx": 1291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0256b854-944a-4fe0-8080-30c74772e76c": {"__data__": {"id_": "0256b854-944a-4fe0-8080-30c74772e76c", "embedding": null, "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e63949f-837a-44d7-95b7-9c008cceb30f", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1554ac5e0869b9cce283033bf01ff93b41d2248fd590769eb1406bfb4d2d82e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa2dec6c-71a5-44d1-9819-e397a3af78b2", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.  ", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.  "}, "hash": "bf4b655561ab0e4421777876c725f17446a85b0e2475fd3c9fad7eb2bf3f62bb", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n", "start_char_idx": 1291, "end_char_idx": 1415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa2dec6c-71a5-44d1-9819-e397a3af78b2": {"__data__": {"id_": "aa2dec6c-71a5-44d1-9819-e397a3af78b2", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.  ", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0256b854-944a-4fe0-8080-30c74772e76c", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those  projected or implied.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0053819806a7737e3169e13a7adade19d8d69123b6a8c565f318282a62ffd67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4df9469-c32f-4f7f-aa5f-58dc19346080", "node_type": "1", "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n", "original_text": "With that, I will now turn the call over to Mike.  \n \n"}, "hash": "2ee62e5c3d4e882519e1e2bbcdf23acc8b54536b74f744bbec1513f4566aa31a", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.  ", "start_char_idx": 1415, "end_char_idx": 1573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4df9469-c32f-4f7f-aa5f-58dc19346080": {"__data__": {"id_": "a4df9469-c32f-4f7f-aa5f-58dc19346080", "embedding": null, "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n", "original_text": "With that, I will now turn the call over to Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa2dec6c-71a5-44d1-9819-e397a3af78b2", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n \n Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.  ", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a83de75ac0b35237c6d9227dc338e99d830cd74719f0ca9ec07e3f39c520e52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a15e290-f4fa-403d-9d6e-3460379ba45b", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n", "original_text": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone. "}, "hash": "ead5866a895acfdc87012707b94fd72f111c8c838414958e9fd0b9e3087244de", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will now turn the call over to Mike.  \n \n", "start_char_idx": 1573, "end_char_idx": 1627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a15e290-f4fa-403d-9d6e-3460379ba45b": {"__data__": {"id_": "6a15e290-f4fa-403d-9d6e-3460379ba45b", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n", "original_text": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4df9469-c32f-4f7f-aa5f-58dc19346080", "node_type": "1", "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis unless they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n", "original_text": "With that, I will now turn the call over to Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e94884311ae282c1d4f38421d962220b1546a08d966ad62e6031fed885f2037f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "027aedf3-8639-4ecb-b371-81c1f38342cd", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter. ", "original_text": "Our first quarter results were in line \nwith our expectations.  "}, "hash": "11352d30933fe29588d81b7be9a0f28fc511d9a3cddc3d788d033958c462dad7", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone. ", "start_char_idx": 1627, "end_char_idx": 1689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "027aedf3-8639-4ecb-b371-81c1f38342cd": {"__data__": {"id_": "027aedf3-8639-4ecb-b371-81c1f38342cd", "embedding": null, "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter. ", "original_text": "Our first quarter results were in line \nwith our expectations.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a15e290-f4fa-403d-9d6e-3460379ba45b", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n", "original_text": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46f471ae779db17719cf45526663cd6ce8d4224d76dd2f05d55030cda72e9e70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3892cc2e-2f79-4e4b-aba6-baac9be08de9", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities. ", "original_text": "As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n"}, "hash": "9f11d3d5dae3ea529ec6b2689fbee2d828aaf5abbebd27384a10c5b3de486518", "class_name": "RelatedNodeInfo"}}, "text": "Our first quarter results were in line \nwith our expectations.  ", "start_char_idx": 1689, "end_char_idx": 1753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3892cc2e-2f79-4e4b-aba6-baac9be08de9": {"__data__": {"id_": "3892cc2e-2f79-4e4b-aba6-baac9be08de9", "embedding": null, "metadata": {"window": "With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities. ", "original_text": "As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "027aedf3-8639-4ecb-b371-81c1f38342cd", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and  limit yourself to one question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter. ", "original_text": "Our first quarter results were in line \nwith our expectations.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e19e7c4bb81713c3509ced7020c682ccdea27fb1af7511dc95aff2b083132fca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "767fdeec-9add-479b-9915-8cfd1792d121", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.  ", "original_text": "In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n"}, "hash": "cedc9a71a48fdc05f403003dc0ed87331c6bec02b764684471cee74f3f08ea92", "class_name": "RelatedNodeInfo"}}, "text": "As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n", "start_char_idx": 1753, "end_char_idx": 1943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "767fdeec-9add-479b-9915-8cfd1792d121": {"__data__": {"id_": "767fdeec-9add-479b-9915-8cfd1792d121", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.  ", "original_text": "In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3892cc2e-2f79-4e4b-aba6-baac9be08de9", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities. ", "original_text": "As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9229a08252a6e50b6488e68658cba48fdfd777c0af2021419c0f7bde058519f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72843e07-db0d-452a-b172-fb81373ffcd2", "node_type": "1", "metadata": {"window": "Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds. ", "original_text": "Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter. "}, "hash": "a2b5e3153a63e62286d552eff7c97df29eaf9b5b0985299fcf84fbea891789b3", "class_name": "RelatedNodeInfo"}}, "text": "In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n", "start_char_idx": 1943, "end_char_idx": 2254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72843e07-db0d-452a-b172-fb81373ffcd2": {"__data__": {"id_": "72843e07-db0d-452a-b172-fb81373ffcd2", "embedding": null, "metadata": {"window": "Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds. ", "original_text": "Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "767fdeec-9add-479b-9915-8cfd1792d121", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.  ", "original_text": "In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37cab7df30d6a856368b05bb88d03b041ea233ba60eebdfb83eb41cd3b52e70f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4719906b-7f3b-4c67-9319-dd44980388b8", "node_type": "1", "metadata": {"window": "As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities. "}, "hash": "8b8552b6030986c01dae5d94791ed5cde8346a10b91e2fe6e40c82e8fff2b641", "class_name": "RelatedNodeInfo"}}, "text": "Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter. ", "start_char_idx": 2254, "end_char_idx": 2381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4719906b-7f3b-4c67-9319-dd44980388b8": {"__data__": {"id_": "4719906b-7f3b-4c67-9319-dd44980388b8", "embedding": null, "metadata": {"window": "As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72843e07-db0d-452a-b172-fb81373ffcd2", "node_type": "1", "metadata": {"window": "Our first quarter results were in line \nwith our expectations.   As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds. ", "original_text": "Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b58e67d31d5f9b6196c788d1797b4c96f8b42d58b9b40d468de103dc609882e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59cc4763-388f-470e-b970-19fc32c4bfa6", "node_type": "1", "metadata": {"window": "In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.  "}, "hash": "14dc9038da10243fde5013f72cfa7c510a7aa6e7335f87d8309db88b658112f4", "class_name": "RelatedNodeInfo"}}, "text": "Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities. ", "start_char_idx": 2381, "end_char_idx": 2540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59cc4763-388f-470e-b970-19fc32c4bfa6": {"__data__": {"id_": "59cc4763-388f-470e-b970-19fc32c4bfa6", "embedding": null, "metadata": {"window": "In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4719906b-7f3b-4c67-9319-dd44980388b8", "node_type": "1", "metadata": {"window": "As we continue to manage through the global pandemic, we're  staying focused \non the near -term priorities and long -term strategies to drive growth and momentum across our \nbusinesses.  \n \n In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abf96e39895a2fdb8bf8e407f29555a4d83dc5357b8c8b339a94a60eb26a4dcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8140f80e-c907-4bc7-8858-087e03997f7e", "node_type": "1", "metadata": {"window": "Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds. "}, "hash": "4fdff90597a60b3abd454711d1b5a3d34db566fcf885f667abdc6d58fab6e658", "class_name": "RelatedNodeInfo"}}, "text": "While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.  ", "start_char_idx": 2540, "end_char_idx": 2697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8140f80e-c907-4bc7-8858-087e03997f7e": {"__data__": {"id_": "8140f80e-c907-4bc7-8858-087e03997f7e", "embedding": null, "metadata": {"window": "Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59cc4763-388f-470e-b970-19fc32c4bfa6", "node_type": "1", "metadata": {"window": "In Pharma, we continue to see sequential volume improvement , and are encouraged by the profit \ngrowth that we saw in the first quarte r. We believe our Pharma business  -- inclusive of our strategic \ngrowth areas of Specialty, Nuclear and Outcomes  -- is well positioned for growth in FY '22  and \nbeyond.  \n \n Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.  ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec7f755f433144e78e0d95a8988813ab42eaaca76832ea64292c1b67683aae69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "269f6b2f-2d00-40c7-8eae-39e68962d863", "node_type": "1", "metadata": {"window": "Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n "}, "hash": "20bf08e49b4721f007059150a2f95c5890d9d2e04768d058450122aa1677a5ae", "class_name": "RelatedNodeInfo"}}, "text": "As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds. ", "start_char_idx": 2697, "end_char_idx": 2815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "269f6b2f-2d00-40c7-8eae-39e68962d863": {"__data__": {"id_": "269f6b2f-2d00-40c7-8eae-39e68962d863", "embedding": null, "metadata": {"window": "Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921e8e364810f80d6a34dbd380a589a916c213aa386177de90d8197a882a87f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8140f80e-c907-4bc7-8858-087e03997f7e", "node_type": "1", "metadata": {"window": "Our Medical segment continued  to be impacted by the disruptions in the global supply ch ain that we \ncalled out last quarter.  Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "deeb59a402e4341d6451e4bade1085d168455f3cc831a5be574b402840f585f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13649259-bad8-449e-a70d-16fcfbb5c752", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n", "original_text": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday. "}, "hash": "87d0ab1607fc79f7134720345e6f3bec933344817794f3cf70c8fc1a1e7599e2", "class_name": "RelatedNodeInfo"}}, "text": "We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "start_char_idx": 2815, "end_char_idx": 2967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13649259-bad8-449e-a70d-16fcfbb5c752": {"__data__": {"id_": "13649259-bad8-449e-a70d-16fcfbb5c752", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n", "original_text": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "269f6b2f-2d00-40c7-8eae-39e68962d863", "node_type": "1", "metadata": {"window": "Recently, these pressures have rapidly escalated , and we are experiencing \nsignificantly elevated product costs due to international freight and commodities.  While we believe the \nmajority of these elevated supply chain c osts are temporary, we do not expect them to return to \nnormalized levels this fiscal year.   As a result, we are lowering our FY '22  outlook for Medical segment \nprofit to adjust for these increased headwinds.  We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "original_text": "We are taking action to mitigate these impacts a cross \nthe enterprise, and we are reaffirming our FY '22  EPS guidance of $5.60 to $5.90 per share.  \n ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "703a4b34ca491212c92869d3e8381b545bdb51d1e5eb5f866bcaa3b0b09966b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c675f69-b3a7-400d-89c8-ec08747a4bf1", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n", "original_text": "We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.  "}, "hash": "c958747d079709fc4f1922f6a99e1e9fc28519b2f88901b8a5cbae628116f133", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday. ", "start_char_idx": 0, "end_char_idx": 229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c675f69-b3a7-400d-89c8-ec08747a4bf1": {"__data__": {"id_": "1c675f69-b3a7-400d-89c8-ec08747a4bf1", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n", "original_text": "We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.  ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13649259-bad8-449e-a70d-16fcfbb5c752", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n", "original_text": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3982f671b3bdbc0b68d2f5d5f805d4310e6a79157982b0510cc1d159b844ca30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1de9a6ce-0625-4ef9-bade-74134b68eb5d", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n", "original_text": "And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders. "}, "hash": "6b6957bc8dc6d45be712e600c85c9cc6ecd23d5300f0ebbe3021e3e3a3c14bf8", "class_name": "RelatedNodeInfo"}}, "text": "We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.  ", "start_char_idx": 229, "end_char_idx": 372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1de9a6ce-0625-4ef9-bade-74134b68eb5d": {"__data__": {"id_": "1de9a6ce-0625-4ef9-bade-74134b68eb5d", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n", "original_text": "And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c675f69-b3a7-400d-89c8-ec08747a4bf1", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n", "original_text": "We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.  ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "866e4daf78cf17af927b2211e60f38e846d091500cd29950d0bc814a935be83c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "702a60a0-9a60-4006-a401-a9c74140ce9d", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n", "original_text": "Looking ahead, we remain confident in our strategy.  \n \n"}, "hash": "f79d91b440e863195f86040cdb150bd8a27ebbdd96375be76c2cf0b4641cd637", "class_name": "RelatedNodeInfo"}}, "text": "And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders. ", "start_char_idx": 372, "end_char_idx": 558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "702a60a0-9a60-4006-a401-a9c74140ce9d": {"__data__": {"id_": "702a60a0-9a60-4006-a401-a9c74140ce9d", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n", "original_text": "Looking ahead, we remain confident in our strategy.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1de9a6ce-0625-4ef9-bade-74134b68eb5d", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n", "original_text": "And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b86019e501775f79f665bce087aa506553bb3df6949af4cc43a0c82f6bd119e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09c50bd0-33c1-42a9-b110-4e6affa1cc0b", "node_type": "1", "metadata": {"window": "We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers. ", "original_text": "Now, I'll turn it over to Jason to discuss our results.  \n \n"}, "hash": "d18761e33a4e45f7c9d89f97b0ff637a8c2881ab285bcb2cb1008477c91d0d11", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead, we remain confident in our strategy.  \n \n", "start_char_idx": 558, "end_char_idx": 614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09c50bd0-33c1-42a9-b110-4e6affa1cc0b": {"__data__": {"id_": "09c50bd0-33c1-42a9-b110-4e6affa1cc0b", "embedding": null, "metadata": {"window": "We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers. ", "original_text": "Now, I'll turn it over to Jason to discuss our results.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "702a60a0-9a60-4006-a401-a9c74140ce9d", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n", "original_text": "Looking ahead, we remain confident in our strategy.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d08b96ba3bd2d558630aed15d4877987ca918321b00ad7c0b0aa2c98f845669", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1436fd30-a053-4b60-819f-134c3a61aa1d", "node_type": "1", "metadata": {"window": "And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n", "original_text": "Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n"}, "hash": "6048ecd692b2143d88accffb002a2bec5aadb4fb98d4a1feff5cc064a7463386", "class_name": "RelatedNodeInfo"}}, "text": "Now, I'll turn it over to Jason to discuss our results.  \n \n", "start_char_idx": 614, "end_char_idx": 674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1436fd30-a053-4b60-819f-134c3a61aa1d": {"__data__": {"id_": "1436fd30-a053-4b60-819f-134c3a61aa1d", "embedding": null, "metadata": {"window": "And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n", "original_text": "Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09c50bd0-33c1-42a9-b110-4e6affa1cc0b", "node_type": "1", "metadata": {"window": "We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers. ", "original_text": "Now, I'll turn it over to Jason to discuss our results.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13bee66fdc2d3eef93082c898973aeb06224c73b098256a99ad956a291735bec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58d6d352-9e20-4770-8c55-025b734ffe4a", "node_type": "1", "metadata": {"window": "Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n", "original_text": "I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n"}, "hash": "05961a5f016f05fa37bcc287aaaa11ced192346e5d518ea341bede4559307116", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n", "start_char_idx": 674, "end_char_idx": 735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58d6d352-9e20-4770-8c55-025b734ffe4a": {"__data__": {"id_": "58d6d352-9e20-4770-8c55-025b734ffe4a", "embedding": null, "metadata": {"window": "Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n", "original_text": "I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1436fd30-a053-4b60-819f-134c3a61aa1d", "node_type": "1", "metadata": {"window": "And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n", "original_text": "Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f099c1f43176d8717223bc854c227fc1bdc8f020959d26178f95a9d856aa60d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5479f15b-470e-46d6-a189-2bae5bb97756", "node_type": "1", "metadata": {"window": "Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n", "original_text": "Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers. "}, "hash": "74b56229b59989a15fd3bd80bd057f9704878fa5bea9e28c5c1854bb5f2f9b4e", "class_name": "RelatedNodeInfo"}}, "text": "I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n", "start_char_idx": 735, "end_char_idx": 877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5479f15b-470e-46d6-a189-2bae5bb97756": {"__data__": {"id_": "5479f15b-470e-46d6-a189-2bae5bb97756", "embedding": null, "metadata": {"window": "Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n", "original_text": "Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58d6d352-9e20-4770-8c55-025b734ffe4a", "node_type": "1", "metadata": {"window": "Looking ahead, we remain confident in our strategy.  \n \n Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n", "original_text": "I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7852f63ac81c95cc33088bf96a2bebcc94913b03640934c007cf6e9015beb620", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf308104-e1dd-4fba-8e83-998db2eb783c", "node_type": "1", "metadata": {"window": "Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n", "original_text": "Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n"}, "hash": "7dd2547709664126e73db30ae731393f358efa4ebb3a83541f9fcbb6ea84fd88", "class_name": "RelatedNodeInfo"}}, "text": "Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers. ", "start_char_idx": 877, "end_char_idx": 1018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf308104-e1dd-4fba-8e83-998db2eb783c": {"__data__": {"id_": "bf308104-e1dd-4fba-8e83-998db2eb783c", "embedding": null, "metadata": {"window": "Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n", "original_text": "Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5479f15b-470e-46d6-a189-2bae5bb97756", "node_type": "1", "metadata": {"window": "Now, I'll turn it over to Jason to discuss our results.  \n \n Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n", "original_text": "Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc7053528452d0800fe95dc6aefb86f5ea45f9fec212568ab7312c998de26d39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7efd170-c39a-4f2d-bc4e-7aff97318a0e", "node_type": "1", "metadata": {"window": "I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions. ", "original_text": "As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n"}, "hash": "2191a079cde5f5bf7da8f361076b67add069ae0c99c5c823f61293ad97bbfd39", "class_name": "RelatedNodeInfo"}}, "text": "Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n", "start_char_idx": 1018, "end_char_idx": 1167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7efd170-c39a-4f2d-bc4e-7aff97318a0e": {"__data__": {"id_": "f7efd170-c39a-4f2d-bc4e-7aff97318a0e", "embedding": null, "metadata": {"window": "I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions. ", "original_text": "As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf308104-e1dd-4fba-8e83-998db2eb783c", "node_type": "1", "metadata": {"window": "Jason Hollar:   Thanks, Mike, and good morning everyone.  \n \n I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n", "original_text": "Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1a1824f00f7428665198c46fddaf1eecc4664a14dd364014a049a1f5ed2da54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10f67a20-6d5e-44cf-b015-f85b4612d98f", "node_type": "1", "metadata": {"window": "Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities. ", "original_text": "SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n"}, "hash": "c064dc6dbe51dbd5b0431d2d0839edb4177418e65d9547d6e4c123353b384eec", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n", "start_char_idx": 1167, "end_char_idx": 1296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10f67a20-6d5e-44cf-b015-f85b4612d98f": {"__data__": {"id_": "10f67a20-6d5e-44cf-b015-f85b4612d98f", "embedding": null, "metadata": {"window": "Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities. ", "original_text": "SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7efd170-c39a-4f2d-bc4e-7aff97318a0e", "node_type": "1", "metadata": {"window": "I will review our first quarter results and updated expectations for fiscal '22 before closing with some \ncomments on capital deployment.  \n \n Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions. ", "original_text": "As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ee2e7f29d42ce507d0e2b8058940a0b52d63597a26484e842fa0dfd620979c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9bb9024-0ba9-432d-a2ea-a5c55ce6ea33", "node_type": "1", "metadata": {"window": "Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n", "original_text": "Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n"}, "hash": "dab297bd3d73a87dd3823eb693b9396066174c089cb134d36f5108cf347e8ddf", "class_name": "RelatedNodeInfo"}}, "text": "SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n", "start_char_idx": 1296, "end_char_idx": 1496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9bb9024-0ba9-432d-a2ea-a5c55ce6ea33": {"__data__": {"id_": "c9bb9024-0ba9-432d-a2ea-a5c55ce6ea33", "embedding": null, "metadata": {"window": "Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n", "original_text": "Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10f67a20-6d5e-44cf-b015-f85b4612d98f", "node_type": "1", "metadata": {"window": "Beginning with total company results , first  quarter revenue increased 13% to $44 billion, driven by \nsales growth from existing customers.  Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities. ", "original_text": "SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40ceb0cffde88c7778ce43023e6a181f8fd053585268c98984029c33604ea439", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "298e8675-67d0-4c8c-bbb9-b1a0e5d44b9a", "node_type": "1", "metadata": {"window": "As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.  ", "original_text": "Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions. "}, "hash": "318126ca8f66f8132c27b54a3d4b61400a39c1e1d4b1fe62679cc5b82e740c96", "class_name": "RelatedNodeInfo"}}, "text": "Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n", "start_char_idx": 1496, "end_char_idx": 1591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "298e8675-67d0-4c8c-bbb9-b1a0e5d44b9a": {"__data__": {"id_": "298e8675-67d0-4c8c-bbb9-b1a0e5d44b9a", "embedding": null, "metadata": {"window": "As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.  ", "original_text": "Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9bb9024-0ba9-432d-a2ea-a5c55ce6ea33", "node_type": "1", "metadata": {"window": "Total gross margin decreased 4% to $1.6 billion driven by the \nCordis divestiture and the net impact of elevated supply chain costs in Medical.   \n \n As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n", "original_text": "Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8bcf788681d9188511f980abed9a7d3d592918451f2781dc44a9a1ff7a0ad17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d19a3d0f-a70e-4a51-b509-c3a74d42b33c", "node_type": "1", "metadata": {"window": "SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year. ", "original_text": "During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities. "}, "hash": "31f52f33595ca5fed5f3bfd8cc9dd1ff4215d58119a096be35a5988148ce40c9", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions. ", "start_char_idx": 1591, "end_char_idx": 1744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d19a3d0f-a70e-4a51-b509-c3a74d42b33c": {"__data__": {"id_": "d19a3d0f-a70e-4a51-b509-c3a74d42b33c", "embedding": null, "metadata": {"window": "SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year. ", "original_text": "During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "298e8675-67d0-4c8c-bbb9-b1a0e5d44b9a", "node_type": "1", "metadata": {"window": "As a reminder, the sale of Cordis was completed on August 2nd and impacted the quarter's results by \napproximately 2 months.  \n \n SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.  ", "original_text": "Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6004b26122b13d25b498f237e6007e59eb4efd9598a0ac10ea3ff7672da849c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22b0dd39-84a4-4e22-8611-5e22f6b8ef8c", "node_type": "1", "metadata": {"window": "Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n", "original_text": "We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n"}, "hash": "0c958176c541f3557e4191e8a14e57ebe8a34304aa8837c8fc330d3b9652eb35", "class_name": "RelatedNodeInfo"}}, "text": "During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities. ", "start_char_idx": 1744, "end_char_idx": 1879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22b0dd39-84a4-4e22-8611-5e22f6b8ef8c": {"__data__": {"id_": "22b0dd39-84a4-4e22-8611-5e22f6b8ef8c", "embedding": null, "metadata": {"window": "Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n", "original_text": "We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d19a3d0f-a70e-4a51-b509-c3a74d42b33c", "node_type": "1", "metadata": {"window": "SG&A increased 1%, reflecting information technology investments and higher costs to support sales \ngrowth, partially offset by the Cordis divestit ure and benefits from cost savings initiatives.  \n \n Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year. ", "original_text": "During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99d707f1a24463b299ef31d8690712fb38f8c5346fd90d69cf8d8b7f99813ff7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "957f0333-3f8f-4272-9512-ceb958c3d2e0", "node_type": "1", "metadata": {"window": "Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n", "original_text": "Our first quarter effective tax rate was approximately 24%.  "}, "hash": "03ef9ce198f2acc3562c68b67dcfd1eb10da9f93d82db18c64054aec69d41474", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n", "start_char_idx": 1879, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "957f0333-3f8f-4272-9512-ceb958c3d2e0": {"__data__": {"id_": "957f0333-3f8f-4272-9512-ceb958c3d2e0", "embedding": null, "metadata": {"window": "Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n", "original_text": "Our first quarter effective tax rate was approximately 24%.  ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22b0dd39-84a4-4e22-8611-5e22f6b8ef8c", "node_type": "1", "metadata": {"window": "Overall, first quarter operating earnings tracked in line with our expectations, down 15%.  \n \n Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n", "original_text": "We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55be31b8d788edf34cebc9b47e26006e31f67b7ef5ac52e70a384492d701764d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac6817cb-d000-4356-9663-c9daf4ec94b0", "node_type": "1", "metadata": {"window": "During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities. ", "original_text": "Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year. "}, "hash": "2ba35a9890362a2534fe71f48f08ff95fef71a765524abbb713b12b5b22bb74c", "class_name": "RelatedNodeInfo"}}, "text": "Our first quarter effective tax rate was approximately 24%.  ", "start_char_idx": 1991, "end_char_idx": 2052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac6817cb-d000-4356-9663-c9daf4ec94b0": {"__data__": {"id_": "ac6817cb-d000-4356-9663-c9daf4ec94b0", "embedding": null, "metadata": {"window": "During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities. ", "original_text": "Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "957f0333-3f8f-4272-9512-ceb958c3d2e0", "node_type": "1", "metadata": {"window": "Moving below the line, Interest  and Other  decreased by $2 million , driven primarily by lower interest \nexpense from continued debt reduction actions.  During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n", "original_text": "Our first quarter effective tax rate was approximately 24%.  ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b01cbcd071869d22e5031025563ccb851437788133372e46007ec497b3477cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6f90ac5-509b-46b8-af0c-79ab171c396a", "node_type": "1", "metadata": {"window": "We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n", "original_text": "This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n"}, "hash": "9857a3ced5c7850ce6459a0261b009339d9741039e9830e2abb5c008dee9008b", "class_name": "RelatedNodeInfo"}}, "text": "Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year. ", "start_char_idx": 2052, "end_char_idx": 2156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6f90ac5-509b-46b8-af0c-79ab171c396a": {"__data__": {"id_": "d6f90ac5-509b-46b8-af0c-79ab171c396a", "embedding": null, "metadata": {"window": "We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n", "original_text": "This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac6817cb-d000-4356-9663-c9daf4ec94b0", "node_type": "1", "metadata": {"window": "During the first quarter , we exercised a make -whole \ncall provision to redeem $572 million of outstanding June 2022 debt maturities.  We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities. ", "original_text": "Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e03896d697e36a45aacdef4199f5232efb4f2c9f665e8c57185c734c81e20d42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5212602-c134-4e74-99e9-ad61f5ce6a13", "node_type": "1", "metadata": {"window": "Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "The net result for the quarter was EPS of $1.29.  \n \n"}, "hash": "23e13ec5cabbc7ca43edea239bfc00fd6f888f9292b42e4c01cb5b2c56c87ff6", "class_name": "RelatedNodeInfo"}}, "text": "This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n", "start_char_idx": 2156, "end_char_idx": 2315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5212602-c134-4e74-99e9-ad61f5ce6a13": {"__data__": {"id_": "b5212602-c134-4e74-99e9-ad61f5ce6a13", "embedding": null, "metadata": {"window": "Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "The net result for the quarter was EPS of $1.29.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6f90ac5-509b-46b8-af0c-79ab171c396a", "node_type": "1", "metadata": {"window": "We continue to expect \nto repay the appro ximately $280 million of remaining June 2022 notes upon maturity.  \n \n Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n", "original_text": "This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1a651f55fee3aee6c792bb37bcd5e95219f4b3476338dea5c52d72faf5142a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0dbcf863-98e2-489a-84f9-f00745210599", "node_type": "1", "metadata": {"window": "Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities. "}, "hash": "243a47259a8242df9c11a4d5075836cc5c490ece9404f071bbfe1ddc5c3c7756", "class_name": "RelatedNodeInfo"}}, "text": "The net result for the quarter was EPS of $1.29.  \n \n", "start_char_idx": 2315, "end_char_idx": 2368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0dbcf863-98e2-489a-84f9-f00745210599": {"__data__": {"id_": "0dbcf863-98e2-489a-84f9-f00745210599", "embedding": null, "metadata": {"window": "Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5212602-c134-4e74-99e9-ad61f5ce6a13", "node_type": "1", "metadata": {"window": "Our first quarter effective tax rate was approximately 24%.   Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "The net result for the quarter was EPS of $1.29.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a3b186a347f8a96462c82638cac4dfed423e36874876caa5c6fe453a4c538da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddea68d1-430f-4189-95be-d57c12b6c79a", "node_type": "1", "metadata": {"window": "This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n"}, "hash": "0281bed17b021216b50c82b13919d868a0256d2536f819237da21156bf199f90", "class_name": "RelatedNodeInfo"}}, "text": "We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities. ", "start_char_idx": 2368, "end_char_idx": 2492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddea68d1-430f-4189-95be-d57c12b6c79a": {"__data__": {"id_": "ddea68d1-430f-4189-95be-d57c12b6c79a", "embedding": null, "metadata": {"window": "This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0dbcf863-98e2-489a-84f9-f00745210599", "node_type": "1", "metadata": {"window": "Average diluted shares outstanding were \n289 million, about 4 million shares fewer than the prior year.  This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95a6b1ae3c123c72d6f3a1d57acc5894e89a7c3bee752dc6daf22dcca5d9462d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f69b74ce-aa1a-4015-95c7-8769c1ad6c62", "node_type": "1", "metadata": {"window": "The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "Now turning to the segments, beginning with Pharma on slide 5\u2026 \n "}, "hash": "32dac3496188c7255ce2d852d15c3ac4034930fc147210566978ff1f15eef8b5", "class_name": "RelatedNodeInfo"}}, "text": "This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n", "start_char_idx": 2492, "end_char_idx": 2625, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f69b74ce-aa1a-4015-95c7-8769c1ad6c62": {"__data__": {"id_": "f69b74ce-aa1a-4015-95c7-8769c1ad6c62", "embedding": null, "metadata": {"window": "The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27bfb634-9113-41d0-a325-ee5b790158c9", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "533417b4ff5d6e50d79b1705ebc72898ba7282de502fc04a2c627b74fe9d7c16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddea68d1-430f-4189-95be-d57c12b6c79a", "node_type": "1", "metadata": {"window": "This reflects prior year share \nrepurchases,  as well as the $500 million share repurchase program initiated in the first quarter and \nrecently completed.  \n \n The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56f6cb04135ef09b4b719d1036c3fced1b3dff41b035f997654dbc9528cc82a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81ea7d56-20b8-4311-a134-59ab96dd5188", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure. ", "original_text": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n"}, "hash": "6006ac7ce6c260b746fcc044879d3d7e2a05488e0370ce6e771d596d435b5e9b", "class_name": "RelatedNodeInfo"}}, "text": "Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "start_char_idx": 2625, "end_char_idx": 2690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81ea7d56-20b8-4311-a134-59ab96dd5188": {"__data__": {"id_": "81ea7d56-20b8-4311-a134-59ab96dd5188", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure. ", "original_text": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f69b74ce-aa1a-4015-95c7-8769c1ad6c62", "node_type": "1", "metadata": {"window": "The net result for the quarter was EPS of $1.29.  \n \n We ended the first quarter with a cash balance of $2.5 billion and no outstan ding borrowings under \nour credit facilities.  This cash balance also reflects our first annual settlement payment into escrow \nunder the proposed opioid settlement agreement.  \n \n Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "original_text": "Now turning to the segments, beginning with Pharma on slide 5\u2026 \n ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aaad5c008ddd2e422c43cb62ee818ab8cd937cf711ebb167f0f1dedbd91bd894", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41f00ef7-18ae-4b0a-ac7b-6c91669a5106", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n", "original_text": "Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19. "}, "hash": "d2bc5d423a00b49031ee5c623979ce6a41b12ed16c6575787dac11a66694d960", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n", "start_char_idx": 0, "end_char_idx": 182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41f00ef7-18ae-4b0a-ac7b-6c91669a5106": {"__data__": {"id_": "41f00ef7-18ae-4b0a-ac7b-6c91669a5106", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n", "original_text": "Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81ea7d56-20b8-4311-a134-59ab96dd5188", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure. ", "original_text": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c61f4ee7a53a7dd62c74b5c88c34879e5c111b668ccadde7aaab8ebfe16c4743", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c31bd46a-795e-449a-a013-d5b5a611bb74", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics. ", "original_text": "This was largely offset by \ninvestments in information technology enhancements.  \n \n"}, "hash": "aa477a1e1015d1f0a2966f21e4da354ccc5cdab7f95ba41d67be6abc88abd549", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19. ", "start_char_idx": 182, "end_char_idx": 344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c31bd46a-795e-449a-a013-d5b5a611bb74": {"__data__": {"id_": "c31bd46a-795e-449a-a013-d5b5a611bb74", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics. ", "original_text": "This was largely offset by \ninvestments in information technology enhancements.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41f00ef7-18ae-4b0a-ac7b-6c91669a5106", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n", "original_text": "Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a8dd98bf70004cef034daac1f04cb9af18286d666abc0fab31ea1071dee3e7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd9ba67f-19e1-440a-a380-2e0e192af402", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.  ", "original_text": "As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure. "}, "hash": "407340c445a48a30863503afd80969c5fbe62d3d79458f9a5ce29990aab33b71", "class_name": "RelatedNodeInfo"}}, "text": "This was largely offset by \ninvestments in information technology enhancements.  \n \n", "start_char_idx": 344, "end_char_idx": 428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd9ba67f-19e1-440a-a380-2e0e192af402": {"__data__": {"id_": "bd9ba67f-19e1-440a-a380-2e0e192af402", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.  ", "original_text": "As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c31bd46a-795e-449a-a013-d5b5a611bb74", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics. ", "original_text": "This was largely offset by \ninvestments in information technology enhancements.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a89dbba1a596306fded62f35ef38f5fe0efd6ca34f8d4e58f0df0c12819f544d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a26959c7-62d6-4460-8fe5-1fe19b2278c0", "node_type": "1", "metadata": {"window": "Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n", "original_text": "This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n"}, "hash": "95fb47ef51cc1ec4b28b088758cdb3423aa91d2bb7c5305d7d4881163e5b3339", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure. ", "start_char_idx": 428, "end_char_idx": 619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a26959c7-62d6-4460-8fe5-1fe19b2278c0": {"__data__": {"id_": "a26959c7-62d6-4460-8fe5-1fe19b2278c0", "embedding": null, "metadata": {"window": "Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n", "original_text": "This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd9ba67f-19e1-440a-a380-2e0e192af402", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.  ", "original_text": "As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30889cd598289040fc13be1bf81d1a4df1ece8f852edfdd957e6d8f81ca12298", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3045797a-7ab3-42c8-b926-cc389a00aa65", "node_type": "1", "metadata": {"window": "This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n", "original_text": "As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics. "}, "hash": "e3e2ab1eab8b964d2f7919985d2c3a563b7c45114e28cf426da5500d7be5cd4e", "class_name": "RelatedNodeInfo"}}, "text": "This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n", "start_char_idx": 619, "end_char_idx": 794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3045797a-7ab3-42c8-b926-cc389a00aa65": {"__data__": {"id_": "3045797a-7ab3-42c8-b926-cc389a00aa65", "embedding": null, "metadata": {"window": "This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n", "original_text": "As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a26959c7-62d6-4460-8fe5-1fe19b2278c0", "node_type": "1", "metadata": {"window": "Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n", "original_text": "This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64c6f985033f89b152e166703a256b712f8bf1c3b559da251c2f80bfca7006c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13611a5b-da69-4eb2-bead-6794badb6c0a", "node_type": "1", "metadata": {"window": "As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture. ", "original_text": "We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.  "}, "hash": "825577f6dc6fdd56887501c825c378210974dd0dbf72d8cdc3ebeb6435f659c7", "class_name": "RelatedNodeInfo"}}, "text": "As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics. ", "start_char_idx": 794, "end_char_idx": 922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13611a5b-da69-4eb2-bead-6794badb6c0a": {"__data__": {"id_": "13611a5b-da69-4eb2-bead-6794badb6c0a", "embedding": null, "metadata": {"window": "As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture. ", "original_text": "We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.  ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3045797a-7ab3-42c8-b926-cc389a00aa65", "node_type": "1", "metadata": {"window": "This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n", "original_text": "As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bde79962ae0f40d4e2be98a983c592844919b17b653ec8c5bf0a8167462da8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84a9366d-81ba-455e-a5ef-2f105506251e", "node_type": "1", "metadata": {"window": "This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs. ", "original_text": "Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n"}, "hash": "37c62a6f9e0bb05d4f333590cd8cbca594652d5590636b5b8017480180af341e", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.  ", "start_char_idx": 922, "end_char_idx": 1029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84a9366d-81ba-455e-a5ef-2f105506251e": {"__data__": {"id_": "84a9366d-81ba-455e-a5ef-2f105506251e", "embedding": null, "metadata": {"window": "This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs. ", "original_text": "Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13611a5b-da69-4eb2-bead-6794badb6c0a", "node_type": "1", "metadata": {"window": "As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure.  This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture. ", "original_text": "We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.  ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1d833c246304c1bb7e2546540bc827114136c4cbcd6d0e1219b766ca968130d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a44daa4-1bbc-4b9f-aa70-23a633d14389", "node_type": "1", "metadata": {"window": "As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n", "original_text": "And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n"}, "hash": "72ea919c429037d9c41bad62b6e6c01d9b736d897fb756cd1bc06bc2c4922395", "class_name": "RelatedNodeInfo"}}, "text": "Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n", "start_char_idx": 1029, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a44daa4-1bbc-4b9f-aa70-23a633d14389": {"__data__": {"id_": "4a44daa4-1bbc-4b9f-aa70-23a633d14389", "embedding": null, "metadata": {"window": "As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n", "original_text": "And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84a9366d-81ba-455e-a5ef-2f105506251e", "node_type": "1", "metadata": {"window": "This rollout  is \ntracking according to plan, and we continue to expect incremental implementation and depreciation \ncosts through the first three  quarters of fiscal '22. \n \n As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs. ", "original_text": "Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49ae4f7c207f850df07388f4093b0a02a5b7ba4fd38b65b6a89e9ced58bc3e5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0593d4e1-8f2f-465b-8afe-34dbdcb3002c", "node_type": "1", "metadata": {"window": "We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight. ", "original_text": "Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture. "}, "hash": "16e14a5eb911135a3bbdee47577f68a353ac1556406a880ae49ce2efbaf05fe1", "class_name": "RelatedNodeInfo"}}, "text": "And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n", "start_char_idx": 1184, "end_char_idx": 1314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0593d4e1-8f2f-465b-8afe-34dbdcb3002c": {"__data__": {"id_": "0593d4e1-8f2f-465b-8afe-34dbdcb3002c", "embedding": null, "metadata": {"window": "We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight. ", "original_text": "Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a44daa4-1bbc-4b9f-aa70-23a633d14389", "node_type": "1", "metadata": {"window": "As Mike mentioned, during the quarter we saw broad -based sequential improvement in \npharmaceutical demand, including generics.  We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n", "original_text": "And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f97aa89e0060e12a85111429347cf45a05dd6ff401dcaf67d15971b4c5c966a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4500e4d-d33b-4db6-b73b-7d9293ae8342", "node_type": "1", "metadata": {"window": "Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year. ", "original_text": "Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs. "}, "hash": "f4ab987324c073a87caeaee2e1472c9b1f379b4c2a1373e2737350fde1ef4fa1", "class_name": "RelatedNodeInfo"}}, "text": "Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture. ", "start_char_idx": 1314, "end_char_idx": 1489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4500e4d-d33b-4db6-b73b-7d9293ae8342": {"__data__": {"id_": "b4500e4d-d33b-4db6-b73b-7d9293ae8342", "embedding": null, "metadata": {"window": "Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year. ", "original_text": "Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0593d4e1-8f2f-465b-8afe-34dbdcb3002c", "node_type": "1", "metadata": {"window": "We continue to expect a recovery of generic volumes to \npre-COVID levels by the end of the calendar year.   Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight. ", "original_text": "Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83ed6952ef17da0d8a31850c5d9244ecfd05b5e8c22b5f0f9d6ae64e155187b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b838084-5ac3-45a9-88f6-3cb495bfc4a3", "node_type": "1", "metadata": {"window": "And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n", "original_text": "To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n"}, "hash": "1947ea046f7b583f40b0f3336055ecd1e4903ac0ad2912f5dd337c58cd732033", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs. ", "start_char_idx": 1489, "end_char_idx": 1583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b838084-5ac3-45a9-88f6-3cb495bfc4a3": {"__data__": {"id_": "2b838084-5ac3-45a9-88f6-3cb495bfc4a3", "embedding": null, "metadata": {"window": "And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n", "original_text": "To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4500e4d-d33b-4db6-b73b-7d9293ae8342", "node_type": "1", "metadata": {"window": "Outside of volumes, our g enerics program \ncontinued to experience generally consistent market dynamics , along with strong performance from \nRed Oak . \n \n And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year. ", "original_text": "Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2188479f30c9ad21496519c5280b5ad09d3cb9968d4ba9421a39d35c8d5990d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79789807-265b-4daf-b97d-cce98bed4437", "node_type": "1", "metadata": {"window": "Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year. ", "original_text": "As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight. "}, "hash": "30064d5afc94098fc13c58b70aa1c8995ee72ef5b46576e081582cf0e0b6f11d", "class_name": "RelatedNodeInfo"}}, "text": "To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n", "start_char_idx": 1583, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79789807-265b-4daf-b97d-cce98bed4437": {"__data__": {"id_": "79789807-265b-4daf-b97d-cce98bed4437", "embedding": null, "metadata": {"window": "Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year. ", "original_text": "As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b838084-5ac3-45a9-88f6-3cb495bfc4a3", "node_type": "1", "metadata": {"window": "And, during the quarter, Pharma saw double -digit contributions from our growth businesses: \nSpecialty, Nuclear and Outcomes . \n \n Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n", "original_text": "To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bcfdd8f665650af153aec2e072fd29aba0e1f8568fac82437685fcee7cf5542c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a73e1908-bb6e-4d64-8cdb-d97866c4e876", "node_type": "1", "metadata": {"window": "Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management. ", "original_text": "In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year. "}, "hash": "6f5a26efa89aa7cd918e5d82620e42df2da2254fc9114b063338adde1d659f64", "class_name": "RelatedNodeInfo"}}, "text": "As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight. ", "start_char_idx": 1735, "end_char_idx": 1968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a73e1908-bb6e-4d64-8cdb-d97866c4e876": {"__data__": {"id_": "a73e1908-bb6e-4d64-8cdb-d97866c4e876", "embedding": null, "metadata": {"window": "Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management. ", "original_text": "In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79789807-265b-4daf-b97d-cce98bed4437", "node_type": "1", "metadata": {"window": "Transiti oning to the Medical segment on slide 6\u2026 \n \nMedical revenue increased 5% to $4.1 billion, driven primarily by PPE sales, partially offset by the \nCordis divestiture.  Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year. ", "original_text": "As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a37520c04448ed785f5bd2bab594cd17bd13ae69eec2d363ef95bfcc369ce8fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a92315d-a906-43a1-b499-c97a491d7609", "node_type": "1", "metadata": {"window": "To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n", "original_text": "And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n"}, "hash": "ded2254f680639e292bbded44394d6fa8c0a8539eacc082c295e726091087c1a", "class_name": "RelatedNodeInfo"}}, "text": "In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year. ", "start_char_idx": 1968, "end_char_idx": 2184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a92315d-a906-43a1-b499-c97a491d7609": {"__data__": {"id_": "7a92315d-a906-43a1-b499-c97a491d7609", "embedding": null, "metadata": {"window": "To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n", "original_text": "And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a73e1908-bb6e-4d64-8cdb-d97866c4e876", "node_type": "1", "metadata": {"window": "Segment profit decreased 46% to $123 million , primarily due to elevated supply \nchain costs.  To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management. ", "original_text": "In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3c4c8be6c35f0408e5da313520ad5a141b5134b8431456a245b23ac024a0a14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4303e111-f371-4573-83fc-ae525466ad7f", "node_type": "1", "metadata": {"window": "As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels. ", "original_text": "We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year. "}, "hash": "98ab1f2757bcab79933114ff4e1b7af5b77f0ce965ba98061ba0614d0e6989b7", "class_name": "RelatedNodeInfo"}}, "text": "And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n", "start_char_idx": 2184, "end_char_idx": 2303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4303e111-f371-4573-83fc-ae525466ad7f": {"__data__": {"id_": "4303e111-f371-4573-83fc-ae525466ad7f", "embedding": null, "metadata": {"window": "As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels. ", "original_text": "We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a92315d-a906-43a1-b499-c97a491d7609", "node_type": "1", "metadata": {"window": "To a lesser extent, this also reflects the impact of the Cordis divestiture, as well as net \nfavorability in the prior year attributed to COVID -19. \n \n As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n", "original_text": "And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89267fdc69f2b3624ad3cfd6fe87ab61c754e6864185c08574ac34c04f4a0a9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a063a29b-71b2-4b0a-af93-f09c7f607f5d", "node_type": "1", "metadata": {"window": "In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "We are taking action, including through pricing and aggressive cost management. "}, "hash": "990285dc84da01aa1fe6c82806d953630950492933a69ef0e3872e43edef8e0d", "class_name": "RelatedNodeInfo"}}, "text": "We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year. ", "start_char_idx": 2303, "end_char_idx": 2415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a063a29b-71b2-4b0a-af93-f09c7f607f5d": {"__data__": {"id_": "a063a29b-71b2-4b0a-af93-f09c7f607f5d", "embedding": null, "metadata": {"window": "In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "We are taking action, including through pricing and aggressive cost management. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4303e111-f371-4573-83fc-ae525466ad7f", "node_type": "1", "metadata": {"window": "As Mike mentioned, Medical segment profit was negatively impacted by increased product costs due \nto significant inflationary pressures in our global supply chain, particularly in the areas of commodities \nand international freight.  In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels. ", "original_text": "We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1aff577411f9ffa298c8ea076ff77476606fe38b10125308107ac1f7f449418", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4286fe1f-6362-437e-91b8-3810b1dbd95d", "node_type": "1", "metadata": {"window": "And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n"}, "hash": "747b098231051ab63ee88f28c5da0f55e50632fce96811e1f8212ef597516735", "class_name": "RelatedNodeInfo"}}, "text": "We are taking action, including through pricing and aggressive cost management. ", "start_char_idx": 2415, "end_char_idx": 2495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4286fe1f-6362-437e-91b8-3810b1dbd95d": {"__data__": {"id_": "4286fe1f-6362-437e-91b8-3810b1dbd95d", "embedding": null, "metadata": {"window": "And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a063a29b-71b2-4b0a-af93-f09c7f607f5d", "node_type": "1", "metadata": {"window": "In commodities, we have seen spikes in some key resins , such as \npolypropylene , that are inputs into our self -manufactured and sourced products , with recent index \nprices nearly double where they were last year.  And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "We are taking action, including through pricing and aggressive cost management. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8f9f0363289888c70765a27535fe44b66ab68527e57b03c4290de1b5d1bdfd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bb8a1ae-00d3-4ec2-b486-23e2298effe7", "node_type": "1", "metadata": {"window": "We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels. "}, "hash": "05e719615a826c37d98acd5750ef13eeacf64821fd0bbcc4eade460ac9e80be5", "class_name": "RelatedNodeInfo"}}, "text": "I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n", "start_char_idx": 2495, "end_char_idx": 2572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bb8a1ae-00d3-4ec2-b486-23e2298effe7": {"__data__": {"id_": "9bb8a1ae-00d3-4ec2-b486-23e2298effe7", "embedding": null, "metadata": {"window": "We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4286fe1f-6362-437e-91b8-3810b1dbd95d", "node_type": "1", "metadata": {"window": "And with international freight, we are seeing ocean \ncontainer costs at  roughly 8  to 10 times  pre-COVID levels.  \n \n We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "051deca8db436942fd4c85f48c786b8f866e63e8d8648675a47c007ef8e536f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ee3a7a6-ebe1-4123-9603-797583466df2", "node_type": "1", "metadata": {"window": "We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n "}, "hash": "42fbba6ee9a36a572cd504a5612f25b726732d31d04b85b688cffbe187faa985", "class_name": "RelatedNodeInfo"}}, "text": "To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels. ", "start_char_idx": 2572, "end_char_idx": 2803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ee3a7a6-ebe1-4123-9603-797583466df2": {"__data__": {"id_": "8ee3a7a6-ebe1-4123-9603-797583466df2", "embedding": null, "metadata": {"window": "We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72a30e96-83fc-428c-b761-b15b1cddf892", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70af345b42f5aadaa43a5a626af649d9e4bf4a873f9bca2db70cfdb2f0bdc6a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bb8a1ae-00d3-4ec2-b486-23e2298effe7", "node_type": "1", "metadata": {"window": "We believe the majority of these headwinds are temporary, but we do not expect them to abate this \nfiscal year.  We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels. ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9968928864a5d6180ba0ea651118057b32f22f25b420943e536b0cebe4e7e5cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5bd8d41-4b90-40c0-b482-9c3c314dc1bd", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%. ", "original_text": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n"}, "hash": "d4f291bd8f00c17e305f37fbe25fd2c957b1a20cfc4de6a3584e241aa2e19298", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "start_char_idx": 2803, "end_char_idx": 2994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5bd8d41-4b90-40c0-b482-9c3c314dc1bd": {"__data__": {"id_": "a5bd8d41-4b90-40c0-b482-9c3c314dc1bd", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%. ", "original_text": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ee3a7a6-ebe1-4123-9603-797583466df2", "node_type": "1", "metadata": {"window": "We are taking action, including through pricing and aggressive cost management.  I will \ndiscuss these i mpacts to our full year Medical outlook shortly.  \n \n To wrap up the quarter, despite some impact from the Delta variant on elective procedure volumes, \noverall our customers continue  to manage effectively and total elective volumes exited the quarter \nnear 95% of pre -COVID levels.  Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "original_text": "Additionally, Lab testing volumes remained significantly elevated \nabove pre -COVID level s, but was not a material driver to the quarter due to the strong performance in \nthe prior year.  \n ", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88a46e15744a39fc182989155aa3487d6998b1ff31950eb82a19827c80587b4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "340747b2-4172-4ca5-95b7-ba208bc1591e", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n", "original_text": "We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n"}, "hash": "01024749662401c54eab443e3c4b7e506df7a2674be39f1c35bf9bc47b4753aa", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n", "start_char_idx": 0, "end_char_idx": 81, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "340747b2-4172-4ca5-95b7-ba208bc1591e": {"__data__": {"id_": "340747b2-4172-4ca5-95b7-ba208bc1591e", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n", "original_text": "We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5bd8d41-4b90-40c0-b482-9c3c314dc1bd", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%. ", "original_text": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3078ec17a446cb824585c6263cd6aa35ca8bc26a6793d24ac9d8a54671bcd18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb78c482-5705-4608-a902-e0617c249182", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n", "original_text": "This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count. "}, "hash": "4a85ce266adb9f212510a8a313e33999e4458ba89737cf2091ba6112158c30ae", "class_name": "RelatedNodeInfo"}}, "text": "We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n", "start_char_idx": 81, "end_char_idx": 157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb78c482-5705-4608-a902-e0617c249182": {"__data__": {"id_": "bb78c482-5705-4608-a902-e0617c249182", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n", "original_text": "This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "340747b2-4172-4ca5-95b7-ba208bc1591e", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n", "original_text": "We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03b650e5e401e46086abf19f2b4bc66d3089191d7e272e37fdf16293006f6fbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3e5f663-5b59-4c35-9675-c0c4904a821b", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits. ", "original_text": "We now expect our annual effective tax rate in the rang e of 23 % to 25%. "}, "hash": "a6a7effad8cefabc67e4c1fb92c02c88620f0a2090fe14c4edfbeee220487a2a", "class_name": "RelatedNodeInfo"}}, "text": "This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count. ", "start_char_idx": 157, "end_char_idx": 277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3e5f663-5b59-4c35-9675-c0c4904a821b": {"__data__": {"id_": "a3e5f663-5b59-4c35-9675-c0c4904a821b", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits. ", "original_text": "We now expect our annual effective tax rate in the rang e of 23 % to 25%. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb78c482-5705-4608-a902-e0617c249182", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n", "original_text": "This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7533a6a43bcf4ed46f91db8a08a20b242ea0be59b063c77947458963d5ecbb7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8944b13-c93e-476b-802a-0e53fa2b1458", "node_type": "1", "metadata": {"window": "We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year. ", "original_text": "We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n"}, "hash": "4d42077b94183bf3bfc0770d55cd15202fe953b687bc7366ab44076a68998ce8", "class_name": "RelatedNodeInfo"}}, "text": "We now expect our annual effective tax rate in the rang e of 23 % to 25%. ", "start_char_idx": 277, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8944b13-c93e-476b-802a-0e53fa2b1458": {"__data__": {"id_": "f8944b13-c93e-476b-802a-0e53fa2b1458", "embedding": null, "metadata": {"window": "We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year. ", "original_text": "We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3e5f663-5b59-4c35-9675-c0c4904a821b", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits. ", "original_text": "We now expect our annual effective tax rate in the rang e of 23 % to 25%. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f0c13845e26c74132b8e5a123d7e85ba52a28eac959fa67dd9f0aa3278e1737", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9b5fcc1-4257-4ceb-9ac7-68a460821e4f", "node_type": "1", "metadata": {"window": "This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n", "original_text": "As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n"}, "hash": "50c109f93fd7376b84eba6766c9a37dd2b86acf9b329c6a12f261f4b2f553bfd", "class_name": "RelatedNodeInfo"}}, "text": "We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n", "start_char_idx": 351, "end_char_idx": 463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9b5fcc1-4257-4ceb-9ac7-68a460821e4f": {"__data__": {"id_": "d9b5fcc1-4257-4ceb-9ac7-68a460821e4f", "embedding": null, "metadata": {"window": "This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n", "original_text": "As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8944b13-c93e-476b-802a-0e53fa2b1458", "node_type": "1", "metadata": {"window": "We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year. ", "original_text": "We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34c2faff7114f505e238c5da819ee167785217819d6087f4904756e81e937073", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea5a02c1-1565-4d68-84fc-3707d436dfa2", "node_type": "1", "metadata": {"window": "We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n", "original_text": "For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits. "}, "hash": "29fa9687d254c6164e2a5b02a4690537d3efc60d87fc0f390c408a64cfa708d4", "class_name": "RelatedNodeInfo"}}, "text": "As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n", "start_char_idx": 463, "end_char_idx": 690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea5a02c1-1565-4d68-84fc-3707d436dfa2": {"__data__": {"id_": "ea5a02c1-1565-4d68-84fc-3707d436dfa2", "embedding": null, "metadata": {"window": "We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n", "original_text": "For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9b5fcc1-4257-4ceb-9ac7-68a460821e4f", "node_type": "1", "metadata": {"window": "This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n", "original_text": "As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "944fdd502d19efe411d4252ad3a7e7ebb970f694ab0564ea0ed9e4507143a2f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd1dbb2f-1fb7-4282-a100-6e8cea710d3a", "node_type": "1", "metadata": {"window": "We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n", "original_text": "This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year. "}, "hash": "8dab4e6b8527da5e1b0d9b0ed860c06494490e371f4143a34220945a7d37abe6", "class_name": "RelatedNodeInfo"}}, "text": "For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits. ", "start_char_idx": 690, "end_char_idx": 788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd1dbb2f-1fb7-4282-a100-6e8cea710d3a": {"__data__": {"id_": "bd1dbb2f-1fb7-4282-a100-6e8cea710d3a", "embedding": null, "metadata": {"window": "We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n", "original_text": "This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea5a02c1-1565-4d68-84fc-3707d436dfa2", "node_type": "1", "metadata": {"window": "We now expect our annual effective tax rate in the rang e of 23 % to 25%.  We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n", "original_text": "For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b41fce6290616de818b22081d562124d3d73d343f4d3ad91de1879787964c87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74cafe3f-d98f-4b4a-9b44-162c910f4503", "node_type": "1", "metadata": {"window": "As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n", "original_text": "Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n"}, "hash": "52739a461f7a4164d7b6f32ece5f74af618890ee7254768ea98f85cd30ea2d22", "class_name": "RelatedNodeInfo"}}, "text": "This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year. ", "start_char_idx": 788, "end_char_idx": 1022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74cafe3f-d98f-4b4a-9b44-162c910f4503": {"__data__": {"id_": "74cafe3f-d98f-4b4a-9b44-162c910f4503", "embedding": null, "metadata": {"window": "As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n", "original_text": "Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd1dbb2f-1fb7-4282-a100-6e8cea710d3a", "node_type": "1", "metadata": {"window": "We also \nnow expect diluted weighted average shares outstanding in the range of 280 million to 282 million.  \n \n As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n", "original_text": "This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e69ce08257839f1bb93ff8b7c543918e00fa926f6f6fa905dcf7b5b6412724fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c50c3abc-ba87-4ce1-8ebc-0e2c408906b1", "node_type": "1", "metadata": {"window": "For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n", "original_text": "Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n"}, "hash": "dee71163e257dd8cf97ae29123422937a1ca86216bca1118034dd4164b4f814f", "class_name": "RelatedNodeInfo"}}, "text": "Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n", "start_char_idx": 1022, "end_char_idx": 1251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c50c3abc-ba87-4ce1-8ebc-0e2c408906b1": {"__data__": {"id_": "c50c3abc-ba87-4ce1-8ebc-0e2c408906b1", "embedding": null, "metadata": {"window": "For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n", "original_text": "Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74cafe3f-d98f-4b4a-9b44-162c910f4503", "node_type": "1", "metadata": {"window": "As for the segment outlooks on slide 9\u2026 \n \nFirst, we are adjusting our Pharma revenue outlook to low  double -digit growth to reflect the strong \nbranded pharmaceutical sales growth that we are seeing from large customers.  \n \n For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n", "original_text": "Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a27c0861a9f90fc52dba2bedda87b530bc408cfc5d802871d8e85665354944e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78803784-4cad-4b9a-9c6d-6b8c03b8dc7a", "node_type": "1", "metadata": {"window": "This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress. ", "original_text": "Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n"}, "hash": "b010094af1e6016e3f54f487dd68bd480cf15efd9c2b2a5fafeba8a76e5daa7d", "class_name": "RelatedNodeInfo"}}, "text": "Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n", "start_char_idx": 1251, "end_char_idx": 1455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78803784-4cad-4b9a-9c6d-6b8c03b8dc7a": {"__data__": {"id_": "78803784-4cad-4b9a-9c6d-6b8c03b8dc7a", "embedding": null, "metadata": {"window": "This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress. ", "original_text": "Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c50c3abc-ba87-4ce1-8ebc-0e2c408906b1", "node_type": "1", "metadata": {"window": "For Medical, we now expect fiscal '22 segment profit to be down mid -single to low double digits.  This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n", "original_text": "Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8a200765580bdc58e77dc2c52b2dd16be8a22621d312bca24b623e4e2283757", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a874db74-d558-4a5e-befe-1d64fd2cbc4d", "node_type": "1", "metadata": {"window": "Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n", "original_text": "And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n"}, "hash": "a229f5da0176f056d99b4dc1e03e8a97b726d52c52938338077e094d5e601021", "class_name": "RelatedNodeInfo"}}, "text": "Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n", "start_char_idx": 1455, "end_char_idx": 1558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a874db74-d558-4a5e-befe-1d64fd2cbc4d": {"__data__": {"id_": "a874db74-d558-4a5e-befe-1d64fd2cbc4d", "embedding": null, "metadata": {"window": "Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n", "original_text": "And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78803784-4cad-4b9a-9c6d-6b8c03b8dc7a", "node_type": "1", "metadata": {"window": "This \nchange is driven by the significant increases in supply c hain cost inflation that I previously  discussed, \nwhich is expected to result in an incremental net headwind of approximately $100 million to $125 \nmillion on the year.  Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress. ", "original_text": "Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1137e453ab44feb99721e4c714ac48d1899c5dc3314d509d9f222dc9e5c3d1e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd2cab71-d2ea-4708-b044-33c36df4fc99", "node_type": "1", "metadata": {"window": "Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024. ", "original_text": "Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n"}, "hash": "05f4a373564f8beea3073c104748ecc68161e283a62baf0c74193368f044dfc7", "class_name": "RelatedNodeInfo"}}, "text": "And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n", "start_char_idx": 1558, "end_char_idx": 1680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd2cab71-d2ea-4708-b044-33c36df4fc99": {"__data__": {"id_": "dd2cab71-d2ea-4708-b044-33c36df4fc99", "embedding": null, "metadata": {"window": "Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024. ", "original_text": "Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a874db74-d558-4a5e-befe-1d64fd2cbc4d", "node_type": "1", "metadata": {"window": "Given the anticipated timing of realizing these cost increases and our mitigating \naction s, as well as the timing of selling higher  cost PPE, we expect a sequential decline in Medical \nsegment profit in the second quarter.  \n \n Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n", "original_text": "And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf35565e8384434e5865b03fa25af5f96ed66c9fd7dbfc227afed4677599eb34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d01e86d1-b298-4667-aac8-0b33bd88f8a6", "node_type": "1", "metadata": {"window": "Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date. ", "original_text": "We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress. "}, "hash": "9821207e4ec4b82c5a3dd8e5b9ba911ea3f5833f67ea44514bc186e6f24261e9", "class_name": "RelatedNodeInfo"}}, "text": "Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n", "start_char_idx": 1680, "end_char_idx": 1933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d01e86d1-b298-4667-aac8-0b33bd88f8a6": {"__data__": {"id_": "d01e86d1-b298-4667-aac8-0b33bd88f8a6", "embedding": null, "metadata": {"window": "Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date. ", "original_text": "We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd2cab71-d2ea-4708-b044-33c36df4fc99", "node_type": "1", "metadata": {"window": "Stepping back, the only large operational item that we see meaningfully different today compared to \nour original fiscal '22 guidance is the incremental impact of elevated supply chain costs in Medical. \n Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024. ", "original_text": "Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8482b8bf5b7b8e95e22230eb2cfac55ae3ddb51393d80c89373f008eacd027e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "255d8878-820e-43dc-8df7-e877665b313d", "node_type": "1", "metadata": {"window": "And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n", "original_text": "As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n"}, "hash": "fb110f6da146d954a32fdb871359ac25b0bbc9a6e662e86a67bb6cc271fa9c50", "class_name": "RelatedNodeInfo"}}, "text": "We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress. ", "start_char_idx": 1933, "end_char_idx": 2042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "255d8878-820e-43dc-8df7-e877665b313d": {"__data__": {"id_": "255d8878-820e-43dc-8df7-e877665b313d", "embedding": null, "metadata": {"window": "And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n", "original_text": "As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d01e86d1-b298-4667-aac8-0b33bd88f8a6", "node_type": "1", "metadata": {"window": "Notably, we do not anticipate any material net impact in Pharma from inflationary supply chain costs. \n And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date. ", "original_text": "We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "376853516e6a90bae1754d785f5ad38d20e4598088d96eed5334fadda037a8fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "351369cf-c669-4500-9fdb-d71d5c5cdac5", "node_type": "1", "metadata": {"window": "Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024. "}, "hash": "8364b4b4e1bf05363fe3a31496502c61f08c591d78f95746ed969e914543c0f5", "class_name": "RelatedNodeInfo"}}, "text": "As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n", "start_char_idx": 2042, "end_char_idx": 2223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "351369cf-c669-4500-9fdb-d71d5c5cdac5": {"__data__": {"id_": "351369cf-c669-4500-9fdb-d71d5c5cdac5", "embedding": null, "metadata": {"window": "Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "255d8878-820e-43dc-8df7-e877665b313d", "node_type": "1", "metadata": {"window": "And, as noted last quarter, we still expect the cadence of our EPS guidanc e to be significantly \nback half weighted.  \n \n Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n", "original_text": "As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7be6fef5423a6a8cd65ef86b3bfd3683104346cd0ebf4365ad87c17cf9acb06a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a1d84a5-2c5a-4c43-8fae-823ec62a7ab0", "node_type": "1", "metadata": {"window": "We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date. "}, "hash": "ff90fd236c402458d677ef049691f03de396bdc7bf3819b61c160ec8c1e7004c", "class_name": "RelatedNodeInfo"}}, "text": "On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024. ", "start_char_idx": 2223, "end_char_idx": 2436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a1d84a5-2c5a-4c43-8fae-823ec62a7ab0": {"__data__": {"id_": "9a1d84a5-2c5a-4c43-8fae-823ec62a7ab0", "embedding": null, "metadata": {"window": "We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "351369cf-c669-4500-9fdb-d71d5c5cdac5", "node_type": "1", "metadata": {"window": "Now to close, an update on capital deployment \u2026 \n \nWe are focused on deploying capital in a balanced, disciplined , and shareholder -friendly manner , and \nwill continue to allocate capital through the lens of our priori ties, which are unchanged.   \n \n We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ddba77cde5f4fe4f352e8da59558aca4b37386c3c764bb516d55b8394bec23f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66b08f8a-19dc-4599-9363-c1da604c795e", "node_type": "1", "metadata": {"window": "As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n"}, "hash": "0c88d12c76d0c0754f0a398af71dba021b150e0f3c0168c4f682649d9ee1cd29", "class_name": "RelatedNodeInfo"}}, "text": "And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date. ", "start_char_idx": 2436, "end_char_idx": 2592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66b08f8a-19dc-4599-9363-c1da604c795e": {"__data__": {"id_": "66b08f8a-19dc-4599-9363-c1da604c795e", "embedding": null, "metadata": {"window": "As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a1d84a5-2c5a-4c43-8fae-823ec62a7ab0", "node_type": "1", "metadata": {"window": "We have been on a journey to improve our balance sheet and our portfolio and have made \ntremendous progress.  As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date. ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04b892e3a8bb22e38d3281e20100d31ac19e37ce5ee4fd29e83cfec717b5a3f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55f9e462-1005-4a70-8b8d-a8cd887f39da", "node_type": "1", "metadata": {"window": "On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "With t hat, I'll turn it back over to Mike.  "}, "hash": "22a60328ae80102b2cde1c14c3296786cef90b33f6e5a4ba17af262217fcf4da", "class_name": "RelatedNodeInfo"}}, "text": "We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n", "start_char_idx": 2592, "end_char_idx": 2823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55f9e462-1005-4a70-8b8d-a8cd887f39da": {"__data__": {"id_": "55f9e462-1005-4a70-8b8d-a8cd887f39da", "embedding": null, "metadata": {"window": "On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "With t hat, I'll turn it back over to Mike.  ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac2170e-3a4e-448d-b690-3779d62717e3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e64ae44c51e6dc24b802a5817b821d3c1c5fd6587ca7c9b8cd63d629c93d15e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66b08f8a-19dc-4599-9363-c1da604c795e", "node_type": "1", "metadata": {"window": "As we look forward, we see our debt paydown beginning to moderate, which \nwill provide an increased ability to be more opportunistic with our return of capital to shareholders.  \n \n On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7ff3b06bbdc51b3567d7dc280b4b820aa3eb0be37155ca6955a0846b7259c90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cc2c8b7-b599-454a-92e0-b8667c83d6a2", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical. ", "original_text": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason. "}, "hash": "e5aa204b5eccb918ef1d465944583c58dca8455ed8290c71049df0b5c888b355", "class_name": "RelatedNodeInfo"}}, "text": "With t hat, I'll turn it back over to Mike.  ", "start_char_idx": 2823, "end_char_idx": 2868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cc2c8b7-b599-454a-92e0-b8667c83d6a2": {"__data__": {"id_": "8cc2c8b7-b599-454a-92e0-b8667c83d6a2", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical. ", "original_text": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55f9e462-1005-4a70-8b8d-a8cd887f39da", "node_type": "1", "metadata": {"window": "On that note, two important updates : \n \nOur Board recently approved a new , three -year authorization to repurchase up to an additional $3 \nbillion of our common stock, expiring at the end of calendar year 2024.  And, we now expect \napproximately $1 billion of share repurchases in fiscal '22, which includes the $ 500 million  of share \nrepur chases executed to date.  We believe that capital deployment, along with the future growth that \nwe expect in both our segments, will be a key driver to the double -digit combined EPS growth and \ndividend yield that we are targeting over the long term.  \n \n With t hat, I'll turn it back over to Mike.  ", "original_text": "With t hat, I'll turn it back over to Mike.  ", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "694061c259c16e66b1b7115955a9fbc4a738f1e4f608b2d6e3e94f9ace671d34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9f2d87c-52f6-40d3-a982-1c64623d53b6", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n", "original_text": "Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients. "}, "hash": "38a6c78a96e63fe4cbf8cea7cd9b1b98a6748e22755e3252450595107bfad2a1", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason. ", "start_char_idx": 0, "end_char_idx": 50, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9f2d87c-52f6-40d3-a982-1c64623d53b6": {"__data__": {"id_": "a9f2d87c-52f6-40d3-a982-1c64623d53b6", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n", "original_text": "Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cc2c8b7-b599-454a-92e0-b8667c83d6a2", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical. ", "original_text": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a789c4345e4d43a439502179bd9de686fc30130777e3b54901905acbab9d66f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a480df9c-cc8c-4f46-8331-e0c2f589c70b", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n", "original_text": "We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n"}, "hash": "e41de02997b05e2bdb57de58de4813017a1a96770a2167a2743cebfbaadcef68", "class_name": "RelatedNodeInfo"}}, "text": "Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients. ", "start_char_idx": 50, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a480df9c-cc8c-4f46-8331-e0c2f589c70b": {"__data__": {"id_": "a480df9c-cc8c-4f46-8331-e0c2f589c70b", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n", "original_text": "We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9f2d87c-52f6-40d3-a982-1c64623d53b6", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n", "original_text": "Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec9994d3b60cc98ea5f5e28a11f72e5c42d2610e73cb66cd4b231b6039a23a1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab4ca7da-c1b9-4f16-a44e-e5c734860335", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n", "original_text": "We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical. "}, "hash": "04e53ed83777ca4927e24fa27f3493d2096ad833fb1cc2a7fc013e426cd1f1c5", "class_name": "RelatedNodeInfo"}}, "text": "We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n", "start_char_idx": 250, "end_char_idx": 380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab4ca7da-c1b9-4f16-a44e-e5c734860335": {"__data__": {"id_": "ab4ca7da-c1b9-4f16-a44e-e5c734860335", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n", "original_text": "We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a480df9c-cc8c-4f46-8331-e0c2f589c70b", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n", "original_text": "We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "100994c010758df76f8d6dfbf70246299c4a58fea70332429a4284bbdc0066fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e012d16f-4e6a-4f98-8e77-75174126e5dd", "node_type": "1", "metadata": {"window": "Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth. ", "original_text": "These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n"}, "hash": "fa0f30df5881a13404a3b745ef9bae3b5a7af9e8ac53ac535e19c127db05cbe4", "class_name": "RelatedNodeInfo"}}, "text": "We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical. ", "start_char_idx": 380, "end_char_idx": 495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e012d16f-4e6a-4f98-8e77-75174126e5dd": {"__data__": {"id_": "e012d16f-4e6a-4f98-8e77-75174126e5dd", "embedding": null, "metadata": {"window": "Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth. ", "original_text": "These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab4ca7da-c1b9-4f16-a44e-e5c734860335", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n", "original_text": "We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5889fa3fa80defe760b937e2e4e74064a57002eb41fdff8ac50edba4d0f826b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee1eeeb2-fd07-442b-83c7-4c3b93bcc6a8", "node_type": "1", "metadata": {"window": "We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint. ", "original_text": "Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n"}, "hash": "c00d31085bb4ad5e0664ca962f971aad67a36a0411e063c67122fdcf5715913f", "class_name": "RelatedNodeInfo"}}, "text": "These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n", "start_char_idx": 495, "end_char_idx": 649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee1eeeb2-fd07-442b-83c7-4c3b93bcc6a8": {"__data__": {"id_": "ee1eeeb2-fd07-442b-83c7-4c3b93bcc6a8", "embedding": null, "metadata": {"window": "We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint. ", "original_text": "Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e012d16f-4e6a-4f98-8e77-75174126e5dd", "node_type": "1", "metadata": {"window": "Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth. ", "original_text": "These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83a2cb3f87aeac6ce5bede455400572cae8e31f679820473288d21cd968be64b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b684b163-579b-42e7-99df-2d645ce0d9a7", "node_type": "1", "metadata": {"window": "We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage. ", "original_text": "First, we are simplifying our operating model . \n \n"}, "hash": "0b1378d26382de3a111ecb95bd5e33f57cbe27475043e5c12b5dc5a8348b05d0", "class_name": "RelatedNodeInfo"}}, "text": "Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n", "start_char_idx": 649, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b684b163-579b-42e7-99df-2d645ce0d9a7": {"__data__": {"id_": "b684b163-579b-42e7-99df-2d645ce0d9a7", "embedding": null, "metadata": {"window": "We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage. ", "original_text": "First, we are simplifying our operating model . \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee1eeeb2-fd07-442b-83c7-4c3b93bcc6a8", "node_type": "1", "metadata": {"window": "We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint. ", "original_text": "Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3174f2cb30d03a8cf5c63303e9aa1fa5d7354fd8fe93a5947c4895d3901d085d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8053db17-c266-47e2-8560-6f4389966deb", "node_type": "1", "metadata": {"window": "These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.  ", "original_text": "We continue to take decisive action to reposition  the business for growth. "}, "hash": "477438489483ce0ecb3463f6030bba93a99da8958ac1e7d83453717ab6231bda", "class_name": "RelatedNodeInfo"}}, "text": "First, we are simplifying our operating model . \n \n", "start_char_idx": 857, "end_char_idx": 908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8053db17-c266-47e2-8560-6f4389966deb": {"__data__": {"id_": "8053db17-c266-47e2-8560-6f4389966deb", "embedding": null, "metadata": {"window": "These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.  ", "original_text": "We continue to take decisive action to reposition  the business for growth. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b684b163-579b-42e7-99df-2d645ce0d9a7", "node_type": "1", "metadata": {"window": "We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical.  These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage. ", "original_text": "First, we are simplifying our operating model . \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50f66a0703f4019bdf68fff49c4502af0eec1204988046a22c31beae674b25a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1c5ae66-8f30-4fe8-9741-dca1de98a62e", "node_type": "1", "metadata": {"window": "Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n", "original_text": "We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint. "}, "hash": "95915c4340d74ca3622bfb526b41a4961e7d0bd4a52038f062ec2b54390b9ef5", "class_name": "RelatedNodeInfo"}}, "text": "We continue to take decisive action to reposition  the business for growth. ", "start_char_idx": 908, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1c5ae66-8f30-4fe8-9741-dca1de98a62e": {"__data__": {"id_": "d1c5ae66-8f30-4fe8-9741-dca1de98a62e", "embedding": null, "metadata": {"window": "Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n", "original_text": "We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8053db17-c266-47e2-8560-6f4389966deb", "node_type": "1", "metadata": {"window": "These ac tions include pricing adjustments, cutting additional costs  throughout \nthe organization  and accelerating additional growth opportunities.  \n \n Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.  ", "original_text": "We continue to take decisive action to reposition  the business for growth. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abb6acea3956b38240250f584a70524513041a5ab4b2180beadd6c6b142480c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c814e47-5143-4e0f-b553-8437b1791db2", "node_type": "1", "metadata": {"window": "First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n", "original_text": "We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage. "}, "hash": "c61e53212025e053f57e7eb0da3af581328a3879d65ff06d562dce524a577e40", "class_name": "RelatedNodeInfo"}}, "text": "We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint. ", "start_char_idx": 984, "end_char_idx": 1096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c814e47-5143-4e0f-b553-8437b1791db2": {"__data__": {"id_": "7c814e47-5143-4e0f-b553-8437b1791db2", "embedding": null, "metadata": {"window": "First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n", "original_text": "We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1c5ae66-8f30-4fe8-9741-dca1de98a62e", "node_type": "1", "metadata": {"window": "Outside of a continual focus on the customer, we are directing our efforts to  3 main areas  that will \nsupport our lo ng-term target of mid -single to high -single  digit growth for the Medical segment . \n \n First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n", "original_text": "We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62d79147634b2364efaab533780871742f693e096dc8a7f5d704a107d588d39b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c3877a4-1554-4b89-98c4-9c8f4664c538", "node_type": "1", "metadata": {"window": "We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n", "original_text": "Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.  "}, "hash": "0929072fe601664feed3bacc6ef09a27b5652b191e229350fae8c2f29265480d", "class_name": "RelatedNodeInfo"}}, "text": "We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage. ", "start_char_idx": 1096, "end_char_idx": 1253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c3877a4-1554-4b89-98c4-9c8f4664c538": {"__data__": {"id_": "6c3877a4-1554-4b89-98c4-9c8f4664c538", "embedding": null, "metadata": {"window": "We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n", "original_text": "Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.  ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c814e47-5143-4e0f-b553-8437b1791db2", "node_type": "1", "metadata": {"window": "First, we are simplifying our operating model . \n \n We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n", "original_text": "We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66fdeb2b16b354cca4f4a3fe1dc78212a7e5b12219e58eccba4debedcbde2bbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ebab35b-5b9f-4fbf-94aa-a190084665c1", "node_type": "1", "metadata": {"window": "We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential. ", "original_text": "We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n"}, "hash": "009e3761df80aba3669887bc54771b46e145403907aefea2dc7df5556897c5b6", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.  ", "start_char_idx": 1253, "end_char_idx": 1380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ebab35b-5b9f-4fbf-94aa-a190084665c1": {"__data__": {"id_": "2ebab35b-5b9f-4fbf-94aa-a190084665c1", "embedding": null, "metadata": {"window": "We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential. ", "original_text": "We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c3877a4-1554-4b89-98c4-9c8f4664c538", "node_type": "1", "metadata": {"window": "We continue to take decisive action to reposition  the business for growth.  We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n", "original_text": "Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.  ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35269c4f8e7447ff58bd5da9aa873d4ef2d863c831aec5ac198c096dd8cb7e7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "740a3194-bfec-4786-99f6-86eab90207de", "node_type": "1", "metadata": {"window": "We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S. ", "original_text": "Second, we are focused on driving mix through commercial excellence . \n \n"}, "hash": "18b9c1c1dd830eac4040abb3c3757d4712ce3cc0743e05b36ab42429ace0def7", "class_name": "RelatedNodeInfo"}}, "text": "We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n", "start_char_idx": 1380, "end_char_idx": 1551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "740a3194-bfec-4786-99f6-86eab90207de": {"__data__": {"id_": "740a3194-bfec-4786-99f6-86eab90207de", "embedding": null, "metadata": {"window": "We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S. ", "original_text": "Second, we are focused on driving mix through commercial excellence . \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ebab35b-5b9f-4fbf-94aa-a190084665c1", "node_type": "1", "metadata": {"window": "We divested the Cordis \nbusiness and have begun si gnificantly reducing our international commercial footprint.  We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential. ", "original_text": "We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "296b8ed0be3fc192960396ce67f79f7088504756a568d2efa723fceaa1fdd636", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b11e6fc9-012b-43a4-8bc2-bff4125b33a4", "node_type": "1", "metadata": {"window": "Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.  ", "original_text": "Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n"}, "hash": "d55c6f9a021d1b1e6a533b72ce9fd9f97d7520cd99fc767159204116d96fbc7f", "class_name": "RelatedNodeInfo"}}, "text": "Second, we are focused on driving mix through commercial excellence . \n \n", "start_char_idx": 1551, "end_char_idx": 1624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b11e6fc9-012b-43a4-8bc2-bff4125b33a4": {"__data__": {"id_": "b11e6fc9-012b-43a4-8bc2-bff4125b33a4", "embedding": null, "metadata": {"window": "Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.  ", "original_text": "Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "740a3194-bfec-4786-99f6-86eab90207de", "node_type": "1", "metadata": {"window": "We have \nannounced and are in the process of exiting 36 initial markets, which will allow us to focus on the \nmarkets where we have a competitive advantage.  Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S. ", "original_text": "Second, we are focused on driving mix through commercial excellence . \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99de7172c86eef5761ac4c5a0bc6d3c49dc2bb5b00a92e6eac0068b501eda596", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16f85ef1-2037-4416-9f31-c0dfd7da636d", "node_type": "1", "metadata": {"window": "We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n", "original_text": "While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential. "}, "hash": "2272e3b9df37bc20b72ea256bf66c2ed4fb358f203a1eaec008629dc5e38b04c", "class_name": "RelatedNodeInfo"}}, "text": "Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n", "start_char_idx": 1624, "end_char_idx": 1850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16f85ef1-2037-4416-9f31-c0dfd7da636d": {"__data__": {"id_": "16f85ef1-2037-4416-9f31-c0dfd7da636d", "embedding": null, "metadata": {"window": "We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n", "original_text": "While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b11e6fc9-012b-43a4-8bc2-bff4125b33a4", "node_type": "1", "metadata": {"window": "Additionally, we are further streamlinin g our \nMedical  manufacturing footprint and modernizing our distribution facilities.   We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.  ", "original_text": "Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1dfd86aeaf6eea08c81319b0424c11ba89969b8627b9074d21f76ebb22551537", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f9cb17e-2a18-4583-835e-44a6c39fb36f", "node_type": "1", "metadata": {"window": "Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n", "original_text": "An increase in private  label penetration across our U.S. "}, "hash": "7c88a3cd3b90ab6b0e84b014bc34c2973d7355e563eb0875504dcf83aba3dcd2", "class_name": "RelatedNodeInfo"}}, "text": "While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential. ", "start_char_idx": 1850, "end_char_idx": 2055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f9cb17e-2a18-4583-835e-44a6c39fb36f": {"__data__": {"id_": "5f9cb17e-2a18-4583-835e-44a6c39fb36f", "embedding": null, "metadata": {"window": "Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n", "original_text": "An increase in private  label penetration across our U.S. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16f85ef1-2037-4416-9f31-c0dfd7da636d", "node_type": "1", "metadata": {"window": "We expect these \nsimplification initiatives to contribute to our $750 million enterprise cost savings target and position us \nto generate sustained long -term growth.  \n \n Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n", "original_text": "While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c289ec752effc0ee04a24e1eb8891d97ed3796d36205c3a15630d8504025d9cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f432a4d-33f1-469d-91cc-f4b054f4fb9a", "node_type": "1", "metadata": {"window": "Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.  ", "original_text": "and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.  "}, "hash": "c3cd43d63b66d9c11898955f9e24d3beed46b68ae936ce5643d524ca4703e027", "class_name": "RelatedNodeInfo"}}, "text": "An increase in private  label penetration across our U.S. ", "start_char_idx": 2055, "end_char_idx": 2113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f432a4d-33f1-469d-91cc-f4b054f4fb9a": {"__data__": {"id_": "7f432a4d-33f1-469d-91cc-f4b054f4fb9a", "embedding": null, "metadata": {"window": "Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.  ", "original_text": "and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.  ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f9cb17e-2a18-4583-835e-44a6c39fb36f", "node_type": "1", "metadata": {"window": "Second, we are focused on driving mix through commercial excellence . \n \n Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n", "original_text": "An increase in private  label penetration across our U.S. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4eab546d62e9d558229f5f39e076ad52b51b92271a8a58f2c9200bc0122b486c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "694bbdc0-e424-4ecf-ae9e-162568a42059", "node_type": "1", "metadata": {"window": "While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n", "original_text": "As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n"}, "hash": "6a23055cc7a30215ac7047c82a83d2958c7e03ed0b5aa4d28906d9283f69247c", "class_name": "RelatedNodeInfo"}}, "text": "and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.  ", "start_char_idx": 2113, "end_char_idx": 2260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "694bbdc0-e424-4ecf-ae9e-162568a42059": {"__data__": {"id_": "694bbdc0-e424-4ecf-ae9e-162568a42059", "embedding": null, "metadata": {"window": "While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n", "original_text": "As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f432a4d-33f1-469d-91cc-f4b054f4fb9a", "node_type": "1", "metadata": {"window": "Our Cardinal brand portfolio has significant breadth , with leading brands and clinically differentiated \nproducts such as Kendall \u2122 compression, Kangaroo\u2122  enteral feeding , and Protexis \u2122 surgical \ngloves, among others.  \n \n While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.  ", "original_text": "and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.  ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1224dfe8b778cb8f6e8ab374c4875a13fc0c20c2b4b81cbb15360685a084be8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6df3bc89-0f8c-4041-9cde-12eefdd7c826", "node_type": "1", "metadata": {"window": "An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n"}, "hash": "ff420af8c64a0540184405f5a0ce4c52ac03c1e12f412e82c2b5335986c2e331", "class_name": "RelatedNodeInfo"}}, "text": "As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n", "start_char_idx": 2260, "end_char_idx": 2427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6df3bc89-0f8c-4041-9cde-12eefdd7c826": {"__data__": {"id_": "6df3bc89-0f8c-4041-9cde-12eefdd7c826", "embedding": null, "metadata": {"window": "An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "694bbdc0-e424-4ecf-ae9e-162568a42059", "node_type": "1", "metadata": {"window": "While we have made important changes to align our commercial organization\u2019s  structure and \nincentives, we recognize that we are under -penetrated  in Cardinal Health brand mix relative to our \npotential.  An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n", "original_text": "As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "256040ab4835dfc0bcf2a14189234ea34370b3bca1604759dbdce456f906bf54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f22d055-e32e-4101-a09b-3ffa9719997f", "node_type": "1", "metadata": {"window": "and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.  "}, "hash": "5cda675ec6c014f0c1b7bd508154fb7968c7f5b3d74cec9d297e7f53fab88c79", "class_name": "RelatedNodeInfo"}}, "text": "And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n", "start_char_idx": 2427, "end_char_idx": 2592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f22d055-e32e-4101-a09b-3ffa9719997f": {"__data__": {"id_": "3f22d055-e32e-4101-a09b-3ffa9719997f", "embedding": null, "metadata": {"window": "and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.  ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6df3bc89-0f8c-4041-9cde-12eefdd7c826", "node_type": "1", "metadata": {"window": "An increase in private  label penetration across our U.S.  and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00396032e1b5ed8a6cdf6f15f48c4312b8226dade3952c7d548fc5747abff7e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "501635b6-7af0-43f5-b0f4-31f543ec217e", "node_type": "1", "metadata": {"window": "As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n"}, "hash": "92f9ba5ea3d07b353f3a2f55666af21eac9ddf3d7d36e0112c6c600db8e6b589", "class_name": "RelatedNodeInfo"}}, "text": "These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.  ", "start_char_idx": 2592, "end_char_idx": 2738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "501635b6-7af0-43f5-b0f4-31f543ec217e": {"__data__": {"id_": "501635b6-7af0-43f5-b0f4-31f543ec217e", "embedding": null, "metadata": {"window": "As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f22d055-e32e-4101-a09b-3ffa9719997f", "node_type": "1", "metadata": {"window": "and in-channel customer base \nrepresents a significant profit opportunity , with even further  opportunities out of channel and \ninternationally.   As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.  ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88296e95ebcb6f80070d6f4d18b7f6f4063f140262a0937cb5f5977ed5526a9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf625c55-8ebe-493b-88f7-3eb39cee431d", "node_type": "1", "metadata": {"window": "And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "In OptiFreight , we continue to expand our customer base and offerings.  "}, "hash": "8699d945ded556443ffda958bd4c16df252bd3cba25fbc204b29c28a0dbb1088", "class_name": "RelatedNodeInfo"}}, "text": "We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n", "start_char_idx": 2738, "end_char_idx": 2862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf625c55-8ebe-493b-88f7-3eb39cee431d": {"__data__": {"id_": "bf625c55-8ebe-493b-88f7-3eb39cee431d", "embedding": null, "metadata": {"window": "And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "In OptiFreight , we continue to expand our customer base and offerings.  ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ddcc55714be69b5d57fdc802924709f68f3df7aa5ab1bb80f5d6ba60704bd23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "501635b6-7af0-43f5-b0f4-31f543ec217e", "node_type": "1", "metadata": {"window": "As we move past the pandemic, we see this as a significant opportunity to both deliver \nsavings for our customers and grow our business over the mid to long term.  \n \n And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "118b8ba4984bc0fa1427091019c59c9c256b839c131e7824e00e5f25740ef460", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08064886-17bd-4ae6-86d2-925ba7cae5ff", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n", "original_text": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home. "}, "hash": "8a68f470bbcd89cd48db6e1668ba44eb5740af6500a93338a4a01d0c05ffcfc0", "class_name": "RelatedNodeInfo"}}, "text": "In OptiFreight , we continue to expand our customer base and offerings.  ", "start_char_idx": 2862, "end_char_idx": 2935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08064886-17bd-4ae6-86d2-925ba7cae5ff": {"__data__": {"id_": "08064886-17bd-4ae6-86d2-925ba7cae5ff", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n", "original_text": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf625c55-8ebe-493b-88f7-3eb39cee431d", "node_type": "1", "metadata": {"window": "And third, we're  fueling our Medical segme nt growth businesses  \u2013 at-Home Solutions and Medical \nServices, which includes OptiFreight Logistics and WaveMark.   \n \n These growth businesses are aligned with industry trends  and positioned to capture market share \nand grow double -digits in FY '22  and beyond.   We continue to invest in technology enhancements and \ninnovative solutions that give our businesses a competitive edge.  \n \n In OptiFreight , we continue to expand our customer base and offerings.  ", "original_text": "In OptiFreight , we continue to expand our customer base and offerings.  ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "377bb0098eac22b3f1c2daf8e994d6539378dd0095248cbd513e45bf134474f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "499e4c14-c429-4cc7-b8d1-90628aed4aed", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base . ", "original_text": "We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n"}, "hash": "83d347164b0b96b1a742682f8676b832c9afeeaa54375ed5af619680579fde9a", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home. ", "start_char_idx": 0, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "499e4c14-c429-4cc7-b8d1-90628aed4aed": {"__data__": {"id_": "499e4c14-c429-4cc7-b8d1-90628aed4aed", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base . ", "original_text": "We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08064886-17bd-4ae6-86d2-925ba7cae5ff", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n", "original_text": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90d67ee26e4229363d65b53a7942c2e736efb6c5c2e3ac66a581122dc406e45a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95471064-3936-48d1-9e8c-94723ad765db", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities. ", "original_text": "Moving to Pharma . "}, "hash": "9b6b594ade1ccb10ce4e6aa865acf8dd59f04de7e5f33c3d591490a04d30f803", "class_name": "RelatedNodeInfo"}}, "text": "We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n", "start_char_idx": 158, "end_char_idx": 265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95471064-3936-48d1-9e8c-94723ad765db": {"__data__": {"id_": "95471064-3936-48d1-9e8c-94723ad765db", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities. ", "original_text": "Moving to Pharma . ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "499e4c14-c429-4cc7-b8d1-90628aed4aed", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base . ", "original_text": "We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53c4e737f8a25a9394d29e17b069836d6dfc17ebdb2bab0d5b6561b5927ead94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7ad6534-6cea-4631-8e64-3f3235999be4", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n", "original_text": "We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n"}, "hash": "28ddfa87048c1f3803544138576aeecd08d87a5f9da461bcbaa8f8a0ee31fe07", "class_name": "RelatedNodeInfo"}}, "text": "Moving to Pharma . ", "start_char_idx": 265, "end_char_idx": 284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7ad6534-6cea-4631-8e64-3f3235999be4": {"__data__": {"id_": "d7ad6534-6cea-4631-8e64-3f3235999be4", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n", "original_text": "We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95471064-3936-48d1-9e8c-94723ad765db", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities. ", "original_text": "Moving to Pharma . ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b900aa4142b044d605ebe2589f362918d3f726ff2813b9c92c1bf28bb545e624", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e9056c9-248a-4508-b48e-5f5fa8882eb2", "node_type": "1", "metadata": {"window": "We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect. ", "original_text": "We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base . "}, "hash": "eb9d92bbe07cbde145836cebe44a7532b76bd5dbff6edd66aa985cb214f3d08a", "class_name": "RelatedNodeInfo"}}, "text": "We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n", "start_char_idx": 284, "end_char_idx": 535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e9056c9-248a-4508-b48e-5f5fa8882eb2": {"__data__": {"id_": "6e9056c9-248a-4508-b48e-5f5fa8882eb2", "embedding": null, "metadata": {"window": "We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect. ", "original_text": "We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base . ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7ad6534-6cea-4631-8e64-3f3235999be4", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n", "original_text": "We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fac8b345f11eab645beaa7ea512a8adb746f7daf6615d98d142274b8f31261ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5160b103-8fd6-4da9-96f9-6fc21f96efd9", "node_type": "1", "metadata": {"window": "Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n", "original_text": "Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities. "}, "hash": "84e2e0755aa962ff064061cc141a6208ce09bad31d392814f9241796a928b8c3", "class_name": "RelatedNodeInfo"}}, "text": "We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base . ", "start_char_idx": 535, "end_char_idx": 667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5160b103-8fd6-4da9-96f9-6fc21f96efd9": {"__data__": {"id_": "5160b103-8fd6-4da9-96f9-6fc21f96efd9", "embedding": null, "metadata": {"window": "Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n", "original_text": "Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e9056c9-248a-4508-b48e-5f5fa8882eb2", "node_type": "1", "metadata": {"window": "We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect. ", "original_text": "We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base . ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8a45519e6b92e96e7dbe785453845f8ee360d3f2c83310fadbd8116530445f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d43cd42-2989-434c-bb6c-8a94f89a000a", "node_type": "1", "metadata": {"window": "We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies. ", "original_text": "Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n"}, "hash": "5891babb6ce1bf128392b731435f2ae1ea6c87ec01a158ca8f7f5c3afb682617", "class_name": "RelatedNodeInfo"}}, "text": "Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities. ", "start_char_idx": 667, "end_char_idx": 986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d43cd42-2989-434c-bb6c-8a94f89a000a": {"__data__": {"id_": "8d43cd42-2989-434c-bb6c-8a94f89a000a", "embedding": null, "metadata": {"window": "We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies. ", "original_text": "Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5160b103-8fd6-4da9-96f9-6fc21f96efd9", "node_type": "1", "metadata": {"window": "Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n", "original_text": "Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56956dc4ab9645934ebd3ce279005a4b68474bbb304798381e90df1b8a3a05b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f60f2f42-cbf5-4c74-994b-4917add9dc2d", "node_type": "1", "metadata": {"window": "We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n", "original_text": "Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect. "}, "hash": "c6ae19fec259bbde8651d6f6c7ea2f772346c05d71b49351369f923f21fb9d5a", "class_name": "RelatedNodeInfo"}}, "text": "Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n", "start_char_idx": 986, "end_char_idx": 1103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f60f2f42-cbf5-4c74-994b-4917add9dc2d": {"__data__": {"id_": "f60f2f42-cbf5-4c74-994b-4917add9dc2d", "embedding": null, "metadata": {"window": "We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n", "original_text": "Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d43cd42-2989-434c-bb6c-8a94f89a000a", "node_type": "1", "metadata": {"window": "We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies. ", "original_text": "Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f9c86b291093ff5d06e41ec59d186c58fe7ac0553a82f9726fc2a0469a75c71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc818b24-f455-4b6c-b93c-265722789ffd", "node_type": "1", "metadata": {"window": "Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years . ", "original_text": "Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n"}, "hash": "deae836a4edf5ecec898b6f458dae8ba418acfbcdd8000f6beb83b51a1158619", "class_name": "RelatedNodeInfo"}}, "text": "Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect. ", "start_char_idx": 1103, "end_char_idx": 1218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc818b24-f455-4b6c-b93c-265722789ffd": {"__data__": {"id_": "cc818b24-f455-4b6c-b93c-265722789ffd", "embedding": null, "metadata": {"window": "Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years . ", "original_text": "Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f60f2f42-cbf5-4c74-994b-4917add9dc2d", "node_type": "1", "metadata": {"window": "We will contin ue to strengthen our core business by focusing in 3 primary areas : \n \nFirst, supporting our diverse customer base .  Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n", "original_text": "Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "595803077de03a241d2cea3774f33d51acc81e8d61ae3488593151bd1eef4825", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e44ef599-e3ae-47e7-af91-c5e835a105a5", "node_type": "1", "metadata": {"window": "Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n", "original_text": "Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies. "}, "hash": "0d71c9f43ca1340b6c97d833cf3da29999e3320e5ce933dfc46cfb9970981fcd", "class_name": "RelatedNodeInfo"}}, "text": "Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n", "start_char_idx": 1218, "end_char_idx": 1364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e44ef599-e3ae-47e7-af91-c5e835a105a5": {"__data__": {"id_": "e44ef599-e3ae-47e7-af91-c5e835a105a5", "embedding": null, "metadata": {"window": "Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n", "original_text": "Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc818b24-f455-4b6c-b93c-265722789ffd", "node_type": "1", "metadata": {"window": "Over 50 years, we\u2019ve  honed our distribution expertise \nand developed  a strong customer base across multiple classes of trade , with leaders in ch ain \npharmacy, direct mail order, grocery , and retail independent customers, all of whom play critical roles \nin providing healthcare  access to their local communities.  Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years . ", "original_text": "Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acc6ee1b4471707801f2971843223459c1a335d663dd3cdfc7f5cddafeb36408", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b53e241e-77d1-4087-9852-54241f91287b", "node_type": "1", "metadata": {"window": "Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth. ", "original_text": "We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n"}, "hash": "1df1184825a8d752154bb8687ef192f31b61794a15f4bc4b43e4d1b962c3aa51", "class_name": "RelatedNodeInfo"}}, "text": "Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies. ", "start_char_idx": 1364, "end_char_idx": 1477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b53e241e-77d1-4087-9852-54241f91287b": {"__data__": {"id_": "b53e241e-77d1-4087-9852-54241f91287b", "embedding": null, "metadata": {"window": "Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth. ", "original_text": "We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e44ef599-e3ae-47e7-af91-c5e835a105a5", "node_type": "1", "metadata": {"window": "Along those lines, during the quarter we \nextended our distribution agreements  with CVS H ealth through FY '27 . \n \n Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n", "original_text": "Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1a93c351107f586068d52f80d0fcde1b12ef19ab660f6b5d4676038c309d60e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e76d7a1-956a-401c-b8cf-38ac4d8e3bad", "node_type": "1", "metadata": {"window": "Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment. ", "original_text": "As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years . "}, "hash": "eccd4328f4f125b8c87fa22532d1468530a7689548ad4b62cfb5c0a3a2d22608", "class_name": "RelatedNodeInfo"}}, "text": "We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n", "start_char_idx": 1477, "end_char_idx": 1668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e76d7a1-956a-401c-b8cf-38ac4d8e3bad": {"__data__": {"id_": "0e76d7a1-956a-401c-b8cf-38ac4d8e3bad", "embedding": null, "metadata": {"window": "Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment. ", "original_text": "As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years . ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b53e241e-77d1-4087-9852-54241f91287b", "node_type": "1", "metadata": {"window": "Second, we're  managing our generics program  to ensure consistent dynamics, which we continue to \nsee and expect.  Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth. ", "original_text": "We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "224d91c0f1eb7093d4116e156e634c53475769bb3f1469e6f8b34c239a668375", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b42441e6-508b-4066-adfb-7577247ec2a2", "node_type": "1", "metadata": {"window": "Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n", "original_text": "And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n"}, "hash": "6f550b0ecd145f96d00ddde4141abebbac4d26b3566be35041083a4eb440dce3", "class_name": "RelatedNodeInfo"}}, "text": "As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years . ", "start_char_idx": 1668, "end_char_idx": 1848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b42441e6-508b-4066-adfb-7577247ec2a2": {"__data__": {"id_": "b42441e6-508b-4066-adfb-7577247ec2a2", "embedding": null, "metadata": {"window": "Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n", "original_text": "And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e76d7a1-956a-401c-b8cf-38ac4d8e3bad", "node_type": "1", "metadata": {"window": "Our generics program is anchored by the scale and expertise of Red Oak Sourcing  \u2013 \na partnership we also recently extended , through FY '29.  \n \n Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment. ", "original_text": "As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years . ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa9bf6c0b7a281b60ed426b9c78938af2e23eab98aa0888c8b63befff0b9eb7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a651dd4-7d71-4232-89a7-e86f54f2a6ba", "node_type": "1", "metadata": {"window": "We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n", "original_text": "In Specialty, key downstream and upstream initiatives will enable our growth. "}, "hash": "817b5c43350e0a4cdb0c6a00678b7086b2aabeea34f785238bf041d02ad06c12", "class_name": "RelatedNodeInfo"}}, "text": "And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n", "start_char_idx": 1848, "end_char_idx": 1950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a651dd4-7d71-4232-89a7-e86f54f2a6ba": {"__data__": {"id_": "4a651dd4-7d71-4232-89a7-e86f54f2a6ba", "embedding": null, "metadata": {"window": "We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n", "original_text": "In Specialty, key downstream and upstream initiatives will enable our growth. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b42441e6-508b-4066-adfb-7577247ec2a2", "node_type": "1", "metadata": {"window": "Third, we've  been investing heavily in our tech nology  to enhance customer experience and drive \nefficiencies.  We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n", "original_text": "And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6588aed6b1fd78e5f7d0307b2f06c7de295246272aca9b2916aeb26248b613da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71160d8c-e606-42f9-a4f3-69e8c8b1c3f6", "node_type": "1", "metadata": {"window": "As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product. ", "original_text": "In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment. "}, "hash": "5174cce4ab2a8fa75d0e3cf0e5dd1bfda86bcf0fcbce80924b027f2f501b5182", "class_name": "RelatedNodeInfo"}}, "text": "In Specialty, key downstream and upstream initiatives will enable our growth. ", "start_char_idx": 1950, "end_char_idx": 2028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71160d8c-e606-42f9-a4f3-69e8c8b1c3f6": {"__data__": {"id_": "71160d8c-e606-42f9-a4f3-69e8c8b1c3f6", "embedding": null, "metadata": {"window": "As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product. ", "original_text": "In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a651dd4-7d71-4232-89a7-e86f54f2a6ba", "node_type": "1", "metadata": {"window": "We are approaching the end of a multi -year investment journey to modernize our IT \ninfrastructure, which will yield meaningful working capital improvements and operational efficiencies.  \n \n As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n", "original_text": "In Specialty, key downstream and upstream initiatives will enable our growth. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4647aa4e93c64662f5750dec4a9cc6096e4e8fe241ba3a6888b92ad4cb6835c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "311a3b80-ab37-4776-9351-54b1e66f9a1f", "node_type": "1", "metadata": {"window": "And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n", "original_text": "We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n"}, "hash": "dd21576b89d87089d9e1914c152512ebc43f089c5292f6a2877291bf4a283cff", "class_name": "RelatedNodeInfo"}}, "text": "In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment. ", "start_char_idx": 2028, "end_char_idx": 2256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "311a3b80-ab37-4776-9351-54b1e66f9a1f": {"__data__": {"id_": "311a3b80-ab37-4776-9351-54b1e66f9a1f", "embedding": null, "metadata": {"window": "And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n", "original_text": "We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71160d8c-e606-42f9-a4f3-69e8c8b1c3f6", "node_type": "1", "metadata": {"window": "As for o ur second overall Pharma objective, fueling our growth businesses, we continue to expect \nthese 3 businesses to realize double -digit growth over the next several years .  And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product. ", "original_text": "In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e3375052c896f968fe9d638a394adcf8dc90a42594c309f14e66f80cb8dd691", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf6664df-de70-409e-87ea-90f552c132ea", "node_type": "1", "metadata": {"window": "In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.  ", "original_text": "We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n"}, "hash": "f34c43c790d5676467ca797c4b2b3bc949337d18577c322ffe285ae6ecec9413", "class_name": "RelatedNodeInfo"}}, "text": "We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n", "start_char_idx": 2256, "end_char_idx": 2414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf6664df-de70-409e-87ea-90f552c132ea": {"__data__": {"id_": "bf6664df-de70-409e-87ea-90f552c132ea", "embedding": null, "metadata": {"window": "In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.  ", "original_text": "We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "311a3b80-ab37-4776-9351-54b1e66f9a1f", "node_type": "1", "metadata": {"window": "And, as these \nbusinesses grow, they will become a bigger portion of the overall Pharma s egment.  \n \n In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n", "original_text": "We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24ee5b2c566bb70e5da5c432e58a4d38063fdac8fc91bf05a38cbe1ea24ddb37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d571119-97c2-450a-bea3-ce9222f847ce", "node_type": "1", "metadata": {"window": "In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product. "}, "hash": "00ca97671dd84bec26a6a8c9616971bbe0f5e0b7a74fabe75001dd6e49c67f92", "class_name": "RelatedNodeInfo"}}, "text": "We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n", "start_char_idx": 2414, "end_char_idx": 2568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d571119-97c2-450a-bea3-ce9222f847ce": {"__data__": {"id_": "8d571119-97c2-450a-bea3-ce9222f847ce", "embedding": null, "metadata": {"window": "In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf6664df-de70-409e-87ea-90f552c132ea", "node_type": "1", "metadata": {"window": "In Specialty, key downstream and upstream initiatives will enable our growth.  In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.  ", "original_text": "We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9522c12e4b6ddb19855c556e3c887ea39e1335c5cb1a98864f0b43fc2bffd99e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88064374-bb66-4f1e-844d-bcbd1828a2c6", "node_type": "1", "metadata": {"window": "We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n"}, "hash": "fc54bc3067920c9c5c2d228b5dec79ac7fd9ab76e5d2b1348c6dafe24e90bd7d", "class_name": "RelatedNodeInfo"}}, "text": "We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product. ", "start_char_idx": 2568, "end_char_idx": 2754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88064374-bb66-4f1e-844d-bcbd1828a2c6": {"__data__": {"id_": "88064374-bb66-4f1e-844d-bcbd1828a2c6", "embedding": null, "metadata": {"window": "We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d571119-97c2-450a-bea3-ce9222f847ce", "node_type": "1", "metadata": {"window": "In Oncology , we are \ncompeting differently downstream by transforming from a distribution -led orientation to a focus on \nsupporting independent oncology practices with sol utions to thrive in a value -based care \nenvironment.  We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b21facb783e32fa3662776c40c7fb097f512a9b8ff417558659a868ca5a16a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a318eb6-36a3-4a0a-9567-54d1dd885904", "node_type": "1", "metadata": {"window": "We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.  "}, "hash": "8488b0d8c7a994ffaa540941196fd6286a7d857ce80f598a2d3a2bc677d7549a", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n", "start_char_idx": 2754, "end_char_idx": 2882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a318eb6-36a3-4a0a-9567-54d1dd885904": {"__data__": {"id_": "5a318eb6-36a3-4a0a-9567-54d1dd885904", "embedding": null, "metadata": {"window": "We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.  ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88064374-bb66-4f1e-844d-bcbd1828a2c6", "node_type": "1", "metadata": {"window": "We are seeing commercial momentum with Navista TS, our technology platform that \nhelps oncology practices improve their performance in value -based care.  \n \n We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d9bc356c7a872f33b490e4e9663772c62303dcc7d9139c367d7060c6b1cf83e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4895ead-c3f8-4ed4-bd03-415c0b823c38", "node_type": "1", "metadata": {"window": "We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  "}, "hash": "3a1fe015f332135430f73018de9579a0f0ac6d4836ca6b551c4a76d94eafd8ef", "class_name": "RelatedNodeInfo"}}, "text": "Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.  ", "start_char_idx": 2882, "end_char_idx": 2990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4895ead-c3f8-4ed4-bd03-415c0b823c38": {"__data__": {"id_": "d4895ead-c3f8-4ed4-bd03-415c0b823c38", "embedding": null, "metadata": {"window": "We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177f5f0430d1e083f4668996a7be601852432c655eeee975a8349e57af67cfbd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a318eb6-36a3-4a0a-9567-54d1dd885904", "node_type": "1", "metadata": {"window": "We have a strong presence in other therapeutic areas, such as Rheumatology , which today is a $4 \nbillion distribution market growing double -digits.  \n \n We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.  ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14763c603ae9fb449b3922eece5925d4ee6c3ca660070a28b542afb1e72762f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22274283-5acd-4d92-8322-5385a7302db3", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n", "original_text": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.  "}, "hash": "fea131468825981547578b275a4ea7d391c34d17bc01d42f4e487b9edff1de97", "class_name": "RelatedNodeInfo"}}, "text": "We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "start_char_idx": 2990, "end_char_idx": 3171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22274283-5acd-4d92-8322-5385a7302db3": {"__data__": {"id_": "22274283-5acd-4d92-8322-5385a7302db3", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n", "original_text": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.  ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4895ead-c3f8-4ed4-bd03-415c0b823c38", "node_type": "1", "metadata": {"window": "We are also encouraged by the anticipated growth in biosimilars as more products come to market , \nsuch as the  FDA\u2019s  approval for the first interchangeable biosimilar insulin product.  We\u2019re  well \npositioned to support the next phase of biosimilar growth as adoption increases in areas outside of \noncology.  \n \n Upstream, we are expecting strong growth from higher -margin services supporting biopharma \nmanufacturers.   We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "original_text": "We operate a leading 3PL supporting hundreds of manufacturers that continues  to \nsee wins and support new products coming to market, such as in the area of cell and gene therapy.  ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3da2b0c470c5ccc3008692d604d764970eb32915972561bda15f86de4d262479", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1af5a485-4139-4f3d-8143-675bb9fecf83", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth. ", "original_text": "We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities. "}, "hash": "56a463a4ac01164b30fee571b99ebf0d6dd8797978d318b9b8bdd37dad556606", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.  ", "start_char_idx": 0, "end_char_idx": 157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1af5a485-4139-4f3d-8143-675bb9fecf83": {"__data__": {"id_": "1af5a485-4139-4f3d-8143-675bb9fecf83", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth. ", "original_text": "We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22274283-5acd-4d92-8322-5385a7302db3", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n", "original_text": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.  ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fb5ffd2d4ab143d72aedbc6c240ee2ed201008b8df0004385ce633c81884d73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ec754da-e027-4986-ae22-0603ddef5de0", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n", "original_text": "We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n"}, "hash": "8d5ad8900f82f6f956b653b1a7bf092fbcf4e3916c208cc2006ae36002705cb5", "class_name": "RelatedNodeInfo"}}, "text": "We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities. ", "start_char_idx": 157, "end_char_idx": 312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ec754da-e027-4986-ae22-0603ddef5de0": {"__data__": {"id_": "7ec754da-e027-4986-ae22-0603ddef5de0", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n", "original_text": "We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1af5a485-4139-4f3d-8143-675bb9fecf83", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth. ", "original_text": "We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "833965c6a688db57031f781756edd81c09484cf08827436cbbb7e9412fcfa761", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "131cda9b-0cc7-42f8-9832-a1f54c9ba956", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation. ", "original_text": "For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n"}, "hash": "4cb2e968d87938e7f0843a9bab4c5d0bac4a599f5f5a546d21ac948083354714", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n", "start_char_idx": 312, "end_char_idx": 402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "131cda9b-0cc7-42f8-9832-a1f54c9ba956": {"__data__": {"id_": "131cda9b-0cc7-42f8-9832-a1f54c9ba956", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation. ", "original_text": "For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ec754da-e027-4986-ae22-0603ddef5de0", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n", "original_text": "We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a909cc6bdc089d00661a569379509573f356258f753ab7db3d388120e6b5d09f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81cc33b6-6b6a-48a2-82f5-27e8bc977706", "node_type": "1", "metadata": {"window": "We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n", "original_text": "And in Outcomes , we continue to see and expect strong growth. "}, "hash": "47ccb836a47ceeb46a0da518ce5f0bd02ed626364e9c317cc0db5d68b5482cbc", "class_name": "RelatedNodeInfo"}}, "text": "For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n", "start_char_idx": 402, "end_char_idx": 587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81cc33b6-6b6a-48a2-82f5-27e8bc977706": {"__data__": {"id_": "81cc33b6-6b6a-48a2-82f5-27e8bc977706", "embedding": null, "metadata": {"window": "We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n", "original_text": "And in Outcomes , we continue to see and expect strong growth. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "131cda9b-0cc7-42f8-9832-a1f54c9ba956", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation. ", "original_text": "For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0de9c8e05aac60e0cb39e9e777c1de17d4d9d32ee1e0ee90916795382ae84fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6cea530-0022-4849-a1a5-1463ca50ca4d", "node_type": "1", "metadata": {"window": "We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.  ", "original_text": "This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n"}, "hash": "bdb6045a63899e01826b79cd53a74ce926cd4d38dd03fb68e6e457ee58a579e6", "class_name": "RelatedNodeInfo"}}, "text": "And in Outcomes , we continue to see and expect strong growth. ", "start_char_idx": 587, "end_char_idx": 650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6cea530-0022-4849-a1a5-1463ca50ca4d": {"__data__": {"id_": "f6cea530-0022-4849-a1a5-1463ca50ca4d", "embedding": null, "metadata": {"window": "We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.  ", "original_text": "This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81cc33b6-6b6a-48a2-82f5-27e8bc977706", "node_type": "1", "metadata": {"window": "We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n", "original_text": "And in Outcomes , we continue to see and expect strong growth. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06e23a2aa99e243ff63ea8e262fb5da978acce1006929ec86f21784448b91a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bdf0b2d-251d-4eab-8794-e1342cbb967f", "node_type": "1", "metadata": {"window": "For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield. ", "original_text": "With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation. "}, "hash": "0c96d77bc869cad13cc9b3651622c26de124b1944423f83d26fe37d992c59b00", "class_name": "RelatedNodeInfo"}}, "text": "This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n", "start_char_idx": 650, "end_char_idx": 885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bdf0b2d-251d-4eab-8794-e1342cbb967f": {"__data__": {"id_": "6bdf0b2d-251d-4eab-8794-e1342cbb967f", "embedding": null, "metadata": {"window": "For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield. ", "original_text": "With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6cea530-0022-4849-a1a5-1463ca50ca4d", "node_type": "1", "metadata": {"window": "We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.  ", "original_text": "This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f57b68b8af2eddd851f47c0dd8e4860e85476f82585794d7312c5830448b9b47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef1bea6b-0eae-456f-8160-8cad49ef49e2", "node_type": "1", "metadata": {"window": "And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n", "original_text": "As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n"}, "hash": "93fc662c6ff9ede1b01e444a607fabaed667c92660bb847590b3d65f7c6f7e11", "class_name": "RelatedNodeInfo"}}, "text": "With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation. ", "start_char_idx": 885, "end_char_idx": 1079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef1bea6b-0eae-456f-8160-8cad49ef49e2": {"__data__": {"id_": "ef1bea6b-0eae-456f-8160-8cad49ef49e2", "embedding": null, "metadata": {"window": "And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n", "original_text": "As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bdf0b2d-251d-4eab-8794-e1342cbb967f", "node_type": "1", "metadata": {"window": "For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield. ", "original_text": "With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8830eddd0efcf868238aacd261b167cce229d744e792ea8fa9d77edc3e0b431c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd05a63e-b5e7-4fb9-bb5e-92037b4e1cb7", "node_type": "1", "metadata": {"window": "This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n", "original_text": "We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.  "}, "hash": "9e42457bbe1c7756b4350f3aeee05b159a693eb203f4465a34daf322e59436e1", "class_name": "RelatedNodeInfo"}}, "text": "As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n", "start_char_idx": 1079, "end_char_idx": 1236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd05a63e-b5e7-4fb9-bb5e-92037b4e1cb7": {"__data__": {"id_": "fd05a63e-b5e7-4fb9-bb5e-92037b4e1cb7", "embedding": null, "metadata": {"window": "This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n", "original_text": "We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.  ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef1bea6b-0eae-456f-8160-8cad49ef49e2", "node_type": "1", "metadata": {"window": "And in Outcomes , we continue to see and expect strong growth.  This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n", "original_text": "As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9534b614ed122eab9e2bb03f9f692499bd7f65b5e9f274aeafb8f1017a5b200", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2ca38fe-0bdb-4f15-9456-ffb1f6113f74", "node_type": "1", "metadata": {"window": "With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022. ", "original_text": "Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield. "}, "hash": "2f3a60015fcd45166d386b5dc7f2072392ae56a13c68e06df7d8770f89ae0169", "class_name": "RelatedNodeInfo"}}, "text": "We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.  ", "start_char_idx": 1236, "end_char_idx": 1465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2ca38fe-0bdb-4f15-9456-ffb1f6113f74": {"__data__": {"id_": "b2ca38fe-0bdb-4f15-9456-ffb1f6113f74", "embedding": null, "metadata": {"window": "With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022. ", "original_text": "Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd05a63e-b5e7-4fb9-bb5e-92037b4e1cb7", "node_type": "1", "metadata": {"window": "This business has added new \npayers and PBMs and is expanding clinical solutions for both independent pharmacies and re tail \nchains to include solutions for medical billing, point  of care testing and other clinical capabilities.  \n \n With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n", "original_text": "We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.  ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "378dc73494c99613b17e22a45c38aaae5b735a7a35c0084fe6dbdf20a7b961c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "496d52bf-863d-4b63-9e88-f8e40be32ed9", "node_type": "1", "metadata": {"window": "As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.  ", "original_text": "These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n"}, "hash": "2ce236c9d725e1f53a6a137318c45807f0aeb1bb670ab5a93e2a3dfe292131c6", "class_name": "RelatedNodeInfo"}}, "text": "Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield. ", "start_char_idx": 1465, "end_char_idx": 1550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "496d52bf-863d-4b63-9e88-f8e40be32ed9": {"__data__": {"id_": "496d52bf-863d-4b63-9e88-f8e40be32ed9", "embedding": null, "metadata": {"window": "As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.  ", "original_text": "These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2ca38fe-0bdb-4f15-9456-ffb1f6113f74", "node_type": "1", "metadata": {"window": "With respect to the Enterprise , we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operat ions and execute our digital transformation.  As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022. ", "original_text": "Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02d5190e47ba8bd658761f20dc9c823c04391724e249336d74c1be703af62945", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56f78a6a-dfab-4451-a447-6fe93f69abd8", "node_type": "1", "metadata": {"window": "We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities. ", "original_text": "Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n"}, "hash": "440f96816ec618bc1d899ff457b4834eb057986cb9dceed02576b3e2c2663302", "class_name": "RelatedNodeInfo"}}, "text": "These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n", "start_char_idx": 1550, "end_char_idx": 1714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56f78a6a-dfab-4451-a447-6fe93f69abd8": {"__data__": {"id_": "56f78a6a-dfab-4451-a447-6fe93f69abd8", "embedding": null, "metadata": {"window": "We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities. ", "original_text": "Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "496d52bf-863d-4b63-9e88-f8e40be32ed9", "node_type": "1", "metadata": {"window": "As I \nmentioned earlier, we recently increased our total cost reduction goal to $750 million by FY '23 , and \nwe are on track to deliver those savings.   \n \n We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.  ", "original_text": "These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6ef6079a4ed8122f6cc0445b7df79f41ac0c6c3be81d1ee121a5e2d2b4cbbe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6de4c3a-a6ad-4465-9bc2-43b09c9c289f", "node_type": "1", "metadata": {"window": "Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company. ", "original_text": "In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022. "}, "hash": "cdbd490038587186ee05d6531f7520f3a704685dbb5c4ca10ce6c3ebfa2fd6c5", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n", "start_char_idx": 1714, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6de4c3a-a6ad-4465-9bc2-43b09c9c289f": {"__data__": {"id_": "a6de4c3a-a6ad-4465-9bc2-43b09c9c289f", "embedding": null, "metadata": {"window": "Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company. ", "original_text": "In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56f78a6a-dfab-4451-a447-6fe93f69abd8", "node_type": "1", "metadata": {"window": "We're  pairing cost reduction efforts with balanced, discipli ned, and shareholder -friendly capital \nallocation with a focus on investing in the business, maintaining a strong balance sheet and returning \ncash to shareholders.   Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities. ", "original_text": "Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f230abf856c0922428910708ec628605dc3e566be166237193fde28a1f846ea8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc6bfb71-08d5-469a-aa59-ae8d0c13d361", "node_type": "1", "metadata": {"window": "These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S. ", "original_text": "At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.  "}, "hash": "cdb960c696549a2d41c8f4a11d4771a0d790fd2e74df51d0383b7321556fab8c", "class_name": "RelatedNodeInfo"}}, "text": "In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022. ", "start_char_idx": 1813, "end_char_idx": 2095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc6bfb71-08d5-469a-aa59-ae8d0c13d361": {"__data__": {"id_": "fc6bfb71-08d5-469a-aa59-ae8d0c13d361", "embedding": null, "metadata": {"window": "These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S. ", "original_text": "At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.  ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6de4c3a-a6ad-4465-9bc2-43b09c9c289f", "node_type": "1", "metadata": {"window": "Long term, we're  targeting a double -digit combined EPS growth and dividend \nyield.  These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company. ", "original_text": "In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb38ebcb261ff76cfaeab452f2cf47db4cf30eba20b79072d42d3d91b79f5252", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd9e06ad-8466-4390-9344-5f07d5467096", "node_type": "1", "metadata": {"window": "Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n", "original_text": "If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities. "}, "hash": "5734786d7d12b9baa1220c8a2650828d876c843c9e7f7a0b96fe240736b8dbc1", "class_name": "RelatedNodeInfo"}}, "text": "At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.  ", "start_char_idx": 2095, "end_char_idx": 2267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd9e06ad-8466-4390-9344-5f07d5467096": {"__data__": {"id_": "bd9e06ad-8466-4390-9344-5f07d5467096", "embedding": null, "metadata": {"window": "Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n", "original_text": "If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc6bfb71-08d5-469a-aa59-ae8d0c13d361", "node_type": "1", "metadata": {"window": "These expec tations are driven by our growth targets for our segments, our commitment to our \ndividend , and our new $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S. ", "original_text": "At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.  ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c91c7df4d2368c5000121595f2b5c7ca8fc344763578454f5f7722aa6a5fb7f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42e8a3d7-ce9a-41c1-888d-f49581beb2ec", "node_type": "1", "metadata": {"window": "In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world. ", "original_text": "This is an important step forward for our company. "}, "hash": "53e4b9154be9db23c2e4d6afd257de64be2ecc27e34e2ca07887d774ffe6a29d", "class_name": "RelatedNodeInfo"}}, "text": "If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities. ", "start_char_idx": 2267, "end_char_idx": 2445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42e8a3d7-ce9a-41c1-888d-f49581beb2ec": {"__data__": {"id_": "42e8a3d7-ce9a-41c1-888d-f49581beb2ec", "embedding": null, "metadata": {"window": "In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world. ", "original_text": "This is an important step forward for our company. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd9e06ad-8466-4390-9344-5f07d5467096", "node_type": "1", "metadata": {"window": "Now, let me provide an update on the proposed opioid settlement agreement and settlement process. \n In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n", "original_text": "If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b40fe84903e3d31d1a35bebd797a48b3304bd71484583284731dc100be97635b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e5adb93-f5a3-48f4-ba90-0d815dda40be", "node_type": "1", "metadata": {"window": "At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n", "original_text": "As we've consistently said, we remain \ncommitted to being part of the solution to the U.S. "}, "hash": "749866725754fceb83540f2b16a2742d04a32b28167ecf5b6dec56139919d87e", "class_name": "RelatedNodeInfo"}}, "text": "This is an important step forward for our company. ", "start_char_idx": 2445, "end_char_idx": 2496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e5adb93-f5a3-48f4-ba90-0d815dda40be": {"__data__": {"id_": "5e5adb93-f5a3-48f4-ba90-0d815dda40be", "embedding": null, "metadata": {"window": "At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n", "original_text": "As we've consistently said, we remain \ncommitted to being part of the solution to the U.S. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42e8a3d7-ce9a-41c1-888d-f49581beb2ec", "node_type": "1", "metadata": {"window": "In Septembe r, we announced that enough states agreed to settle to proceed to the next phase , and  \neach participating state is offering its political subdivisions the opportunity to participate in the \nsettlement for an additional 120 -day period, which ends on January 2 , 2022.  At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world. ", "original_text": "This is an important step forward for our company. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4516da890c9ff43c772f6ba0c3e686dad18f52dcccb40e9fe5090e6fb996ba9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d1c5b50-a521-49e6-9b1e-f33c5f150331", "node_type": "1", "metadata": {"window": "If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n", "original_text": "opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n"}, "hash": "8c1eca21a141b9caca56c0c177ecdb90eba060d000bf8c45a0ef06bf20e04ac0", "class_name": "RelatedNodeInfo"}}, "text": "As we've consistently said, we remain \ncommitted to being part of the solution to the U.S. ", "start_char_idx": 2496, "end_char_idx": 2587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d1c5b50-a521-49e6-9b1e-f33c5f150331": {"__data__": {"id_": "1d1c5b50-a521-49e6-9b1e-f33c5f150331", "embedding": null, "metadata": {"window": "If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n", "original_text": "opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e5adb93-f5a3-48f4-ba90-0d815dda40be", "node_type": "1", "metadata": {"window": "At that point, each of the \ndistributors and the states will have the opportunity to determine whether there is a sufficient \nparticipation to proceed with the agreement.   If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n", "original_text": "As we've consistently said, we remain \ncommitted to being part of the solution to the U.S. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac1b1f5af26f6dc5f5eb13a32428c3b44fdc27a7d92709409fda15107a0bc655", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fb09fc5-7b78-46c9-b3bb-7f0da8c41a0f", "node_type": "1", "metadata": {"window": "This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n", "original_text": "Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world. "}, "hash": "b1130a9da7dc4f01510b245d5aac89747d38384385b121ece95f9c8f1264cf81", "class_name": "RelatedNodeInfo"}}, "text": "opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n", "start_char_idx": 2587, "end_char_idx": 2714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fb09fc5-7b78-46c9-b3bb-7f0da8c41a0f": {"__data__": {"id_": "1fb09fc5-7b78-46c9-b3bb-7f0da8c41a0f", "embedding": null, "metadata": {"window": "This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n", "original_text": "Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d1c5b50-a521-49e6-9b1e-f33c5f150331", "node_type": "1", "metadata": {"window": "If all conditions are satisfied, this agreement would result \nin the settlement of a substantial majority of opioid lawsuits filed by the state and local governmental \nentities.  This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n", "original_text": "opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ce2d858dcfafa6af07428bd7adbd69485db5133648cd1f803093a911ca3d44c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a97d9e60-67fe-44c1-b823-713ad491fc9c", "node_type": "1", "metadata": {"window": "As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you. ", "original_text": "We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n"}, "hash": "770f6b7ac95c79b70cf40c9527fa6bb6773af06e37c9edf66b7e0528fa41508c", "class_name": "RelatedNodeInfo"}}, "text": "Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world. ", "start_char_idx": 2714, "end_char_idx": 2816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a97d9e60-67fe-44c1-b823-713ad491fc9c": {"__data__": {"id_": "a97d9e60-67fe-44c1-b823-713ad491fc9c", "embedding": null, "metadata": {"window": "As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you. ", "original_text": "We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fb09fc5-7b78-46c9-b3bb-7f0da8c41a0f", "node_type": "1", "metadata": {"window": "This is an important step forward for our company.  As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n", "original_text": "Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3d33c2362831ec5980564020cb08beddf92ed6f77d5dc389e6fcd22f3d81324", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17a03335-ce0c-4019-9255-e730141164d5", "node_type": "1", "metadata": {"window": "opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad. ", "original_text": "In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n"}, "hash": "cc91cae12f32d360f334639f82272152598d3f1d9500a7560945c1d5757605ff", "class_name": "RelatedNodeInfo"}}, "text": "We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n", "start_char_idx": 2816, "end_char_idx": 2994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17a03335-ce0c-4019-9255-e730141164d5": {"__data__": {"id_": "17a03335-ce0c-4019-9255-e730141164d5", "embedding": null, "metadata": {"window": "opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad. ", "original_text": "In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a97d9e60-67fe-44c1-b823-713ad491fc9c", "node_type": "1", "metadata": {"window": "As we've consistently said, we remain \ncommitted to being part of the solution to the U.S.  opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you. ", "original_text": "We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bcbe905974b6fd8346106df3a41d8974d2b48a200ba486c64b4e1d85f98973c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "275913b6-8fc0-4fb7-955b-943645742df5", "node_type": "1", "metadata": {"window": "Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "And now, Jason and I will take your questions.  \n \n"}, "hash": "d184b998bd45a07fb62a453528c6268c3ece030aef4ae962c22b59132b234a6f", "class_name": "RelatedNodeInfo"}}, "text": "In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n", "start_char_idx": 2994, "end_char_idx": 3137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "275913b6-8fc0-4fb7-955b-943645742df5": {"__data__": {"id_": "275913b6-8fc0-4fb7-955b-943645742df5", "embedding": null, "metadata": {"window": "Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "And now, Jason and I will take your questions.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17a03335-ce0c-4019-9255-e730141164d5", "node_type": "1", "metadata": {"window": "opioid epidemic an d believe that settlement would \nprovide relief for our communities and certainty for our shareholders.  \n \n Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad. ", "original_text": "In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c6adfa4f524bca727c1a31509fa4ceaca0d1daa8fe02076542ffad8a1509cbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b463bbd-40f1-48f3-b9d6-f618c4312ae4", "node_type": "1", "metadata": {"window": "We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "Operator:  Thank you. "}, "hash": "825c5cd52ee1c87e55e22eb28c97bb36b3a0bfa9bdb6b13cd0f672846b036bed", "class_name": "RelatedNodeInfo"}}, "text": "And now, Jason and I will take your questions.  \n \n", "start_char_idx": 3137, "end_char_idx": 3188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b463bbd-40f1-48f3-b9d6-f618c4312ae4": {"__data__": {"id_": "9b463bbd-40f1-48f3-b9d6-f618c4312ae4", "embedding": null, "metadata": {"window": "We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "Operator:  Thank you. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "275913b6-8fc0-4fb7-955b-943645742df5", "node_type": "1", "metadata": {"window": "Turning to ESG  \u2013 these  priorities remain critical to achieving a healthier, more sustainable world.  We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "And now, Jason and I will take your questions.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ca343a1bed15e69501bc8c69444ed611945f1e9f40f9fdeed12320c18cd4a66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab361b74-a015-4269-81ca-94b93e0db030", "node_type": "1", "metadata": {"window": "In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad. "}, "hash": "ce7fd735384bde9462e6187ee2fb687de9ffc9b61749bdb5fcbcad3265a6a292", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 3188, "end_char_idx": 3210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab361b74-a015-4269-81ca-94b93e0db030": {"__data__": {"id_": "ab361b74-a015-4269-81ca-94b93e0db030", "embedding": null, "metadata": {"window": "In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b463bbd-40f1-48f3-b9d6-f618c4312ae4", "node_type": "1", "metadata": {"window": "We \nrecently announced goals to reduce Scope 1 and Sc ope 2 greenhouse gas emissions by 50% by \n2030 , and increase  minority representation in our global workforce by 2030.  \n \n In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "Operator:  Thank you. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "282794acb9b79322e82a220a1322e785c71771fe1f956ea559b48e01affcc903", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d9ac62e-3396-4232-95db-f2b3822e0887", "node_type": "1", "metadata": {"window": "And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "If you are using a speakerphone, please make sure your mute function is "}, "hash": "5b296497065862e0a404177b8134c3975d5c2230649e442f1e1471ac5aeeb84e", "class_name": "RelatedNodeInfo"}}, "text": "And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad. ", "start_char_idx": 3210, "end_char_idx": 3316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d9ac62e-3396-4232-95db-f2b3822e0887": {"__data__": {"id_": "9d9ac62e-3396-4232-95db-f2b3822e0887", "embedding": null, "metadata": {"window": "And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "If you are using a speakerphone, please make sure your mute function is ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "910b2b5830161e58f7d15faabad1e3661c7809b124ac462a7c79b3628c03c09a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab361b74-a015-4269-81ca-94b93e0db030", "node_type": "1", "metadata": {"window": "In closing, what we do matters , and it is our privilege to serve our customers, their patients , and their \ncommunities around the world.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad. ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab27e193ed7f86e1a50849f85418a970010a5b8993c93c6a4c15e52db65891be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c26ed8b-f540-4491-9f5a-7a93d65f437f", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P. ", "original_text": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.  "}, "hash": "97557da10479c5ad54e288bfc06d20416d509268c44c85eb41ae0b0b57478e35", "class_name": "RelatedNodeInfo"}}, "text": "If you are using a speakerphone, please make sure your mute function is ", "start_char_idx": 3316, "end_char_idx": 3388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c26ed8b-f540-4491-9f5a-7a93d65f437f": {"__data__": {"id_": "0c26ed8b-f540-4491-9f5a-7a93d65f437f", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P. ", "original_text": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.  ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d9ac62e-3396-4232-95db-f2b3822e0887", "node_type": "1", "metadata": {"window": "And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  And if you would like to ask a question, please signal by pressing \u201cstar,\u201d \u201c1\u201d on \nyour telephone keypad.  If you are using a speakerphone, please make sure your mute function is ", "original_text": "If you are using a speakerphone, please make sure your mute function is ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32e0adfc67e8d776ea93c55019882e4363c02f74068e76cbff693aad3a11a7be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9af985a-c095-4182-a657-7cb4376e0f08", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n", "original_text": "Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad. "}, "hash": "2fda9738cf58904e6ae34e234249afd686cf8afdb77c7c07e2a500bf231f9848", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.  ", "start_char_idx": 0, "end_char_idx": 75, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9af985a-c095-4182-a657-7cb4376e0f08": {"__data__": {"id_": "c9af985a-c095-4182-a657-7cb4376e0f08", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n", "original_text": "Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c26ed8b-f540-4491-9f5a-7a93d65f437f", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P. ", "original_text": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.  ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465ddf1a9a60077cd4d4c17e4651370a1953655c6b1fc66f2fc3eafbd4e74724", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dbe70e7-f3cb-429e-8f57-d8871651f4f4", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much. ", "original_text": "We\u2019ll pause for a moment to assemble the queue.  \n \n"}, "hash": "4d0319a2c82bf9e89fcfb873d6350b79af0fba387d43a52e3050289ca54d7fb8", "class_name": "RelatedNodeInfo"}}, "text": "Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad. ", "start_char_idx": 75, "end_char_idx": 162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dbe70e7-f3cb-429e-8f57-d8871651f4f4": {"__data__": {"id_": "1dbe70e7-f3cb-429e-8f57-d8871651f4f4", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much. ", "original_text": "We\u2019ll pause for a moment to assemble the queue.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9af985a-c095-4182-a657-7cb4376e0f08", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n", "original_text": "Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50f99ba6430e65a6c3347b8fa4d63c38e465e8ebda356c372b0a3289f67feb53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8ad445f-e58d-450f-88a8-632dc924672b", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments. ", "original_text": "And our first question will come from Lisa Gill with J.P. "}, "hash": "69b46940913f1f05664e109be4cccdd024cc5088ae8ac8f96b9d01db4daa6a4b", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ll pause for a moment to assemble the queue.  \n \n", "start_char_idx": 162, "end_char_idx": 214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8ad445f-e58d-450f-88a8-632dc924672b": {"__data__": {"id_": "a8ad445f-e58d-450f-88a8-632dc924672b", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments. ", "original_text": "And our first question will come from Lisa Gill with J.P. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dbe70e7-f3cb-429e-8f57-d8871651f4f4", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much. ", "original_text": "We\u2019ll pause for a moment to assemble the queue.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22f916599800fe92dec0700a7531dcd121ab050a1d24866b3227ccdf40af5990", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26c03fb6-47c6-44cb-a1fd-3e461126907c", "node_type": "1", "metadata": {"window": "Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products. ", "original_text": "Morgan.  \n \n"}, "hash": "1b988953f0475938be44fd3722316d8418a6829a530216e65cccf3f8023a552e", "class_name": "RelatedNodeInfo"}}, "text": "And our first question will come from Lisa Gill with J.P. ", "start_char_idx": 214, "end_char_idx": 272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26c03fb6-47c6-44cb-a1fd-3e461126907c": {"__data__": {"id_": "26c03fb6-47c6-44cb-a1fd-3e461126907c", "embedding": null, "metadata": {"window": "Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products. ", "original_text": "Morgan.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8ad445f-e58d-450f-88a8-632dc924672b", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments. ", "original_text": "And our first question will come from Lisa Gill with J.P. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cd45790e4029edeb0376ab7917f6f5b989100dd91cda196f92606e089143013", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d4d473a-72de-46f6-86ac-7e2035c5005b", "node_type": "1", "metadata": {"window": "We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products? ", "original_text": "Lisa Gill:  Thanks very much. "}, "hash": "03fa5b430014e9b48baf7dc8a154d012827fe59748ed1e103ae1b23365072606", "class_name": "RelatedNodeInfo"}}, "text": "Morgan.  \n \n", "start_char_idx": 272, "end_char_idx": 284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d4d473a-72de-46f6-86ac-7e2035c5005b": {"__data__": {"id_": "4d4d473a-72de-46f6-86ac-7e2035c5005b", "embedding": null, "metadata": {"window": "We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products? ", "original_text": "Lisa Gill:  Thanks very much. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26c03fb6-47c6-44cb-a1fd-3e461126907c", "node_type": "1", "metadata": {"window": "Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products. ", "original_text": "Morgan.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a11117d24537ce22540f6b6ae4e3c5e3c994c54e3b858a6d32927c16d986d52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c78066fd-875d-496d-bd45-bd033d157b8a", "node_type": "1", "metadata": {"window": "And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products? ", "original_text": "Thank you for all the comments. "}, "hash": "99333ab268fe2ffe3222357b2e5850345fb147d8c9769afdd55492ccf007faf6", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Thanks very much. ", "start_char_idx": 284, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c78066fd-875d-496d-bd45-bd033d157b8a": {"__data__": {"id_": "c78066fd-875d-496d-bd45-bd033d157b8a", "embedding": null, "metadata": {"window": "And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products? ", "original_text": "Thank you for all the comments. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d4d473a-72de-46f6-86ac-7e2035c5005b", "node_type": "1", "metadata": {"window": "We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products? ", "original_text": "Lisa Gill:  Thanks very much. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cda28b59ce97287a734e75b9b23e246bc25190a107ae107aa8afb056af7b373", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d93670d-8f11-48f7-89da-3cdecb2e71b4", "node_type": "1", "metadata": {"window": "Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n", "original_text": "Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products. "}, "hash": "eee725cbfbacbc4aa66fadb0b729abd110675ab0cfcd43e744fb11f6199bee43", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for all the comments. ", "start_char_idx": 314, "end_char_idx": 346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d93670d-8f11-48f7-89da-3cdecb2e71b4": {"__data__": {"id_": "5d93670d-8f11-48f7-89da-3cdecb2e71b4", "embedding": null, "metadata": {"window": "Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n", "original_text": "Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c78066fd-875d-496d-bd45-bd033d157b8a", "node_type": "1", "metadata": {"window": "And our first question will come from Lisa Gill with J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products? ", "original_text": "Thank you for all the comments. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c47a8466de26a4710c93239cf2713dd4d439f8a19d2291cfc77c038f378b7652", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "543ca4e0-8fd2-484d-901b-e6e7bc4c4ad9", "node_type": "1", "metadata": {"window": "Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa. ", "original_text": "One, can you remind us what percentage of \nsales today are Cardinal -branded products? "}, "hash": "95bbf861752034c79a72a51cb9414c8a1eff03d45421157412185a5c688dafe9", "class_name": "RelatedNodeInfo"}}, "text": "Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products. ", "start_char_idx": 346, "end_char_idx": 535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "543ca4e0-8fd2-484d-901b-e6e7bc4c4ad9": {"__data__": {"id_": "543ca4e0-8fd2-484d-901b-e6e7bc4c4ad9", "embedding": null, "metadata": {"window": "Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa. ", "original_text": "One, can you remind us what percentage of \nsales today are Cardinal -branded products? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d93670d-8f11-48f7-89da-3cdecb2e71b4", "node_type": "1", "metadata": {"window": "Morgan.  \n \n Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n", "original_text": "Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541e5dfc5529a444c69b521d8ba54a0b2c2814ddc26155184adc58f1e07d1edb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4020eae1-f668-4012-af07-26973372b537", "node_type": "1", "metadata": {"window": "Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions. ", "original_text": "And  then two, can you talk about the margin differential \non those products? "}, "hash": "c55418685aaa17b2248cdd4e64b76789b0d71f7577d5feb9867fd7a9a21e3f17", "class_name": "RelatedNodeInfo"}}, "text": "One, can you remind us what percentage of \nsales today are Cardinal -branded products? ", "start_char_idx": 535, "end_char_idx": 622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4020eae1-f668-4012-af07-26973372b537": {"__data__": {"id_": "4020eae1-f668-4012-af07-26973372b537", "embedding": null, "metadata": {"window": "Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions. ", "original_text": "And  then two, can you talk about the margin differential \non those products? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "543ca4e0-8fd2-484d-901b-e6e7bc4c4ad9", "node_type": "1", "metadata": {"window": "Lisa Gill:  Thanks very much.  Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa. ", "original_text": "One, can you remind us what percentage of \nsales today are Cardinal -branded products? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "437d0a1d2cbbaf99386547c55064f1b77debe048c7e34dbd0ecc75962059d8cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d7650f5-cb12-4935-8db3-5759d0232bde", "node_type": "1", "metadata": {"window": "Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given. ", "original_text": "And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n"}, "hash": "60c22f126dcc90f15c941b4b9fb07249e4d672f649e775b090a9dfcb5f19dcb2", "class_name": "RelatedNodeInfo"}}, "text": "And  then two, can you talk about the margin differential \non those products? ", "start_char_idx": 622, "end_char_idx": 700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d7650f5-cb12-4935-8db3-5759d0232bde": {"__data__": {"id_": "1d7650f5-cb12-4935-8db3-5759d0232bde", "embedding": null, "metadata": {"window": "Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given. ", "original_text": "And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4020eae1-f668-4012-af07-26973372b537", "node_type": "1", "metadata": {"window": "Thank you for all the comments.  Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions. ", "original_text": "And  then two, can you talk about the margin differential \non those products? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "becee7dd80afb264c7b41c8ffb3458f354ed5b31d7604e0bf3047593c784650e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dc4557e-966f-4076-ac17-75b4a3068b5f", "node_type": "1", "metadata": {"window": "One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this. ", "original_text": "Mike Kaufmann:  Thanks, Lisa. "}, "hash": "6c343a0872ff084c4c0afce718fc8cacb1163c0f9144c20d2d6f51eeb5ff8816", "class_name": "RelatedNodeInfo"}}, "text": "And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n", "start_char_idx": 700, "end_char_idx": 922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dc4557e-966f-4076-ac17-75b4a3068b5f": {"__data__": {"id_": "9dc4557e-966f-4076-ac17-75b4a3068b5f", "embedding": null, "metadata": {"window": "One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this. ", "original_text": "Mike Kaufmann:  Thanks, Lisa. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d7650f5-cb12-4935-8db3-5759d0232bde", "node_type": "1", "metadata": {"window": "Mike, I just want to go back to your \ncomments around simplifying the operating model on the medical supply side, and where you talked \nabout driving the mix of Cardinal -branded products.  One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given. ", "original_text": "And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62f6677227305f9e04db769d3651aa516b170abdb7e9770db2f27708f3a62361", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b17af86-c972-4e29-a6c6-20741cdeb85f", "node_type": "1", "metadata": {"window": "And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow. ", "original_text": "Thanks for the questions. "}, "hash": "62aeab2b539cfb6468bb806bfed3de1b239f661df630f229a38d09599df5117a", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks, Lisa. ", "start_char_idx": 922, "end_char_idx": 952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b17af86-c972-4e29-a6c6-20741cdeb85f": {"__data__": {"id_": "8b17af86-c972-4e29-a6c6-20741cdeb85f", "embedding": null, "metadata": {"window": "And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow. ", "original_text": "Thanks for the questions. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dc4557e-966f-4076-ac17-75b4a3068b5f", "node_type": "1", "metadata": {"window": "One, can you remind us what percentage of \nsales today are Cardinal -branded products?  And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this. ", "original_text": "Mike Kaufmann:  Thanks, Lisa. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5b5fcdeab1d514d754445bdbafac542b8c8a2e2f84753de53d8d17900e7662e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d86720fd-86e1-47e3-864d-0c468785be03", "node_type": "1", "metadata": {"window": "And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after. ", "original_text": "Tough questions to answer because these \naren't things we have historically given. "}, "hash": "0c164b1e145abf44b20515821196564ce21f2fc76bab99794564db034cb7c67d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the questions. ", "start_char_idx": 952, "end_char_idx": 978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d86720fd-86e1-47e3-864d-0c468785be03": {"__data__": {"id_": "d86720fd-86e1-47e3-864d-0c468785be03", "embedding": null, "metadata": {"window": "And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after. ", "original_text": "Tough questions to answer because these \naren't things we have historically given. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b17af86-c972-4e29-a6c6-20741cdeb85f", "node_type": "1", "metadata": {"window": "And  then two, can you talk about the margin differential \non those products?  And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow. ", "original_text": "Thanks for the questions. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aef88df58accf06469d34e78c1049f0a5523c9456884f6d42dbe386819ba7690", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49ce993a-1f01-4413-ba4f-b4ce2047430d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there. ", "original_text": "Obviously, I can say this. "}, "hash": "d8979a43951c4e50ac2bb6da37ac9241ceb40158d0c496096c83b8c337c2b636", "class_name": "RelatedNodeInfo"}}, "text": "Tough questions to answer because these \naren't things we have historically given. ", "start_char_idx": 978, "end_char_idx": 1061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49ce993a-1f01-4413-ba4f-b4ce2047430d": {"__data__": {"id_": "49ce993a-1f01-4413-ba4f-b4ce2047430d", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there. ", "original_text": "Obviously, I can say this. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d86720fd-86e1-47e3-864d-0c468785be03", "node_type": "1", "metadata": {"window": "And then my third and last question would just be that now that you have the \ndivestiture of Cordis behind you \u2013 the sale of Cordis behind you \u2013 are there other assets within \nMedical t hat would make sense to divest?  \n \n Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after. ", "original_text": "Tough questions to answer because these \naren't things we have historically given. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad51cb3033ccd04eed59e6390281aca5b76827ebb4316fa9aba8d64cd1b861a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aea051ea-9d43-48a4-ba00-2c586f46c36d", "node_type": "1", "metadata": {"window": "Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n", "original_text": "We believe there is plenty of room \nto grow. "}, "hash": "4ac13552ee5a8a0dbf8fc9f8448ed4fff72e9dcb8f9bcf6dd84777c8b087315b", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, I can say this. ", "start_char_idx": 1061, "end_char_idx": 1088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aea051ea-9d43-48a4-ba00-2c586f46c36d": {"__data__": {"id_": "aea051ea-9d43-48a4-ba00-2c586f46c36d", "embedding": null, "metadata": {"window": "Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n", "original_text": "We believe there is plenty of room \nto grow. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49ce993a-1f01-4413-ba4f-b4ce2047430d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Lisa.  Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there. ", "original_text": "Obviously, I can say this. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64f0c6ebf2439942e61dc5316cffc165e12589e02b367fe70151fb027e324549", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fc86186-1479-459f-b950-0176efa2e2fd", "node_type": "1", "metadata": {"window": "Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand. ", "original_text": "Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after. "}, "hash": "c065a29d19c4371fa8c566955e1e7e2275367fa73a96780788a145a5e3d964fe", "class_name": "RelatedNodeInfo"}}, "text": "We believe there is plenty of room \nto grow. ", "start_char_idx": 1088, "end_char_idx": 1133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fc86186-1479-459f-b950-0176efa2e2fd": {"__data__": {"id_": "5fc86186-1479-459f-b950-0176efa2e2fd", "embedding": null, "metadata": {"window": "Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand. ", "original_text": "Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aea051ea-9d43-48a4-ba00-2c586f46c36d", "node_type": "1", "metadata": {"window": "Thanks for the questions.  Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n", "original_text": "We believe there is plenty of room \nto grow. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28a423317b0c7cbd862863c96902af2d8a3658a167096fa3a21ace69ae61b8de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96bcdc03-a91d-410f-841a-1139ea35d397", "node_type": "1", "metadata": {"window": "Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand. ", "original_text": "So we think there's \nplenty of opportunity there. "}, "hash": "db69311225445fffa1460df3610c7d9e7c7a7c23a56e427b24d1b8e3f497bcef", "class_name": "RelatedNodeInfo"}}, "text": "Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after. ", "start_char_idx": 1133, "end_char_idx": 1298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96bcdc03-a91d-410f-841a-1139ea35d397": {"__data__": {"id_": "96bcdc03-a91d-410f-841a-1139ea35d397", "embedding": null, "metadata": {"window": "Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand. ", "original_text": "So we think there's \nplenty of opportunity there. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fc86186-1479-459f-b950-0176efa2e2fd", "node_type": "1", "metadata": {"window": "Tough questions to answer because these \naren't things we have historically given.  Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand. ", "original_text": "Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bba79b39f35eea2cf95492b9f4568021ed0e745804b2d8c16ff991ab9fcc533", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83ac524e-2962-492a-8181-18fd09325223", "node_type": "1", "metadata": {"window": "We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n", "original_text": "It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n"}, "hash": "17950430109815a4aa44ae08074acc1572abd93f1ccb8902358470195a44033d", "class_name": "RelatedNodeInfo"}}, "text": "So we think there's \nplenty of opportunity there. ", "start_char_idx": 1298, "end_char_idx": 1348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83ac524e-2962-492a-8181-18fd09325223": {"__data__": {"id_": "83ac524e-2962-492a-8181-18fd09325223", "embedding": null, "metadata": {"window": "We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n", "original_text": "It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96bcdc03-a91d-410f-841a-1139ea35d397", "node_type": "1", "metadata": {"window": "Obviously, I can say this.  We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand. ", "original_text": "So we think there's \nplenty of opportunity there. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3efebf05777ff7519dc691bbd10239e9b0b7e6c0f14e1f1ed7ed40bb1c6e22af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50871397-4c29-4151-a2bf-01986e4bb0a0", "node_type": "1", "metadata": {"window": "Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win. ", "original_text": "As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand. "}, "hash": "ee49085a671e343ec22b1b5b7b4dea863adbe4d78785e86647776fef803bb596", "class_name": "RelatedNodeInfo"}}, "text": "It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n", "start_char_idx": 1348, "end_char_idx": 1467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50871397-4c29-4151-a2bf-01986e4bb0a0": {"__data__": {"id_": "50871397-4c29-4151-a2bf-01986e4bb0a0", "embedding": null, "metadata": {"window": "Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win. ", "original_text": "As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83ac524e-2962-492a-8181-18fd09325223", "node_type": "1", "metadata": {"window": "We believe there is plenty of room \nto grow.  Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n", "original_text": "It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e45c7aed1848e4d4ca0c1a1b5e5cf53840f0e1475e1cb9f3b9f0581effc1a4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7998afb-2b1e-4625-a2c5-765308cc75e3", "node_type": "1", "metadata": {"window": "So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries. ", "original_text": "There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand. "}, "hash": "ef612e3165344639e135605e6103a3591e8cf525b3761b758af1bbcf1080a9d2", "class_name": "RelatedNodeInfo"}}, "text": "As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand. ", "start_char_idx": 1467, "end_char_idx": 1581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7998afb-2b1e-4625-a2c5-765308cc75e3": {"__data__": {"id_": "e7998afb-2b1e-4625-a2c5-765308cc75e3", "embedding": null, "metadata": {"window": "So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries. ", "original_text": "There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50871397-4c29-4151-a2bf-01986e4bb0a0", "node_type": "1", "metadata": {"window": "Some of our ac counts were significantly penetrated in and others obviously were less \npenetrated in, so we do have good targets by account that we are going after.  So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win. ", "original_text": "As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a41f06c5e917fcfc7e04435e5a52f30c74cb02da53b1e6a4c6addd9134dbfd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e72fdb1-e486-443a-8d3c-717def42dd3e", "node_type": "1", "metadata": {"window": "It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera. ", "original_text": "But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n"}, "hash": "9a496b00c0d333499c57b6a91c4deaac08b843b65bf2887e1797a8f3d5b40ca5", "class_name": "RelatedNodeInfo"}}, "text": "There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand. ", "start_char_idx": 1581, "end_char_idx": 1696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e72fdb1-e486-443a-8d3c-717def42dd3e": {"__data__": {"id_": "9e72fdb1-e486-443a-8d3c-717def42dd3e", "embedding": null, "metadata": {"window": "It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera. ", "original_text": "But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7998afb-2b1e-4625-a2c5-765308cc75e3", "node_type": "1", "metadata": {"window": "So we think there's \nplenty of opportunity there.  It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries. ", "original_text": "There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7a7c5ca016f7fd909367546010b82ec58394c99ec32bd9447d65ef510abcc9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7085d3c9-79df-43ee-8fe8-1bfd001f9796", "node_type": "1", "metadata": {"window": "As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n", "original_text": "And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win. "}, "hash": "e62c9a07cdd1c708e64d56ca3eae5834152f7df7d31b5ca6e6aea9bac85be01b", "class_name": "RelatedNodeInfo"}}, "text": "But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n", "start_char_idx": 1696, "end_char_idx": 1841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7085d3c9-79df-43ee-8fe8-1bfd001f9796": {"__data__": {"id_": "7085d3c9-79df-43ee-8fe8-1bfd001f9796", "embedding": null, "metadata": {"window": "As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n", "original_text": "And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e72fdb1-e486-443a-8d3c-717def42dd3e", "node_type": "1", "metadata": {"window": "It's one of the key reasons we believe in our longer -term guidance for \nMedical is the fact that we can do that.   \n \n As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera. ", "original_text": "But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "538bbcb7d100aabfae4bdc0e241f619732a744c9241525f94b7ee3d276139511", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99215f82-70ac-450e-a6da-7977d3c65c4e", "node_type": "1", "metadata": {"window": "There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen. ", "original_text": "There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries. "}, "hash": "c6a4b76343cda3480d66fd9df430dfebcace8a08ae282be1676a57b5db33c085", "class_name": "RelatedNodeInfo"}}, "text": "And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win. ", "start_char_idx": 1841, "end_char_idx": 2017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99215f82-70ac-450e-a6da-7977d3c65c4e": {"__data__": {"id_": "99215f82-70ac-450e-a6da-7977d3c65c4e", "embedding": null, "metadata": {"window": "There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen. ", "original_text": "There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7085d3c9-79df-43ee-8fe8-1bfd001f9796", "node_type": "1", "metadata": {"window": "As far as margin rates go, generally, they are much more higher as a percentage and dollars than \nnational brand.  There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n", "original_text": "And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9e23a321efe321e627ba8bee8301a9d0313b02244d867064f571a2328807504", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7001605f-fc0d-4ff4-8897-3dbdbfaf134e", "node_type": "1", "metadata": {"window": "But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n", "original_text": "So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera. "}, "hash": "273b122389147e9833810b088571a5e48bd0ada5aa7da68f75b00eb2b18c3ed8", "class_name": "RelatedNodeInfo"}}, "text": "There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries. ", "start_char_idx": 2017, "end_char_idx": 2189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7001605f-fc0d-4ff4-8897-3dbdbfaf134e": {"__data__": {"id_": "7001605f-fc0d-4ff4-8897-3dbdbfaf134e", "embedding": null, "metadata": {"window": "But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n", "original_text": "So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99215f82-70ac-450e-a6da-7977d3c65c4e", "node_type": "1", "metadata": {"window": "There are times in certain preferred brand programs, which is why we have them, that \nwe do prefer national brand.  But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen. ", "original_text": "There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e739cdeef30bebc49836eb56d69b618ada234d142816d8902c0a18371d298166", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9d61bee-d129-4a7f-bbe9-7f7c77602c02", "node_type": "1", "metadata": {"window": "And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question. ", "original_text": "We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n"}, "hash": "166374d90757957eea9eb19dd0a31c6cb828faf5e6dd5c112b68266cac58bc72", "class_name": "RelatedNodeInfo"}}, "text": "So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera. ", "start_char_idx": 2189, "end_char_idx": 2407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9d61bee-d129-4a7f-bbe9-7f7c77602c02": {"__data__": {"id_": "c9d61bee-d129-4a7f-bbe9-7f7c77602c02", "embedding": null, "metadata": {"window": "And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question. ", "original_text": "We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7001605f-fc0d-4ff4-8897-3dbdbfaf134e", "node_type": "1", "metadata": {"window": "But in general, as a rule of thumb, our margin rates are much more \nsignificant on our Cardinal -sourced or Cardinal -manufactured products.  \n \n And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n", "original_text": "So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4bef374fba2a96fd1d8e60dd148d4b7096afa0235828bafaed981cf0b6f1074f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5a0886c-8cef-438c-8051-34e87e63a70c", "node_type": "1", "metadata": {"window": "There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here. ", "original_text": "Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen. "}, "hash": "42e8d88646cc0efdab10c1aaa8059e7492ed741b676a21bdbea3f0b760cd8e72", "class_name": "RelatedNodeInfo"}}, "text": "We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n", "start_char_idx": 2407, "end_char_idx": 2571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5a0886c-8cef-438c-8051-34e87e63a70c": {"__data__": {"id_": "c5a0886c-8cef-438c-8051-34e87e63a70c", "embedding": null, "metadata": {"window": "There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here. ", "original_text": "Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9d61bee-d129-4a7f-bbe9-7f7c77602c02", "node_type": "1", "metadata": {"window": "And then, lastly, around Cordis, we're always looking at our entire portfolio of businesse s to make \nsure we have the right type of businesses where we are positioned to win.  There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question. ", "original_text": "We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "381a3af827c8fd0a57cf21e2df34f7aa7114987acee1cd9cb032b0bbd416314b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8dc2f95-fb54-4c7f-9cca-fbd426ec8ead", "node_type": "1", "metadata": {"window": "So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22? ", "original_text": "Please go \nahead.  \n \n"}, "hash": "23761a813b750037261f2942059b3e7d8e8ef3b384dc3bcf94b4465ae95be7bc", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen. ", "start_char_idx": 2571, "end_char_idx": 2659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8dc2f95-fb54-4c7f-9cca-fbd426ec8ead": {"__data__": {"id_": "e8dc2f95-fb54-4c7f-9cca-fbd426ec8ead", "embedding": null, "metadata": {"window": "So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22? ", "original_text": "Please go \nahead.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5a0886c-8cef-438c-8051-34e87e63a70c", "node_type": "1", "metadata": {"window": "There's nothing that sticks \nout to me in terms of a certain product category or that, but we are as I mentioned in my prepared \nremarks, that we are exiting 36 countries.  So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here. ", "original_text": "Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de5e5f74993780f6280a6f32e8901aaffead8a65004cf08db2924d492d797995", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "213980cf-3827-4ca3-a492-1318fc26fb15", "node_type": "1", "metadata": {"window": "We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about? ", "original_text": "Charles Rhyee:  Thanks for taking the question. "}, "hash": "6d166c6bacd1d13ce8d8e6e3bc171b595a9789e6cfaecddea9a591a38ef9b661", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 2659, "end_char_idx": 2681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "213980cf-3827-4ca3-a492-1318fc26fb15": {"__data__": {"id_": "213980cf-3827-4ca3-a492-1318fc26fb15", "embedding": null, "metadata": {"window": "We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about? ", "original_text": "Charles Rhyee:  Thanks for taking the question. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8dc2f95-fb54-4c7f-9cca-fbd426ec8ead", "node_type": "1", "metadata": {"window": "So  not only do we look at products, but we look at products \nby country and countries, and where we don't believe we have significant growth opportunity, where \nthere might be too much risk versus benefit, et cetera.  We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22? ", "original_text": "Please go \nahead.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f3e61569d2781cd5c55e49a13d8cd1e4463fb0856fd4e8fa0c36ae53ae6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2c41cae-d574-479a-80ae-96644f4201cd", "node_type": "1", "metadata": {"window": "Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year? ", "original_text": "Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here. "}, "hash": "f5ff5207d7f1129082cf140581ee740e062a38544060ba559e17c16134730dec", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  Thanks for taking the question. ", "start_char_idx": 2681, "end_char_idx": 2729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2c41cae-d574-479a-80ae-96644f4201cd": {"__data__": {"id_": "a2c41cae-d574-479a-80ae-96644f4201cd", "embedding": null, "metadata": {"window": "Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year? ", "original_text": "Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "213980cf-3827-4ca3-a492-1318fc26fb15", "node_type": "1", "metadata": {"window": "We have made real conscious decisions to \naggressively manage the number of countries in, which is why we are exiting 36 countries to help \nsimplify the model.  \n \n Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about? ", "original_text": "Charles Rhyee:  Thanks for taking the question. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e42faffaca85a6c0c73d9a66270508baab8aeca146f1fbe893dead36c15e267", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "570a0a0e-6924-44f0-866f-a6cf2917159c", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year? ", "original_text": "I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22? "}, "hash": "184076c7d694fc3c4b35fbc44be06ff3b227ab898a4c8ceadbca0c2d9b11fe34", "class_name": "RelatedNodeInfo"}}, "text": "Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here. ", "start_char_idx": 2729, "end_char_idx": 2831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "570a0a0e-6924-44f0-866f-a6cf2917159c": {"__data__": {"id_": "570a0a0e-6924-44f0-866f-a6cf2917159c", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year? ", "original_text": "I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2c41cae-d574-479a-80ae-96644f4201cd", "node_type": "1", "metadata": {"window": "Operator:  Alright, and up next, we will take a question from Charles Rhyee with Cowen.  Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year? ", "original_text": "Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here. ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1126016968485509e037d1de06b6cd3b19e9c33588bf05f4b5fc8e753e6431b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cab207c-e86d-4bbd-bc17-d95e033fa111", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "And is that a  5-year target that we \nshould be thinking about? "}, "hash": "fd5efafee403fa079cca8830c4e4a59a718027ac5fae43b67e20f85573aeadc7", "class_name": "RelatedNodeInfo"}}, "text": "I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22? ", "start_char_idx": 2831, "end_char_idx": 2961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cab207c-e86d-4bbd-bc17-d95e033fa111": {"__data__": {"id_": "2cab207c-e86d-4bbd-bc17-d95e033fa111", "embedding": null, "metadata": {"window": "Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "And is that a  5-year target that we \nshould be thinking about? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "570a0a0e-6924-44f0-866f-a6cf2917159c", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year? ", "original_text": "I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e76343f00bb84b7f6ae7a5dc985264fae99ccba20b5cda0315f75230b989819a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1dc5dc3-da43-4f73-8f12-044bb62d00a7", "node_type": "1", "metadata": {"window": "Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "Or are we jumping off from fiscal '21 as sort of the baseline year? "}, "hash": "dab4d1f3806b30b6a27012f176950d899b089e706e4e999ef310aad3be17c1b6", "class_name": "RelatedNodeInfo"}}, "text": "And is that a  5-year target that we \nshould be thinking about? ", "start_char_idx": 2961, "end_char_idx": 3025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1dc5dc3-da43-4f73-8f12-044bb62d00a7": {"__data__": {"id_": "e1dc5dc3-da43-4f73-8f12-044bb62d00a7", "embedding": null, "metadata": {"window": "Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "Or are we jumping off from fiscal '21 as sort of the baseline year? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cab207c-e86d-4bbd-bc17-d95e033fa111", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Thanks for taking the question.  Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "And is that a  5-year target that we \nshould be thinking about? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb1be9485063adb2856affdf0de54bfae58e71354da30c4124509a97ec0a9505", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c4cf3a0-1dde-490c-85dd-8105a5c76b66", "node_type": "1", "metadata": {"window": "I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year? "}, "hash": "bab259b4f69d8d52c4b080499b8fd4b440a74ebb96aaae7cf7f1263e3a3e581a", "class_name": "RelatedNodeInfo"}}, "text": "Or are we jumping off from fiscal '21 as sort of the baseline year? ", "start_char_idx": 3025, "end_char_idx": 3093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c4cf3a0-1dde-490c-85dd-8105a5c76b66": {"__data__": {"id_": "9c4cf3a0-1dde-490c-85dd-8105a5c76b66", "embedding": null, "metadata": {"window": "I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1dc5dc3-da43-4f73-8f12-044bb62d00a7", "node_type": "1", "metadata": {"window": "Mike and Jason, want to just talk a little bit about the \nlong-term growth targets a little bit here.  I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "Or are we jumping off from fiscal '21 as sort of the baseline year? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5937bfebe680faaaba1f675eca2dd3e0e5ccfc7c4d806b43f22924ee724b857", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13e01cbf-00da-4a49-9b2e-bacefbcb330c", "node_type": "1", "metadata": {"window": "And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "And then, lastly, those higher freight and shipping "}, "hash": "198eb5046196d6c2de43092021ed375267d0af4a3a2e3177f40d6feb94dbf74d", "class_name": "RelatedNodeInfo"}}, "text": "And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year? ", "start_char_idx": 3093, "end_char_idx": 3365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13e01cbf-00da-4a49-9b2e-bacefbcb330c": {"__data__": {"id_": "13e01cbf-00da-4a49-9b2e-bacefbcb330c", "embedding": null, "metadata": {"window": "And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "And then, lastly, those higher freight and shipping ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1981756176d1f53186f9560fdf31919d827c52c6fe22dac6ced6275c9515b472", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c4cf3a0-1dde-490c-85dd-8105a5c76b66", "node_type": "1", "metadata": {"window": "I guess first is when we're starting the jump -off point for \nthese \u2013 for the earnings growth \u2013 are you starting from fiscal '22?  And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year? ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6256ba08ccf37171abfb7812be6a7e4fdbd3cfe3717d81f3e781656f39241a3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad4afe8b-fc81-4908-a259-54e898eff11c", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.  ", "original_text": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets? "}, "hash": "45df5c030dfedc668e1984bd0f92f2a2bee9ca305232f72cff509ae2f131d39d", "class_name": "RelatedNodeInfo"}}, "text": "And then, lastly, those higher freight and shipping ", "start_char_idx": 3365, "end_char_idx": 3417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad4afe8b-fc81-4908-a259-54e898eff11c": {"__data__": {"id_": "ad4afe8b-fc81-4908-a259-54e898eff11c", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.  ", "original_text": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets? ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13e01cbf-00da-4a49-9b2e-bacefbcb330c", "node_type": "1", "metadata": {"window": "And is that a  5-year target that we \nshould be thinking about?  Or are we jumping off from fiscal '21 as sort of the baseline year?  And then \nsecondly, within that, can you just remind us again sort of what the \u2013 obviously, the earnings this year \nare back half -weighted \u2013 just remind us what the tailwinds that we should be considering as we build \nout our model for the remainder of this fiscal year?  And then, lastly, those higher freight and shipping ", "original_text": "And then, lastly, those higher freight and shipping ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9dba49e8010b0ee34b93bae3eb92d04febf197627b8c026ccab4768405c70526", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5e4f0e9-d886-44af-b274-cab2f09f6b4a", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points. ", "original_text": "Thanks.  \n \n"}, "hash": "85a479371bcbbd8603d2db61e890bbbc088f5aad4ba43c2ce59eca925ca126fb", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets? ", "start_char_idx": 0, "end_char_idx": 130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5e4f0e9-d886-44af-b274-cab2f09f6b4a": {"__data__": {"id_": "d5e4f0e9-d886-44af-b274-cab2f09f6b4a", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points. ", "original_text": "Thanks.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad4afe8b-fc81-4908-a259-54e898eff11c", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.  ", "original_text": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets? ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b0788624c705bab5c2c68d885059756fd43edf278352e79c369545d5336321d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f988bcb0-d57c-4b3f-ab4d-f1fac4a8150c", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n", "original_text": "Jason Hollar:  Okay, hi . "}, "hash": "10d05986398c188b66d16e52ba7022ae21af23fc0c5b5420f58f3d55dd757c71", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 130, "end_char_idx": 142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f988bcb0-d57c-4b3f-ab4d-f1fac4a8150c": {"__data__": {"id_": "f988bcb0-d57c-4b3f-ab4d-f1fac4a8150c", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n", "original_text": "Jason Hollar:  Okay, hi . ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5e4f0e9-d886-44af-b274-cab2f09f6b4a", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points. ", "original_text": "Thanks.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6d6b080fc3d8afd022c25ab18bfcab73115d334aca554380ecbf0bb8a328ea2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a0c31ea-1608-4066-b33d-e6e290f0b14a", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary. ", "original_text": "Good morning.  "}, "hash": "e2eb247e3f302c194a075722894889ac3a4e36cb318b06726bea416afbf4c258", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Okay, hi . ", "start_char_idx": 142, "end_char_idx": 168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a0c31ea-1608-4066-b33d-e6e290f0b14a": {"__data__": {"id_": "5a0c31ea-1608-4066-b33d-e6e290f0b14a", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary. ", "original_text": "Good morning.  ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f988bcb0-d57c-4b3f-ab4d-f1fac4a8150c", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n", "original_text": "Jason Hollar:  Okay, hi . ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5c5eb1c62dea38ec44a7a0ff23b49fe804100926ec688a53bf6c54e2dd061ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f3b4804-c08e-4caf-807d-d89fa65ac418", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term. ", "original_text": "Yes, this is Jason, I'll try to capture all those points. "}, "hash": "8488ae04db86d2ab30b175d5af5b968d00ab71a7e064c13bfbd1449d0948172b", "class_name": "RelatedNodeInfo"}}, "text": "Good morning.  ", "start_char_idx": 168, "end_char_idx": 183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f3b4804-c08e-4caf-807d-d89fa65ac418": {"__data__": {"id_": "9f3b4804-c08e-4caf-807d-d89fa65ac418", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term. ", "original_text": "Yes, this is Jason, I'll try to capture all those points. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a0c31ea-1608-4066-b33d-e6e290f0b14a", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary. ", "original_text": "Good morning.  ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4456771cb089a04e73723d75fb62e703459554fb8a4a51729e2e9c22e4b2c510", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dcdf35b-8bd2-4d8a-953f-fc6a24f5ba35", "node_type": "1", "metadata": {"window": "Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term. ", "original_text": "Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n"}, "hash": "13c71670d8ebd57679a1485f9a1c45bb723775f8f999a8742d463f04ab160bf8", "class_name": "RelatedNodeInfo"}}, "text": "Yes, this is Jason, I'll try to capture all those points. ", "start_char_idx": 183, "end_char_idx": 241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dcdf35b-8bd2-4d8a-953f-fc6a24f5ba35": {"__data__": {"id_": "2dcdf35b-8bd2-4d8a-953f-fc6a24f5ba35", "embedding": null, "metadata": {"window": "Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term. ", "original_text": "Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f3b4804-c08e-4caf-807d-d89fa65ac418", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term. ", "original_text": "Yes, this is Jason, I'll try to capture all those points. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeea325a6de03731823befcb2893a28d4f2a011669761251cc2f11adad50d8fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4dc018a-4a52-44cc-90e4-7f3358b13224", "node_type": "1", "metadata": {"window": "Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right? ", "original_text": "As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary. "}, "hash": "e9cb27c1770e9907aaaa7c0e2f210bd5af9808147728221e468a05b7ab1b5879", "class_name": "RelatedNodeInfo"}}, "text": "Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n", "start_char_idx": 241, "end_char_idx": 357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4dc018a-4a52-44cc-90e4-7f3358b13224": {"__data__": {"id_": "c4dc018a-4a52-44cc-90e4-7f3358b13224", "embedding": null, "metadata": {"window": "Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right? ", "original_text": "As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dcdf35b-8bd2-4d8a-953f-fc6a24f5ba35", "node_type": "1", "metadata": {"window": "Jason Hollar:  Okay, hi .  Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term. ", "original_text": "Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdc236ded0628b2a052e5359acc444a960ecc35650483ff2257c195081daba9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "716c16c0-4f76-4b99-b4b5-2a9288fa738a", "node_type": "1", "metadata": {"window": "Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets. ", "original_text": "It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term. "}, "hash": "81245781204d81abd27c054fc4c6652368978f0e5dc6017677aeade368dd39a3", "class_name": "RelatedNodeInfo"}}, "text": "As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary. ", "start_char_idx": 357, "end_char_idx": 512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "716c16c0-4f76-4b99-b4b5-2a9288fa738a": {"__data__": {"id_": "716c16c0-4f76-4b99-b4b5-2a9288fa738a", "embedding": null, "metadata": {"window": "Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets. ", "original_text": "It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4dc018a-4a52-44cc-90e4-7f3358b13224", "node_type": "1", "metadata": {"window": "Good morning.   Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right? ", "original_text": "As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cb3c4edb4c0f3705b025090494127a0b051a417c93ddf2835fd8204d4172fef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc8a51d1-77ce-47d8-bc1e-c96e094a8408", "node_type": "1", "metadata": {"window": "Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs. ", "original_text": "And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term. "}, "hash": "0b022cba0fefb5cf5a568ccb6560ab4d3d6d7bfeea9fac46eb3b6e793c25738b", "class_name": "RelatedNodeInfo"}}, "text": "It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term. ", "start_char_idx": 512, "end_char_idx": 607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc8a51d1-77ce-47d8-bc1e-c96e094a8408": {"__data__": {"id_": "bc8a51d1-77ce-47d8-bc1e-c96e094a8408", "embedding": null, "metadata": {"window": "Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs. ", "original_text": "And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "716c16c0-4f76-4b99-b4b5-2a9288fa738a", "node_type": "1", "metadata": {"window": "Yes, this is Jason, I'll try to capture all those points.  Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets. ", "original_text": "It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86579fcf6efc39fa0a4827dd627f748b030cff14a947785094af2a10f00ef16b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95215568-0d20-4eab-8183-9cedaebe6ea0", "node_type": "1", "metadata": {"window": "As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n", "original_text": "And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right? "}, "hash": "a5e5222277e744f330b1f8145a90c4a3560dca1f01b89569997aa75090156bf0", "class_name": "RelatedNodeInfo"}}, "text": "And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term. ", "start_char_idx": 607, "end_char_idx": 755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95215568-0d20-4eab-8183-9cedaebe6ea0": {"__data__": {"id_": "95215568-0d20-4eab-8183-9cedaebe6ea0", "embedding": null, "metadata": {"window": "As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n", "original_text": "And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right? ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc8a51d1-77ce-47d8-bc1e-c96e094a8408", "node_type": "1", "metadata": {"window": "Your \nquestion is certainly fair as it relates to trying to define the baseline for those longer -term targets.  \n \n As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs. ", "original_text": "And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a1eee565720e4202d735762680b73879ab50b9b9fc6cd4ece1ed2ef0a7aa52a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d39fde06-a319-41df-a697-e96f466ebf40", "node_type": "1", "metadata": {"window": "It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs. ", "original_text": "So it is in a \nmore normalized state when we provide those targets. "}, "hash": "ad0902edb5e93041ec38fdd3fb20e3c9ee5c6c55e89710640efd566a62012223", "class_name": "RelatedNodeInfo"}}, "text": "And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right? ", "start_char_idx": 755, "end_char_idx": 861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d39fde06-a319-41df-a697-e96f466ebf40": {"__data__": {"id_": "d39fde06-a319-41df-a697-e96f466ebf40", "embedding": null, "metadata": {"window": "It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs. ", "original_text": "So it is in a \nmore normalized state when we provide those targets. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95215568-0d20-4eab-8183-9cedaebe6ea0", "node_type": "1", "metadata": {"window": "As we indicated in the remarks today, we do anticipate this additional $100 million to $125 million \nrelated to the inflationary environment as temporary.  It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n", "original_text": "And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right? ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31a4110a99acd176aafc493b422d298c9ada710847e28f3c8211ccf3bf00026e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e12a19b4-b628-4c76-80e6-2aa8c7d7b318", "node_type": "1", "metadata": {"window": "And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities. ", "original_text": "You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs. "}, "hash": "a701912bb383f8d27b9ed189d18121756aca2b7d45023c2e5fadaec22aa3589d", "class_name": "RelatedNodeInfo"}}, "text": "So it is in a \nmore normalized state when we provide those targets. ", "start_char_idx": 861, "end_char_idx": 929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e12a19b4-b628-4c76-80e6-2aa8c7d7b318": {"__data__": {"id_": "e12a19b4-b628-4c76-80e6-2aa8c7d7b318", "embedding": null, "metadata": {"window": "And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities. ", "original_text": "You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d39fde06-a319-41df-a697-e96f466ebf40", "node_type": "1", "metadata": {"window": "It's difficult certainly to define exactly if that's \nshort term, medium term, or longer term.  And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs. ", "original_text": "So it is in a \nmore normalized state when we provide those targets. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ecf332da01350728422fb4d7bb778253c8a604d389865131425990d82152d18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0380933a-c072-4497-b842-3c69aa2904ec", "node_type": "1", "metadata": {"window": "And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States. ", "original_text": "But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n"}, "hash": "9a673f480c766d6de47b3eb239584aef527ac1fcb85002c33501c2bc0f6266f1", "class_name": "RelatedNodeInfo"}}, "text": "You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs. ", "start_char_idx": 929, "end_char_idx": 1103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0380933a-c072-4497-b842-3c69aa2904ec": {"__data__": {"id_": "0380933a-c072-4497-b842-3c69aa2904ec", "embedding": null, "metadata": {"window": "And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States. ", "original_text": "But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e12a19b4-b628-4c76-80e6-2aa8c7d7b318", "node_type": "1", "metadata": {"window": "And at the  current moment, we would expect those to revert \nback to some normalized level in a time frame that is relatively short to medium term.  And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities. ", "original_text": "You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3d35071d5ab995011132868264fccebe12be0dcfdc12e8a16d42a7236333bdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7be62860-c765-4554-90b8-80a9ffdc325b", "node_type": "1", "metadata": {"window": "So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels. ", "original_text": "And then as it relates to more specifics around the elevated supply chain  costs. "}, "hash": "e8ef75dd0a0ca9692298914fa1a360a049afef69f4132c6ddff84243b47c479c", "class_name": "RelatedNodeInfo"}}, "text": "But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n", "start_char_idx": 1103, "end_char_idx": 1324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7be62860-c765-4554-90b8-80a9ffdc325b": {"__data__": {"id_": "7be62860-c765-4554-90b8-80a9ffdc325b", "embedding": null, "metadata": {"window": "So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels. ", "original_text": "And then as it relates to more specifics around the elevated supply chain  costs. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0380933a-c072-4497-b842-3c69aa2904ec", "node_type": "1", "metadata": {"window": "And so when \nwe talk about these longer -term targets, we are not presuming that type of tailwind, right?  So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States. ", "original_text": "But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a07970a2f79e3f40d8160cf82eafc45f545bb5e8ef9af0359b49cbe59926a3c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9379087b-37b1-4c2a-a605-7af6cb38e11c", "node_type": "1", "metadata": {"window": "You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future. ", "original_text": "We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities. "}, "hash": "06417e6f230f200ff274ed5a28a78a32565a309f691eecaf46d02c5e512b6e41", "class_name": "RelatedNodeInfo"}}, "text": "And then as it relates to more specifics around the elevated supply chain  costs. ", "start_char_idx": 1324, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9379087b-37b1-4c2a-a605-7af6cb38e11c": {"__data__": {"id_": "9379087b-37b1-4c2a-a605-7af6cb38e11c", "embedding": null, "metadata": {"window": "You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future. ", "original_text": "We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7be62860-c765-4554-90b8-80a9ffdc325b", "node_type": "1", "metadata": {"window": "So it is in a \nmore normalized state when we provide those targets.  You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels. ", "original_text": "And then as it relates to more specifics around the elevated supply chain  costs. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ea90ae003c63365b55d4c0dd6156a11778d4f742494f63cc6941329746e48d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fc86513-8e91-47c3-8089-637ae98202b7", "node_type": "1", "metadata": {"window": "But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene. ", "original_text": "In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States. "}, "hash": "c2e305a49e9f2b47943cc3818452864405e8eb2c1c706e3e6b2f0edee6ae4547", "class_name": "RelatedNodeInfo"}}, "text": "We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities. ", "start_char_idx": 1406, "end_char_idx": 1523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fc86513-8e91-47c3-8089-637ae98202b7": {"__data__": {"id_": "8fc86513-8e91-47c3-8089-637ae98202b7", "embedding": null, "metadata": {"window": "But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene. ", "original_text": "In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9379087b-37b1-4c2a-a605-7af6cb38e11c", "node_type": "1", "metadata": {"window": "You referenced 5 years, I'd say 3 to 5 years is \na reasonable type of time frame for average types of performance levels to get a broad perspective \non the ins and the outs.  But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future. ", "original_text": "We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e97d0820aaa1e3d75c92ec6afcb4a7c19319447b26a814e956646c929de9161e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c578a7e8-f1bc-49e4-b45b-e37dea63f901", "node_type": "1", "metadata": {"window": "And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically. ", "original_text": "We're seeing that cost \nup 8 to 10 times versus pre -COVID levels. "}, "hash": "c89d24fedab9eab851167b1be4704875251e1aaee8913d36effa391b224a31aa", "class_name": "RelatedNodeInfo"}}, "text": "In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States. ", "start_char_idx": 1523, "end_char_idx": 1819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c578a7e8-f1bc-49e4-b45b-e37dea63f901": {"__data__": {"id_": "c578a7e8-f1bc-49e4-b45b-e37dea63f901", "embedding": null, "metadata": {"window": "And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically. ", "original_text": "We're seeing that cost \nup 8 to 10 times versus pre -COVID levels. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fc86513-8e91-47c3-8089-637ae98202b7", "node_type": "1", "metadata": {"window": "But we would not expect big shock s associated with items like that, \ndivestitures and acquisitions, things of that nature would also be normalized out of that so that we're \ngetting at that core type of performance.  \n \n And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene. ", "original_text": "In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d85b03c43cd57ef6b20ec6227c54af873dc202630531679e253d88a63eab91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7279f662-6d2c-400f-be00-00dc6f6b8656", "node_type": "1", "metadata": {"window": "We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future. ", "original_text": "Certainly, we would expect tha t to be significantly lower at \nsome point in the future. "}, "hash": "a5a982af1549ce7530e49828f7212f27a12ebc950419c71bbef4fe6b0b903dbb", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing that cost \nup 8 to 10 times versus pre -COVID levels. ", "start_char_idx": 1819, "end_char_idx": 1886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7279f662-6d2c-400f-be00-00dc6f6b8656": {"__data__": {"id_": "7279f662-6d2c-400f-be00-00dc6f6b8656", "embedding": null, "metadata": {"window": "We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future. ", "original_text": "Certainly, we would expect tha t to be significantly lower at \nsome point in the future. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c578a7e8-f1bc-49e4-b45b-e37dea63f901", "node_type": "1", "metadata": {"window": "And then as it relates to more specifics around the elevated supply chain  costs.  We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically. ", "original_text": "We're seeing that cost \nup 8 to 10 times versus pre -COVID levels. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbd0787f9d455ab25883aba0d25f6b277b52fe7017f57a78fb612f022ed9eaed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62949e60-24e6-4a7a-bb03-3edb34c3634c", "node_type": "1", "metadata": {"window": "In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n", "original_text": "And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene. "}, "hash": "8bb3b95b90c3a2e15746572a17e09f56fe6aa2e8a926bed22a6de6beb9eda007", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, we would expect tha t to be significantly lower at \nsome point in the future. ", "start_char_idx": 1886, "end_char_idx": 1975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62949e60-24e6-4a7a-bb03-3edb34c3634c": {"__data__": {"id_": "62949e60-24e6-4a7a-bb03-3edb34c3634c", "embedding": null, "metadata": {"window": "In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n", "original_text": "And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7279f662-6d2c-400f-be00-00dc6f6b8656", "node_type": "1", "metadata": {"window": "We highlighted within \nour remarks that it's really just 2 key areas: the international freight and the commodities.  In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future. ", "original_text": "Certainly, we would expect tha t to be significantly lower at \nsome point in the future. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e24b1e4858641034b40a127181c6dbbc5fdef8b694ba8c11524b1e417d604f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98dff14b-4c0a-4971-a6ba-252f832d7663", "node_type": "1", "metadata": {"window": "We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume. ", "original_text": "Those levels are more like 2x what we've seen historically. "}, "hash": "331eeae61b89b14726d2f7add84106aa530a44fd986e6960b68215313cc7d8eb", "class_name": "RelatedNodeInfo"}}, "text": "And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene. ", "start_char_idx": 1975, "end_char_idx": 2081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98dff14b-4c0a-4971-a6ba-252f832d7663": {"__data__": {"id_": "98dff14b-4c0a-4971-a6ba-252f832d7663", "embedding": null, "metadata": {"window": "We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume. ", "original_text": "Those levels are more like 2x what we've seen historically. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62949e60-24e6-4a7a-bb03-3edb34c3634c", "node_type": "1", "metadata": {"window": "In both \ncases, the reason we believe that they're temporary is that they are at multiple levels higher than \nwhat we've historically seen on international freight, which is essentially the cost of getting a shipping \ncontainer shipped from overseas locations, such as Asia to the United States.  We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n", "original_text": "And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "850edec5d520fa8456857867bec810649d86fae9d9e0255b129aeee40102a2c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3593808a-bf41-46db-bb7f-7aa50c3164f1", "node_type": "1", "metadata": {"window": "Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected. ", "original_text": "So \nagain, we would expect those to  get back to a more normalized state at some point in the future. "}, "hash": "fb6082a5daef6f2012dca14ed6c77e272d7d775ca5cdddfd65d471be393d52d6", "class_name": "RelatedNodeInfo"}}, "text": "Those levels are more like 2x what we've seen historically. ", "start_char_idx": 2081, "end_char_idx": 2141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3593808a-bf41-46db-bb7f-7aa50c3164f1": {"__data__": {"id_": "3593808a-bf41-46db-bb7f-7aa50c3164f1", "embedding": null, "metadata": {"window": "Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected. ", "original_text": "So \nagain, we would expect those to  get back to a more normalized state at some point in the future. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98dff14b-4c0a-4971-a6ba-252f832d7663", "node_type": "1", "metadata": {"window": "We're seeing that cost \nup 8 to 10 times versus pre -COVID levels.  Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume. ", "original_text": "Those levels are more like 2x what we've seen historically. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "348705529971458e85930a869077a07d25f76f30a9fb0836ebf44dc1547ec7b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56f4bb68-0e16-44f8-a25b-b85d22919a3d", "node_type": "1", "metadata": {"window": "And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters. ", "original_text": "But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n"}, "hash": "53bd69418641601cbe89cf32478f486f075dcd1e8e1f9eb61719a7a5c23f3a3b", "class_name": "RelatedNodeInfo"}}, "text": "So \nagain, we would expect those to  get back to a more normalized state at some point in the future. ", "start_char_idx": 2141, "end_char_idx": 2243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56f4bb68-0e16-44f8-a25b-b85d22919a3d": {"__data__": {"id_": "56f4bb68-0e16-44f8-a25b-b85d22919a3d", "embedding": null, "metadata": {"window": "And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters. ", "original_text": "But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3593808a-bf41-46db-bb7f-7aa50c3164f1", "node_type": "1", "metadata": {"window": "Certainly, we would expect tha t to be significantly lower at \nsome point in the future.  And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected. ", "original_text": "So \nagain, we would expect those to  get back to a more normalized state at some point in the future. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc67e197c87c5c349d40ed4d18954cd7b2fcd580762e9b7a401adf35026f2d12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01b2cd11-dcc2-4418-b961-c4d29dfeb4ef", "node_type": "1", "metadata": {"window": "Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4. ", "original_text": "And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume. "}, "hash": "bbb7742c1eedc544708b1cebc9f52c900936a53568ff56136fd8c8b207e9d444", "class_name": "RelatedNodeInfo"}}, "text": "But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n", "start_char_idx": 2243, "end_char_idx": 2346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01b2cd11-dcc2-4418-b961-c4d29dfeb4ef": {"__data__": {"id_": "01b2cd11-dcc2-4418-b961-c4d29dfeb4ef", "embedding": null, "metadata": {"window": "Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4. ", "original_text": "And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56f4bb68-0e16-44f8-a25b-b85d22919a3d", "node_type": "1", "metadata": {"window": "And on the commodities, we're talking about a lot of different types of \npolymers, such as polypropylene.  Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters. ", "original_text": "But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd5cc28c2aefee11775e45f54131eb62908ff5be4b7763f57c4a683f882779d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "294a8623-fd69-4b87-a01d-e7da861126a5", "node_type": "1", "metadata": {"window": "So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n", "original_text": "So that continues to be as e xpected. "}, "hash": "b209dc894453e8cb8bc615d4269fe1c3aa5b66d98a425080543c415e801892ce", "class_name": "RelatedNodeInfo"}}, "text": "And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume. ", "start_char_idx": 2346, "end_char_idx": 2669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "294a8623-fd69-4b87-a01d-e7da861126a5": {"__data__": {"id_": "294a8623-fd69-4b87-a01d-e7da861126a5", "embedding": null, "metadata": {"window": "So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n", "original_text": "So that continues to be as e xpected. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01b2cd11-dcc2-4418-b961-c4d29dfeb4ef", "node_type": "1", "metadata": {"window": "Those levels are more like 2x what we've seen historically.  So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4. ", "original_text": "And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681ba59a703fbea9934d5a03785b17fc4e44a7e45814c530b1962d8819c98f5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56ffdfbb-d918-42f7-b9b5-d29b02ddc6a4", "node_type": "1", "metadata": {"window": "But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that. ", "original_text": "And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters. "}, "hash": "e20d0186fcdcf61a95a9a1d7fb374eb79da96d747d39f80b2f8805b7d1079409", "class_name": "RelatedNodeInfo"}}, "text": "So that continues to be as e xpected. ", "start_char_idx": 2669, "end_char_idx": 2707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56ffdfbb-d918-42f7-b9b5-d29b02ddc6a4": {"__data__": {"id_": "56ffdfbb-d918-42f7-b9b5-d29b02ddc6a4", "embedding": null, "metadata": {"window": "But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that. ", "original_text": "And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "294a8623-fd69-4b87-a01d-e7da861126a5", "node_type": "1", "metadata": {"window": "So \nagain, we would expect those to  get back to a more normalized state at some point in the future.  But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n", "original_text": "So that continues to be as e xpected. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e855023ae4e2726cf1ff6b055b16a84be0b78ceaa2be601de812b919b0984fce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3056b351-137a-4cf8-adc5-e2787e26bf77", "node_type": "1", "metadata": {"window": "And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat. ", "original_text": "Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4. "}, "hash": "1d88068491f8d8e30413e26d798b0a0873a64ff8d2e1ccf28510d24e3094bd85", "class_name": "RelatedNodeInfo"}}, "text": "And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters. ", "start_char_idx": 2707, "end_char_idx": 2860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3056b351-137a-4cf8-adc5-e2787e26bf77": {"__data__": {"id_": "3056b351-137a-4cf8-adc5-e2787e26bf77", "embedding": null, "metadata": {"window": "And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat. ", "original_text": "Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56ffdfbb-d918-42f7-b9b5-d29b02ddc6a4", "node_type": "1", "metadata": {"window": "But \nagain, those are not tailwinds to get us to these targets, those targets are more normalized.  \n \n And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that. ", "original_text": "And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e914821432dc1c414d4d9da4a7dc03c50f008e8927a6e69a75ad1b580d96bf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24a9bc83-b6ea-4313-ab25-b6141dee1f11", "node_type": "1", "metadata": {"window": "So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing. ", "original_text": "So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n"}, "hash": "9ff73a8a8ee02f9d8788ffa04b8885ff6232c3cee7539be9dac122a1ef3bcf74", "class_name": "RelatedNodeInfo"}}, "text": "Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4. ", "start_char_idx": 2860, "end_char_idx": 2991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24a9bc83-b6ea-4313-ab25-b6141dee1f11": {"__data__": {"id_": "24a9bc83-b6ea-4313-ab25-b6141dee1f11", "embedding": null, "metadata": {"window": "So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing. ", "original_text": "So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3056b351-137a-4cf8-adc5-e2787e26bf77", "node_type": "1", "metadata": {"window": "And in terms of the second half, different cadence of our results for the various businesse s, we did \nindicate that \u2013 well, with Pharma, we would expect the second half to continue to improve steadily \nversus where we're at today just as it relates to getting back to more normalized state for underlying \ngeneric volume.  So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat. ", "original_text": "Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7526b02f04393d9ae507b9a05884ae43d6b2778ccef0e82c8f6cd358ffdd1849", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "227b8164-6776-4c01-b43e-886ad9ae521c", "node_type": "1", "metadata": {"window": "And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence. ", "original_text": "On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that. "}, "hash": "bbaf6055bd92f00c62de02de27cbb59c1207029eed1186e93c839850b1eea253", "class_name": "RelatedNodeInfo"}}, "text": "So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n", "start_char_idx": 2991, "end_char_idx": 3079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "227b8164-6776-4c01-b43e-886ad9ae521c": {"__data__": {"id_": "227b8164-6776-4c01-b43e-886ad9ae521c", "embedding": null, "metadata": {"window": "And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence. ", "original_text": "On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24a9bc83-b6ea-4313-ab25-b6141dee1f11", "node_type": "1", "metadata": {"window": "So that continues to be as e xpected.  And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing. ", "original_text": "So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b40d6ceae063645599e05fbaf29bcb2f254bed8f1354cad0f513f3972a4b295", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1c3a140-36e4-4382-a37c-76902a961bec", "node_type": "1", "metadata": {"window": "Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar. ", "original_text": "And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat. "}, "hash": "a74ddd35da256b3177921dda374d067e922b0c4b277808a0b42a8f337b80cfee", "class_name": "RelatedNodeInfo"}}, "text": "On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that. ", "start_char_idx": 3079, "end_char_idx": 3312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1c3a140-36e4-4382-a37c-76902a961bec": {"__data__": {"id_": "f1c3a140-36e4-4382-a37c-76902a961bec", "embedding": null, "metadata": {"window": "Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar. ", "original_text": "And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "227b8164-6776-4c01-b43e-886ad9ae521c", "node_type": "1", "metadata": {"window": "And also as expected, our investments in our \ntechnology investments we indicated would be front -end loaded, especially with the first three \nquarters.  Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence. ", "original_text": "On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1aa83ef3480e6fa7139a1783f932651b0caa3acf10c8014376a8685393e1caca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d3691b3-27fd-4dc6-bcb6-c6fe13c11060", "node_type": "1", "metadata": {"window": "So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing. "}, "hash": "f48c12a872af516ca538635da4440ae542a94e28281df3c92ed099f662e5f107", "class_name": "RelatedNodeInfo"}}, "text": "And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat. ", "start_char_idx": 3312, "end_char_idx": 3423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d3691b3-27fd-4dc6-bcb6-c6fe13c11060": {"__data__": {"id_": "0d3691b3-27fd-4dc6-bcb6-c6fe13c11060", "embedding": null, "metadata": {"window": "So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1c3a140-36e4-4382-a37c-76902a961bec", "node_type": "1", "metadata": {"window": "Primarily as it relates to that fourth quarter, we started to implement those cost increases in \nthe final implementation last Q4.  So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar. ", "original_text": "And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2014f7c5a0907e5666fc5f299721b52f3562a2dbc94205184e8f365be968a86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51282aaf-3053-46fb-9906-828663f1884c", "node_type": "1", "metadata": {"window": "On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "So we have that Q1 to Q2 cadence. "}, "hash": "43719799129dc5da4fb5db9d363c7bbc378c52844f43fa580a86506d2fe88432", "class_name": "RelatedNodeInfo"}}, "text": "In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing. ", "start_char_idx": 3423, "end_char_idx": 3531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51282aaf-3053-46fb-9906-828663f1884c": {"__data__": {"id_": "51282aaf-3053-46fb-9906-828663f1884c", "embedding": null, "metadata": {"window": "On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "So we have that Q1 to Q2 cadence. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d3691b3-27fd-4dc6-bcb6-c6fe13c11060", "node_type": "1", "metadata": {"window": "So we start to get the full year effect of that as we exit the third \nquarter here.  \n \n On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aa0ff1bb48e67c51195fac466bf1ce4de58300f7a7b7543eb3e1ea5b923690b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba6366bd-82a6-4a31-b85b-e5a885c34228", "node_type": "1", "metadata": {"window": "And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar. "}, "hash": "1e1eac58795bf9743f631c476ee81694add31e96fb309f04e7c19117c5f41b46", "class_name": "RelatedNodeInfo"}}, "text": "So we have that Q1 to Q2 cadence. ", "start_char_idx": 3531, "end_char_idx": 3565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba6366bd-82a6-4a31-b85b-e5a885c34228": {"__data__": {"id_": "ba6366bd-82a6-4a31-b85b-e5a885c34228", "embedding": null, "metadata": {"window": "And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51282aaf-3053-46fb-9906-828663f1884c", "node_type": "1", "metadata": {"window": "On the Medical side, we did indicate a sequential decline from Q1 to Q2 and that's just related to the \ntiming of realizing the supply chain  costs I was just walking through, and all the mitigating actions that \ngo along with that.  And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "So we have that Q1 to Q2 cadence. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8f58075544e58ab449aa3a92d039c324e89730c068e625bd9772949e3830c82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3d67f08-3a7c-491d-87bd-98d6f17fcb79", "node_type": "1", "metadata": {"window": "In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "And then in all of our businesses, we expect ongoing stronger "}, "hash": "f33ae2882974eb5438ad223235591c1f6b0b9413e5c55f1b72214d7a12e9ff18", "class_name": "RelatedNodeInfo"}}, "text": "And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar. ", "start_char_idx": 3565, "end_char_idx": 3743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3d67f08-3a7c-491d-87bd-98d6f17fcb79": {"__data__": {"id_": "a3d67f08-3a7c-491d-87bd-98d6f17fcb79", "embedding": null, "metadata": {"window": "In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "And then in all of our businesses, we expect ongoing stronger ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "205fea278cec8605c0e13f114d3ae362140358779afb3a99fe8cd42143a3fff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba6366bd-82a6-4a31-b85b-e5a885c34228", "node_type": "1", "metadata": {"window": "And then also recall that we cited the COVID favorability in Q2 of last year, that is \nnot expected to repeat.  In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar. ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68e03e7ad292ff4742045d6d4bdca4e94104eeee51a6f4ee4febd3ee8812aba8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f1ea861-abeb-4fcf-a99c-d749605e20cf", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you. ", "original_text": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year. "}, "hash": "4312714764b6021b6712a0878ae247e5eb0c639c16fecca4b8b31eb004f2004a", "class_name": "RelatedNodeInfo"}}, "text": "And then in all of our businesses, we expect ongoing stronger ", "start_char_idx": 3743, "end_char_idx": 3805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f1ea861-abeb-4fcf-a99c-d749605e20cf": {"__data__": {"id_": "4f1ea861-abeb-4fcf-a99c-d749605e20cf", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you. ", "original_text": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3d67f08-3a7c-491d-87bd-98d6f17fcb79", "node_type": "1", "metadata": {"window": "In fact, we expect that to be a headwind this 2Q, prima rily as a result of the \nPPE price and cost timing.  So we have that Q1 to Q2 cadence.  And then of course, in the fourth \nquarter of this fiscal year, we'd expect a significant COVID tailwind associated with the comparison \nbenefit from the PPE in the prior ye ar.  And then in all of our businesses, we expect ongoing stronger ", "original_text": "And then in all of our businesses, we expect ongoing stronger ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7de311fac0a021b542379b99e8ed003719ef5ed1187066cdd984287da87f75ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94e42d7d-7741-4d1a-adce-8cdd13b94986", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary. ", "original_text": "Next question.  \n \n"}, "hash": "1b2741648a582a2e295508af278d4d39e14df77b224389041848c967c1da24e0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year. ", "start_char_idx": 0, "end_char_idx": 180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94e42d7d-7741-4d1a-adce-8cdd13b94986": {"__data__": {"id_": "94e42d7d-7741-4d1a-adce-8cdd13b94986", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary. ", "original_text": "Next question.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f1ea861-abeb-4fcf-a99c-d749605e20cf", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you. ", "original_text": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f0df2a3444a8cadc90620aeae7e5ce0183730d627abb2b7e040808409a0d400", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9084a20d-f4a7-4c33-9a90-579a4df55962", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere. ", "original_text": "Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n"}, "hash": "d43ec86a9e6e2cf474d65e16e9d0800312f51b16c69980619d468a4a6ff16268", "class_name": "RelatedNodeInfo"}}, "text": "Next question.  \n \n", "start_char_idx": 180, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9084a20d-f4a7-4c33-9a90-579a4df55962": {"__data__": {"id_": "9084a20d-f4a7-4c33-9a90-579a4df55962", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere. ", "original_text": "Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94e42d7d-7741-4d1a-adce-8cdd13b94986", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary. ", "original_text": "Next question.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fa3ec98abc22c0cfc11f538bdc94890cfa62a0b3f637fab56040b891277131a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc0ae8f9-29a1-4a47-b6d4-953410a86d77", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there. ", "original_text": "Eric Percher:  Thank you. "}, "hash": "3c2db59c6235809a0e4f3bec916b82824a0b15a0e5b92701807f5d5c5b37f314", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n", "start_char_idx": 199, "end_char_idx": 284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc0ae8f9-29a1-4a47-b6d4-953410a86d77": {"__data__": {"id_": "fc0ae8f9-29a1-4a47-b6d4-953410a86d77", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there. ", "original_text": "Eric Percher:  Thank you. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9084a20d-f4a7-4c33-9a90-579a4df55962", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere. ", "original_text": "Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0892e9919780f15bb3cf321bb79e4cb147f907d4d8eba8dc9e9743b1f5c8a142", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16f04b7a-789c-4643-9a35-36f4eb0fe087", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade? ", "original_text": "Appreciate the supply chain commentary. "}, "hash": "10d087452962130aea1ac725371bb9a7a6c20134bd96b3672ee832cb9b1171d2", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:  Thank you. ", "start_char_idx": 284, "end_char_idx": 310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16f04b7a-789c-4643-9a35-36f4eb0fe087": {"__data__": {"id_": "16f04b7a-789c-4643-9a35-36f4eb0fe087", "embedding": null, "metadata": {"window": "Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade? ", "original_text": "Appreciate the supply chain commentary. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc0ae8f9-29a1-4a47-b6d4-953410a86d77", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there. ", "original_text": "Eric Percher:  Thank you. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0fe4eb968b13c992108ff403d3530bb3d62a7e8628a6770c512316541857c70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "605faf57-dd2c-432c-8208-cf703c4a5404", "node_type": "1", "metadata": {"window": "Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n", "original_text": "I'd like to get a little bit deeper \nhere. "}, "hash": "7c016c39e307a8942a668cad3da46f24865954322730c94503cc46a37c5e9ae3", "class_name": "RelatedNodeInfo"}}, "text": "Appreciate the supply chain commentary. ", "start_char_idx": 310, "end_char_idx": 350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "605faf57-dd2c-432c-8208-cf703c4a5404": {"__data__": {"id_": "605faf57-dd2c-432c-8208-cf703c4a5404", "embedding": null, "metadata": {"window": "Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n", "original_text": "I'd like to get a little bit deeper \nhere. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16f04b7a-789c-4643-9a35-36f4eb0fe087", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade? ", "original_text": "Appreciate the supply chain commentary. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7fe42ae459e5791369690a8b748ac3b315ac7097d45d33541cbe74d4bd5597d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e405582-73c7-47d4-b0c9-754cfe3e7746", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question. ", "original_text": "We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there. "}, "hash": "fbbcb6dfbbbd22cdb2df9846b038b3511aeb22340b6105ff508a330bd4cad3cc", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to get a little bit deeper \nhere. ", "start_char_idx": 350, "end_char_idx": 393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e405582-73c7-47d4-b0c9-754cfe3e7746": {"__data__": {"id_": "0e405582-73c7-47d4-b0c9-754cfe3e7746", "embedding": null, "metadata": {"window": "Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question. ", "original_text": "We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "605faf57-dd2c-432c-8208-cf703c4a5404", "node_type": "1", "metadata": {"window": "Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n", "original_text": "I'd like to get a little bit deeper \nhere. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fff049f4e4a6cd28d101900f54da6e73a551e61ee5f95a0d3279be2aa0b74de5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43753e7f-2442-47e5-b4ab-22c545f141f8", "node_type": "1", "metadata": {"window": "Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help. ", "original_text": "And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade? "}, "hash": "d446a6102b11b60ceef204d196352873b22528b3389cfdde858b3de53b05a436", "class_name": "RelatedNodeInfo"}}, "text": "We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there. ", "start_char_idx": 393, "end_char_idx": 567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43753e7f-2442-47e5-b4ab-22c545f141f8": {"__data__": {"id_": "43753e7f-2442-47e5-b4ab-22c545f141f8", "embedding": null, "metadata": {"window": "Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help. ", "original_text": "And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade? ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e405582-73c7-47d4-b0c9-754cfe3e7746", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.  Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question. ", "original_text": "We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf59db16ab0580a9d8434d3189fe4776d94eac58ff275197cc6649002f8a201e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cbb097b-da73-4f60-9a60-055f99d7d06b", "node_type": "1", "metadata": {"window": "I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost. ", "original_text": "And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n"}, "hash": "ff71abb6e09e4250e57d864f87e80e1282203afbc1b1ab35ea63750abb0629f9", "class_name": "RelatedNodeInfo"}}, "text": "And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade? ", "start_char_idx": 567, "end_char_idx": 700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cbb097b-da73-4f60-9a60-055f99d7d06b": {"__data__": {"id_": "7cbb097b-da73-4f60-9a60-055f99d7d06b", "embedding": null, "metadata": {"window": "I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost. ", "original_text": "And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43753e7f-2442-47e5-b4ab-22c545f141f8", "node_type": "1", "metadata": {"window": "Appreciate the supply chain commentary.  I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help. ", "original_text": "And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade? ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d024b10cd89073fad5b2f7f4f78b94c7ad5d54849a8767ed2c09dcee8c2f6da0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cc84ce7-3b3b-423a-86fe-007ca4010b47", "node_type": "1", "metadata": {"window": "We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n", "original_text": "Mike Kaufmann:  Yes, thanks for the question. "}, "hash": "d191cb8380f83049112bd963a0be38be121d970e4119dda20c12aab936418b62", "class_name": "RelatedNodeInfo"}}, "text": "And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n", "start_char_idx": 700, "end_char_idx": 880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cc84ce7-3b3b-423a-86fe-007ca4010b47": {"__data__": {"id_": "1cc84ce7-3b3b-423a-86fe-007ca4010b47", "embedding": null, "metadata": {"window": "We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n", "original_text": "Mike Kaufmann:  Yes, thanks for the question. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cbb097b-da73-4f60-9a60-055f99d7d06b", "node_type": "1", "metadata": {"window": "I'd like to get a little bit deeper \nhere.  We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost. ", "original_text": "And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921760613e41f31e7788870d27f38e1fe1e88d78659e21f7bdfd6faa4de6d6d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae2f9902-f2c0-4729-a882-927a9885f7e5", "node_type": "1", "metadata": {"window": "And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities. ", "original_text": "So let me see if I could help. "}, "hash": "b0e169c8567585383b86b56a26ae4f2c4fa1389e623d7cc54914f653f269eef4", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, thanks for the question. ", "start_char_idx": 880, "end_char_idx": 926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae2f9902-f2c0-4729-a882-927a9885f7e5": {"__data__": {"id_": "ae2f9902-f2c0-4729-a882-927a9885f7e5", "embedding": null, "metadata": {"window": "And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities. ", "original_text": "So let me see if I could help. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cc84ce7-3b3b-423a-86fe-007ca4010b47", "node_type": "1", "metadata": {"window": "We used to have guidance on commodity impact, so I think anything you can provide relative to \n$17 million of revenue or the cost that you incur to give us some sense there.  And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n", "original_text": "Mike Kaufmann:  Yes, thanks for the question. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c5f1d165ff25a0032a1671913cb5bb614dc443dba791233051b48348587194", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98695a0a-47fb-44dc-86bd-f4abcf42301f", "node_type": "1", "metadata": {"window": "And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us. ", "original_text": "First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost. "}, "hash": "a6685b1419381caed94889d5ce6b917789fae255c3c01592d7d3b3e6d9e4dc6a", "class_name": "RelatedNodeInfo"}}, "text": "So let me see if I could help. ", "start_char_idx": 926, "end_char_idx": 957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98695a0a-47fb-44dc-86bd-f4abcf42301f": {"__data__": {"id_": "98695a0a-47fb-44dc-86bd-f4abcf42301f", "embedding": null, "metadata": {"window": "And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us. ", "original_text": "First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae2f9902-f2c0-4729-a882-927a9885f7e5", "node_type": "1", "metadata": {"window": "And then thinking about \ncommodity and freight, what is clearly passed along versus what represents a decision that has to be \nmade?  And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities. ", "original_text": "So let me see if I could help. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7206def7c3008f0808cc6dc81f931a27bc29596ecfeb434eae499a9987af4f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afde9dcb-5727-4887-ba9c-b2a0670bb231", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost. ", "original_text": "So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n"}, "hash": "fc5c5432de042830ba31b494fb2a699ac86334bbb4d91898552fb2b20b2c365a", "class_name": "RelatedNodeInfo"}}, "text": "First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost. ", "start_char_idx": 957, "end_char_idx": 1083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afde9dcb-5727-4887-ba9c-b2a0670bb231": {"__data__": {"id_": "afde9dcb-5727-4887-ba9c-b2a0670bb231", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost. ", "original_text": "So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98695a0a-47fb-44dc-86bd-f4abcf42301f", "node_type": "1", "metadata": {"window": "And what I'm really lookin g for is $100 million to $125 million of increased expense, what does \nthat represent relative to the total expense that you're seeing pass through?  \n \n Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us. ", "original_text": "First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d63620127146bb37b1c00f7a66bc0eadd7f7b01c4817d7db9fcd5a0b8ca0cc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3955dbe8-db0a-47e3-89cc-b076dd4a31cb", "node_type": "1", "metadata": {"window": "So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant. ", "original_text": "What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities. "}, "hash": "cf293d738695fdf37963763ad44e47f390132bb9cecaaa9f0d6eed63132a9cc3", "class_name": "RelatedNodeInfo"}}, "text": "So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n", "start_char_idx": 1083, "end_char_idx": 1364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3955dbe8-db0a-47e3-89cc-b076dd4a31cb": {"__data__": {"id_": "3955dbe8-db0a-47e3-89cc-b076dd4a31cb", "embedding": null, "metadata": {"window": "So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant. ", "original_text": "What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afde9dcb-5727-4887-ba9c-b2a0670bb231", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, thanks for the question.  So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost. ", "original_text": "So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9806384ad9d70f5f3467d9691dee6dcb21442f3b10306f2786297a1415da354f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f6494e4-2fe1-416b-a11f-8b532515f4ca", "node_type": "1", "metadata": {"window": "First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n", "original_text": "And those, we feel, will create an incremental $100 million to $125 million of \ncost for us. "}, "hash": "7cd2d57f133fe673cd82bea859fbe8605a0a6c97871f1e6504d5b906147fc7c3", "class_name": "RelatedNodeInfo"}}, "text": "What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities. ", "start_char_idx": 1364, "end_char_idx": 1591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f6494e4-2fe1-416b-a11f-8b532515f4ca": {"__data__": {"id_": "7f6494e4-2fe1-416b-a11f-8b532515f4ca", "embedding": null, "metadata": {"window": "First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n", "original_text": "And those, we feel, will create an incremental $100 million to $125 million of \ncost for us. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3955dbe8-db0a-47e3-89cc-b076dd4a31cb", "node_type": "1", "metadata": {"window": "So let me see if I could help.  First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant. ", "original_text": "What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e64592d0f32e728ce7fb003558131bb2f59e5622a8f226f31fb0cf35f54c3af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28597111-3490-4744-b228-6164919b9fd6", "node_type": "1", "metadata": {"window": "So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that? ", "original_text": "Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost. "}, "hash": "933b712071a9770733dfe8516153539ffb6086032749ae19642a3f9f78780dbe", "class_name": "RelatedNodeInfo"}}, "text": "And those, we feel, will create an incremental $100 million to $125 million of \ncost for us. ", "start_char_idx": 1591, "end_char_idx": 1684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28597111-3490-4744-b228-6164919b9fd6": {"__data__": {"id_": "28597111-3490-4744-b228-6164919b9fd6", "embedding": null, "metadata": {"window": "So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that? ", "original_text": "Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f6494e4-2fe1-416b-a11f-8b532515f4ca", "node_type": "1", "metadata": {"window": "First of all, we, as you \nknow,  called out in our fourth quarter of last year that we did expect elevated supply chain cost.  So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n", "original_text": "And those, we feel, will create an incremental $100 million to $125 million of \ncost for us. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "958c5e4eef3e27b527c507d25a4a77779d2b8f1fdf4b1eb5789d7dbf7ab1a0c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e9cf254-0a6c-4918-b4b6-096b768c98e7", "node_type": "1", "metadata": {"window": "What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through. ", "original_text": "So they were both very, very significant. "}, "hash": "c057d59abb8542afab3892afb9c2238a3715938943fd14b1e091ca85c549ac00", "class_name": "RelatedNodeInfo"}}, "text": "Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost. ", "start_char_idx": 1684, "end_char_idx": 1834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e9cf254-0a6c-4918-b4b6-096b768c98e7": {"__data__": {"id_": "5e9cf254-0a6c-4918-b4b6-096b768c98e7", "embedding": null, "metadata": {"window": "What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through. ", "original_text": "So they were both very, very significant. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28597111-3490-4744-b228-6164919b9fd6", "node_type": "1", "metadata": {"window": "So in \nour guidance for this year for the Medical segment, we already assumed a certain amount of elevated \nsupply chain cost, some of which we had planned already to offset through cost reductions, pricing \nactions and those types of things, and that was originally built in.  \n \n What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that? ", "original_text": "Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08d8ca7d7f7d2c3f88e992739c6c26f6a3bdc1fd95646f31ae281e4e3538b85f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a95f3b1f-b8a0-480d-b433-1061db96dd51", "node_type": "1", "metadata": {"window": "And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not. ", "original_text": "We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n"}, "hash": "19ae2ec272ac317ec0bba0422d256c96ef0f4c760f7c50fb756bd301d0940897", "class_name": "RelatedNodeInfo"}}, "text": "So they were both very, very significant. ", "start_char_idx": 1834, "end_char_idx": 1876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a95f3b1f-b8a0-480d-b433-1061db96dd51": {"__data__": {"id_": "a95f3b1f-b8a0-480d-b433-1061db96dd51", "embedding": null, "metadata": {"window": "And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not. ", "original_text": "We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e9cf254-0a6c-4918-b4b6-096b768c98e7", "node_type": "1", "metadata": {"window": "What we saw during the quarter, particularly as the quarter went on, was a significant increase in \nthose supply chain costs, most notably in in ternational freight high containers that we talked about as \nwell as commodities.  And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through. ", "original_text": "So they were both very, very significant. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37ddeb13bb085d351816a05507dfe4767e772aad1373ff56f17e91a08443a979", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f1a83ba-4695-4139-8f2a-28402c61e49f", "node_type": "1", "metadata": {"window": "Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated. ", "original_text": "So what are we doing about that? "}, "hash": "ec8b63d9245fcbb315b2a2e51bb732be8be4dd0bdca3a55429096532e633d1c2", "class_name": "RelatedNodeInfo"}}, "text": "We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n", "start_char_idx": 1876, "end_char_idx": 2223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f1a83ba-4695-4139-8f2a-28402c61e49f": {"__data__": {"id_": "5f1a83ba-4695-4139-8f2a-28402c61e49f", "embedding": null, "metadata": {"window": "Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated. ", "original_text": "So what are we doing about that? ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a95f3b1f-b8a0-480d-b433-1061db96dd51", "node_type": "1", "metadata": {"window": "And those, we feel, will create an incremental $100 million to $125 million of \ncost for us.  Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not. ", "original_text": "We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8a0de0d9ff1e1b7f8d349e65e96613031d84ee2a23e2f2cf018ec4792844185", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5abca40-5d9a-4c3d-a32a-7a234d90d64b", "node_type": "1", "metadata": {"window": "So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough. ", "original_text": "That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through. "}, "hash": "a3d90a3b43d7ed2519b991e8abe35565a7154cf708a38c5101788112e6a98b10", "class_name": "RelatedNodeInfo"}}, "text": "So what are we doing about that? ", "start_char_idx": 2223, "end_char_idx": 2256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5abca40-5d9a-4c3d-a32a-7a234d90d64b": {"__data__": {"id_": "c5abca40-5d9a-4c3d-a32a-7a234d90d64b", "embedding": null, "metadata": {"window": "So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough. ", "original_text": "That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f1a83ba-4695-4139-8f2a-28402c61e49f", "node_type": "1", "metadata": {"window": "Roughly, I would say that $100 million to $125 million is split relatively evenly b etween the \nimpact of commodities and the impact of freight cost.  So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated. ", "original_text": "So what are we doing about that? ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e2947260390575da07dce988e29c7754ecd816a81e6e32be8f6f1fb396aee69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5bb1c0d-c729-4dfe-b6dc-83dafcc884d4", "node_type": "1", "metadata": {"window": "We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs. ", "original_text": "It's hard to really talk about exactly which ones you can \npass through or not. "}, "hash": "9f4a5438eb16d48d347b827d3d59d9cfdc51af91874e4e9c470cbaa726ed0369", "class_name": "RelatedNodeInfo"}}, "text": "That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through. ", "start_char_idx": 2256, "end_char_idx": 2475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5bb1c0d-c729-4dfe-b6dc-83dafcc884d4": {"__data__": {"id_": "d5bb1c0d-c729-4dfe-b6dc-83dafcc884d4", "embedding": null, "metadata": {"window": "We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs. ", "original_text": "It's hard to really talk about exactly which ones you can \npass through or not. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5abca40-5d9a-4c3d-a32a-7a234d90d64b", "node_type": "1", "metadata": {"window": "So they were both very, very significant.  We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough. ", "original_text": "That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579b47d707b39e01fb902f0c9d49aa1394550b2bfe2611414a9620503c614695", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b709a58-7979-48f6-8143-41ba5716a601", "node_type": "1", "metadata": {"window": "So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment. ", "original_text": "The market is very complicated. "}, "hash": "7f2eb2c3ba5cd4290bab674b1f6630c022c9c823549663ae85bb43776797a1cf", "class_name": "RelatedNodeInfo"}}, "text": "It's hard to really talk about exactly which ones you can \npass through or not. ", "start_char_idx": 2475, "end_char_idx": 2555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b709a58-7979-48f6-8143-41ba5716a601": {"__data__": {"id_": "6b709a58-7979-48f6-8143-41ba5716a601", "embedding": null, "metadata": {"window": "So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment. ", "original_text": "The market is very complicated. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5bb1c0d-c729-4dfe-b6dc-83dafcc884d4", "node_type": "1", "metadata": {"window": "We \nsaw other minor ones in other areas, but those were the really 2 big ones, both of which we believe \nare temporary because, one, as Jason said earl ier, they're at all -time highs for the most part, \nsignificantly higher than where they were and we believe that over time, the market will adjust and \nthose will be able to come back down.  \n \n So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs. ", "original_text": "It's hard to really talk about exactly which ones you can \npass through or not. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faf3687f14cb3292d86233c97dd16eefb611906aed7fed46c619b273e68d1958", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d425a5c-f80f-4152-a441-69b51f06121b", "node_type": "1", "metadata": {"window": "That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n", "original_text": "There are contracts that we have to work \nthrough. "}, "hash": "f0cf256ccec717c14c0a4b681ef401a4da89bac4912d9a9747412ac7bf6a7930", "class_name": "RelatedNodeInfo"}}, "text": "The market is very complicated. ", "start_char_idx": 2555, "end_char_idx": 2587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d425a5c-f80f-4152-a441-69b51f06121b": {"__data__": {"id_": "2d425a5c-f80f-4152-a441-69b51f06121b", "embedding": null, "metadata": {"window": "That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n", "original_text": "There are contracts that we have to work \nthrough. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b709a58-7979-48f6-8143-41ba5716a601", "node_type": "1", "metadata": {"window": "So what are we doing about that?  That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment. ", "original_text": "The market is very complicated. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e728ec14f5937770816d9b79830553151d39797d61ae1c476da135fdeef5f4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa2c6242-a394-4f10-a467-d62e761e34e1", "node_type": "1", "metadata": {"window": "It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company. ", "original_text": "We have to work with our partners, both the hospitals and the GPOs. "}, "hash": "1c94bf285d0200e7e938dc2d4beb685199ccaf839e18f95ee175b26a76aacee2", "class_name": "RelatedNodeInfo"}}, "text": "There are contracts that we have to work \nthrough. ", "start_char_idx": 2587, "end_char_idx": 2638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa2c6242-a394-4f10-a467-d62e761e34e1": {"__data__": {"id_": "fa2c6242-a394-4f10-a467-d62e761e34e1", "embedding": null, "metadata": {"window": "It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company. ", "original_text": "We have to work with our partners, both the hospitals and the GPOs. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d425a5c-f80f-4152-a441-69b51f06121b", "node_type": "1", "metadata": {"window": "That is a net number, the $100 mil lion to $125 million, obviously, \nsince we called that out as the adjustment to Medical guidance, is that we are getting after it through \npricing actions, passing some of it through.  It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n", "original_text": "There are contracts that we have to work \nthrough. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4131559e5ccd169cac7e98ce1bd260a681d91d6840dc1589ebfad63dd0abd292", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fda1fab6-b2b0-4ea4-bea5-920b167dfa04", "node_type": "1", "metadata": {"window": "The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there. ", "original_text": "We have to \nunderstand the supply and demand dynamics of each item in the environment. "}, "hash": "aa8cd275f53e6e866ed4e2c3d72e4bd80bcba2ee0df9a75cf33a21807af8d77b", "class_name": "RelatedNodeInfo"}}, "text": "We have to work with our partners, both the hospitals and the GPOs. ", "start_char_idx": 2638, "end_char_idx": 2706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fda1fab6-b2b0-4ea4-bea5-920b167dfa04": {"__data__": {"id_": "fda1fab6-b2b0-4ea4-bea5-920b167dfa04", "embedding": null, "metadata": {"window": "The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there. ", "original_text": "We have to \nunderstand the supply and demand dynamics of each item in the environment. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa2c6242-a394-4f10-a467-d62e761e34e1", "node_type": "1", "metadata": {"window": "It's hard to really talk about exactly which ones you can \npass through or not.  The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company. ", "original_text": "We have to work with our partners, both the hospitals and the GPOs. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "701afcd45e93773ea562218d8375c9209382071b0674bc9bc31f03aade41cb8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "530c5d5e-146b-4586-b53a-4c0cc1855a40", "node_type": "1", "metadata": {"window": "There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n", "original_text": "And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n"}, "hash": "186f563cb8c817938126d2dd760abf2e4044c896ca6cde27bf5480bb9f3b7511", "class_name": "RelatedNodeInfo"}}, "text": "We have to \nunderstand the supply and demand dynamics of each item in the environment. ", "start_char_idx": 2706, "end_char_idx": 2793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "530c5d5e-146b-4586-b53a-4c0cc1855a40": {"__data__": {"id_": "530c5d5e-146b-4586-b53a-4c0cc1855a40", "embedding": null, "metadata": {"window": "There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n", "original_text": "And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fda1fab6-b2b0-4ea4-bea5-920b167dfa04", "node_type": "1", "metadata": {"window": "The market is very complicated.  There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there. ", "original_text": "We have to \nunderstand the supply and demand dynamics of each item in the environment. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0745d84c54464b9a98435182a07ca60cb4cb159608a0a1305bcffae49fdf2ffb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c9fa03b-5c3e-48ae-946a-cdfc71ce8905", "node_type": "1", "metadata": {"window": "We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes. ", "original_text": "And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company. "}, "hash": "a34bf432ba954606002119b6ac70003ef25a7d25c4c6e84a3100a31b0f5b009f", "class_name": "RelatedNodeInfo"}}, "text": "And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n", "start_char_idx": 2793, "end_char_idx": 2938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c9fa03b-5c3e-48ae-946a-cdfc71ce8905": {"__data__": {"id_": "9c9fa03b-5c3e-48ae-946a-cdfc71ce8905", "embedding": null, "metadata": {"window": "We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes. ", "original_text": "And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "530c5d5e-146b-4586-b53a-4c0cc1855a40", "node_type": "1", "metadata": {"window": "There are contracts that we have to work \nthrough.  We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n", "original_text": "And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "059190611084473c98c0ddf62b6ad368cd18ab7994c1196dbee6b9fecb7f8684", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc7c5d09-ff17-4b60-b0cc-aef9e1c00818", "node_type": "1", "metadata": {"window": "We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts. ", "original_text": "We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there. "}, "hash": "25e8cef36ac5ba8d6f2b51803940343a8f4612a380a5a374f8def1255ac287be", "class_name": "RelatedNodeInfo"}}, "text": "And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company. ", "start_char_idx": 2938, "end_char_idx": 3068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc7c5d09-ff17-4b60-b0cc-aef9e1c00818": {"__data__": {"id_": "bc7c5d09-ff17-4b60-b0cc-aef9e1c00818", "embedding": null, "metadata": {"window": "We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts. ", "original_text": "We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c9fa03b-5c3e-48ae-946a-cdfc71ce8905", "node_type": "1", "metadata": {"window": "We have to work with our partners, both the hospitals and the GPOs.  We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes. ", "original_text": "And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b27d06df6931b2c53ce588ee5c3ba091d009925399e2560fa9f5b422297e5250", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bee39490-2ee1-46cc-8d12-2252808ab394", "node_type": "1", "metadata": {"window": "And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "So those are \nsome, I hope, some helpful comments.  \n \n"}, "hash": "007f4e8bb03a67e7336dd638dc829550cb139f85641d3aa782e4aee48ef13dcf", "class_name": "RelatedNodeInfo"}}, "text": "We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there. ", "start_char_idx": 3068, "end_char_idx": 3214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bee39490-2ee1-46cc-8d12-2252808ab394": {"__data__": {"id_": "bee39490-2ee1-46cc-8d12-2252808ab394", "embedding": null, "metadata": {"window": "And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "So those are \nsome, I hope, some helpful comments.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc7c5d09-ff17-4b60-b0cc-aef9e1c00818", "node_type": "1", "metadata": {"window": "We have to \nunderstand the supply and demand dynamics of each item in the environment.  And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts. ", "original_text": "We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9a976f2e157c42a75b7f994a231331a5b7e154e394efe4013d7ddbdc2657cb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6ae0dda-7b39-4ece-9980-f74114eeba6a", "node_type": "1", "metadata": {"window": "And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "Jason Hollar:  Yes. "}, "hash": "bf7fe3ef5bc8727dcbe59efee92206cf8998d7452e6170f2cce6fd452301998a", "class_name": "RelatedNodeInfo"}}, "text": "So those are \nsome, I hope, some helpful comments.  \n \n", "start_char_idx": 3214, "end_char_idx": 3269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6ae0dda-7b39-4ece-9980-f74114eeba6a": {"__data__": {"id_": "e6ae0dda-7b39-4ece-9980-f74114eeba6a", "embedding": null, "metadata": {"window": "And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "Jason Hollar:  Yes. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bee39490-2ee1-46cc-8d12-2252808ab394", "node_type": "1", "metadata": {"window": "And so, we are \nworking through and understanding all of those factors, but there is some additional pricing action \nbuilt into that number.  \n \n And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "So those are \nsome, I hope, some helpful comments.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "233eeb47d0efb864b51cfb979f4cfd84fc8eba98cfa9041dc10b5d0baac0d65a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75f7e881-c842-4bd0-b1fb-b55687f45aac", "node_type": "1", "metadata": {"window": "We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts. "}, "hash": "2e1ae01e8db4d1d1fd2bbd107704d2189cc9a951bcd120c424e03dd5eee7a829", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes. ", "start_char_idx": 3269, "end_char_idx": 3289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75f7e881-c842-4bd0-b1fb-b55687f45aac": {"__data__": {"id_": "75f7e881-c842-4bd0-b1fb-b55687f45aac", "embedding": null, "metadata": {"window": "We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6ae0dda-7b39-4ece-9980-f74114eeba6a", "node_type": "1", "metadata": {"window": "And then obviously, since we maintain guidance for the entire company, we are taking aggressive \ncost actions across the company.  We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "Jason Hollar:  Yes. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6631c3bb953877b583696f42ad624a222dbf8b41c8af86f4dd1b00d8e98d851d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4f8e8b3-7394-434b-bb61-87821bc5f49d", "node_type": "1", "metadata": {"window": "So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer "}, "hash": "2cac0a40751d6b411292b36d7b9204285d67bd5f1c9a66bca38f940b38337c24", "class_name": "RelatedNodeInfo"}}, "text": "And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts. ", "start_char_idx": 3289, "end_char_idx": 3373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4f8e8b3-7394-434b-bb61-87821bc5f49d": {"__data__": {"id_": "a4f8e8b3-7394-434b-bb61-87821bc5f49d", "embedding": null, "metadata": {"window": "So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ba762980d6f27d0726c79e099d5e2e602cfd6bbc1bb2bcbfabc910977f23951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75f7e881-c842-4bd0-b1fb-b55687f45aac", "node_type": "1", "metadata": {"window": "We  are leveraging our improved balance sheet, and we are also \nfocusing on our growth businesses and pushing our teams to do more, faster there.  So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0dc76a5d9b8afb73dc834a27651d78095579e5a9fb174247d92e194ac8f7ca0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c058aaa-0508-4862-b229-e2352d0309c2", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost. ", "original_text": " \nPage 11 of 15 \n \nexpected duration. "}, "hash": "730aa08c1e1ddb17fb799c692b1aee60450ff11c2f8bfa9fa3cd1b93761c2241", "class_name": "RelatedNodeInfo"}}, "text": "It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "start_char_idx": 3373, "end_char_idx": 3486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c058aaa-0508-4862-b229-e2352d0309c2": {"__data__": {"id_": "2c058aaa-0508-4862-b229-e2352d0309c2", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost. ", "original_text": " \nPage 11 of 15 \n \nexpected duration. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4f8e8b3-7394-434b-bb61-87821bc5f49d", "node_type": "1", "metadata": {"window": "So those are \nsome, I hope, some helpful comments.  \n \n Jason Hollar:  Yes.  And the only thing I'd add is that this inc rease is not \u2013 it's related to 2 parts.  It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "original_text": "It's a \ngreater increase in both of these areas of international freight and commodities, but it's also a longer ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1031e4e8ed79e18132e5db2f3514fe4f1d601d73b8bbff6b721144d872c8376d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fd54ac1-458d-4e89-b21e-6b6167dd1e33", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through. ", "original_text": "We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n"}, "hash": "a712145cecaf97ceb4e67dd81ac2b779d3ca3e99aad1bd3f64319ec24ac857a2", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 15 \n \nexpected duration. ", "start_char_idx": 0, "end_char_idx": 38, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fd54ac1-458d-4e89-b21e-6b6167dd1e33": {"__data__": {"id_": "1fd54ac1-458d-4e89-b21e-6b6167dd1e33", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through. ", "original_text": "We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c058aaa-0508-4862-b229-e2352d0309c2", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost. ", "original_text": " \nPage 11 of 15 \n \nexpected duration. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "480dbd3701d0a3c54c9aaf8943ceda9419a52139191006a57324dbcaf0f6f624", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "450b1fc0-1aa8-44b8-94ac-ca7dc4a63545", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much. ", "original_text": "And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n"}, "hash": "869811de13761e2067a9182ce0ce919b2f5c8cf3f07224888fc6b7731b98321a", "class_name": "RelatedNodeInfo"}}, "text": "We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n", "start_char_idx": 38, "end_char_idx": 178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "450b1fc0-1aa8-44b8-94ac-ca7dc4a63545": {"__data__": {"id_": "450b1fc0-1aa8-44b8-94ac-ca7dc4a63545", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much. ", "original_text": "And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fd54ac1-458d-4e89-b21e-6b6167dd1e33", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through. ", "original_text": "We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af3e939fd3c6a94148fc329daf1e8d7c5829b36a65858d5acf37a656bc68d1da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0458fcbd-9f08-4fca-8ce6-634a14eb3cb3", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n", "original_text": "With PPE, we saw many, many times higher total impact on that product cost. "}, "hash": "8aa55ab27702818df144f908717a9cbc9bd105eea7696762011636313e9f8141", "class_name": "RelatedNodeInfo"}}, "text": "And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n", "start_char_idx": 178, "end_char_idx": 288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0458fcbd-9f08-4fca-8ce6-634a14eb3cb3": {"__data__": {"id_": "0458fcbd-9f08-4fca-8ce6-634a14eb3cb3", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n", "original_text": "With PPE, we saw many, many times higher total impact on that product cost. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "450b1fc0-1aa8-44b8-94ac-ca7dc4a63545", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much. ", "original_text": "And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c972acb4a4d53b3252355064e5bac9f5affcfac462eb276da0a9cf862c7a176", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc28e6aa-0574-46c1-b841-e5c4a3512c9f", "node_type": "1", "metadata": {"window": "We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n", "original_text": "And so we saw a much \nmore significant number of dollars in both cost and revenue that came through. "}, "hash": "7d4b84dc06564d418d1f206c6a84e59eccbd4cd69e47928b44e13523aac965b7", "class_name": "RelatedNodeInfo"}}, "text": "With PPE, we saw many, many times higher total impact on that product cost. ", "start_char_idx": 288, "end_char_idx": 364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc28e6aa-0574-46c1-b841-e5c4a3512c9f": {"__data__": {"id_": "bc28e6aa-0574-46c1-b841-e5c4a3512c9f", "embedding": null, "metadata": {"window": "We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n", "original_text": "And so we saw a much \nmore significant number of dollars in both cost and revenue that came through. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0458fcbd-9f08-4fca-8ce6-634a14eb3cb3", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n", "original_text": "With PPE, we saw many, many times higher total impact on that product cost. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6dded4fb8ffd7a5c9ef7db6fc5569088a49cf45bc8fd28d38e2294b15a1f965", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ec3e019-e43d-46e1-bc2f-15c7ce5354c7", "node_type": "1", "metadata": {"window": "And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks. ", "original_text": "While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much. "}, "hash": "3bd4e359e86f0b88a43fec9447525889a59fcb959e7a60b6033a80302eae6af5", "class_name": "RelatedNodeInfo"}}, "text": "And so we saw a much \nmore significant number of dollars in both cost and revenue that came through. ", "start_char_idx": 364, "end_char_idx": 465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ec3e019-e43d-46e1-bc2f-15c7ce5354c7": {"__data__": {"id_": "5ec3e019-e43d-46e1-bc2f-15c7ce5354c7", "embedding": null, "metadata": {"window": "And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks. ", "original_text": "While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc28e6aa-0574-46c1-b841-e5c4a3512c9f", "node_type": "1", "metadata": {"window": "We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n", "original_text": "And so we saw a much \nmore significant number of dollars in both cost and revenue that came through. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fee84d8cad0bf5aede040d6529871285135dcc49460b9e22b4f09a63a61bae8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94435c02-42d6-4c36-9e99-5b8173a78567", "node_type": "1", "metadata": {"window": "With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question. ", "original_text": "Next question.  \n \n"}, "hash": "98c557bc821e9a2ffc3fd2333b1f5db26b60931577875c88f1c563a9741c68f7", "class_name": "RelatedNodeInfo"}}, "text": "While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much. ", "start_char_idx": 465, "end_char_idx": 601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94435c02-42d6-4c36-9e99-5b8173a78567": {"__data__": {"id_": "94435c02-42d6-4c36-9e99-5b8173a78567", "embedding": null, "metadata": {"window": "With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question. ", "original_text": "Next question.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ec3e019-e43d-46e1-bc2f-15c7ce5354c7", "node_type": "1", "metadata": {"window": "And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks. ", "original_text": "While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00893784a15affa7d374fe13eb322d7b0379a4a94865bca8a19e2b77d51f76a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32f6cf84-fb38-46bb-895e-20ea5d3a9d55", "node_type": "1", "metadata": {"window": "And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate. ", "original_text": "Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n"}, "hash": "dd3060af04f3c4181a0838be3c28e3c336c5fe060efa241ceb44d2dda3cb4ed8", "class_name": "RelatedNodeInfo"}}, "text": "Next question.  \n \n", "start_char_idx": 601, "end_char_idx": 620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32f6cf84-fb38-46bb-895e-20ea5d3a9d55": {"__data__": {"id_": "32f6cf84-fb38-46bb-895e-20ea5d3a9d55", "embedding": null, "metadata": {"window": "And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate. ", "original_text": "Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94435c02-42d6-4c36-9e99-5b8173a78567", "node_type": "1", "metadata": {"window": "With PPE, we saw many, many times higher total impact on that product cost.  And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question. ", "original_text": "Next question.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19821227d679c8fc6167ac07052b12c9f382bee136c9b29d16adc0b2b30d9fd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab2cc8e7-86ae-411b-b762-0865567961c9", "node_type": "1", "metadata": {"window": "While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance? ", "original_text": "Kevin Caliendo:   Thanks. "}, "hash": "0654f08aef4c82ea5c1baae81b8f102e19b0aab4bf2d220265d5671ae842eb28", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n", "start_char_idx": 620, "end_char_idx": 687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab2cc8e7-86ae-411b-b762-0865567961c9": {"__data__": {"id_": "ab2cc8e7-86ae-411b-b762-0865567961c9", "embedding": null, "metadata": {"window": "While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance? ", "original_text": "Kevin Caliendo:   Thanks. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32f6cf84-fb38-46bb-895e-20ea5d3a9d55", "node_type": "1", "metadata": {"window": "And so we saw a much \nmore significant number of dollars in both cost and revenue that came through.  While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate. ", "original_text": "Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d65af1023a326c9f34fc646bc1fc1ad451ebd06a9dcbeb331393b7242c672e5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06515981-4f39-4435-92ef-6f6fb0591d58", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room? ", "original_text": "Thanks for taking my question. "}, "hash": "3ce25c697e9e5750f728ca9d5ec345e39e0649b7bda2120b4a1f3489290b76f0", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo:   Thanks. ", "start_char_idx": 687, "end_char_idx": 713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06515981-4f39-4435-92ef-6f6fb0591d58": {"__data__": {"id_": "06515981-4f39-4435-92ef-6f6fb0591d58", "embedding": null, "metadata": {"window": "Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room? ", "original_text": "Thanks for taking my question. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab2cc8e7-86ae-411b-b762-0865567961c9", "node_type": "1", "metadata": {"window": "While this is still \nsignificant, it's much less meaningful from a revenue perspective and it's not moving that needle \nnearly as much.  Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance? ", "original_text": "Kevin Caliendo:   Thanks. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650559f75595ba11e5e486563244c5740eff6d64e5bff5dbee22df59d6f132c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89242551-9aa4-4863-80dc-bf6762ee53e7", "node_type": "1", "metadata": {"window": "Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n", "original_text": "So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate. "}, "hash": "ded77c52cb3dc7dcae525286cc7ae997cf77a475aca0a8fb4eda3c5cfe4e98fb", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my question. ", "start_char_idx": 713, "end_char_idx": 744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89242551-9aa4-4863-80dc-bf6762ee53e7": {"__data__": {"id_": "89242551-9aa4-4863-80dc-bf6762ee53e7", "embedding": null, "metadata": {"window": "Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n", "original_text": "So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06515981-4f39-4435-92ef-6f6fb0591d58", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room? ", "original_text": "Thanks for taking my question. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd7ad84d25b3ca30e18704b2d152cd6417dea806223198c3b17fa0cfb0452a93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f602f917-b12c-4cde-a94c-d0cab57b9ba7", "node_type": "1", "metadata": {"window": "Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes. ", "original_text": "Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance? "}, "hash": "490a39e4d79f4c3c5244967451095392946602306f0dafd8de90862b258bedda", "class_name": "RelatedNodeInfo"}}, "text": "So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate. ", "start_char_idx": 744, "end_char_idx": 929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f602f917-b12c-4cde-a94c-d0cab57b9ba7": {"__data__": {"id_": "f602f917-b12c-4cde-a94c-d0cab57b9ba7", "embedding": null, "metadata": {"window": "Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes. ", "original_text": "Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance? ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89242551-9aa4-4863-80dc-bf6762ee53e7", "node_type": "1", "metadata": {"window": "Operator:  And next, we'll  hear from Kevin Caliendo with UBS.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n", "original_text": "So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8282bf1800a51ea40e5a6a5c231c0acb07d1ccb09b437d29f70d8b7469db56eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72fb3114-13a3-4b56-b8e2-726071e6dd14", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n", "original_text": "Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room? "}, "hash": "ee79671ec2747f1bc3a0f3f0e1c0b26904ded7a50e88ca1e1617a17488ecdc94", "class_name": "RelatedNodeInfo"}}, "text": "Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance? ", "start_char_idx": 929, "end_char_idx": 1012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72fb3114-13a3-4b56-b8e2-726071e6dd14": {"__data__": {"id_": "72fb3114-13a3-4b56-b8e2-726071e6dd14", "embedding": null, "metadata": {"window": "Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n", "original_text": "Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room? ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f602f917-b12c-4cde-a94c-d0cab57b9ba7", "node_type": "1", "metadata": {"window": "Kevin Caliendo:   Thanks.  Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes. ", "original_text": "Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance? ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57f66414f216d0c20821bf04c49a4467da15ae301ec2f7b7146c4cd7628ba8de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed7c3e4e-8d3c-4c3b-bddc-474f911b9c7c", "node_type": "1", "metadata": {"window": "So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses. ", "original_text": "How should we think abo ut that?  \n \n"}, "hash": "90d52333f4eff13cd68733debed3fc4a49125678930ebf1618cfa9da2992e6d0", "class_name": "RelatedNodeInfo"}}, "text": "Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room? ", "start_char_idx": 1012, "end_char_idx": 1145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed7c3e4e-8d3c-4c3b-bddc-474f911b9c7c": {"__data__": {"id_": "ed7c3e4e-8d3c-4c3b-bddc-474f911b9c7c", "embedding": null, "metadata": {"window": "So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses. ", "original_text": "How should we think abo ut that?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72fb3114-13a3-4b56-b8e2-726071e6dd14", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n", "original_text": "Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room? ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45e2e75c77aa13b562a80d88c8248c27495efed012d1cc0794b3e6cf4610d4eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f49bb022-5e8c-4737-9aba-b4f4cd2a2cf6", "node_type": "1", "metadata": {"window": "Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions. ", "original_text": "Jason Hollar:  Yes. "}, "hash": "256c639a0afc0f4abc0281e7d5eb8550e0cb8b7b4697eecbc77419c61e330ea7", "class_name": "RelatedNodeInfo"}}, "text": "How should we think abo ut that?  \n \n", "start_char_idx": 1145, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f49bb022-5e8c-4737-9aba-b4f4cd2a2cf6": {"__data__": {"id_": "f49bb022-5e8c-4737-9aba-b4f4cd2a2cf6", "embedding": null, "metadata": {"window": "Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions. ", "original_text": "Jason Hollar:  Yes. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed7c3e4e-8d3c-4c3b-bddc-474f911b9c7c", "node_type": "1", "metadata": {"window": "So if I'm doing the math right, it appears the \nbad guy, that is the incremental supply chain cost, is larger than the good guy of the lower share \ncount and perhaps  a lower tax rate.  Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses. ", "original_text": "How should we think abo ut that?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f973f9a8440ad099d1495d872547849b7db794203ea2db8dad214b86228c33b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36f14e96-8562-4c6e-90db-a482131832ff", "node_type": "1", "metadata": {"window": "Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function. ", "original_text": "I think your math is accurate for the items that we typically provide in guidance. \n"}, "hash": "cec312a1342101d31baa311d3e59e06051331f68ff069241dc9c826a28f9ad7c", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes. ", "start_char_idx": 1182, "end_char_idx": 1202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36f14e96-8562-4c6e-90db-a482131832ff": {"__data__": {"id_": "36f14e96-8562-4c6e-90db-a482131832ff", "embedding": null, "metadata": {"window": "Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function. ", "original_text": "I think your math is accurate for the items that we typically provide in guidance. \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f49bb022-5e8c-4737-9aba-b4f4cd2a2cf6", "node_type": "1", "metadata": {"window": "Am I doing \u2013 am I thinking about that right in the fact that you \ndidn't guidance?  Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions. ", "original_text": "Jason Hollar:  Yes. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92b2c60335638e48e0046a82176902bfcee0e11966e624f05c6c806e22110c51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f687cd8-e3b7-4238-b9ce-b17793a81630", "node_type": "1", "metadata": {"window": "How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n", "original_text": "One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses. "}, "hash": "528db6f364d5a33c830df0f60020a384ee01e34414c5706566404f87c0ca70a2", "class_name": "RelatedNodeInfo"}}, "text": "I think your math is accurate for the items that we typically provide in guidance. \n", "start_char_idx": 1202, "end_char_idx": 1286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f687cd8-e3b7-4238-b9ce-b17793a81630": {"__data__": {"id_": "6f687cd8-e3b7-4238-b9ce-b17793a81630", "embedding": null, "metadata": {"window": "How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n", "original_text": "One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36f14e96-8562-4c6e-90db-a482131832ff", "node_type": "1", "metadata": {"window": "Is that just you're still within the range, but maybe it's the lower end of the range or \nyou're just giving yourself a little room?  How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function. ", "original_text": "I think your math is accurate for the items that we typically provide in guidance. \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97fe3587dff5c4dab5419f137bbd92056c9b9088bfb26b4e8f8d2001d8e712d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86c57975-019d-4d61-9b8f-d0177a659cbc", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n", "original_text": "And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions. "}, "hash": "c2b047672769663a4becb60e16aaddf1310d57a32203bda7ceff3fa890b632cc", "class_name": "RelatedNodeInfo"}}, "text": "One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses. ", "start_char_idx": 1286, "end_char_idx": 1395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86c57975-019d-4d61-9b8f-d0177a659cbc": {"__data__": {"id_": "86c57975-019d-4d61-9b8f-d0177a659cbc", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n", "original_text": "And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f687cd8-e3b7-4238-b9ce-b17793a81630", "node_type": "1", "metadata": {"window": "How should we think abo ut that?  \n \n Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n", "original_text": "One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1219816e47e41a795c99ea289e8f10ff72d3e9b8148e9401db808667080e8b88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ce5980d-f03f-4a60-b868-bb1f641ec756", "node_type": "1", "metadata": {"window": "I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America. ", "original_text": "The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function. "}, "hash": "e318862b666a8efe70cda0c6df63d62f98d941276dc620554ab3c85c200e7f2c", "class_name": "RelatedNodeInfo"}}, "text": "And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions. ", "start_char_idx": 1395, "end_char_idx": 1505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ce5980d-f03f-4a60-b868-bb1f641ec756": {"__data__": {"id_": "9ce5980d-f03f-4a60-b868-bb1f641ec756", "embedding": null, "metadata": {"window": "I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America. ", "original_text": "The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86c57975-019d-4d61-9b8f-d0177a659cbc", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n", "original_text": "And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e32366e9cf09bc25dd457ac6b674c04a74385c6a6d261c11e3dbfe4fc6d4c0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64a132ed-cc12-493f-9f48-6db628da9cb2", "node_type": "1", "metadata": {"window": "One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n", "original_text": "So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n"}, "hash": "4a040cef2a35b76f1e1f826f672de175a6c50ef30979f92ea8229614658d75d3", "class_name": "RelatedNodeInfo"}}, "text": "The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function. ", "start_char_idx": 1505, "end_char_idx": 1642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64a132ed-cc12-493f-9f48-6db628da9cb2": {"__data__": {"id_": "64a132ed-cc12-493f-9f48-6db628da9cb2", "embedding": null, "metadata": {"window": "One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n", "original_text": "So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ce5980d-f03f-4a60-b868-bb1f641ec756", "node_type": "1", "metadata": {"window": "I think your math is accurate for the items that we typically provide in guidance. \n One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America. ", "original_text": "The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46c220045343c3a2f928f839049a6b15080b352c9ce28b14447041e3e0266726", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ff195d2-62c2-4258-89a5-5c7742c00888", "node_type": "1", "metadata": {"window": "And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning. ", "original_text": "Kevin Moran: Next question, please.  \n \n"}, "hash": "d440e58521727d0cbf41546bfdf77042b83a9db2d22bf42d492dfe5470189e0d", "class_name": "RelatedNodeInfo"}}, "text": "So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n", "start_char_idx": 1642, "end_char_idx": 1864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ff195d2-62c2-4258-89a5-5c7742c00888": {"__data__": {"id_": "7ff195d2-62c2-4258-89a5-5c7742c00888", "embedding": null, "metadata": {"window": "And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning. ", "original_text": "Kevin Moran: Next question, please.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64a132ed-cc12-493f-9f48-6db628da9cb2", "node_type": "1", "metadata": {"window": "One area that's not explicitly called out, but is implied, is just the underlying other corporate \nexpenses.  And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n", "original_text": "So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a745250416a063f65e84d214025b412a0dff86370b9f868ff3956725cec9cd93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e3db2ae-dae8-4d17-8cfe-d3998f814b5c", "node_type": "1", "metadata": {"window": "The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain. ", "original_text": "Operator:  And next we'll hear from Michael Cherny with Bank of America. "}, "hash": "a7e225b55146fc902075d13c1c19fa39a81bf8eb0e93b8755bb1e172ee90af5e", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran: Next question, please.  \n \n", "start_char_idx": 1864, "end_char_idx": 1904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e3db2ae-dae8-4d17-8cfe-d3998f814b5c": {"__data__": {"id_": "8e3db2ae-dae8-4d17-8cfe-d3998f814b5c", "embedding": null, "metadata": {"window": "The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain. ", "original_text": "Operator:  And next we'll hear from Michael Cherny with Bank of America. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ff195d2-62c2-4258-89a5-5c7742c00888", "node_type": "1", "metadata": {"window": "And as we referenced a few times al ready in Mike's specific comments, there's broad -\nbased cost reductions.  The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning. ", "original_text": "Kevin Moran: Next question, please.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3cb97827597ce621423baff0ee2fc3c1dee4b3edcd4184c8b690f9b2477dff9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33b04eb6-d3a8-404f-b6f2-231c8b10a1c7", "node_type": "1", "metadata": {"window": "So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches. ", "original_text": "Please go ahead.  \n \n"}, "hash": "f8475be37bd232425f3c45c73a8e4a68c803a5360ee3523f80af0005c3a51be2", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And next we'll hear from Michael Cherny with Bank of America. ", "start_char_idx": 1904, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33b04eb6-d3a8-404f-b6f2-231c8b10a1c7": {"__data__": {"id_": "33b04eb6-d3a8-404f-b6f2-231c8b10a1c7", "embedding": null, "metadata": {"window": "So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches. ", "original_text": "Please go ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e3db2ae-dae8-4d17-8cfe-d3998f814b5c", "node_type": "1", "metadata": {"window": "The $750 million program, which we increased by $250 million last quarter is \nenterprise -wide and that includes the corporate function.  So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain. ", "original_text": "Operator:  And next we'll hear from Michael Cherny with Bank of America. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65e8e3c6c50c6d31ba16ab3870716a78c0df9a4cd92310d35183b92cf56811f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b384a697-0d52-4c59-b70f-2bd4986b6b0c", "node_type": "1", "metadata": {"window": "Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past. ", "original_text": "Michael Cherny:  Good morning. "}, "hash": "7dc68945b434de41794912c28af12d8dffc403d35e50f1e6cf976054913c214c", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1977, "end_char_idx": 1998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b384a697-0d52-4c59-b70f-2bd4986b6b0c": {"__data__": {"id_": "b384a697-0d52-4c59-b70f-2bd4986b6b0c", "embedding": null, "metadata": {"window": "Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past. ", "original_text": "Michael Cherny:  Good morning. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33b04eb6-d3a8-404f-b6f2-231c8b10a1c7", "node_type": "1", "metadata": {"window": "So we have identified additional corporate \ncost r eduction actions that are not included in either of the segments, but do fall through to the bottom \nline, the total segment profit as well as our earnings per share.  \n \n Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches. ", "original_text": "Please go ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fce7a8a7a21ca5667b2be578be356b23cf92c4f7d34301b74530be30e93176d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45d5d2db-29fa-4ec5-95ff-1be6d9e01978", "node_type": "1", "metadata": {"window": "Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n", "original_text": "I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain. "}, "hash": "f5996d0766f60851223e3d69dc1300586982c6fcb5be43972d94e823e808ee41", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny:  Good morning. ", "start_char_idx": 1998, "end_char_idx": 2029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45d5d2db-29fa-4ec5-95ff-1be6d9e01978": {"__data__": {"id_": "45d5d2db-29fa-4ec5-95ff-1be6d9e01978", "embedding": null, "metadata": {"window": "Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n", "original_text": "I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b384a697-0d52-4c59-b70f-2bd4986b6b0c", "node_type": "1", "metadata": {"window": "Kevin Moran: Next question, please.  \n \n Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past. ", "original_text": "Michael Cherny:  Good morning. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29a4227c7558e7864cfce08bcbe4704b576b8ad5a14ed07b277db837f6344efe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9be27e8d-d98a-4246-a8a4-b5d887b2009d", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes. ", "original_text": "I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches. "}, "hash": "3e562f2372c1dcbd16117cdd6104b3331b5dcd5ea99d43fdbaaf0d0d751f4c08", "class_name": "RelatedNodeInfo"}}, "text": "I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain. ", "start_char_idx": 2029, "end_char_idx": 2200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9be27e8d-d98a-4246-a8a4-b5d887b2009d": {"__data__": {"id_": "9be27e8d-d98a-4246-a8a4-b5d887b2009d", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes. ", "original_text": "I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45d5d2db-29fa-4ec5-95ff-1be6d9e01978", "node_type": "1", "metadata": {"window": "Operator:  And next we'll hear from Michael Cherny with Bank of America.  Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n", "original_text": "I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5513b68ef85446ed82339128a51d82ba597478264e7379f0b7297d4f6e0ee73d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51e2d3e6-f708-4992-8175-f91a3be9c63b", "node_type": "1", "metadata": {"window": "Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question. ", "original_text": "That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past. "}, "hash": "3bf49595d468f484ee5d3229f974ce2ec2ec156dff868fa8a16d055a128cbea3", "class_name": "RelatedNodeInfo"}}, "text": "I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches. ", "start_char_idx": 2200, "end_char_idx": 2327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51e2d3e6-f708-4992-8175-f91a3be9c63b": {"__data__": {"id_": "51e2d3e6-f708-4992-8175-f91a3be9c63b", "embedding": null, "metadata": {"window": "Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question. ", "original_text": "That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9be27e8d-d98a-4246-a8a4-b5d887b2009d", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes. ", "original_text": "I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650cab4f97877d82399e927b10f1e27aab7b578f881df6fd930cc762ad66518d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04b6ea6a-b237-4fee-839a-8e81a583db9d", "node_type": "1", "metadata": {"window": "I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one. ", "original_text": "And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n"}, "hash": "b0dd0320dc5c5e000cfcc3551e9b0e0e357e9ebf1606b7e5fd70ded9b2f16542", "class_name": "RelatedNodeInfo"}}, "text": "That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past. ", "start_char_idx": 2327, "end_char_idx": 2685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04b6ea6a-b237-4fee-839a-8e81a583db9d": {"__data__": {"id_": "04b6ea6a-b237-4fee-839a-8e81a583db9d", "embedding": null, "metadata": {"window": "I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one. ", "original_text": "And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51e2d3e6-f708-4992-8175-f91a3be9c63b", "node_type": "1", "metadata": {"window": "Michael Cherny:  Good morning.  I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question. ", "original_text": "That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77a917980edbfad08ac20bd6d977d0b94127d7a884bb2fcec93473dd5fe8813d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b211bf13-cdca-4a43-a669-3b6e30cec7e2", "node_type": "1", "metadata": {"window": "I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others. ", "original_text": "Mike Kaufmann:  Yes. "}, "hash": "ea9188bff320d9cb20b6ad39fe7a12377ba3398b5481151bc07ce2037b9aaab2", "class_name": "RelatedNodeInfo"}}, "text": "And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n", "start_char_idx": 2685, "end_char_idx": 3015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b211bf13-cdca-4a43-a669-3b6e30cec7e2": {"__data__": {"id_": "b211bf13-cdca-4a43-a669-3b6e30cec7e2", "embedding": null, "metadata": {"window": "I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others. ", "original_text": "Mike Kaufmann:  Yes. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04b6ea6a-b237-4fee-839a-8e81a583db9d", "node_type": "1", "metadata": {"window": "I want to dive a little bit more into some of the long -term guidance \nand compare and contrast it with the dynamics you're seeing right now in terms of the supply chain.  I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one. ", "original_text": "And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd1f1c4182c95a51bda1c47baad2eb37c092f263054151b6dd91364c371128a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "171281ce-85c8-4016-ab98-e0f53cf86e27", "node_type": "1", "metadata": {"window": "That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "I really appreciate the question. "}, "hash": "35e1f465782bcf94485650db5ff393b7e38e2ef63edbeb446157d963ad3871c5", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes. ", "start_char_idx": 3015, "end_char_idx": 3036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "171281ce-85c8-4016-ab98-e0f53cf86e27": {"__data__": {"id_": "171281ce-85c8-4016-ab98-e0f53cf86e27", "embedding": null, "metadata": {"window": "That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "I really appreciate the question. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b211bf13-cdca-4a43-a669-3b6e30cec7e2", "node_type": "1", "metadata": {"window": "I \nknow that a lo t of these are out of your control, and clearly, some companies in the space are seeing \nsimilar approaches.  That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others. ", "original_text": "Mike Kaufmann:  Yes. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49ebd84d2208d64116ac7828673c5e0bc9c8a961576f5bd5a2ce172b3e5d79f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76c55d98-800c-4d13-813f-c89a95147db3", "node_type": "1", "metadata": {"window": "And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "It's a really good one. "}, "hash": "b63e072f878d267c412b38bd5bffb988baf851276da2dc48200fb4a20225b9cc", "class_name": "RelatedNodeInfo"}}, "text": "I really appreciate the question. ", "start_char_idx": 3036, "end_char_idx": 3070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76c55d98-800c-4d13-813f-c89a95147db3": {"__data__": {"id_": "76c55d98-800c-4d13-813f-c89a95147db3", "embedding": null, "metadata": {"window": "And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "It's a really good one. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "171281ce-85c8-4016-ab98-e0f53cf86e27", "node_type": "1", "metadata": {"window": "That being said, as you think about the ways you're interacting with your \ncustomers now, interacting with your partners and supplier partners, are t here any ways that you can \ncontinue to evolve your business so that maybe we don't see ever spikes like this, but some of the \nfluctuations and volatility that you have seen in the supply chain in the past.  And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "I really appreciate the question. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79841c3d73b5202517aaa8a8685caed86a3f1f0280e68999720c6bb2c8853e34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5be0684f-738b-4b38-a5ed-ac78d8da85ee", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others. "}, "hash": "18038c67c3cb2425d468da14db5376b2e70f7de2aba1d2a75433baa1ab4ceb94", "class_name": "RelatedNodeInfo"}}, "text": "It's a really good one. ", "start_char_idx": 3070, "end_char_idx": 3094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5be0684f-738b-4b38-a5ed-ac78d8da85ee": {"__data__": {"id_": "5be0684f-738b-4b38-a5ed-ac78d8da85ee", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76c55d98-800c-4d13-813f-c89a95147db3", "node_type": "1", "metadata": {"window": "And I'm thinking in \nparticular on some of the raw material cost spikes that do come up from time to time, are ways that \ncan be mitigated in a more systematic fashion going forward, so we don't have this level of volatility \nand level of surprise for stuff that, as I mentioned, a lot of it tends to be out o f your control.  \n \n Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "It's a really good one. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ce36132ca4d090186079a831472f1216b43ffa0418fae8ebbf8c89e85033f71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7ac0e86-c81d-48e9-a467-553511426f17", "node_type": "1", "metadata": {"window": "I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  "}, "hash": "efb498b0338f78a2d1e1da206856a856329974df72b19c2c04cb7558e4cf85cc", "class_name": "RelatedNodeInfo"}}, "text": "So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others. ", "start_char_idx": 3094, "end_char_idx": 3254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7ac0e86-c81d-48e9-a467-553511426f17": {"__data__": {"id_": "a7ac0e86-c81d-48e9-a467-553511426f17", "embedding": null, "metadata": {"window": "I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fdce9011a24b40b26e141747b4af390e801b083c421b791be435f17fa791c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5be0684f-738b-4b38-a5ed-ac78d8da85ee", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.  I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abe1c257c57c19d12ff39cf66dd50631ad3045479ff6836ceb73dc339c2b31e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80b3bdfa-5925-43ec-94dd-6b08c128cc92", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth. ", "original_text": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model. "}, "hash": "1d4cb0719ddee10e9e7edaeec161282f7eb4f4e45997318dc3afd6fa7b90026a", "class_name": "RelatedNodeInfo"}}, "text": "So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "start_char_idx": 3254, "end_char_idx": 3484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80b3bdfa-5925-43ec-94dd-6b08c128cc92": {"__data__": {"id_": "80b3bdfa-5925-43ec-94dd-6b08c128cc92", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth. ", "original_text": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7ac0e86-c81d-48e9-a467-553511426f17", "node_type": "1", "metadata": {"window": "I really appreciate the question.  It's a really good one.  So let me step back and \nhit a couple of different pieces, and I'll finish with your question on Medical, but I'll take a shot here to \nemphasize a few others.  So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "original_text": "So  there's really, I would say, 3 obviously components to our long -term \ntarget, which our long -term target we're talking about is having a double -digit combined EPS growth \nand dividend yield on average, as Jason mentioned.  ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48b66f57f95da8b5a43b15f4b163ca07226c53a4a47f6bd362ebecb985f4450b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc2205f9-6d2a-4668-bc77-5dd834c9bf8f", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n", "original_text": "And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance. "}, "hash": "b80e10d9a611b03b719843f32c6262847e1e3b45fe60a4952aba472365242a32", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model. ", "start_char_idx": 0, "end_char_idx": 312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc2205f9-6d2a-4668-bc77-5dd834c9bf8f": {"__data__": {"id_": "dc2205f9-6d2a-4668-bc77-5dd834c9bf8f", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n", "original_text": "And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80b3bdfa-5925-43ec-94dd-6b08c128cc92", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth. ", "original_text": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cac17c57d4687ba8702a420063f3cf5e9b69dce3e02dc2a23a2d59c3cf94ca91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "660085e4-251c-4c20-8c98-cb66b56acc87", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n", "original_text": "Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting. "}, "hash": "e6c5988b0373d7ac492e74c9ad8e777829679093cf40f59ec3ff54dd8be8094f", "class_name": "RelatedNodeInfo"}}, "text": "And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance. ", "start_char_idx": 312, "end_char_idx": 447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "660085e4-251c-4c20-8c98-cb66b56acc87": {"__data__": {"id_": "660085e4-251c-4c20-8c98-cb66b56acc87", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n", "original_text": "Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc2205f9-6d2a-4668-bc77-5dd834c9bf8f", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n", "original_text": "And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b857a19cd910d7087fb97d9dd15966ed7adae439f1eb73724970b0adb2caec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9cbdabd-b7bc-4c82-adb1-dbb63a3ec278", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things. ", "original_text": "For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth. "}, "hash": "1bf8c3fa0fdbf743a79da4062c78992d9b6c65f9134f054e0b5bf9021d16a920", "class_name": "RelatedNodeInfo"}}, "text": "Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting. ", "start_char_idx": 447, "end_char_idx": 730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9cbdabd-b7bc-4c82-adb1-dbb63a3ec278": {"__data__": {"id_": "b9cbdabd-b7bc-4c82-adb1-dbb63a3ec278", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things. ", "original_text": "For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "660085e4-251c-4c20-8c98-cb66b56acc87", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n", "original_text": "Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f41a4e007e15dd0710d6d5b640971b605c466ea1185bd7a8eb6cabb0d09fbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a571d0d1-0afd-428d-bd02-3a4211777e7a", "node_type": "1", "metadata": {"window": "And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses. ", "original_text": "So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n"}, "hash": "93101d9af2ca8e5a406f1c27727330e09a59ca3a445c542c8b893750cb627d3c", "class_name": "RelatedNodeInfo"}}, "text": "For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth. ", "start_char_idx": 730, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a571d0d1-0afd-428d-bd02-3a4211777e7a": {"__data__": {"id_": "a571d0d1-0afd-428d-bd02-3a4211777e7a", "embedding": null, "metadata": {"window": "And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses. ", "original_text": "So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9cbdabd-b7bc-4c82-adb1-dbb63a3ec278", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things. ", "original_text": "For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0ce34b51453d58a1aeb65843568b82b0627033510541a52cf0c5de2d71052b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb45c661-ae1c-4b9d-9ff3-dbbd81e56357", "node_type": "1", "metadata": {"window": "Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n", "original_text": "And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n"}, "hash": "b7e2c2e9f9909a5649216c45e9c9a6d26c7a1c324c180c8dd4fb29cf36f205a7", "class_name": "RelatedNodeInfo"}}, "text": "So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n", "start_char_idx": 857, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb45c661-ae1c-4b9d-9ff3-dbbd81e56357": {"__data__": {"id_": "bb45c661-ae1c-4b9d-9ff3-dbbd81e56357", "embedding": null, "metadata": {"window": "Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n", "original_text": "And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a571d0d1-0afd-428d-bd02-3a4211777e7a", "node_type": "1", "metadata": {"window": "And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses. ", "original_text": "So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c0c7aab045642f4c322aeb16f7e4117e437740830897d50abc37ebf454f1b0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99404296-f973-4ced-b138-cc86ccb0cc84", "node_type": "1", "metadata": {"window": "For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent. ", "original_text": "On Medical, as you mentioned, it's a couple of different things. "}, "hash": "a3c87d735d7cc3c46c14827765088669560f4f0860ee449b4f8b935d7aca67fc", "class_name": "RelatedNodeInfo"}}, "text": "And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n", "start_char_idx": 1019, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99404296-f973-4ced-b138-cc86ccb0cc84": {"__data__": {"id_": "99404296-f973-4ced-b138-cc86ccb0cc84", "embedding": null, "metadata": {"window": "For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent. ", "original_text": "On Medical, as you mentioned, it's a couple of different things. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb45c661-ae1c-4b9d-9ff3-dbbd81e56357", "node_type": "1", "metadata": {"window": "Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n", "original_text": "And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5acf769a85ee6d9a3d9e72235231215145772f1bc3ce1fcd9f27177541885e3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12fbf7d0-96f9-430e-9373-aebf19d0ce9a", "node_type": "1", "metadata": {"window": "So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down. ", "original_text": "It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses. "}, "hash": "1f28be122383c40df6317094bb02a960304abc6682be21547e922ed983f3b082", "class_name": "RelatedNodeInfo"}}, "text": "On Medical, as you mentioned, it's a couple of different things. ", "start_char_idx": 1175, "end_char_idx": 1240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12fbf7d0-96f9-430e-9373-aebf19d0ce9a": {"__data__": {"id_": "12fbf7d0-96f9-430e-9373-aebf19d0ce9a", "embedding": null, "metadata": {"window": "So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down. ", "original_text": "It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99404296-f973-4ced-b138-cc86ccb0cc84", "node_type": "1", "metadata": {"window": "For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth.  So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent. ", "original_text": "On Medical, as you mentioned, it's a couple of different things. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e334c274ce28c5752112329482334c14278d2c8b0b994e822b0fc520ed7736e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0335857e-4cc7-4337-9829-a7553ebff089", "node_type": "1", "metadata": {"window": "And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n", "original_text": "I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n"}, "hash": "69a95c61637ed8de0249fe531be14ee2390473eb7321da57e80a99d6e2221e2f", "class_name": "RelatedNodeInfo"}}, "text": "It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses. ", "start_char_idx": 1240, "end_char_idx": 1339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0335857e-4cc7-4337-9829-a7553ebff089": {"__data__": {"id_": "0335857e-4cc7-4337-9829-a7553ebff089", "embedding": null, "metadata": {"window": "And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n", "original_text": "I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12fbf7d0-96f9-430e-9373-aebf19d0ce9a", "node_type": "1", "metadata": {"window": "So we believe the combination of getting that PD business \nstabilized, which we're seeing and then seeing the growth there is really what's going to drive that. \n And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down. ", "original_text": "It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe9a961b765151884bae239b6f8f3e84bddebe5941365f68b0934be69f756657", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc103864-a474-4884-9bdf-1aa3d9c4bb3b", "node_type": "1", "metadata": {"window": "On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain. ", "original_text": "Our discussions with our customers are being very transparent. "}, "hash": "74786381993d9a10d5c02552e7bc497974d26fc07cc1af7d93ebd47676a41397", "class_name": "RelatedNodeInfo"}}, "text": "I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n", "start_char_idx": 1339, "end_char_idx": 1741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc103864-a474-4884-9bdf-1aa3d9c4bb3b": {"__data__": {"id_": "dc103864-a474-4884-9bdf-1aa3d9c4bb3b", "embedding": null, "metadata": {"window": "On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain. ", "original_text": "Our discussions with our customers are being very transparent. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0335857e-4cc7-4337-9829-a7553ebff089", "node_type": "1", "metadata": {"window": "And then, of course, we mentioned the use of capital being able to  \u2013 having our debt lower \ncommitment to our dividend and then the share repurchases.  \n \n On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n", "original_text": "I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9128e365d741dcbee668add56e4747e927db39ff2a190a58420e0c1fe92be427", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35ea8e6b-ad3f-4533-bc66-7b9143e64b90", "node_type": "1", "metadata": {"window": "It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n", "original_text": "We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down. "}, "hash": "50ab4c2ccf1fc60d2efa4c4096aeb514c00d648c5ed464b02c9821740eada006", "class_name": "RelatedNodeInfo"}}, "text": "Our discussions with our customers are being very transparent. ", "start_char_idx": 1741, "end_char_idx": 1804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35ea8e6b-ad3f-4533-bc66-7b9143e64b90": {"__data__": {"id_": "35ea8e6b-ad3f-4533-bc66-7b9143e64b90", "embedding": null, "metadata": {"window": "It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n", "original_text": "We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc103864-a474-4884-9bdf-1aa3d9c4bb3b", "node_type": "1", "metadata": {"window": "On Medical, as you mentioned, it's a couple of different things.  It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain. ", "original_text": "Our discussions with our customers are being very transparent. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b51aa8f0ee5d4a73cfdd9737340d26cd56fd1348ebf7d1eb0436544250146433", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e174487c-e0a5-4e14-bf9d-c22b0239c532", "node_type": "1", "metadata": {"window": "I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right. ", "original_text": "We're not \u2013 we're willing to pass lower costs back on to them. \n"}, "hash": "37606ae4f9977631e0a4654aa758da93244b38a1a650cfb14ddea95e12bad632", "class_name": "RelatedNodeInfo"}}, "text": "We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down. ", "start_char_idx": 1804, "end_char_idx": 1981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e174487c-e0a5-4e14-bf9d-c22b0239c532": {"__data__": {"id_": "e174487c-e0a5-4e14-bf9d-c22b0239c532", "embedding": null, "metadata": {"window": "I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right. ", "original_text": "We're not \u2013 we're willing to pass lower costs back on to them. \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35ea8e6b-ad3f-4533-bc66-7b9143e64b90", "node_type": "1", "metadata": {"window": "It's simplifying our operating model, \nfocusing on driving mix, and fueling our growth businesses.  I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n", "original_text": "We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "290f3f2b0c7e8dcddfedd9056f7963dc18d51b6d7d41db1df6c9151f44600544", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ece0d10-f0d8-4bdc-aff1-829c72b796be", "node_type": "1", "metadata": {"window": "Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse. ", "original_text": "Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain. "}, "hash": "656194ebd301371c1f63e01bbbc2775f8d9c6bcc402361ff0046d0f3342c720f", "class_name": "RelatedNodeInfo"}}, "text": "We're not \u2013 we're willing to pass lower costs back on to them. \n", "start_char_idx": 1981, "end_char_idx": 2045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ece0d10-f0d8-4bdc-aff1-829c72b796be": {"__data__": {"id_": "2ece0d10-f0d8-4bdc-aff1-829c72b796be", "embedding": null, "metadata": {"window": "Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse. ", "original_text": "Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e174487c-e0a5-4e14-bf9d-c22b0239c532", "node_type": "1", "metadata": {"window": "I won't go into those details because we \ndid it in the comments, but to your question on what kind of changes can we make that help, it's really \n\u2013 one of the things we are working on with customers right now is how do we change our contracts \nwith our customers to give us more flexibility when there is sudden significant changes in the supply \nchain, that there is some ability to raise price.  \n \n Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right. ", "original_text": "We're not \u2013 we're willing to pass lower costs back on to them. \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a077f4f25d7c4d03d219665991cfdb841dd55cdb28743a5b837e00d45fe0313a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49abd47c-2ce9-4549-9ee6-7b116b995b93", "node_type": "1", "metadata": {"window": "We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n", "original_text": "So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n"}, "hash": "150958cf899b3dbe023ec8c385e8faba65cae27851a299145d4d6e6ca3537f8c", "class_name": "RelatedNodeInfo"}}, "text": "Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain. ", "start_char_idx": 2045, "end_char_idx": 2265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49abd47c-2ce9-4549-9ee6-7b116b995b93": {"__data__": {"id_": "49abd47c-2ce9-4549-9ee6-7b116b995b93", "embedding": null, "metadata": {"window": "We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n", "original_text": "So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ece0d10-f0d8-4bdc-aff1-829c72b796be", "node_type": "1", "metadata": {"window": "Our discussions with our customers are being very transparent.  We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse. ", "original_text": "Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d7d7a97745af104905992a2e88849a145e45c83743317764dcd926474f82653", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d88b006c-547b-4992-bee7-98df032d55bf", "node_type": "1", "metadata": {"window": "We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today. ", "original_text": "Operator:  All right. "}, "hash": "021f37e43ee5ca3f5ae25a83a10c9b1fc954310405031ea86b44e1476e1cb6de", "class_name": "RelatedNodeInfo"}}, "text": "So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n", "start_char_idx": 2265, "end_char_idx": 2514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d88b006c-547b-4992-bee7-98df032d55bf": {"__data__": {"id_": "d88b006c-547b-4992-bee7-98df032d55bf", "embedding": null, "metadata": {"window": "We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today. ", "original_text": "Operator:  All right. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49abd47c-2ce9-4549-9ee6-7b116b995b93", "node_type": "1", "metadata": {"window": "We want to be able to make sure that \nif we're able to do that,  we're very willing to tie those things to indexes and things, so they understand \nthat, as they come back down.  We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n", "original_text": "So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "429f6dfbc6f1160505c70f08f2f4ceaf2f1509cce8fe4c32b847c275e2aa90b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a68ab75-e2e8-4c54-a432-0648c8d5446e", "node_type": "1", "metadata": {"window": "Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question. ", "original_text": "And our next question will come from Jailendra Singh with Credit Suisse. "}, "hash": "7b7f31bef1f94a08183084198544f75c5528f3a54df507848d9300c95d8c84c4", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  All right. ", "start_char_idx": 2514, "end_char_idx": 2536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a68ab75-e2e8-4c54-a432-0648c8d5446e": {"__data__": {"id_": "3a68ab75-e2e8-4c54-a432-0648c8d5446e", "embedding": null, "metadata": {"window": "Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question. ", "original_text": "And our next question will come from Jailendra Singh with Credit Suisse. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d88b006c-547b-4992-bee7-98df032d55bf", "node_type": "1", "metadata": {"window": "We're not \u2013 we're willing to pass lower costs back on to them. \n Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today. ", "original_text": "Operator:  All right. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12df810e8d2d48fbe4ea197bf2ac7ed929cc293d4946cf9b02271eb978f6a5d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e80cb903-c6f5-478b-98b3-d44f0923cd2d", "node_type": "1", "metadata": {"window": "So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments? ", "original_text": "Please \ngo ahead.  \n \n"}, "hash": "24162de672e343c52063e89f27c6c70b267d65a4f5b45810f42b785cf647f462", "class_name": "RelatedNodeInfo"}}, "text": "And our next question will come from Jailendra Singh with Credit Suisse. ", "start_char_idx": 2536, "end_char_idx": 2609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e80cb903-c6f5-478b-98b3-d44f0923cd2d": {"__data__": {"id_": "e80cb903-c6f5-478b-98b3-d44f0923cd2d", "embedding": null, "metadata": {"window": "So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments? ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a68ab75-e2e8-4c54-a432-0648c8d5446e", "node_type": "1", "metadata": {"window": "Because we don't want to look at this as a \u2013 necessarily a chance to improve our margins \u2013 we'd like \nto do that through driving mix and launching more products, not on the backs of our customers during \na supply chain.  So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question. ", "original_text": "And our next question will come from Jailendra Singh with Credit Suisse. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb213cc9219dcc7f798943b13cabf73bef5428fc58f1b52f0698d5d23a29baa8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fab3547-420b-426d-9e15-04af3bd2d367", "node_type": "1", "metadata": {"window": "Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n", "original_text": "Adam Heussner:  Hi,  this is Adam on for Jailendra today. "}, "hash": "244f9e008e810837ea3337bc95d2d293022d9c6e2f0dfac7c65d791d9b19457d", "class_name": "RelatedNodeInfo"}}, "text": "Please \ngo ahead.  \n \n", "start_char_idx": 2609, "end_char_idx": 2631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fab3547-420b-426d-9e15-04af3bd2d367": {"__data__": {"id_": "4fab3547-420b-426d-9e15-04af3bd2d367", "embedding": null, "metadata": {"window": "Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n", "original_text": "Adam Heussner:  Hi,  this is Adam on for Jailendra today. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e80cb903-c6f5-478b-98b3-d44f0923cd2d", "node_type": "1", "metadata": {"window": "So, we are working with them to create contracting methods that will allow us to be \nable to pass those on as well as he lp them understand what are the metrics we will do to be able to \nknow for them when they changed the other direction, too.  \n \n Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments? ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6e1ce187b9eb3bfae9334c5f2369f4d17a326f26f4567ea418446e2e3e7d967", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e1a2d75-8fc9-45b1-bcc5-03a52be810d7", "node_type": "1", "metadata": {"window": "And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes. ", "original_text": "Thanks for taking the question. "}, "hash": "67f226ab0be93c8310f8411d42941b1f62662847274fd48fe5bc36597d11261f", "class_name": "RelatedNodeInfo"}}, "text": "Adam Heussner:  Hi,  this is Adam on for Jailendra today. ", "start_char_idx": 2631, "end_char_idx": 2689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e1a2d75-8fc9-45b1-bcc5-03a52be810d7": {"__data__": {"id_": "1e1a2d75-8fc9-45b1-bcc5-03a52be810d7", "embedding": null, "metadata": {"window": "And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes. ", "original_text": "Thanks for taking the question. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fab3547-420b-426d-9e15-04af3bd2d367", "node_type": "1", "metadata": {"window": "Operator:  All right.  And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n", "original_text": "Adam Heussner:  Hi,  this is Adam on for Jailendra today. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fd08cc76b985ee17f163843ebbb2cd666710d2b1c2fb50504a67c71cf79ef6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "878db290-d9c0-4043-a166-9c2c9257f3bf", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam. ", "original_text": "Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments? "}, "hash": "e1ff563fb34b1449b8fc5f05eaff170da24dfdf6916c3ae2b4952a4bfc5ddacf", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 2689, "end_char_idx": 2721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "878db290-d9c0-4043-a166-9c2c9257f3bf": {"__data__": {"id_": "878db290-d9c0-4043-a166-9c2c9257f3bf", "embedding": null, "metadata": {"window": "Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam. ", "original_text": "Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments? ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e1a2d75-8fc9-45b1-bcc5-03a52be810d7", "node_type": "1", "metadata": {"window": "And our next question will come from Jailendra Singh with Credit Suisse.  Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes. ", "original_text": "Thanks for taking the question. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c24877e38c9c9608778036bc5aaed0b1e7af78fcbbaf03927a3c79f54f9117bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c296e71-91ea-4706-86fe-190c0897ed1c", "node_type": "1", "metadata": {"window": "Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason. ", "original_text": "Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n"}, "hash": "ebefa8225769bd1ea90e3823427f14f77ac8fb8a3a92d78a903498be2b84cad5", "class_name": "RelatedNodeInfo"}}, "text": "Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments? ", "start_char_idx": 2721, "end_char_idx": 2878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c296e71-91ea-4706-86fe-190c0897ed1c": {"__data__": {"id_": "2c296e71-91ea-4706-86fe-190c0897ed1c", "embedding": null, "metadata": {"window": "Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason. ", "original_text": "Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "878db290-d9c0-4043-a166-9c2c9257f3bf", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam. ", "original_text": "Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments? ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a698ba38c2fc9c4d84ce40a506d059a7c461fdea6bba5209286ae84eecfdd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c6fd982-5a52-44d3-b22f-8747f03a9200", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that. ", "original_text": "Jason Hollar:  Yes. "}, "hash": "3d12015594b612a78a8f57120e0dda8daf5a92100e6506bbf2ca9225a349a33c", "class_name": "RelatedNodeInfo"}}, "text": "Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n", "start_char_idx": 2878, "end_char_idx": 3037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c6fd982-5a52-44d3-b22f-8747f03a9200": {"__data__": {"id_": "8c6fd982-5a52-44d3-b22f-8747f03a9200", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that. ", "original_text": "Jason Hollar:  Yes. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c296e71-91ea-4706-86fe-190c0897ed1c", "node_type": "1", "metadata": {"window": "Adam Heussner:  Hi,  this is Adam on for Jailendra today.  Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason. ", "original_text": "Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e35fec08a1d8cea091a95aa06185b87cb72ff4d1298bd76962d866d9c711f80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d903d5f0-9ba5-4d30-a0c1-44820c205984", "node_type": "1", "metadata": {"window": "Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be. ", "original_text": "Good morning, Adam. "}, "hash": "ca8ec9c85a5385c3d5f66662403edfb5a7737f88eada627fe63fad43e98a046f", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes. ", "start_char_idx": 3037, "end_char_idx": 3057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d903d5f0-9ba5-4d30-a0c1-44820c205984": {"__data__": {"id_": "d903d5f0-9ba5-4d30-a0c1-44820c205984", "embedding": null, "metadata": {"window": "Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be. ", "original_text": "Good morning, Adam. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c6fd982-5a52-44d3-b22f-8747f03a9200", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that. ", "original_text": "Jason Hollar:  Yes. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a37d5ef888fa7e58af76376711a7d87a6a1e4b35278767a442ce41d37f0eef1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af1a3711-3f70-4c72-903c-fa699feaf582", "node_type": "1", "metadata": {"window": "Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course. ", "original_text": "This is Jason. "}, "hash": "d8643b0d2074f08bb605e7240b178d53d62443f80cf8e2afc8c7fd2b7d8c7f04", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, Adam. ", "start_char_idx": 3057, "end_char_idx": 3077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af1a3711-3f70-4c72-903c-fa699feaf582": {"__data__": {"id_": "af1a3711-3f70-4c72-903c-fa699feaf582", "embedding": null, "metadata": {"window": "Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course. ", "original_text": "This is Jason. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d903d5f0-9ba5-4d30-a0c1-44820c205984", "node_type": "1", "metadata": {"window": "Going back \nto your long -term growth target, just wondering if you take into account the capital allocated to the \nanticipated opioid fulfillment payments?  Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be. ", "original_text": "Good morning, Adam. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e804bd4590096424dfcd7ab1ffd745056efbf3b0a1f062c703c73e3b61413a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e7e2dab-afed-4e05-89e3-37233b541f8a", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer. ", "original_text": "Yes, so that would incorporate that. "}, "hash": "d711b14eb6313f7a53c7a92e9726fc17035957139da844732aebf5754d64481b", "class_name": "RelatedNodeInfo"}}, "text": "This is Jason. ", "start_char_idx": 3077, "end_char_idx": 3092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e7e2dab-afed-4e05-89e3-37233b541f8a": {"__data__": {"id_": "7e7e2dab-afed-4e05-89e3-37233b541f8a", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer. ", "original_text": "Yes, so that would incorporate that. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af1a3711-3f70-4c72-903c-fa699feaf582", "node_type": "1", "metadata": {"window": "Or how we should be thinking abo ut that potential impact as it \nrelates to being able to invest across some of your growth and higher -margin businesses?  \n \n Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course. ", "original_text": "This is Jason. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53f5a09d0d5709dededeb77a2b957c3002a04df0d157af7323059666a9b60c75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3925d66a-af3a-459c-a919-bad5c3e7f326", "node_type": "1", "metadata": {"window": "Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline. ", "original_text": "As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be. "}, "hash": "ffe2948af55b83662b20dde636e8cae40e942794212ef5868697be5f86aff1cd", "class_name": "RelatedNodeInfo"}}, "text": "Yes, so that would incorporate that. ", "start_char_idx": 3092, "end_char_idx": 3129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3925d66a-af3a-459c-a919-bad5c3e7f326": {"__data__": {"id_": "3925d66a-af3a-459c-a919-bad5c3e7f326", "embedding": null, "metadata": {"window": "Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline. ", "original_text": "As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e7e2dab-afed-4e05-89e3-37233b541f8a", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer. ", "original_text": "Yes, so that would incorporate that. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fafc76a984b578e64416071fec2590b1ccfb4593de899d6b25d561b10019d278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f090eb67-5903-4df3-979b-865db115f43c", "node_type": "1", "metadata": {"window": "This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well. ", "original_text": "That's all based upon our current set of assumptions, \nof course. "}, "hash": "5951c80eb0e677be65fa0136e41bcc5f6ca4ac198164edd7fcadc91aab160047", "class_name": "RelatedNodeInfo"}}, "text": "As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be. ", "start_char_idx": 3129, "end_char_idx": 3279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f090eb67-5903-4df3-979b-865db115f43c": {"__data__": {"id_": "f090eb67-5903-4df3-979b-865db115f43c", "embedding": null, "metadata": {"window": "This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well. ", "original_text": "That's all based upon our current set of assumptions, \nof course. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3925d66a-af3a-459c-a919-bad5c3e7f326", "node_type": "1", "metadata": {"window": "Good morning, Adam.  This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline. ", "original_text": "As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ed2a77977b7c09591f4677e0291abb505e319e3706961621ac96633495085f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98824340-c5dc-41bf-a871-786431248c36", "node_type": "1", "metadata": {"window": "Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that. ", "original_text": "And if that would change materially, then that would change the answer. "}, "hash": "c6ff72fcf7f615c5db7be79b6c9ac410c51ee4e9a5570775b591e462b1499276", "class_name": "RelatedNodeInfo"}}, "text": "That's all based upon our current set of assumptions, \nof course. ", "start_char_idx": 3279, "end_char_idx": 3345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98824340-c5dc-41bf-a871-786431248c36": {"__data__": {"id_": "98824340-c5dc-41bf-a871-786431248c36", "embedding": null, "metadata": {"window": "Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that. ", "original_text": "And if that would change materially, then that would change the answer. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f090eb67-5903-4df3-979b-865db115f43c", "node_type": "1", "metadata": {"window": "This is Jason.  Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well. ", "original_text": "That's all based upon our current set of assumptions, \nof course. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5adab6abe1b4c9063a8a1f3a7e8c8f7c2d5e90332f753206d1aaebf519bc1f49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c51e29e9-2384-4834-bd1d-907d6e9d5790", "node_type": "1", "metadata": {"window": "As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "But based upon \nwhat we know now, that would be the baseline. "}, "hash": "50a1ea4807c47ce5db64accdbd8652518263ecf36f008dd7650d9770f1e8bf2e", "class_name": "RelatedNodeInfo"}}, "text": "And if that would change materially, then that would change the answer. ", "start_char_idx": 3345, "end_char_idx": 3417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c51e29e9-2384-4834-bd1d-907d6e9d5790": {"__data__": {"id_": "c51e29e9-2384-4834-bd1d-907d6e9d5790", "embedding": null, "metadata": {"window": "As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "But based upon \nwhat we know now, that would be the baseline. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98824340-c5dc-41bf-a871-786431248c36", "node_type": "1", "metadata": {"window": "Yes, so that would incorporate that.  As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that. ", "original_text": "And if that would change materially, then that would change the answer. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee31627d7063a330cda8ae98cb2ce6f752fe058f38bc63ed9e353f4774d0620a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1014dd5-9840-46fb-959a-c00d6bcac39b", "node_type": "1", "metadata": {"window": "That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well. "}, "hash": "ab61c2b401cfcc03ec12e308a014d640133f39949516dfcf5db4072d160a52b6", "class_name": "RelatedNodeInfo"}}, "text": "But based upon \nwhat we know now, that would be the baseline. ", "start_char_idx": 3417, "end_char_idx": 3479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1014dd5-9840-46fb-959a-c00d6bcac39b": {"__data__": {"id_": "e1014dd5-9840-46fb-959a-c00d6bcac39b", "embedding": null, "metadata": {"window": "That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c51e29e9-2384-4834-bd1d-907d6e9d5790", "node_type": "1", "metadata": {"window": "As we \nthink about the capital deployment si de of that, we have for quite some time now included in an \nexpectation of what those payments would be.  That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "But based upon \nwhat we know now, that would be the baseline. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "334d6fc8f2ca441f4c9932106d0d8a64c41e4e1f31da7776702859fc9cfb5ab4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abac5b5c-bf25-425c-ac83-0e6fd736bc03", "node_type": "1", "metadata": {"window": "And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that. "}, "hash": "9d9ca815c73011e9b02ebaa284ccc5647bb0e810003125ea742d35a86b2a0861", "class_name": "RelatedNodeInfo"}}, "text": "For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well. ", "start_char_idx": 3479, "end_char_idx": 3597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abac5b5c-bf25-425c-ac83-0e6fd736bc03": {"__data__": {"id_": "abac5b5c-bf25-425c-ac83-0e6fd736bc03", "embedding": null, "metadata": {"window": "And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1014dd5-9840-46fb-959a-c00d6bcac39b", "node_type": "1", "metadata": {"window": "That's all based upon our current set of assumptions, \nof course.  And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "079fc44b56ba1f66b88f58df7690241a29b54c00c575d9d5631bff4e44accf14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b07cc9f-7c66-491c-aa01-b231caff88ed", "node_type": "1", "metadata": {"window": "But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "Next \nquestion.  "}, "hash": "96ab45b81a0f128f6b0e4997748426467630939b7cb7710217f7c1528c710fc4", "class_name": "RelatedNodeInfo"}}, "text": "So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that. ", "start_char_idx": 3597, "end_char_idx": 3728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b07cc9f-7c66-491c-aa01-b231caff88ed": {"__data__": {"id_": "9b07cc9f-7c66-491c-aa01-b231caff88ed", "embedding": null, "metadata": {"window": "But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "Next \nquestion.  ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e35826f100c2589f824595c41e3cb58112be2799c27626fec07ca63e592cc99", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abac5b5c-bf25-425c-ac83-0e6fd736bc03", "node_type": "1", "metadata": {"window": "And if that would change materially, then that would change the answer.  But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dcd2814540e6c18e64d06f327acaa70ecbe9ce014ed2d6558a446070b4ef64e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d07e96e6-73f3-41c6-8293-cdc90de7cdc4", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody. ", "original_text": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays. "}, "hash": "3e32a247fea10143df8bf97bccf3621afaf70413e0f749792c5e3c2c24da69be", "class_name": "RelatedNodeInfo"}}, "text": "Next \nquestion.  ", "start_char_idx": 3728, "end_char_idx": 3745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d07e96e6-73f3-41c6-8293-cdc90de7cdc4": {"__data__": {"id_": "d07e96e6-73f3-41c6-8293-cdc90de7cdc4", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody. ", "original_text": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b07cc9f-7c66-491c-aa01-b231caff88ed", "node_type": "1", "metadata": {"window": "But based upon \nwhat we know now, that would be the baseline.  For example, the $3 billion share repurchase \nauthorization that we have just completed is inclusive of that as well.  So part of the capital outlay that \nwe would expect over that period of time and this would be  the available capital beyond that.  Next \nquestion.  ", "original_text": "Next \nquestion.  ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d850c7642340e078e6b4f231a78434b10328baed24b55bca288764bce0aea5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d759623-5427-4e9b-a43a-8f59e6ccc511", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n", "original_text": "Please go ahead.  \n \n"}, "hash": "286b57b1003e8fdce8d2aef65e7cbab8f8f1e6101b0be66dcca1678300e1d6b5", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays. ", "start_char_idx": 0, "end_char_idx": 103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d759623-5427-4e9b-a43a-8f59e6ccc511": {"__data__": {"id_": "7d759623-5427-4e9b-a43a-8f59e6ccc511", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n", "original_text": "Please go ahead.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d07e96e6-73f3-41c6-8293-cdc90de7cdc4", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody. ", "original_text": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "549183f947e99193e1661fee905864923b1b9e79a322b50f6639a39cd8f6d0b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e69b78e-8f2f-421c-83be-0ad66e048ebb", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels. ", "original_text": "Steven Valiquette:  Hi, thanks. "}, "hash": "953d35069011339458e63257b3bbf847ac4f2cd6b9edd0b9a085d163a7bd216d", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 103, "end_char_idx": 124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e69b78e-8f2f-421c-83be-0ad66e048ebb": {"__data__": {"id_": "1e69b78e-8f2f-421c-83be-0ad66e048ebb", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels. ", "original_text": "Steven Valiquette:  Hi, thanks. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d759623-5427-4e9b-a43a-8f59e6ccc511", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n", "original_text": "Please go ahead.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174ff7ee8dbf3202bb554b9cea851c67274f9eb7123ea5e10977fe5c186b68da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7035c024-c966-4cd1-945a-c71693f464d0", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22? ", "original_text": "Good morning everybody. "}, "hash": "616003ec8dba5ac9edf6b58867e78fca4304e364947f6cb319c8e2e497b65d82", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette:  Hi, thanks. ", "start_char_idx": 124, "end_char_idx": 156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7035c024-c966-4cd1-945a-c71693f464d0": {"__data__": {"id_": "7035c024-c966-4cd1-945a-c71693f464d0", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22? ", "original_text": "Good morning everybody. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e69b78e-8f2f-421c-83be-0ad66e048ebb", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels. ", "original_text": "Steven Valiquette:  Hi, thanks. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1e57da3713fbc67d9b8fb983583ed53764173ce2bd8fa5bc91a80e0f2f361f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd207bef-0dc4-4e8f-8c2b-abe77a3a92ab", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment? ", "original_text": "So just a question on the Medical segment. \n"}, "hash": "46c6fe28c3f6845643841e24aff189e7f227275e973cfc30a3576e1cebd0b025", "class_name": "RelatedNodeInfo"}}, "text": "Good morning everybody. ", "start_char_idx": 156, "end_char_idx": 180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd207bef-0dc4-4e8f-8c2b-abe77a3a92ab": {"__data__": {"id_": "dd207bef-0dc4-4e8f-8c2b-abe77a3a92ab", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment? ", "original_text": "So just a question on the Medical segment. \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7035c024-c966-4cd1-945a-c71693f464d0", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22? ", "original_text": "Good morning everybody. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7ce1ce00e525fa33fb8d2e7eeea2dadec7fbde8c025cb8319f7814aca686797", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e49baafe-0007-4630-a628-919ea7146855", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n", "original_text": "You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels. "}, "hash": "0ab29183471ebdde5560dc1c6893cca0a3a3df36469a6dcc289b2832efa8b47e", "class_name": "RelatedNodeInfo"}}, "text": "So just a question on the Medical segment. \n", "start_char_idx": 180, "end_char_idx": 224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e49baafe-0007-4630-a628-919ea7146855": {"__data__": {"id_": "e49baafe-0007-4630-a628-919ea7146855", "embedding": null, "metadata": {"window": "Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n", "original_text": "You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd207bef-0dc4-4e8f-8c2b-abe77a3a92ab", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment? ", "original_text": "So just a question on the Medical segment. \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5bd7f513149248d117ef3eedef0147d2aea3ac377d87b0bc6f3eb2d060dddce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d1c8a1a-8323-4d21-b331-2a0b473b2cbe", "node_type": "1", "metadata": {"window": "Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes. ", "original_text": "I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22? "}, "hash": "13692383ceaf25f87cb30d997c9bc1f0ba3772134092ba2b3d7c8228cc413a28", "class_name": "RelatedNodeInfo"}}, "text": "You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels. ", "start_char_idx": 224, "end_char_idx": 369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d1c8a1a-8323-4d21-b331-2a0b473b2cbe": {"__data__": {"id_": "6d1c8a1a-8323-4d21-b331-2a0b473b2cbe", "embedding": null, "metadata": {"window": "Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes. ", "original_text": "I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22? ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e49baafe-0007-4630-a628-919ea7146855", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Hi, thanks.  Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n", "original_text": "You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f52550ff16d075527e8f2d97142960637b8da862185731ad2c9be4c2a881f099", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55ec75bc-b632-4cfd-a6d8-92982f815aee", "node_type": "1", "metadata": {"window": "So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter. ", "original_text": "And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment? "}, "hash": "bc7a22f2df3fd3e6cb09eb140b94873b79cf2889a59c73038b9f8c0d1f234847", "class_name": "RelatedNodeInfo"}}, "text": "I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22? ", "start_char_idx": 369, "end_char_idx": 504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55ec75bc-b632-4cfd-a6d8-92982f815aee": {"__data__": {"id_": "55ec75bc-b632-4cfd-a6d8-92982f815aee", "embedding": null, "metadata": {"window": "So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter. ", "original_text": "And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment? ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d1c8a1a-8323-4d21-b331-2a0b473b2cbe", "node_type": "1", "metadata": {"window": "Good morning everybody.  So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes. ", "original_text": "I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22? ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87196f4e0e505ebe04aadedbfafd6a92ad1e150ea91e3e7e504e33215b0f8fe2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7881a53e-6317-4318-8012-c29140dfb3ca", "node_type": "1", "metadata": {"window": "You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels. ", "original_text": "Thanks.  \n \n"}, "hash": "ee5f29ef38d002b960b8d32e0a55bb652636b709c11f02d0dc5c26ae1260b27f", "class_name": "RelatedNodeInfo"}}, "text": "And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment? ", "start_char_idx": 504, "end_char_idx": 631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7881a53e-6317-4318-8012-c29140dfb3ca": {"__data__": {"id_": "7881a53e-6317-4318-8012-c29140dfb3ca", "embedding": null, "metadata": {"window": "You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels. ", "original_text": "Thanks.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55ec75bc-b632-4cfd-a6d8-92982f815aee", "node_type": "1", "metadata": {"window": "So just a question on the Medical segment. \n You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter. ", "original_text": "And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment? ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d934350feee33dad5d32484f2b4bebe9df9930a6981226898afd390394da9946", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "817f10b8-aa45-41f5-b931-65be23ca7182", "node_type": "1", "metadata": {"window": "I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%. ", "original_text": "Jason Hollar:  Yes. "}, "hash": "85a39a6d507d0ae63a18d7ffff974199e4ff79927927e48d17485c17aa2f2f75", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 631, "end_char_idx": 643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "817f10b8-aa45-41f5-b931-65be23ca7182": {"__data__": {"id_": "817f10b8-aa45-41f5-b931-65be23ca7182", "embedding": null, "metadata": {"window": "I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%. ", "original_text": "Jason Hollar:  Yes. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7881a53e-6317-4318-8012-c29140dfb3ca", "node_type": "1", "metadata": {"window": "You mentioned that despite some impact from the Delta variant that the total elective volumes exited \nthe quarter near 95% of pre -COVID levels.  I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels. ", "original_text": "Thanks.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ade8cc8850a8abd0b815cb9a74f8700f28dbfb517ba2516c5af043a2526faad7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc0e3e10-c6e6-479b-9348-eeba3981ac39", "node_type": "1", "metadata": {"window": "And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant. ", "original_text": "The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter. "}, "hash": "ffdea8fc807d03c81398a16413866fac075527cb6006e77ff33286dab3ff5dc0", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes. ", "start_char_idx": 643, "end_char_idx": 663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc0e3e10-c6e6-479b-9348-eeba3981ac39": {"__data__": {"id_": "bc0e3e10-c6e6-479b-9348-eeba3981ac39", "embedding": null, "metadata": {"window": "And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant. ", "original_text": "The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "817f10b8-aa45-41f5-b931-65be23ca7182", "node_type": "1", "metadata": {"window": "I guess I'm curious if there's any updates on your \nassumptions for the pace of return of procedures for the remainde r of fiscal '22?  And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%. ", "original_text": "Jason Hollar:  Yes. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8258af7c7371c382df89c5b3d08b22e7f534a3394e3dc3c3aa649908c4d87d55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d687589c-b363-4993-92a6-e654691f2b09", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.  ", "original_text": "We started the quarter at close to pre -COVID levels. "}, "hash": "5a556d4dbd012a73d01ab9e9fdfd6b6a0b18a697d786e23a54aac096706b19f0", "class_name": "RelatedNodeInfo"}}, "text": "The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter. ", "start_char_idx": 663, "end_char_idx": 783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d687589c-b363-4993-92a6-e654691f2b09": {"__data__": {"id_": "d687589c-b363-4993-92a6-e654691f2b09", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.  ", "original_text": "We started the quarter at close to pre -COVID levels. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc0e3e10-c6e6-479b-9348-eeba3981ac39", "node_type": "1", "metadata": {"window": "And is this also a \npositive factor that helps to offset some of the negatives that you discussed within the Medical \nsegment?  Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant. ", "original_text": "The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0c6d9a90d18ff43c8a0bc5cc7836782724ea3998938f6c931c398d7beca9fd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ce6b6d2-11f8-4dc4-9651-58cfb11622ab", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve. ", "original_text": "And as we \nindicated, we exited and then back at about 95%. "}, "hash": "d69eff3d1721c7fa6491046cc328b53ad8e3a39e7b826fb153d9fc469b10c976", "class_name": "RelatedNodeInfo"}}, "text": "We started the quarter at close to pre -COVID levels. ", "start_char_idx": 783, "end_char_idx": 837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ce6b6d2-11f8-4dc4-9651-58cfb11622ab": {"__data__": {"id_": "7ce6b6d2-11f8-4dc4-9651-58cfb11622ab", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve. ", "original_text": "And as we \nindicated, we exited and then back at about 95%. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d687589c-b363-4993-92a6-e654691f2b09", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.  ", "original_text": "We started the quarter at close to pre -COVID levels. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92f84f59bbb3284f4ebe4fb20eecf562e196a7cf9975344160e2cc6f3156a1c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0668c72a-0c2e-4c21-8f08-5f5284db3166", "node_type": "1", "metadata": {"window": "The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n", "original_text": "And we think that's primarily attributed to the Delta \nvariant. "}, "hash": "49c15f576f516d8903ac9342e98f6def8b15fea60579e9e205d4de41cd8bf4a2", "class_name": "RelatedNodeInfo"}}, "text": "And as we \nindicated, we exited and then back at about 95%. ", "start_char_idx": 837, "end_char_idx": 897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0668c72a-0c2e-4c21-8f08-5f5284db3166": {"__data__": {"id_": "0668c72a-0c2e-4c21-8f08-5f5284db3166", "embedding": null, "metadata": {"window": "The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n", "original_text": "And we think that's primarily attributed to the Delta \nvariant. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ce6b6d2-11f8-4dc4-9651-58cfb11622ab", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve. ", "original_text": "And as we \nindicated, we exited and then back at about 95%. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4da64fdf9f14a4612ec1c849de5bb58a9ea43d14d9007b518eb8bc57ab8c30e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e076b600-eba6-438b-ad98-6f3c6e2f907d", "node_type": "1", "metadata": {"window": "We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus. ", "original_text": "So we see that trending in the right direction.  "}, "hash": "aa92c43299f490d06d570fe06383349dff0a2c0ed0c5c24fcd632426b7a44e6a", "class_name": "RelatedNodeInfo"}}, "text": "And we think that's primarily attributed to the Delta \nvariant. ", "start_char_idx": 897, "end_char_idx": 961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e076b600-eba6-438b-ad98-6f3c6e2f907d": {"__data__": {"id_": "e076b600-eba6-438b-ad98-6f3c6e2f907d", "embedding": null, "metadata": {"window": "We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus. ", "original_text": "So we see that trending in the right direction.  ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0668c72a-0c2e-4c21-8f08-5f5284db3166", "node_type": "1", "metadata": {"window": "The \u2013 there was a little bit of a reduction in that base \u2013 in that level of elective  \nprocedures in the first quarter.  We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n", "original_text": "And we think that's primarily attributed to the Delta \nvariant. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1aafc5f180ae788fed0848649f9ecc68b9c663da2715f6e148c18985528aa5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcef4aa9-c7d0-4f0f-8dc7-97649c66aa5f", "node_type": "1", "metadata": {"window": "And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter. ", "original_text": "And with the pace of the virus since then, we \nfeel that will continue to improve. "}, "hash": "a5fac04df16096dcba9fc1bd7b21a3634bb8afee2ad72cdce17f3b3657d0c537", "class_name": "RelatedNodeInfo"}}, "text": "So we see that trending in the right direction.  ", "start_char_idx": 961, "end_char_idx": 1010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcef4aa9-c7d0-4f0f-8dc7-97649c66aa5f": {"__data__": {"id_": "bcef4aa9-c7d0-4f0f-8dc7-97649c66aa5f", "embedding": null, "metadata": {"window": "And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter. ", "original_text": "And with the pace of the virus since then, we \nfeel that will continue to improve. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e076b600-eba6-438b-ad98-6f3c6e2f907d", "node_type": "1", "metadata": {"window": "We started the quarter at close to pre -COVID levels.  And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus. ", "original_text": "So we see that trending in the right direction.  ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c94392969e34565f0985f275b86681c877b7f24b8c7e2c5f25c522039f023af1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70eb499d-de91-465f-968a-4ec5b8993a2d", "node_type": "1", "metadata": {"window": "And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward. ", "original_text": "And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n"}, "hash": "fef7cc95612dd835dd8cbcf7a9e67713271f33e77d48b646ade172c147752302", "class_name": "RelatedNodeInfo"}}, "text": "And with the pace of the virus since then, we \nfeel that will continue to improve. ", "start_char_idx": 1010, "end_char_idx": 1093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70eb499d-de91-465f-968a-4ec5b8993a2d": {"__data__": {"id_": "70eb499d-de91-465f-968a-4ec5b8993a2d", "embedding": null, "metadata": {"window": "And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward. ", "original_text": "And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcef4aa9-c7d0-4f0f-8dc7-97649c66aa5f", "node_type": "1", "metadata": {"window": "And as we \nindicated, we exited and then back at about 95%.  And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter. ", "original_text": "And with the pace of the virus since then, we \nfeel that will continue to improve. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "644a4542b1c81ce755afe15a7ed723e4d0fb4f21fc29b83da900690cc92cac7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6c455bd-ad96-4ccd-a3eb-66c0f52da9fe", "node_type": "1", "metadata": {"window": "So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n", "original_text": "So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus. "}, "hash": "50295de857253aef5da38d9123dba63c974e64a51573b86b812a8ec1b76202ce", "class_name": "RelatedNodeInfo"}}, "text": "And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n", "start_char_idx": 1093, "end_char_idx": 1276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6c455bd-ad96-4ccd-a3eb-66c0f52da9fe": {"__data__": {"id_": "b6c455bd-ad96-4ccd-a3eb-66c0f52da9fe", "embedding": null, "metadata": {"window": "So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n", "original_text": "So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70eb499d-de91-465f-968a-4ec5b8993a2d", "node_type": "1", "metadata": {"window": "And we think that's primarily attributed to the Delta \nvariant.  So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward. ", "original_text": "And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1be36190643ad0b1d616b99fae4d89589654667908365422249f4d7b395f428c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da7cbef0-e495-4732-8566-127eb6031fa3", "node_type": "1", "metadata": {"window": "And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n", "original_text": "So it's nothing significant that we saw in the quarter. "}, "hash": "ad6e90b4de4ef01356e5681b54d4e6b2a3f4be038de15517859e2c401fd47508", "class_name": "RelatedNodeInfo"}}, "text": "So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus. ", "start_char_idx": 1276, "end_char_idx": 1415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da7cbef0-e495-4732-8566-127eb6031fa3": {"__data__": {"id_": "da7cbef0-e495-4732-8566-127eb6031fa3", "embedding": null, "metadata": {"window": "And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n", "original_text": "So it's nothing significant that we saw in the quarter. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6c455bd-ad96-4ccd-a3eb-66c0f52da9fe", "node_type": "1", "metadata": {"window": "So we see that trending in the right direction.   And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n", "original_text": "So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92875d1de0244d39c8e807ee5ed946909abfc52874023141cb904a00435dda55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbbbf0b1-b409-451d-887c-b82077213b60", "node_type": "1", "metadata": {"window": "And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys. ", "original_text": "And as a \nresult, we don't anticipate there being wild flu ctuations going forward. "}, "hash": "0fb397c5cf016fede8581a4b889c80678ae997c443a42cacff61ead9d9fc5af6", "class_name": "RelatedNodeInfo"}}, "text": "So it's nothing significant that we saw in the quarter. ", "start_char_idx": 1415, "end_char_idx": 1471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbbbf0b1-b409-451d-887c-b82077213b60": {"__data__": {"id_": "dbbbf0b1-b409-451d-887c-b82077213b60", "embedding": null, "metadata": {"window": "And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys. ", "original_text": "And as a \nresult, we don't anticipate there being wild flu ctuations going forward. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da7cbef0-e495-4732-8566-127eb6031fa3", "node_type": "1", "metadata": {"window": "And with the pace of the virus since then, we \nfeel that will continue to improve.  And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n", "original_text": "So it's nothing significant that we saw in the quarter. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0062b2dbd4d36e90cf38fe0c8baf9ddb3efc33c74a85cd312d4678e4ca48a57d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "412f5a82-c0b0-4385-b1e9-105cff2478b7", "node_type": "1", "metadata": {"window": "So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart. ", "original_text": "Next question.  \n \n"}, "hash": "7d3c5ac8ac4dadadf8cbd1ffd7895005355c6c25adf724b763c22808596e3805", "class_name": "RelatedNodeInfo"}}, "text": "And as a \nresult, we don't anticipate there being wild flu ctuations going forward. ", "start_char_idx": 1471, "end_char_idx": 1555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "412f5a82-c0b0-4385-b1e9-105cff2478b7": {"__data__": {"id_": "412f5a82-c0b0-4385-b1e9-105cff2478b7", "embedding": null, "metadata": {"window": "So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart. ", "original_text": "Next question.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbbbf0b1-b409-451d-887c-b82077213b60", "node_type": "1", "metadata": {"window": "And importantly, what we saw in the quarter is we saw an \nimprovement in our lab business that effectively offset that modest deterioration in the amount of \nelective procedur es. \n \n So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys. ", "original_text": "And as a \nresult, we don't anticipate there being wild flu ctuations going forward. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "664c795028125432d0cb25522ade689016f4983329fad376d7b8c88bffa5a7b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "458f65cc-f29b-4122-80f3-7945e3fa2677", "node_type": "1", "metadata": {"window": "So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n", "original_text": "Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n"}, "hash": "222ed0daf60c614ad7feff3ef834497e5a4530fa55852f7b321a017df09d21d2", "class_name": "RelatedNodeInfo"}}, "text": "Next question.  \n \n", "start_char_idx": 1555, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "458f65cc-f29b-4122-80f3-7945e3fa2677": {"__data__": {"id_": "458f65cc-f29b-4122-80f3-7945e3fa2677", "embedding": null, "metadata": {"window": "So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n", "original_text": "Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "412f5a82-c0b0-4385-b1e9-105cff2478b7", "node_type": "1", "metadata": {"window": "So what we're seeing right now, is that those two items tend to generally offset both good and bad, \ndepending upon the pace of the virus.  So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart. ", "original_text": "Next question.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2dc474fb81416c0ecbe4da3d286755344656190c4d8a8a6d6aa6f9499ca2e511", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "381c6c28-3992-4096-8cab-c6dc96ac70df", "node_type": "1", "metadata": {"window": "And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit. ", "original_text": "George Hill:  Hi, good morning guys. "}, "hash": "621ba5b39b744e9b685fa8281a309588de68493588f4e6c71496053e8fc6ec75", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n", "start_char_idx": 1574, "end_char_idx": 1660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "381c6c28-3992-4096-8cab-c6dc96ac70df": {"__data__": {"id_": "381c6c28-3992-4096-8cab-c6dc96ac70df", "embedding": null, "metadata": {"window": "And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit. ", "original_text": "George Hill:  Hi, good morning guys. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "458f65cc-f29b-4122-80f3-7945e3fa2677", "node_type": "1", "metadata": {"window": "So it's nothing significant that we saw in the quarter.  And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n", "original_text": "Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3560310b8b59f71fcfa593616763da6c74a939c958656f10d734c6bc1cf28b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89e14d5a-da07-4024-b35b-abd44543e9de", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n", "original_text": "And this is the second time this earnings season I've been \nStuart. "}, "hash": "bade6c9a3cdbea5da1e96b8af31cc577585b54f8c2813a5eaea549a80fa159e3", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Hi, good morning guys. ", "start_char_idx": 1660, "end_char_idx": 1697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89e14d5a-da07-4024-b35b-abd44543e9de": {"__data__": {"id_": "89e14d5a-da07-4024-b35b-abd44543e9de", "embedding": null, "metadata": {"window": "Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n", "original_text": "And this is the second time this earnings season I've been \nStuart. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "381c6c28-3992-4096-8cab-c6dc96ac70df", "node_type": "1", "metadata": {"window": "And as a \nresult, we don't anticipate there being wild flu ctuations going forward.  Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit. ", "original_text": "George Hill:  Hi, good morning guys. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61091665b71ff6886b703bf032d6fb798a95e5b286343c90b390b237099ccacf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "936a2467-0b8d-4272-8697-940e1c1e052b", "node_type": "1", "metadata": {"window": "Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings. ", "original_text": "Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n"}, "hash": "a974b004ee25bb5cd993ebf3aaafa53c4d44701572d1e56a14409349dd5000af", "class_name": "RelatedNodeInfo"}}, "text": "And this is the second time this earnings season I've been \nStuart. ", "start_char_idx": 1697, "end_char_idx": 1765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "936a2467-0b8d-4272-8697-940e1c1e052b": {"__data__": {"id_": "936a2467-0b8d-4272-8697-940e1c1e052b", "embedding": null, "metadata": {"window": "Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings. ", "original_text": "Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89e14d5a-da07-4024-b35b-abd44543e9de", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n", "original_text": "And this is the second time this earnings season I've been \nStuart. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "830792dc8df8742590b228d18ac137f4b364f5dda8d191b6467a4169566f4167", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03ce3a2a-c056-4428-a01e-6bed0a9c9804", "node_type": "1", "metadata": {"window": "George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this. ", "original_text": "Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit. "}, "hash": "495e50095b3c6f35681f11ffc1749ff4ea48e0a5aba3ed26f668f3b385b271e7", "class_name": "RelatedNodeInfo"}}, "text": "Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n", "start_char_idx": 1765, "end_char_idx": 2023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03ce3a2a-c056-4428-a01e-6bed0a9c9804": {"__data__": {"id_": "03ce3a2a-c056-4428-a01e-6bed0a9c9804", "embedding": null, "metadata": {"window": "George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this. ", "original_text": "Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "936a2467-0b8d-4272-8697-940e1c1e052b", "node_type": "1", "metadata": {"window": "Operator:  And next, we will take a question from Stuart Hill with Deutsche Bank.  \n \n George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings. ", "original_text": "Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd95c8721c3112cba60ed3935d121d2e8d95f56a985378a901880c6ca2d5ccc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e489d9d-8328-4c4f-b35f-bfe9d217af96", "node_type": "1", "metadata": {"window": "And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur. ", "original_text": "And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n"}, "hash": "78d4fb76fcc7313f782490e4dd3c2be632a7d4c3e1a969016dc2ab0096ddc681", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit. ", "start_char_idx": 2023, "end_char_idx": 2361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e489d9d-8328-4c4f-b35f-bfe9d217af96": {"__data__": {"id_": "5e489d9d-8328-4c4f-b35f-bfe9d217af96", "embedding": null, "metadata": {"window": "And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur. ", "original_text": "And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03ce3a2a-c056-4428-a01e-6bed0a9c9804", "node_type": "1", "metadata": {"window": "George Hill:  Hi, good morning guys.  And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this. ", "original_text": "Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12daaaf88a11227b72fd46d3e761c910094137ef07ae3eb6343d098f73fc74a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ee45df8-2fc9-45fb-b197-94a7c2f0df8e", "node_type": "1", "metadata": {"window": "Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment. ", "original_text": "So the guidance on Medical and Pharma was real ly about operating earnings. "}, "hash": "20a7d8eb1461d0e99df3841b2f0bd2d67f29c957e1a6aff48f18c4af5d67832d", "class_name": "RelatedNodeInfo"}}, "text": "And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n", "start_char_idx": 2361, "end_char_idx": 2532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ee45df8-2fc9-45fb-b197-94a7c2f0df8e": {"__data__": {"id_": "3ee45df8-2fc9-45fb-b197-94a7c2f0df8e", "embedding": null, "metadata": {"window": "Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment. ", "original_text": "So the guidance on Medical and Pharma was real ly about operating earnings. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e489d9d-8328-4c4f-b35f-bfe9d217af96", "node_type": "1", "metadata": {"window": "And this is the second time this earnings season I've been \nStuart.  Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur. ", "original_text": "And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bde1818a67545164576b9bd5f145b8ca7577e4604e051478f8c18e4e38adacb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df38657f-e5fb-41a9-915c-db907065292f", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo. ", "original_text": "And I would also say \nthat M&A is not a top priority in this. "}, "hash": "7a137324ec787f1ec1a7f0dae8769dcb2a8ecfb07386b7608e1b0088e2849333", "class_name": "RelatedNodeInfo"}}, "text": "So the guidance on Medical and Pharma was real ly about operating earnings. ", "start_char_idx": 2532, "end_char_idx": 2608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df38657f-e5fb-41a9-915c-db907065292f": {"__data__": {"id_": "df38657f-e5fb-41a9-915c-db907065292f", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo. ", "original_text": "And I would also say \nthat M&A is not a top priority in this. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ee45df8-2fc9-45fb-b197-94a7c2f0df8e", "node_type": "1", "metadata": {"window": "Jason and Mike, just kind of  a quick question on the long -term guide, which is, I guess, over \nthe long term, how do you think about the underlying operating earnings growth contribution versus \nthe capital deployment or inorganic growth contribution?  \n \n Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment. ", "original_text": "So the guidance on Medical and Pharma was real ly about operating earnings. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17628822d3dcd7ff6c289066d9e00c3dca64850aaab0d4442a0f284e40197f58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53e08043-fbb3-4e58-8531-1ae8fa27c209", "node_type": "1", "metadata": {"window": "And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley. ", "original_text": "That may occur. "}, "hash": "161e09cdbbdc74eb71aefa2eff6a7bb415b246aa6537b0bc92ff691d1090901e", "class_name": "RelatedNodeInfo"}}, "text": "And I would also say \nthat M&A is not a top priority in this. ", "start_char_idx": 2608, "end_char_idx": 2670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53e08043-fbb3-4e58-8531-1ae8fa27c209": {"__data__": {"id_": "53e08043-fbb3-4e58-8531-1ae8fa27c209", "embedding": null, "metadata": {"window": "And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley. ", "original_text": "That may occur. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df38657f-e5fb-41a9-915c-db907065292f", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Well, I think if you know as you break down the long -term targets, when we were \nreally talking about Pharma being low single digits to mid -single -digit growth, we're really talking \nabout the operating earnings of that segment being in the low single to mid -single, Medical being in \nmid-single to high single digit.  And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo. ", "original_text": "And I would also say \nthat M&A is not a top priority in this. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c6f04d1f5f5c9328841a1f021dbb50e90f9d6f35ce2887d4e20ba57a6586ef37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87562aea-b07f-4b80-be1b-bf63dc0929c6", "node_type": "1", "metadata": {"window": "So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n", "original_text": "And we may have some of that here and there, \nand that is one option with capital deployment. "}, "hash": "0085e430ba63dd2795a30bf0dd9d338571f26f59a68baca702ddca15d1bc027b", "class_name": "RelatedNodeInfo"}}, "text": "That may occur. ", "start_char_idx": 2670, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87562aea-b07f-4b80-be1b-bf63dc0929c6": {"__data__": {"id_": "87562aea-b07f-4b80-be1b-bf63dc0929c6", "embedding": null, "metadata": {"window": "So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n", "original_text": "And we may have some of that here and there, \nand that is one option with capital deployment. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53e08043-fbb3-4e58-8531-1ae8fa27c209", "node_type": "1", "metadata": {"window": "And then the rest of it would come from our dividend yield as well as \ncapital deployment around repo to get to the double -digit combined EPS growth and dividend yield. \n So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley. ", "original_text": "That may occur. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c41599b4ea33c2e95995abb1062fe7f3212eb49f05386664ca47ac163d351307", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "377068da-4f45-4fcd-b127-212eedab42eb", "node_type": "1", "metadata": {"window": "And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi. ", "original_text": "But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo. "}, "hash": "4e60db87d40e8ae4d0f0ab1c3f1fb200d19dc20cf2aa767c29c448d061ef16c8", "class_name": "RelatedNodeInfo"}}, "text": "And we may have some of that here and there, \nand that is one option with capital deployment. ", "start_char_idx": 2686, "end_char_idx": 2780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "377068da-4f45-4fcd-b127-212eedab42eb": {"__data__": {"id_": "377068da-4f45-4fcd-b127-212eedab42eb", "embedding": null, "metadata": {"window": "And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi. ", "original_text": "But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87562aea-b07f-4b80-be1b-bf63dc0929c6", "node_type": "1", "metadata": {"window": "So the guidance on Medical and Pharma was real ly about operating earnings.  And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n", "original_text": "And we may have some of that here and there, \nand that is one option with capital deployment. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a169332ceed10735bf7c7d22c88539eb1ccee1243ed9cad9934fa356dd4799ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dac9a7fd-35b0-4934-9153-b3724abe642a", "node_type": "1", "metadata": {"window": "That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning. ", "original_text": "Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley. "}, "hash": "5fa833b7acc3a5f4836495f9283e13a0b0550defc6f0e290925e71eb0ab33ed5", "class_name": "RelatedNodeInfo"}}, "text": "But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo. ", "start_char_idx": 2780, "end_char_idx": 2915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dac9a7fd-35b0-4934-9153-b3724abe642a": {"__data__": {"id_": "dac9a7fd-35b0-4934-9153-b3724abe642a", "embedding": null, "metadata": {"window": "That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning. ", "original_text": "Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "377068da-4f45-4fcd-b127-212eedab42eb", "node_type": "1", "metadata": {"window": "And I would also say \nthat M&A is not a top priority in this.  That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi. ", "original_text": "But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d9b0a673c1038d2b8b1c41050bc071346cddf29a1a30f81cd9ef0d32e00b49e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50f23761-b43f-4469-ac31-a78bd79eb1fb", "node_type": "1", "metadata": {"window": "And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis. ", "original_text": "Please go \nahead.  \n \n"}, "hash": "baead9af7c6d4d3a0f5abb54d07997274dc63071ce86f0e5eab5e8a30e8fa81f", "class_name": "RelatedNodeInfo"}}, "text": "Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley. ", "start_char_idx": 2915, "end_char_idx": 3021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50f23761-b43f-4469-ac31-a78bd79eb1fb": {"__data__": {"id_": "50f23761-b43f-4469-ac31-a78bd79eb1fb", "embedding": null, "metadata": {"window": "And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis. ", "original_text": "Please go \nahead.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dac9a7fd-35b0-4934-9153-b3724abe642a", "node_type": "1", "metadata": {"window": "That may occur.  And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning. ", "original_text": "Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a03d22a2630729a8a1ea579175858ef35d6464c3fa983c98cfd64479b279e23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33b24c1e-919f-4217-bf68-80939107e8f8", "node_type": "1", "metadata": {"window": "But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023? ", "original_text": "Ricky Goldwasser:  Yes, hi. "}, "hash": "be759c2d51d4a87accff5f461bb38eb217c61348efeedbac95cf418474b0d586", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 3021, "end_char_idx": 3043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33b24c1e-919f-4217-bf68-80939107e8f8": {"__data__": {"id_": "33b24c1e-919f-4217-bf68-80939107e8f8", "embedding": null, "metadata": {"window": "But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023? ", "original_text": "Ricky Goldwasser:  Yes, hi. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50f23761-b43f-4469-ac31-a78bd79eb1fb", "node_type": "1", "metadata": {"window": "And we may have some of that here and there, \nand that is one option with capital deployment.  But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis. ", "original_text": "Please go \nahead.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03be2c2409a32108066e54c7cef817b69b2667df191336b75a781ae31eb6d710", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4f788ee-0e3e-4087-b7b1-98c9eb01b76f", "node_type": "1", "metadata": {"window": "Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "Good morning. "}, "hash": "92b9c0fc64a64b578920928a70d7d39aca8163387a3a6eda861dd6259f48ada9", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  Yes, hi. ", "start_char_idx": 3043, "end_char_idx": 3071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4f788ee-0e3e-4087-b7b1-98c9eb01b76f": {"__data__": {"id_": "d4f788ee-0e3e-4087-b7b1-98c9eb01b76f", "embedding": null, "metadata": {"window": "Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "Good morning. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33b24c1e-919f-4217-bf68-80939107e8f8", "node_type": "1", "metadata": {"window": "But this is really more focused on what we talked \nabout, operating earnings growth, as well as dividend yield and opportunistic repo.  Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023? ", "original_text": "Ricky Goldwasser:  Yes, hi. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d0cc05670c4249c12fb0585ba0b3b57773a48a3a47f386c8282d08db67c406b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4c27623-ede8-4dd4-aa0b-34e47f716fa4", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis. "}, "hash": "0d95288f1b0aa2f7ccd262586fb25bd6d3b4e5a6639661bf7290e4bf0eab4c77", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 3071, "end_char_idx": 3085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4c27623-ede8-4dd4-aa0b-34e47f716fa4": {"__data__": {"id_": "f4c27623-ede8-4dd4-aa0b-34e47f716fa4", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4f788ee-0e3e-4087-b7b1-98c9eb01b76f", "node_type": "1", "metadata": {"window": "Next question..  \n \nOperator:  And our last question will come from Ricky Goldwasser with Morgan Stanley.  Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "Good morning. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e890d43edc26f54c8030576fbb9fe4c521d61f3067d3981477fbdcf63594b5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0660d59-10fe-4a3f-808b-d71b044f06e7", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023? "}, "hash": "7750287fc12e548b6ee2cccfc773b5f1947fd6528d504aa4447c1e26b6159955", "class_name": "RelatedNodeInfo"}}, "text": "So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis. ", "start_char_idx": 3085, "end_char_idx": 3205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0660d59-10fe-4a3f-808b-d71b044f06e7": {"__data__": {"id_": "d0660d59-10fe-4a3f-808b-d71b044f06e7", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023? ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4c27623-ede8-4dd4-aa0b-34e47f716fa4", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c3c27beb725a960d44f83b0330b876b228ab4b8de551776c3a34b2c716668a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd1e5588-ad1e-444b-9e28-67cefeffe05c", "node_type": "1", "metadata": {"window": "Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "So that's the first part of the question.  "}, "hash": "cc958ceaa6c603f00b43eb90774ae350921771852663f8d51f10572106725252", "class_name": "RelatedNodeInfo"}}, "text": "So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023? ", "start_char_idx": 3205, "end_char_idx": 3407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd1e5588-ad1e-444b-9e28-67cefeffe05c": {"__data__": {"id_": "dd1e5588-ad1e-444b-9e28-67cefeffe05c", "embedding": null, "metadata": {"window": "Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "So that's the first part of the question.  ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1853377811ef294e5e05af755279e453debf1f2151905a6307469532e1cd7856", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0660d59-10fe-4a3f-808b-d71b044f06e7", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yes, hi.  Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023? ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5badba1e143f35d1e41340b5264a62d8dbf779a1171ef0195dbd37257f117a54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dec30737-8d0d-4f18-a691-e2306a3a627f", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n", "original_text": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain. "}, "hash": "62e30da8213356e80bf575571521366199c91f8876f38ba2c6e5e3aa804ef546", "class_name": "RelatedNodeInfo"}}, "text": "So that's the first part of the question.  ", "start_char_idx": 3407, "end_char_idx": 3450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dec30737-8d0d-4f18-a691-e2306a3a627f": {"__data__": {"id_": "dec30737-8d0d-4f18-a691-e2306a3a627f", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n", "original_text": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd1e5588-ad1e-444b-9e28-67cefeffe05c", "node_type": "1", "metadata": {"window": "Good morning.  So on the long -term double -digit growth, I know we talked \nabout the growth rate being sort of on a normalized basis.  So, should we take that long -term double -\ndigit growth back out from 2022 guidance \u2013 sort of the abnormal costs that you're seeing, normalize \nfor them and then apply that growth rate to get to 2023?  So that's the first part of the question.  ", "original_text": "So that's the first part of the question.  ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbb3408bff74e837f8cae612b18bf85b6921b089e4c8da2da401dff90b124945", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "698fd18d-e6ca-43df-8a17-bd9e8fbcb2bb", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure. ", "original_text": "What's the contribution of labor cost to that \nheadwind? "}, "hash": "cfbb20aefa05d52640c14ce7ba95347cb6d4cfef67fa64ec54bcd6cedeea480d", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain. ", "start_char_idx": 0, "end_char_idx": 179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "698fd18d-e6ca-43df-8a17-bd9e8fbcb2bb": {"__data__": {"id_": "698fd18d-e6ca-43df-8a17-bd9e8fbcb2bb", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure. ", "original_text": "What's the contribution of labor cost to that \nheadwind? ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dec30737-8d0d-4f18-a691-e2306a3a627f", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n", "original_text": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "102892462f62de66c23d117aa51d39aba5e5cd734b12e3388ce28bc4a4f9ef45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0aa4366-cb77-47c2-9025-eff96edbe85e", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky. ", "original_text": "Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down. "}, "hash": "1f672cbb7b944014ccfc93ea81af87b0b91ccd4c41114e6271d8fa0cdaed156e", "class_name": "RelatedNodeInfo"}}, "text": "What's the contribution of labor cost to that \nheadwind? ", "start_char_idx": 179, "end_char_idx": 236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0aa4366-cb77-47c2-9025-eff96edbe85e": {"__data__": {"id_": "c0aa4366-cb77-47c2-9025-eff96edbe85e", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky. ", "original_text": "Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "698fd18d-e6ca-43df-8a17-bd9e8fbcb2bb", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure. ", "original_text": "What's the contribution of labor cost to that \nheadwind? ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ca93e57dfb87fc488758c23537851d68e560ad09cb4ececd450333882f84938", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6300fd1e-fa1c-4087-8afa-2aaf255a515f", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start. ", "original_text": "S o how should we \nthink about that component within the additional cost?  \n \n"}, "hash": "eaea666f82b7a86d6f6a24f47a58cf5de01fb2f546768bf18f2f2e6ddba0d437", "class_name": "RelatedNodeInfo"}}, "text": "Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down. ", "start_char_idx": 236, "end_char_idx": 409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6300fd1e-fa1c-4087-8afa-2aaf255a515f": {"__data__": {"id_": "6300fd1e-fa1c-4087-8afa-2aaf255a515f", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start. ", "original_text": "S o how should we \nthink about that component within the additional cost?  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0aa4366-cb77-47c2-9025-eff96edbe85e", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky. ", "original_text": "Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdc7246d8cb079b422e84e526f670b36eb8e628b93fd1fa3dec7f5b186916863", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2198856d-05a1-4553-8764-ab47fe7e5613", "node_type": "1", "metadata": {"window": "What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year. ", "original_text": "Jason Hollar:  Sure. "}, "hash": "a2668b303156b891554d6ffdd5f7156b058fda9b46fa2a304512013260d6ea13", "class_name": "RelatedNodeInfo"}}, "text": "S o how should we \nthink about that component within the additional cost?  \n \n", "start_char_idx": 409, "end_char_idx": 487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2198856d-05a1-4553-8764-ab47fe7e5613": {"__data__": {"id_": "2198856d-05a1-4553-8764-ab47fe7e5613", "embedding": null, "metadata": {"window": "What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year. ", "original_text": "Jason Hollar:  Sure. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6300fd1e-fa1c-4087-8afa-2aaf255a515f", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start. ", "original_text": "S o how should we \nthink about that component within the additional cost?  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae457c1c4e2acacb0156abce6e350abea6b3ac2dfc43c7fd7cf4d92a7531becd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "580c8b78-4ed0-4966-8652-e383a6e0454c", "node_type": "1", "metadata": {"window": "Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time. ", "original_text": "Good morning, Ricky. "}, "hash": "d23d6867a1756dc58061e90e316da4c21143a7733098753add5c81cc5064e0c7", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure. ", "start_char_idx": 487, "end_char_idx": 508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "580c8b78-4ed0-4966-8652-e383a6e0454c": {"__data__": {"id_": "580c8b78-4ed0-4966-8652-e383a6e0454c", "embedding": null, "metadata": {"window": "Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time. ", "original_text": "Good morning, Ricky. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2198856d-05a1-4553-8764-ab47fe7e5613", "node_type": "1", "metadata": {"window": "What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year. ", "original_text": "Jason Hollar:  Sure. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae354f549989e9b5a01ec464e44c4a8e7f2506347a2e9ac07bdbbf771e1574be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bffc3de2-7435-42d6-aa2f-6e0efdec0540", "node_type": "1", "metadata": {"window": "S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n", "original_text": "This is Jason, I'll start. "}, "hash": "fc2acf9a21f289d362dd4e08f9ec7cae2cca963b3004ccbf4c31a78989240aa8", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, Ricky. ", "start_char_idx": 508, "end_char_idx": 529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bffc3de2-7435-42d6-aa2f-6e0efdec0540": {"__data__": {"id_": "bffc3de2-7435-42d6-aa2f-6e0efdec0540", "embedding": null, "metadata": {"window": "S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n", "original_text": "This is Jason, I'll start. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "580c8b78-4ed0-4966-8652-e383a6e0454c", "node_type": "1", "metadata": {"window": "Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time. ", "original_text": "Good morning, Ricky. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "643a2b4273dd20e0707771ce951b2cd543b60b285668c345d36d76611f2c7cc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21de8db9-90d6-49f1-babb-1343538eec73", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses. ", "original_text": "As we talk about our long -term \ntargets, it's not expected or intended to be each and every year. "}, "hash": "7295ce3cf8af32b27b0ce2c363f4e2ebeb7144fd55ce1e68917bd28cc6a2a49c", "class_name": "RelatedNodeInfo"}}, "text": "This is Jason, I'll start. ", "start_char_idx": 529, "end_char_idx": 556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21de8db9-90d6-49f1-babb-1343538eec73": {"__data__": {"id_": "21de8db9-90d6-49f1-babb-1343538eec73", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses. ", "original_text": "As we talk about our long -term \ntargets, it's not expected or intended to be each and every year. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bffc3de2-7435-42d6-aa2f-6e0efdec0540", "node_type": "1", "metadata": {"window": "S o how should we \nthink about that component within the additional cost?  \n \n Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n", "original_text": "This is Jason, I'll start. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ebf41cafb87ad8462754335f72bc234e09a2e953326681067ad03cbfbe340c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c3c70b6-f328-48c5-a12e-5c6024dfd70e", "node_type": "1", "metadata": {"window": "Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22. ", "original_text": "There's a reason t hat we do highlight \nthat as an average over that period of time. "}, "hash": "73e49cba391c2069277d7e94db8f3cd0477a75c7eb95f0eda063954704421302", "class_name": "RelatedNodeInfo"}}, "text": "As we talk about our long -term \ntargets, it's not expected or intended to be each and every year. ", "start_char_idx": 556, "end_char_idx": 655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c3c70b6-f328-48c5-a12e-5c6024dfd70e": {"__data__": {"id_": "3c3c70b6-f328-48c5-a12e-5c6024dfd70e", "embedding": null, "metadata": {"window": "Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22. ", "original_text": "There's a reason t hat we do highlight \nthat as an average over that period of time. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21de8db9-90d6-49f1-babb-1343538eec73", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.  Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses. ", "original_text": "As we talk about our long -term \ntargets, it's not expected or intended to be each and every year. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eedec1266364ddd3cd1f193343869bbad1c9fc2283b2eea66777b1d86e36e3e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a485dfc-6682-4afc-8b2b-cf089cac0ab8", "node_type": "1", "metadata": {"window": "This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23. ", "original_text": "So we are not providing fiscal '23 guidance with the \nstatement.  \n \n"}, "hash": "b59a1619cccc237a869583a995031af137f328de25b61d0436bbd7a93b3e87b6", "class_name": "RelatedNodeInfo"}}, "text": "There's a reason t hat we do highlight \nthat as an average over that period of time. ", "start_char_idx": 655, "end_char_idx": 740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a485dfc-6682-4afc-8b2b-cf089cac0ab8": {"__data__": {"id_": "5a485dfc-6682-4afc-8b2b-cf089cac0ab8", "embedding": null, "metadata": {"window": "This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23. ", "original_text": "So we are not providing fiscal '23 guidance with the \nstatement.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c3c70b6-f328-48c5-a12e-5c6024dfd70e", "node_type": "1", "metadata": {"window": "Good morning, Ricky.  This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22. ", "original_text": "There's a reason t hat we do highlight \nthat as an average over that period of time. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca02018487e19ca396f430f97b3edb8c2cf9f82f4397d399782a39d5d949bb4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ae8d378-4070-45c1-8e1f-5c09cfd2ce26", "node_type": "1", "metadata": {"window": "As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future. ", "original_text": "With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses. "}, "hash": "b76deb3dea4fcea2fd806e95783312c470ebeee7042e8adf8328b91569765cae", "class_name": "RelatedNodeInfo"}}, "text": "So we are not providing fiscal '23 guidance with the \nstatement.  \n \n", "start_char_idx": 740, "end_char_idx": 809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ae8d378-4070-45c1-8e1f-5c09cfd2ce26": {"__data__": {"id_": "7ae8d378-4070-45c1-8e1f-5c09cfd2ce26", "embedding": null, "metadata": {"window": "As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future. ", "original_text": "With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a485dfc-6682-4afc-8b2b-cf089cac0ab8", "node_type": "1", "metadata": {"window": "This is Jason, I'll start.  As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23. ", "original_text": "So we are not providing fiscal '23 guidance with the \nstatement.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "564591b690a77694b39043ba8bbfc5b579ef7f1b9b442fa839260f8221fb4f11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9f4c34c-7882-4a8a-88c7-70e31ea195d0", "node_type": "1", "metadata": {"window": "There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n", "original_text": "And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22. "}, "hash": "d3fdd0497db15850613a9d4433fdf477c22ffdd931e1a5659b788aa3cb23aa61", "class_name": "RelatedNodeInfo"}}, "text": "With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses. ", "start_char_idx": 809, "end_char_idx": 978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9f4c34c-7882-4a8a-88c7-70e31ea195d0": {"__data__": {"id_": "f9f4c34c-7882-4a8a-88c7-70e31ea195d0", "embedding": null, "metadata": {"window": "There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n", "original_text": "And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ae8d378-4070-45c1-8e1f-5c09cfd2ce26", "node_type": "1", "metadata": {"window": "As we talk about our long -term \ntargets, it's not expected or intended to be each and every year.  There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future. ", "original_text": "With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d2ce14026be1ebb2f3e9626126b415b69e2c04067d9626bb015942c80933447", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f61d384-d4e7-4485-ab3e-b69d09bb2737", "node_type": "1", "metadata": {"window": "So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one. ", "original_text": "We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23. "}, "hash": "d834a858dc2b8f20c37d3939cefd3f84baee98e92d4b76174007024a7c33e8a4", "class_name": "RelatedNodeInfo"}}, "text": "And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22. ", "start_char_idx": 978, "end_char_idx": 1188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f61d384-d4e7-4485-ab3e-b69d09bb2737": {"__data__": {"id_": "4f61d384-d4e7-4485-ab3e-b69d09bb2737", "embedding": null, "metadata": {"window": "So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one. ", "original_text": "We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9f4c34c-7882-4a8a-88c7-70e31ea195d0", "node_type": "1", "metadata": {"window": "There's a reason t hat we do highlight \nthat as an average over that period of time.  So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n", "original_text": "And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bda61f5650dc070b24f4adb2fda313d7352def345dc78385a5a2b5817d7cd52c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4697386b-b340-43ad-92a6-3d7f64c681bb", "node_type": "1", "metadata": {"window": "With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter. ", "original_text": "That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future. "}, "hash": "b2ba3a2e852795f1382d354c05b76ff9dfbfdd5de98ea647e052f1acaac95cc7", "class_name": "RelatedNodeInfo"}}, "text": "We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23. ", "start_char_idx": 1188, "end_char_idx": 1286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4697386b-b340-43ad-92a6-3d7f64c681bb": {"__data__": {"id_": "4697386b-b340-43ad-92a6-3d7f64c681bb", "embedding": null, "metadata": {"window": "With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter. ", "original_text": "That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f61d384-d4e7-4485-ab3e-b69d09bb2737", "node_type": "1", "metadata": {"window": "So we are not providing fiscal '23 guidance with the \nstatement.  \n \n With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one. ", "original_text": "We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "646d7c43be0a4613d6e8a7d5e13c8c74fc25ec28974399d4de91d1d47db58615", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26f52930-103d-46a4-9f6b-54d012f7225f", "node_type": "1", "metadata": {"window": "And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n", "original_text": "That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n"}, "hash": "a9e7e61821ba51e68f2a44a37675180c4862a350434a7cfea368cf4c3e9152d7", "class_name": "RelatedNodeInfo"}}, "text": "That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future. ", "start_char_idx": 1286, "end_char_idx": 1397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26f52930-103d-46a4-9f6b-54d012f7225f": {"__data__": {"id_": "26f52930-103d-46a4-9f6b-54d012f7225f", "embedding": null, "metadata": {"window": "And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n", "original_text": "That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4697386b-b340-43ad-92a6-3d7f64c681bb", "node_type": "1", "metadata": {"window": "With that said, we think that there are, over these longer periods of time, that these would be the \nprimary drivers and expect ations we would have for our businesses.  And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter. ", "original_text": "That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a3c23429b187e9882f9fbc2de112eaa0349467bbec25ade1123f6642767d9bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a2bcde0-a782-4f8f-b43a-7dcdf0b9c121", "node_type": "1", "metadata": {"window": "We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight. ", "original_text": "And then your question about labor is a great one. "}, "hash": "2d8d03c51a36ddcee23b16230ea06c166f197b4425ce87300528c7295eaeec4f", "class_name": "RelatedNodeInfo"}}, "text": "That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n", "start_char_idx": 1397, "end_char_idx": 1490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a2bcde0-a782-4f8f-b43a-7dcdf0b9c121": {"__data__": {"id_": "6a2bcde0-a782-4f8f-b43a-7dcdf0b9c121", "embedding": null, "metadata": {"window": "We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight. ", "original_text": "And then your question about labor is a great one. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26f52930-103d-46a4-9f6b-54d012f7225f", "node_type": "1", "metadata": {"window": "And \u2013 but how you described it \nabout the normalized level, as an example, that $100 million to $125 million, we're \u2013 we indicated that \nwe anticipate these costs remain elevated for the balance of fiscal '22.  We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n", "original_text": "That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08819cfb66149e2a8195b498f72173171c307f9cb62c2801dd94769c13fe515b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a098961-208e-4b11-ad0e-a2fe535e69c8", "node_type": "1", "metadata": {"window": "That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation. ", "original_text": "We did not call it out because it is very consistent \nwith what we had last quarter. "}, "hash": "0446afdc0bc1388fb0018fe0b0b08e646fd89a1cf970174938724cf06268ca67", "class_name": "RelatedNodeInfo"}}, "text": "And then your question about labor is a great one. ", "start_char_idx": 1490, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a098961-208e-4b11-ad0e-a2fe535e69c8": {"__data__": {"id_": "5a098961-208e-4b11-ad0e-a2fe535e69c8", "embedding": null, "metadata": {"window": "That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation. ", "original_text": "We did not call it out because it is very consistent \nwith what we had last quarter. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a2bcde0-a782-4f8f-b43a-7dcdf0b9c121", "node_type": "1", "metadata": {"window": "We are not taking a position at \nthis point as to how much, if any, carries over into fiscal '23.  That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight. ", "original_text": "And then your question about labor is a great one. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e770ac3f47c6b5eaafccfe3c096a5e93dbf3039f2da570cbf1890e8416fdee25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a324e5b-aeb7-4b22-9782-3774dd59453f", "node_type": "1", "metadata": {"window": "That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n", "original_text": "So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n"}, "hash": "31b041fb5055ebbd4558bb0bf78333d5b1376f798b1a976dd0618edb7ebee750", "class_name": "RelatedNodeInfo"}}, "text": "We did not call it out because it is very consistent \nwith what we had last quarter. ", "start_char_idx": 1541, "end_char_idx": 1626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a324e5b-aeb7-4b22-9782-3774dd59453f": {"__data__": {"id_": "7a324e5b-aeb7-4b22-9782-3774dd59453f", "embedding": null, "metadata": {"window": "That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n", "original_text": "So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a098961-208e-4b11-ad0e-a2fe535e69c8", "node_type": "1", "metadata": {"window": "That is a terrific example of an important \nelement of fiscal '23 guidance that we will provide in the future.  That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation. ", "original_text": "We did not call it out because it is very consistent \nwith what we had last quarter. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff6e3a077ebd2f789aa36111378bb6b09327f43b6357f79dc511e20107985196", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1465bbd2-1e43-4cfc-8bc2-02ce8ad6e8d5", "node_type": "1", "metadata": {"window": "And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today. ", "original_text": "But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight. "}, "hash": "53b698749b07457916f6e27c376f98ee256c22c8dec514be8faa259be082bce2", "class_name": "RelatedNodeInfo"}}, "text": "So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n", "start_char_idx": 1626, "end_char_idx": 1858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1465bbd2-1e43-4cfc-8bc2-02ce8ad6e8d5": {"__data__": {"id_": "1465bbd2-1e43-4cfc-8bc2-02ce8ad6e8d5", "embedding": null, "metadata": {"window": "And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today. ", "original_text": "But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a324e5b-aeb7-4b22-9782-3774dd59453f", "node_type": "1", "metadata": {"window": "That is not, at this point, something \nthat we feel comfo rtable being able to identify.  \n \n And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n", "original_text": "So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cf950b23420c0c27a3c554478e7813fb04f798b25e623c238628aa9230ca2dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbeeb12b-d218-4a2f-94c0-88ac8e69ba08", "node_type": "1", "metadata": {"window": "We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n", "original_text": "Those are clearly the most significant items that drive that fluctuation. "}, "hash": "b6547386789a5b21a3d381560485f88fb2949b22f4052e9790ccae8b75f39bd8", "class_name": "RelatedNodeInfo"}}, "text": "But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight. ", "start_char_idx": 1858, "end_char_idx": 2078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbeeb12b-d218-4a2f-94c0-88ac8e69ba08": {"__data__": {"id_": "dbeeb12b-d218-4a2f-94c0-88ac8e69ba08", "embedding": null, "metadata": {"window": "We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n", "original_text": "Those are clearly the most significant items that drive that fluctuation. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1465bbd2-1e43-4cfc-8bc2-02ce8ad6e8d5", "node_type": "1", "metadata": {"window": "And then your question about labor is a great one.  We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today. ", "original_text": "But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45de136588a5e6bbeb399fd0de07b3b0aa3cc532f59cbab9fcf8e33a356619ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "766755b9-b799-4ccc-a640-06e684aba9e6", "node_type": "1", "metadata": {"window": "So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions. ", "original_text": "And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n"}, "hash": "5068e5e7dea39979da0f870e49f346c1d51016628b666412023a39da153c3c4f", "class_name": "RelatedNodeInfo"}}, "text": "Those are clearly the most significant items that drive that fluctuation. ", "start_char_idx": 2078, "end_char_idx": 2152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "766755b9-b799-4ccc-a640-06e684aba9e6": {"__data__": {"id_": "766755b9-b799-4ccc-a640-06e684aba9e6", "embedding": null, "metadata": {"window": "So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions. ", "original_text": "And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbeeb12b-d218-4a2f-94c0-88ac8e69ba08", "node_type": "1", "metadata": {"window": "We did not call it out because it is very consistent \nwith what we had last quarter.  So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n", "original_text": "Those are clearly the most significant items that drive that fluctuation. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3555faed7fe42540734d0b4fbbe8d63d779e056129ab18339eec6e25feadddc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54bb171f-a584-48ce-bee9-25ab5a352be2", "node_type": "1", "metadata": {"window": "But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts. ", "original_text": "Operator:  And that concludes our Q&A session for today. "}, "hash": "f4dae96c67e11dc2dd8799ff5a69b7f38cf54a1a57db293a05eb26826fae4ed9", "class_name": "RelatedNodeInfo"}}, "text": "And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n", "start_char_idx": 2152, "end_char_idx": 2376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54bb171f-a584-48ce-bee9-25ab5a352be2": {"__data__": {"id_": "54bb171f-a584-48ce-bee9-25ab5a352be2", "embedding": null, "metadata": {"window": "But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts. ", "original_text": "Operator:  And that concludes our Q&A session for today. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "766755b9-b799-4ccc-a640-06e684aba9e6", "node_type": "1", "metadata": {"window": "So, while labor inflation and those pressures are very real for us like \nthe whole industr y, we are not seeing anything new and unique this quarter versus last quarter and so \nwe're not adding in any additional costs for that.  \n \n But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions. ", "original_text": "And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c487c4c320a846afa8320a872b767cb3f2866a522d2ec02f6a1bdf49821229e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07f56dd0-da21-45f3-ad97-9c260bdba631", "node_type": "1", "metadata": {"window": "Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n", "original_text": "I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n"}, "hash": "04927f829bdb55d760caf8197967ab104def7833d85fba942a9f9e4143f7dcf9", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And that concludes our Q&A session for today. ", "start_char_idx": 2376, "end_char_idx": 2433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07f56dd0-da21-45f3-ad97-9c260bdba631": {"__data__": {"id_": "07f56dd0-da21-45f3-ad97-9c260bdba631", "embedding": null, "metadata": {"window": "Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n", "original_text": "I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54bb171f-a584-48ce-bee9-25ab5a352be2", "node_type": "1", "metadata": {"window": "But I would also highlight that even what was included in the original guidance was not nearly as \nsubstantial as the co st that we're referencing for what was included before for commodities and \ninternational freight.  Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts. ", "original_text": "Operator:  And that concludes our Q&A session for today. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c7871f6877512bcaa332558867782a4a89e5621284cce3d80df45cccf77c88c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "625099d9-164c-4ed7-bb1a-5214660f5eca", "node_type": "1", "metadata": {"window": "And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business. ", "original_text": "Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions. "}, "hash": "661c2d0a27e0e02018fe4b641527fac1421f7d0343b969c93844969e88e8808e", "class_name": "RelatedNodeInfo"}}, "text": "I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n", "start_char_idx": 2433, "end_char_idx": 2513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "625099d9-164c-4ed7-bb1a-5214660f5eca": {"__data__": {"id_": "625099d9-164c-4ed7-bb1a-5214660f5eca", "embedding": null, "metadata": {"window": "And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business. ", "original_text": "Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07f56dd0-da21-45f3-ad97-9c260bdba631", "node_type": "1", "metadata": {"window": "Those are clearly the most significant items that drive that fluctuation.  And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n", "original_text": "I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7614d5be6516e3fdcedd2a15a38a5bb25e10a82cb0335547dd08e3fa34177ddc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bad1ec1-8b0f-43e6-ae23-c61c9f6780f6", "node_type": "1", "metadata": {"window": "Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "I like to conclude with just a few thoughts. "}, "hash": "f060521bdcd83d4590de02ee00a20951527dc157b3d3cda7eef31cb11fe08544", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions. ", "start_char_idx": 2513, "end_char_idx": 2631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bad1ec1-8b0f-43e6-ae23-c61c9f6780f6": {"__data__": {"id_": "9bad1ec1-8b0f-43e6-ae23-c61c9f6780f6", "embedding": null, "metadata": {"window": "Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "I like to conclude with just a few thoughts. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "625099d9-164c-4ed7-bb1a-5214660f5eca", "node_type": "1", "metadata": {"window": "And items \nlike labor as well as more domestic -related costs such as, domestic transp ortation and other fuel, are \nall relatively low compared to those other two primary items of international freight and commodities.  \n \n Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business. ", "original_text": "Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab4789536c52434735c4bacd7fe73e8511563e6488a06b8cb98b7fb5eecaa52d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa00deb2-10ed-405a-b14e-d60f8fab5560", "node_type": "1", "metadata": {"window": "I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n"}, "hash": "54a2a7c305c379b597ba485e7827e8169e0696426c5a13a5bc983797e40f6bf3", "class_name": "RelatedNodeInfo"}}, "text": "I like to conclude with just a few thoughts. ", "start_char_idx": 2631, "end_char_idx": 2676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa00deb2-10ed-405a-b14e-d60f8fab5560": {"__data__": {"id_": "fa00deb2-10ed-405a-b14e-d60f8fab5560", "embedding": null, "metadata": {"window": "I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bad1ec1-8b0f-43e6-ae23-c61c9f6780f6", "node_type": "1", "metadata": {"window": "Operator:  And that concludes our Q&A session for today.  I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "I like to conclude with just a few thoughts. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60bca08bdc9422188992bedbf959345eb527ce20e4b4b268329d858fa4e56ec4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a16b452a-ee00-4871-b978-7010d8b96129", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business. "}, "hash": "1c63e7e2b74bc5b876cd0a95743de79802f11f9b7534519db0f0aaacca24f38a", "class_name": "RelatedNodeInfo"}}, "text": "I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n", "start_char_idx": 2676, "end_char_idx": 3013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a16b452a-ee00-4871-b978-7010d8b96129": {"__data__": {"id_": "a16b452a-ee00-4871-b978-7010d8b96129", "embedding": null, "metadata": {"window": "Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa00deb2-10ed-405a-b14e-d60f8fab5560", "node_type": "1", "metadata": {"window": "I will turn the call back over to CEO, Mike \nKaufmann, for closing remarks.  \n \n Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d46d8628e5d381df4ab9fdf67ca147159c9218c27977983e3a8ccb83cae2f34c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb15a653-0fc1-494d-8bd3-aa1c6424b664", "node_type": "1", "metadata": {"window": "I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n "}, "hash": "5d51a587ccb2072ed2efdae7ed71a10d99c20805adc5d665b768b22ae7caea51", "class_name": "RelatedNodeInfo"}}, "text": "Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business. ", "start_char_idx": 3013, "end_char_idx": 3146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb15a653-0fc1-494d-8bd3-aa1c6424b664": {"__data__": {"id_": "fb15a653-0fc1-494d-8bd3-aa1c6424b664", "embedding": null, "metadata": {"window": "I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a38781de2a06f6f75c4ff923b34c6bb96e59016b20b3f697a9271aef01dc3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a16b452a-ee00-4871-b978-7010d8b96129", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  I want to thank everybody for taking the time to be on the call today and for all of \nyour questions.  I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6bca54ba9b17a938fd899b8d7b9aa13ed08e820bdc10d3c6bbf0852e392e411", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa1a75ab-cd5f-4946-842f-f5ccb7771507", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call. ", "original_text": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided. "}, "hash": "6537111c43682741e16b6760a8ed0712dbf70e5c7748870ddf2987224fb99c87", "class_name": "RelatedNodeInfo"}}, "text": "With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "start_char_idx": 3146, "end_char_idx": 3429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa1a75ab-cd5f-4946-842f-f5ccb7771507": {"__data__": {"id_": "aa1a75ab-cd5f-4946-842f-f5ccb7771507", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call. ", "original_text": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided. ", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66cd87968d568301f37718338e07fef79bb97d6f9eb556cb4b95dac14ed2415a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb15a653-0fc1-494d-8bd3-aa1c6424b664", "node_type": "1", "metadata": {"window": "I like to conclude with just a few thoughts.  I know the elevated product costs within \nthe Medical segment incurred a lot of atten tion here today, but I want to just reiterate that, one, we do \nbelieve a majority of these costs are temporary; two, that we are taking aggressive enterprise -wide \nactions to help mitigate; and three, we did reaffirm our non -GAAP EPS guidance.  \n \n Additionally , in Pharma, we're encouraged by the profit growth we saw in the quarter, and the ongoing \nresiliency in this business.  With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "original_text": "With an additional $3 billion share repurchase authorization and our \ncommitment to our dividend, we are positioned to return capital to s hareholders while prioritizing \ninvestment in our growth businesses, simplifying our operating model and strengthening our core \nbusinesses.  \n ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3890ff8eef694b5043cc97dce5938ac92623fe68cffb071b88871a6b9d5ce292", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73196145-d83b-41da-a3ae-7b2095e8aa41", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation. ", "original_text": "With that, th ank you again. "}, "hash": "1dbf84dbcd23a16b68eec0fa160459171d5374660a49fa306513b85cd219de57", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided. ", "start_char_idx": 0, "end_char_idx": 124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73196145-d83b-41da-a3ae-7b2095e8aa41": {"__data__": {"id_": "73196145-d83b-41da-a3ae-7b2095e8aa41", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation. ", "original_text": "With that, th ank you again. ", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66cd87968d568301f37718338e07fef79bb97d6f9eb556cb4b95dac14ed2415a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa1a75ab-cd5f-4946-842f-f5ccb7771507", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call. ", "original_text": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided. ", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a711240c0587cdd6f1ce808a307819eede73cf698797ee57854fc75222d9a213", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b9f1ca9-95ce-4e2f-85c9-a47410c6f936", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation.  You may now \ndisconnect.  \n \n \n ", "original_text": "We hope you all have a good day.  \n \n"}, "hash": "ffa383ae6c902586f8cb29ebac33ba3209ba46ba2cd04a4e8cf53c3f2e74e07b", "class_name": "RelatedNodeInfo"}}, "text": "With that, th ank you again. ", "start_char_idx": 124, "end_char_idx": 153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b9f1ca9-95ce-4e2f-85c9-a47410c6f936": {"__data__": {"id_": "4b9f1ca9-95ce-4e2f-85c9-a47410c6f936", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation.  You may now \ndisconnect.  \n \n \n ", "original_text": "We hope you all have a good day.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66cd87968d568301f37718338e07fef79bb97d6f9eb556cb4b95dac14ed2415a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73196145-d83b-41da-a3ae-7b2095e8aa41", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation. ", "original_text": "With that, th ank you again. ", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f997e611ac3b4af04f9209764157c0dfc1adf2b7ce5c0976e073248b2d4fa9d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd21c577-1456-47a1-83e0-c9aacfc6e296", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation.  You may now \ndisconnect.  \n \n \n ", "original_text": "Operator:  And this concludes today's call. "}, "hash": "e5e04fb169968c318e0b28d51629d6f268088293a3151cdc0e84062b62c8c439", "class_name": "RelatedNodeInfo"}}, "text": "We hope you all have a good day.  \n \n", "start_char_idx": 153, "end_char_idx": 190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd21c577-1456-47a1-83e0-c9aacfc6e296": {"__data__": {"id_": "fd21c577-1456-47a1-83e0-c9aacfc6e296", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation.  You may now \ndisconnect.  \n \n \n ", "original_text": "Operator:  And this concludes today's call. ", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66cd87968d568301f37718338e07fef79bb97d6f9eb556cb4b95dac14ed2415a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b9f1ca9-95ce-4e2f-85c9-a47410c6f936", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation.  You may now \ndisconnect.  \n \n \n ", "original_text": "We hope you all have a good day.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51d46023585bae9b9093176b50c4fe3272e05eeca6d87c3242a006bd0dc4dd15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63e9c30e-52a6-45d0-a37a-915c0ab4af84", "node_type": "1", "metadata": {"window": "With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation.  You may now \ndisconnect.  \n \n \n ", "original_text": "We thank you again for your participation. "}, "hash": "8e6b49751c682b2d568690ac2bfe67af67cf904c6bdcf42801912327fa47010c", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And this concludes today's call. ", "start_char_idx": 190, "end_char_idx": 234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63e9c30e-52a6-45d0-a37a-915c0ab4af84": {"__data__": {"id_": "63e9c30e-52a6-45d0-a37a-915c0ab4af84", "embedding": null, "metadata": {"window": "With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation.  You may now \ndisconnect.  \n \n \n ", "original_text": "We thank you again for your participation. ", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66cd87968d568301f37718338e07fef79bb97d6f9eb556cb4b95dac14ed2415a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd21c577-1456-47a1-83e0-c9aacfc6e296", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation.  You may now \ndisconnect.  \n \n \n ", "original_text": "Operator:  And this concludes today's call. ", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "816ed030f85d915737a166aad1d5d21f468bc55c21fd98f699432a74cf5c293b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfecd884-cb70-41ad-b28d-ad535139e5b2", "node_type": "1", "metadata": {"window": "We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation.  You may now \ndisconnect.  \n \n \n ", "original_text": "You may now \ndisconnect.  \n \n \n "}, "hash": "0a56617e016047f99a21f1f2ae8d438e529f06c16bf93e3c42c9e398aecf5e27", "class_name": "RelatedNodeInfo"}}, "text": "We thank you again for your participation. ", "start_char_idx": 234, "end_char_idx": 277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfecd884-cb70-41ad-b28d-ad535139e5b2": {"__data__": {"id_": "cfecd884-cb70-41ad-b28d-ad535139e5b2", "embedding": null, "metadata": {"window": "We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation.  You may now \ndisconnect.  \n \n \n ", "original_text": "You may now \ndisconnect.  \n \n \n ", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66cd87968d568301f37718338e07fef79bb97d6f9eb556cb4b95dac14ed2415a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63e9c30e-52a6-45d0-a37a-915c0ab4af84", "node_type": "1", "metadata": {"window": "With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call.  We thank you again for your participation.  You may now \ndisconnect.  \n \n \n ", "original_text": "We thank you again for your participation. ", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2068c60f51179e0585cbb8db8453787736a26191a17539325e878df7d964a062", "class_name": "RelatedNodeInfo"}}, "text": "You may now \ndisconnect.  \n \n \n ", "start_char_idx": 277, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"f8be2f47-1816-414e-ac75-f27d3d25d1d1": {"doc_hash": "f62f1e7d020956eda78612b9040b1bdfc6e1cf3edec96168afc78c41a0b2c17b", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "3c057e0c-565a-40a8-b28b-c265be499c15": {"doc_hash": "c2c6bde3f78377ffa46780892355180e056a0776e5ec22163f20feddb4f438ca", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "6d56136e-972c-4797-975a-d7d13926d78f": {"doc_hash": "a49eb664fcf6daf1cc04264a59492e5b9617d9f32607da956f5d2cdc01f3e09f", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "1b714e93-c618-4c48-b41e-9d1f90bdd661": {"doc_hash": "c1fd400f3bc9b31e1ed5458959761d4e0b5737570f02ebc7bc0434f004d713a9", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "dcf02825-daab-41d5-9467-a086b729efcf": {"doc_hash": "927910611736537dc11689581c60593545e3186021776f2af097776c73e87f67", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "18dc4bd9-473b-4549-9890-ff2ad3357164": {"doc_hash": "06175810b2504b6fe0a037721463c7cd8a87ce281068fe865a32599a7be114a8", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "fec8e4ab-6ec3-4bbd-b1d6-9f7e2007e6ea": {"doc_hash": "40b96d4d392b661b12814d86281a035890aad5286fb344259ce2fc90fa111553", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "bea57437-c45c-4873-af12-7b66f6a49ac8": {"doc_hash": "9daae0ff44f50288715edb49dd019385afe5fda331a8643ac9ade441127fd2f0", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "f8acd3d2-d179-48e6-9143-503f3ab1f628": {"doc_hash": "993ff6105e9f55b8d96ef338bdfd44b4d7e362781f184f8c3ff54ecb03d1203f", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "9917a0ac-b6fa-4d50-9f11-46e87be9e29c": {"doc_hash": "db8dd29235be97281e8df75a308de26f17844a13202f2e4b8d29f1dbaf3f2a99", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "08f868bb-9703-4559-abc8-ed6d99d0280f": {"doc_hash": "0eea394eb96d1a263930186257116cc59b8b34bd30a15a97cdd0bfb6e030881d", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "8057e9b8-c2a9-4bdc-88a5-c71ec088357c": {"doc_hash": "f2216b6f68151bd347936e56cd0f59b260a06b833944ef5785a3f8451afffaf4", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "004a8dcd-4ea3-4861-a921-fffbd5c0a6e7": {"doc_hash": "1f3a1affa8f230b8132b906d726809d57aace19d7a7d40e0cba3bded94d94feb", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "4e63949f-837a-44d7-95b7-9c008cceb30f": {"doc_hash": "c1554ac5e0869b9cce283033bf01ff93b41d2248fd590769eb1406bfb4d2d82e", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "0256b854-944a-4fe0-8080-30c74772e76c": {"doc_hash": "d0053819806a7737e3169e13a7adade19d8d69123b6a8c565f318282a62ffd67", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "aa2dec6c-71a5-44d1-9819-e397a3af78b2": {"doc_hash": "5a83de75ac0b35237c6d9227dc338e99d830cd74719f0ca9ec07e3f39c520e52", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "a4df9469-c32f-4f7f-aa5f-58dc19346080": {"doc_hash": "e94884311ae282c1d4f38421d962220b1546a08d966ad62e6031fed885f2037f", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "6a15e290-f4fa-403d-9d6e-3460379ba45b": {"doc_hash": "46f471ae779db17719cf45526663cd6ce8d4224d76dd2f05d55030cda72e9e70", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "027aedf3-8639-4ecb-b371-81c1f38342cd": {"doc_hash": "e19e7c4bb81713c3509ced7020c682ccdea27fb1af7511dc95aff2b083132fca", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "3892cc2e-2f79-4e4b-aba6-baac9be08de9": {"doc_hash": "e9229a08252a6e50b6488e68658cba48fdfd777c0af2021419c0f7bde058519f", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "767fdeec-9add-479b-9915-8cfd1792d121": {"doc_hash": "37cab7df30d6a856368b05bb88d03b041ea233ba60eebdfb83eb41cd3b52e70f", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "72843e07-db0d-452a-b172-fb81373ffcd2": {"doc_hash": "8b58e67d31d5f9b6196c788d1797b4c96f8b42d58b9b40d468de103dc609882e", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "4719906b-7f3b-4c67-9319-dd44980388b8": {"doc_hash": "abf96e39895a2fdb8bf8e407f29555a4d83dc5357b8c8b339a94a60eb26a4dcf", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "59cc4763-388f-470e-b970-19fc32c4bfa6": {"doc_hash": "ec7f755f433144e78e0d95a8988813ab42eaaca76832ea64292c1b67683aae69", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "8140f80e-c907-4bc7-8858-087e03997f7e": {"doc_hash": "deeb59a402e4341d6451e4bade1085d168455f3cc831a5be574b402840f585f7", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "269f6b2f-2d00-40c7-8eae-39e68962d863": {"doc_hash": "703a4b34ca491212c92869d3e8381b545bdb51d1e5eb5f866bcaa3b0b09966b5", "ref_doc_id": "73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4"}, "13649259-bad8-449e-a70d-16fcfbb5c752": {"doc_hash": "3982f671b3bdbc0b68d2f5d5f805d4310e6a79157982b0510cc1d159b844ca30", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "1c675f69-b3a7-400d-89c8-ec08747a4bf1": {"doc_hash": "866e4daf78cf17af927b2211e60f38e846d091500cd29950d0bc814a935be83c", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "1de9a6ce-0625-4ef9-bade-74134b68eb5d": {"doc_hash": "2b86019e501775f79f665bce087aa506553bb3df6949af4cc43a0c82f6bd119e", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "702a60a0-9a60-4006-a401-a9c74140ce9d": {"doc_hash": "3d08b96ba3bd2d558630aed15d4877987ca918321b00ad7c0b0aa2c98f845669", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "09c50bd0-33c1-42a9-b110-4e6affa1cc0b": {"doc_hash": "13bee66fdc2d3eef93082c898973aeb06224c73b098256a99ad956a291735bec", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "1436fd30-a053-4b60-819f-134c3a61aa1d": {"doc_hash": "4f099c1f43176d8717223bc854c227fc1bdc8f020959d26178f95a9d856aa60d", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "58d6d352-9e20-4770-8c55-025b734ffe4a": {"doc_hash": "7852f63ac81c95cc33088bf96a2bebcc94913b03640934c007cf6e9015beb620", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "5479f15b-470e-46d6-a189-2bae5bb97756": {"doc_hash": "cc7053528452d0800fe95dc6aefb86f5ea45f9fec212568ab7312c998de26d39", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "bf308104-e1dd-4fba-8e83-998db2eb783c": {"doc_hash": "b1a1824f00f7428665198c46fddaf1eecc4664a14dd364014a049a1f5ed2da54", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "f7efd170-c39a-4f2d-bc4e-7aff97318a0e": {"doc_hash": "3ee2e7f29d42ce507d0e2b8058940a0b52d63597a26484e842fa0dfd620979c9", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "10f67a20-6d5e-44cf-b015-f85b4612d98f": {"doc_hash": "40ceb0cffde88c7778ce43023e6a181f8fd053585268c98984029c33604ea439", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "c9bb9024-0ba9-432d-a2ea-a5c55ce6ea33": {"doc_hash": "a8bcf788681d9188511f980abed9a7d3d592918451f2781dc44a9a1ff7a0ad17", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "298e8675-67d0-4c8c-bbb9-b1a0e5d44b9a": {"doc_hash": "6004b26122b13d25b498f237e6007e59eb4efd9598a0ac10ea3ff7672da849c0", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "d19a3d0f-a70e-4a51-b509-c3a74d42b33c": {"doc_hash": "99d707f1a24463b299ef31d8690712fb38f8c5346fd90d69cf8d8b7f99813ff7", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "22b0dd39-84a4-4e22-8611-5e22f6b8ef8c": {"doc_hash": "55be31b8d788edf34cebc9b47e26006e31f67b7ef5ac52e70a384492d701764d", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "957f0333-3f8f-4272-9512-ceb958c3d2e0": {"doc_hash": "4b01cbcd071869d22e5031025563ccb851437788133372e46007ec497b3477cd", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "ac6817cb-d000-4356-9663-c9daf4ec94b0": {"doc_hash": "e03896d697e36a45aacdef4199f5232efb4f2c9f665e8c57185c734c81e20d42", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "d6f90ac5-509b-46b8-af0c-79ab171c396a": {"doc_hash": "f1a651f55fee3aee6c792bb37bcd5e95219f4b3476338dea5c52d72faf5142a7", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "b5212602-c134-4e74-99e9-ad61f5ce6a13": {"doc_hash": "2a3b186a347f8a96462c82638cac4dfed423e36874876caa5c6fe453a4c538da", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "0dbcf863-98e2-489a-84f9-f00745210599": {"doc_hash": "95a6b1ae3c123c72d6f3a1d57acc5894e89a7c3bee752dc6daf22dcca5d9462d", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "ddea68d1-430f-4189-95be-d57c12b6c79a": {"doc_hash": "56f6cb04135ef09b4b719d1036c3fced1b3dff41b035f997654dbc9528cc82a3", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "f69b74ce-aa1a-4015-95c7-8769c1ad6c62": {"doc_hash": "aaad5c008ddd2e422c43cb62ee818ab8cd937cf711ebb167f0f1dedbd91bd894", "ref_doc_id": "27bfb634-9113-41d0-a325-ee5b790158c9"}, "81ea7d56-20b8-4311-a134-59ab96dd5188": {"doc_hash": "c61f4ee7a53a7dd62c74b5c88c34879e5c111b668ccadde7aaab8ebfe16c4743", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "41f00ef7-18ae-4b0a-ac7b-6c91669a5106": {"doc_hash": "6a8dd98bf70004cef034daac1f04cb9af18286d666abc0fab31ea1071dee3e7f", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "c31bd46a-795e-449a-a013-d5b5a611bb74": {"doc_hash": "a89dbba1a596306fded62f35ef38f5fe0efd6ca34f8d4e58f0df0c12819f544d", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "bd9ba67f-19e1-440a-a380-2e0e192af402": {"doc_hash": "30889cd598289040fc13be1bf81d1a4df1ece8f852edfdd957e6d8f81ca12298", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "a26959c7-62d6-4460-8fe5-1fe19b2278c0": {"doc_hash": "64c6f985033f89b152e166703a256b712f8bf1c3b559da251c2f80bfca7006c2", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "3045797a-7ab3-42c8-b926-cc389a00aa65": {"doc_hash": "9bde79962ae0f40d4e2be98a983c592844919b17b653ec8c5bf0a8167462da8b", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "13611a5b-da69-4eb2-bead-6794badb6c0a": {"doc_hash": "c1d833c246304c1bb7e2546540bc827114136c4cbcd6d0e1219b766ca968130d", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "84a9366d-81ba-455e-a5ef-2f105506251e": {"doc_hash": "49ae4f7c207f850df07388f4093b0a02a5b7ba4fd38b65b6a89e9ced58bc3e5b", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "4a44daa4-1bbc-4b9f-aa70-23a633d14389": {"doc_hash": "8f97aa89e0060e12a85111429347cf45a05dd6ff401dcaf67d15971b4c5c966a", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "0593d4e1-8f2f-465b-8afe-34dbdcb3002c": {"doc_hash": "83ed6952ef17da0d8a31850c5d9244ecfd05b5e8c22b5f0f9d6ae64e155187b5", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "b4500e4d-d33b-4db6-b73b-7d9293ae8342": {"doc_hash": "c2188479f30c9ad21496519c5280b5ad09d3cb9968d4ba9421a39d35c8d5990d", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "2b838084-5ac3-45a9-88f6-3cb495bfc4a3": {"doc_hash": "bcfdd8f665650af153aec2e072fd29aba0e1f8568fac82437685fcee7cf5542c", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "79789807-265b-4daf-b97d-cce98bed4437": {"doc_hash": "a37520c04448ed785f5bd2bab594cd17bd13ae69eec2d363ef95bfcc369ce8fa", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "a73e1908-bb6e-4d64-8cdb-d97866c4e876": {"doc_hash": "b3c4c8be6c35f0408e5da313520ad5a141b5134b8431456a245b23ac024a0a14", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "7a92315d-a906-43a1-b499-c97a491d7609": {"doc_hash": "89267fdc69f2b3624ad3cfd6fe87ab61c754e6864185c08574ac34c04f4a0a9c", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "4303e111-f371-4573-83fc-ae525466ad7f": {"doc_hash": "b1aff577411f9ffa298c8ea076ff77476606fe38b10125308107ac1f7f449418", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "a063a29b-71b2-4b0a-af93-f09c7f607f5d": {"doc_hash": "f8f9f0363289888c70765a27535fe44b66ab68527e57b03c4290de1b5d1bdfd8", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "4286fe1f-6362-437e-91b8-3810b1dbd95d": {"doc_hash": "051deca8db436942fd4c85f48c786b8f866e63e8d8648675a47c007ef8e536f7", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "9bb8a1ae-00d3-4ec2-b486-23e2298effe7": {"doc_hash": "9968928864a5d6180ba0ea651118057b32f22f25b420943e536b0cebe4e7e5cd", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "8ee3a7a6-ebe1-4123-9603-797583466df2": {"doc_hash": "88a46e15744a39fc182989155aa3487d6998b1ff31950eb82a19827c80587b4b", "ref_doc_id": "72a30e96-83fc-428c-b761-b15b1cddf892"}, "a5bd8d41-4b90-40c0-b482-9c3c314dc1bd": {"doc_hash": "a3078ec17a446cb824585c6263cd6aa35ca8bc26a6793d24ac9d8a54671bcd18", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "340747b2-4172-4ca5-95b7-ba208bc1591e": {"doc_hash": "03b650e5e401e46086abf19f2b4bc66d3089191d7e272e37fdf16293006f6fbe", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "bb78c482-5705-4608-a902-e0617c249182": {"doc_hash": "7533a6a43bcf4ed46f91db8a08a20b242ea0be59b063c77947458963d5ecbb7b", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "a3e5f663-5b59-4c35-9675-c0c4904a821b": {"doc_hash": "8f0c13845e26c74132b8e5a123d7e85ba52a28eac959fa67dd9f0aa3278e1737", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "f8944b13-c93e-476b-802a-0e53fa2b1458": {"doc_hash": "34c2faff7114f505e238c5da819ee167785217819d6087f4904756e81e937073", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "d9b5fcc1-4257-4ceb-9ac7-68a460821e4f": {"doc_hash": "944fdd502d19efe411d4252ad3a7e7ebb970f694ab0564ea0ed9e4507143a2f0", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "ea5a02c1-1565-4d68-84fc-3707d436dfa2": {"doc_hash": "6b41fce6290616de818b22081d562124d3d73d343f4d3ad91de1879787964c87", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "bd1dbb2f-1fb7-4282-a100-6e8cea710d3a": {"doc_hash": "e69ce08257839f1bb93ff8b7c543918e00fa926f6f6fa905dcf7b5b6412724fb", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "74cafe3f-d98f-4b4a-9b44-162c910f4503": {"doc_hash": "a27c0861a9f90fc52dba2bedda87b530bc408cfc5d802871d8e85665354944e5", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "c50c3abc-ba87-4ce1-8ebc-0e2c408906b1": {"doc_hash": "d8a200765580bdc58e77dc2c52b2dd16be8a22621d312bca24b623e4e2283757", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "78803784-4cad-4b9a-9c6d-6b8c03b8dc7a": {"doc_hash": "1137e453ab44feb99721e4c714ac48d1899c5dc3314d509d9f222dc9e5c3d1e2", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "a874db74-d558-4a5e-befe-1d64fd2cbc4d": {"doc_hash": "cf35565e8384434e5865b03fa25af5f96ed66c9fd7dbfc227afed4677599eb34", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "dd2cab71-d2ea-4708-b044-33c36df4fc99": {"doc_hash": "8482b8bf5b7b8e95e22230eb2cfac55ae3ddb51393d80c89373f008eacd027e0", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "d01e86d1-b298-4667-aac8-0b33bd88f8a6": {"doc_hash": "376853516e6a90bae1754d785f5ad38d20e4598088d96eed5334fadda037a8fe", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "255d8878-820e-43dc-8df7-e877665b313d": {"doc_hash": "7be6fef5423a6a8cd65ef86b3bfd3683104346cd0ebf4365ad87c17cf9acb06a", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "351369cf-c669-4500-9fdb-d71d5c5cdac5": {"doc_hash": "7ddba77cde5f4fe4f352e8da59558aca4b37386c3c764bb516d55b8394bec23f", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "9a1d84a5-2c5a-4c43-8fae-823ec62a7ab0": {"doc_hash": "04b892e3a8bb22e38d3281e20100d31ac19e37ce5ee4fd29e83cfec717b5a3f1", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "66b08f8a-19dc-4599-9363-c1da604c795e": {"doc_hash": "d7ff3b06bbdc51b3567d7dc280b4b820aa3eb0be37155ca6955a0846b7259c90", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "55f9e462-1005-4a70-8b8d-a8cd887f39da": {"doc_hash": "694061c259c16e66b1b7115955a9fbc4a738f1e4f608b2d6e3e94f9ace671d34", "ref_doc_id": "0ac2170e-3a4e-448d-b690-3779d62717e3"}, "8cc2c8b7-b599-454a-92e0-b8667c83d6a2": {"doc_hash": "a789c4345e4d43a439502179bd9de686fc30130777e3b54901905acbab9d66f7", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "a9f2d87c-52f6-40d3-a982-1c64623d53b6": {"doc_hash": "ec9994d3b60cc98ea5f5e28a11f72e5c42d2610e73cb66cd4b231b6039a23a1c", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "a480df9c-cc8c-4f46-8331-e0c2f589c70b": {"doc_hash": "100994c010758df76f8d6dfbf70246299c4a58fea70332429a4284bbdc0066fe", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "ab4ca7da-c1b9-4f16-a44e-e5c734860335": {"doc_hash": "d5889fa3fa80defe760b937e2e4e74064a57002eb41fdff8ac50edba4d0f826b", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "e012d16f-4e6a-4f98-8e77-75174126e5dd": {"doc_hash": "83a2cb3f87aeac6ce5bede455400572cae8e31f679820473288d21cd968be64b", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "ee1eeeb2-fd07-442b-83c7-4c3b93bcc6a8": {"doc_hash": "3174f2cb30d03a8cf5c63303e9aa1fa5d7354fd8fe93a5947c4895d3901d085d", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "b684b163-579b-42e7-99df-2d645ce0d9a7": {"doc_hash": "50f66a0703f4019bdf68fff49c4502af0eec1204988046a22c31beae674b25a9", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "8053db17-c266-47e2-8560-6f4389966deb": {"doc_hash": "abb6acea3956b38240250f584a70524513041a5ab4b2180beadd6c6b142480c6", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "d1c5ae66-8f30-4fe8-9741-dca1de98a62e": {"doc_hash": "62d79147634b2364efaab533780871742f693e096dc8a7f5d704a107d588d39b", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "7c814e47-5143-4e0f-b553-8437b1791db2": {"doc_hash": "66fdeb2b16b354cca4f4a3fe1dc78212a7e5b12219e58eccba4debedcbde2bbe", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "6c3877a4-1554-4b89-98c4-9c8f4664c538": {"doc_hash": "35269c4f8e7447ff58bd5da9aa873d4ef2d863c831aec5ac198c096dd8cb7e7a", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "2ebab35b-5b9f-4fbf-94aa-a190084665c1": {"doc_hash": "296b8ed0be3fc192960396ce67f79f7088504756a568d2efa723fceaa1fdd636", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "740a3194-bfec-4786-99f6-86eab90207de": {"doc_hash": "99de7172c86eef5761ac4c5a0bc6d3c49dc2bb5b00a92e6eac0068b501eda596", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "b11e6fc9-012b-43a4-8bc2-bff4125b33a4": {"doc_hash": "1dfd86aeaf6eea08c81319b0424c11ba89969b8627b9074d21f76ebb22551537", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "16f85ef1-2037-4416-9f31-c0dfd7da636d": {"doc_hash": "c289ec752effc0ee04a24e1eb8891d97ed3796d36205c3a15630d8504025d9cf", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "5f9cb17e-2a18-4583-835e-44a6c39fb36f": {"doc_hash": "4eab546d62e9d558229f5f39e076ad52b51b92271a8a58f2c9200bc0122b486c", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "7f432a4d-33f1-469d-91cc-f4b054f4fb9a": {"doc_hash": "f1224dfe8b778cb8f6e8ab374c4875a13fc0c20c2b4b81cbb15360685a084be8", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "694bbdc0-e424-4ecf-ae9e-162568a42059": {"doc_hash": "256040ab4835dfc0bcf2a14189234ea34370b3bca1604759dbdce456f906bf54", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "6df3bc89-0f8c-4041-9cde-12eefdd7c826": {"doc_hash": "00396032e1b5ed8a6cdf6f15f48c4312b8226dade3952c7d548fc5747abff7e3", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "3f22d055-e32e-4101-a09b-3ffa9719997f": {"doc_hash": "88296e95ebcb6f80070d6f4d18b7f6f4063f140262a0937cb5f5977ed5526a9c", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "501635b6-7af0-43f5-b0f4-31f543ec217e": {"doc_hash": "118b8ba4984bc0fa1427091019c59c9c256b839c131e7824e00e5f25740ef460", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "bf625c55-8ebe-493b-88f7-3eb39cee431d": {"doc_hash": "377bb0098eac22b3f1c2daf8e994d6539378dd0095248cbd513e45bf134474f4", "ref_doc_id": "7d8e6b24-d522-40a9-8411-7a6cd0e70190"}, "08064886-17bd-4ae6-86d2-925ba7cae5ff": {"doc_hash": "90d67ee26e4229363d65b53a7942c2e736efb6c5c2e3ac66a581122dc406e45a", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "499e4c14-c429-4cc7-b8d1-90628aed4aed": {"doc_hash": "53c4e737f8a25a9394d29e17b069836d6dfc17ebdb2bab0d5b6561b5927ead94", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "95471064-3936-48d1-9e8c-94723ad765db": {"doc_hash": "b900aa4142b044d605ebe2589f362918d3f726ff2813b9c92c1bf28bb545e624", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "d7ad6534-6cea-4631-8e64-3f3235999be4": {"doc_hash": "fac8b345f11eab645beaa7ea512a8adb746f7daf6615d98d142274b8f31261ae", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "6e9056c9-248a-4508-b48e-5f5fa8882eb2": {"doc_hash": "f8a45519e6b92e96e7dbe785453845f8ee360d3f2c83310fadbd8116530445f0", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "5160b103-8fd6-4da9-96f9-6fc21f96efd9": {"doc_hash": "56956dc4ab9645934ebd3ce279005a4b68474bbb304798381e90df1b8a3a05b1", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "8d43cd42-2989-434c-bb6c-8a94f89a000a": {"doc_hash": "9f9c86b291093ff5d06e41ec59d186c58fe7ac0553a82f9726fc2a0469a75c71", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "f60f2f42-cbf5-4c74-994b-4917add9dc2d": {"doc_hash": "595803077de03a241d2cea3774f33d51acc81e8d61ae3488593151bd1eef4825", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "cc818b24-f455-4b6c-b93c-265722789ffd": {"doc_hash": "acc6ee1b4471707801f2971843223459c1a335d663dd3cdfc7f5cddafeb36408", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "e44ef599-e3ae-47e7-af91-c5e835a105a5": {"doc_hash": "a1a93c351107f586068d52f80d0fcde1b12ef19ab660f6b5d4676038c309d60e", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "b53e241e-77d1-4087-9852-54241f91287b": {"doc_hash": "224d91c0f1eb7093d4116e156e634c53475769bb3f1469e6f8b34c239a668375", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "0e76d7a1-956a-401c-b8cf-38ac4d8e3bad": {"doc_hash": "fa9bf6c0b7a281b60ed426b9c78938af2e23eab98aa0888c8b63befff0b9eb7b", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "b42441e6-508b-4066-adfb-7577247ec2a2": {"doc_hash": "6588aed6b1fd78e5f7d0307b2f06c7de295246272aca9b2916aeb26248b613da", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "4a651dd4-7d71-4232-89a7-e86f54f2a6ba": {"doc_hash": "4647aa4e93c64662f5750dec4a9cc6096e4e8fe241ba3a6888b92ad4cb6835c6", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "71160d8c-e606-42f9-a4f3-69e8c8b1c3f6": {"doc_hash": "7e3375052c896f968fe9d638a394adcf8dc90a42594c309f14e66f80cb8dd691", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "311a3b80-ab37-4776-9351-54b1e66f9a1f": {"doc_hash": "24ee5b2c566bb70e5da5c432e58a4d38063fdac8fc91bf05a38cbe1ea24ddb37", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "bf6664df-de70-409e-87ea-90f552c132ea": {"doc_hash": "9522c12e4b6ddb19855c556e3c887ea39e1335c5cb1a98864f0b43fc2bffd99e", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "8d571119-97c2-450a-bea3-ce9222f847ce": {"doc_hash": "9b21facb783e32fa3662776c40c7fb097f512a9b8ff417558659a868ca5a16a4", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "88064374-bb66-4f1e-844d-bcbd1828a2c6": {"doc_hash": "8d9bc356c7a872f33b490e4e9663772c62303dcc7d9139c367d7060c6b1cf83e", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "5a318eb6-36a3-4a0a-9567-54d1dd885904": {"doc_hash": "14763c603ae9fb449b3922eece5925d4ee6c3ca660070a28b542afb1e72762f5", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "d4895ead-c3f8-4ed4-bd03-415c0b823c38": {"doc_hash": "3da2b0c470c5ccc3008692d604d764970eb32915972561bda15f86de4d262479", "ref_doc_id": "f8fabbd3-2905-4e3a-94ee-316d3497adce"}, "22274283-5acd-4d92-8322-5385a7302db3": {"doc_hash": "7fb5ffd2d4ab143d72aedbc6c240ee2ed201008b8df0004385ce633c81884d73", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "1af5a485-4139-4f3d-8143-675bb9fecf83": {"doc_hash": "833965c6a688db57031f781756edd81c09484cf08827436cbbb7e9412fcfa761", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "7ec754da-e027-4986-ae22-0603ddef5de0": {"doc_hash": "a909cc6bdc089d00661a569379509573f356258f753ab7db3d388120e6b5d09f", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "131cda9b-0cc7-42f8-9832-a1f54c9ba956": {"doc_hash": "d0de9c8e05aac60e0cb39e9e777c1de17d4d9d32ee1e0ee90916795382ae84fc", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "81cc33b6-6b6a-48a2-82f5-27e8bc977706": {"doc_hash": "a06e23a2aa99e243ff63ea8e262fb5da978acce1006929ec86f21784448b91a3", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "f6cea530-0022-4849-a1a5-1463ca50ca4d": {"doc_hash": "f57b68b8af2eddd851f47c0dd8e4860e85476f82585794d7312c5830448b9b47", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "6bdf0b2d-251d-4eab-8794-e1342cbb967f": {"doc_hash": "8830eddd0efcf868238aacd261b167cce229d744e792ea8fa9d77edc3e0b431c", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "ef1bea6b-0eae-456f-8160-8cad49ef49e2": {"doc_hash": "f9534b614ed122eab9e2bb03f9f692499bd7f65b5e9f274aeafb8f1017a5b200", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "fd05a63e-b5e7-4fb9-bb5e-92037b4e1cb7": {"doc_hash": "378dc73494c99613b17e22a45c38aaae5b735a7a35c0084fe6dbdf20a7b961c3", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "b2ca38fe-0bdb-4f15-9456-ffb1f6113f74": {"doc_hash": "02d5190e47ba8bd658761f20dc9c823c04391724e249336d74c1be703af62945", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "496d52bf-863d-4b63-9e88-f8e40be32ed9": {"doc_hash": "f6ef6079a4ed8122f6cc0445b7df79f41ac0c6c3be81d1ee121a5e2d2b4cbbe5", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "56f78a6a-dfab-4451-a447-6fe93f69abd8": {"doc_hash": "f230abf856c0922428910708ec628605dc3e566be166237193fde28a1f846ea8", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "a6de4c3a-a6ad-4465-9bc2-43b09c9c289f": {"doc_hash": "cb38ebcb261ff76cfaeab452f2cf47db4cf30eba20b79072d42d3d91b79f5252", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "fc6bfb71-08d5-469a-aa59-ae8d0c13d361": {"doc_hash": "c91c7df4d2368c5000121595f2b5c7ca8fc344763578454f5f7722aa6a5fb7f9", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "bd9e06ad-8466-4390-9344-5f07d5467096": {"doc_hash": "b40fe84903e3d31d1a35bebd797a48b3304bd71484583284731dc100be97635b", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "42e8a3d7-ce9a-41c1-888d-f49581beb2ec": {"doc_hash": "4516da890c9ff43c772f6ba0c3e686dad18f52dcccb40e9fe5090e6fb996ba9d", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "5e5adb93-f5a3-48f4-ba90-0d815dda40be": {"doc_hash": "ac1b1f5af26f6dc5f5eb13a32428c3b44fdc27a7d92709409fda15107a0bc655", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "1d1c5b50-a521-49e6-9b1e-f33c5f150331": {"doc_hash": "9ce2d858dcfafa6af07428bd7adbd69485db5133648cd1f803093a911ca3d44c", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "1fb09fc5-7b78-46c9-b3bb-7f0da8c41a0f": {"doc_hash": "a3d33c2362831ec5980564020cb08beddf92ed6f77d5dc389e6fcd22f3d81324", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "a97d9e60-67fe-44c1-b823-713ad491fc9c": {"doc_hash": "3bcbe905974b6fd8346106df3a41d8974d2b48a200ba486c64b4e1d85f98973c", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "17a03335-ce0c-4019-9255-e730141164d5": {"doc_hash": "5c6adfa4f524bca727c1a31509fa4ceaca0d1daa8fe02076542ffad8a1509cbf", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "275913b6-8fc0-4fb7-955b-943645742df5": {"doc_hash": "9ca343a1bed15e69501bc8c69444ed611945f1e9f40f9fdeed12320c18cd4a66", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "9b463bbd-40f1-48f3-b9d6-f618c4312ae4": {"doc_hash": "282794acb9b79322e82a220a1322e785c71771fe1f956ea559b48e01affcc903", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "ab361b74-a015-4269-81ca-94b93e0db030": {"doc_hash": "ab27e193ed7f86e1a50849f85418a970010a5b8993c93c6a4c15e52db65891be", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "9d9ac62e-3396-4232-95db-f2b3822e0887": {"doc_hash": "32e0adfc67e8d776ea93c55019882e4363c02f74068e76cbff693aad3a11a7be", "ref_doc_id": "9f0d8936-98ed-4c2e-907b-d810ba967b41"}, "0c26ed8b-f540-4491-9f5a-7a93d65f437f": {"doc_hash": "465ddf1a9a60077cd4d4c17e4651370a1953655c6b1fc66f2fc3eafbd4e74724", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "c9af985a-c095-4182-a657-7cb4376e0f08": {"doc_hash": "50f99ba6430e65a6c3347b8fa4d63c38e465e8ebda356c372b0a3289f67feb53", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "1dbe70e7-f3cb-429e-8f57-d8871651f4f4": {"doc_hash": "22f916599800fe92dec0700a7531dcd121ab050a1d24866b3227ccdf40af5990", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "a8ad445f-e58d-450f-88a8-632dc924672b": {"doc_hash": "0cd45790e4029edeb0376ab7917f6f5b989100dd91cda196f92606e089143013", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "26c03fb6-47c6-44cb-a1fd-3e461126907c": {"doc_hash": "6a11117d24537ce22540f6b6ae4e3c5e3c994c54e3b858a6d32927c16d986d52", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "4d4d473a-72de-46f6-86ac-7e2035c5005b": {"doc_hash": "0cda28b59ce97287a734e75b9b23e246bc25190a107ae107aa8afb056af7b373", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "c78066fd-875d-496d-bd45-bd033d157b8a": {"doc_hash": "c47a8466de26a4710c93239cf2713dd4d439f8a19d2291cfc77c038f378b7652", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "5d93670d-8f11-48f7-89da-3cdecb2e71b4": {"doc_hash": "541e5dfc5529a444c69b521d8ba54a0b2c2814ddc26155184adc58f1e07d1edb", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "543ca4e0-8fd2-484d-901b-e6e7bc4c4ad9": {"doc_hash": "437d0a1d2cbbaf99386547c55064f1b77debe048c7e34dbd0ecc75962059d8cb", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "4020eae1-f668-4012-af07-26973372b537": {"doc_hash": "becee7dd80afb264c7b41c8ffb3458f354ed5b31d7604e0bf3047593c784650e", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "1d7650f5-cb12-4935-8db3-5759d0232bde": {"doc_hash": "62f6677227305f9e04db769d3651aa516b170abdb7e9770db2f27708f3a62361", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "9dc4557e-966f-4076-ac17-75b4a3068b5f": {"doc_hash": "f5b5fcdeab1d514d754445bdbafac542b8c8a2e2f84753de53d8d17900e7662e", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "8b17af86-c972-4e29-a6c6-20741cdeb85f": {"doc_hash": "aef88df58accf06469d34e78c1049f0a5523c9456884f6d42dbe386819ba7690", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "d86720fd-86e1-47e3-864d-0c468785be03": {"doc_hash": "ad51cb3033ccd04eed59e6390281aca5b76827ebb4316fa9aba8d64cd1b861a7", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "49ce993a-1f01-4413-ba4f-b4ce2047430d": {"doc_hash": "64f0c6ebf2439942e61dc5316cffc165e12589e02b367fe70151fb027e324549", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "aea051ea-9d43-48a4-ba00-2c586f46c36d": {"doc_hash": "28a423317b0c7cbd862863c96902af2d8a3658a167096fa3a21ace69ae61b8de", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "5fc86186-1479-459f-b950-0176efa2e2fd": {"doc_hash": "5bba79b39f35eea2cf95492b9f4568021ed0e745804b2d8c16ff991ab9fcc533", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "96bcdc03-a91d-410f-841a-1139ea35d397": {"doc_hash": "3efebf05777ff7519dc691bbd10239e9b0b7e6c0f14e1f1ed7ed40bb1c6e22af", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "83ac524e-2962-492a-8181-18fd09325223": {"doc_hash": "7e45c7aed1848e4d4ca0c1a1b5e5cf53840f0e1475e1cb9f3b9f0581effc1a4e", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "50871397-4c29-4151-a2bf-01986e4bb0a0": {"doc_hash": "4a41f06c5e917fcfc7e04435e5a52f30c74cb02da53b1e6a4c6addd9134dbfd5", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "e7998afb-2b1e-4625-a2c5-765308cc75e3": {"doc_hash": "d7a7c5ca016f7fd909367546010b82ec58394c99ec32bd9447d65ef510abcc9d", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "9e72fdb1-e486-443a-8d3c-717def42dd3e": {"doc_hash": "538bbcb7d100aabfae4bdc0e241f619732a744c9241525f94b7ee3d276139511", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "7085d3c9-79df-43ee-8fe8-1bfd001f9796": {"doc_hash": "c9e23a321efe321e627ba8bee8301a9d0313b02244d867064f571a2328807504", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "99215f82-70ac-450e-a6da-7977d3c65c4e": {"doc_hash": "e739cdeef30bebc49836eb56d69b618ada234d142816d8902c0a18371d298166", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "7001605f-fc0d-4ff4-8897-3dbdbfaf134e": {"doc_hash": "4bef374fba2a96fd1d8e60dd148d4b7096afa0235828bafaed981cf0b6f1074f", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "c9d61bee-d129-4a7f-bbe9-7f7c77602c02": {"doc_hash": "381a3af827c8fd0a57cf21e2df34f7aa7114987acee1cd9cb032b0bbd416314b", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "c5a0886c-8cef-438c-8051-34e87e63a70c": {"doc_hash": "de5e5f74993780f6280a6f32e8901aaffead8a65004cf08db2924d492d797995", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "e8dc2f95-fb54-4c7f-9cca-fbd426ec8ead": {"doc_hash": "bd01f3e61569d2781cd5c55e49a13d8cd1e4463fb0856fd4e8fa0c36ae53ae6c", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "213980cf-3827-4ca3-a492-1318fc26fb15": {"doc_hash": "2e42faffaca85a6c0c73d9a66270508baab8aeca146f1fbe893dead36c15e267", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "a2c41cae-d574-479a-80ae-96644f4201cd": {"doc_hash": "d1126016968485509e037d1de06b6cd3b19e9c33588bf05f4b5fc8e753e6431b", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "570a0a0e-6924-44f0-866f-a6cf2917159c": {"doc_hash": "e76343f00bb84b7f6ae7a5dc985264fae99ccba20b5cda0315f75230b989819a", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "2cab207c-e86d-4bbd-bc17-d95e033fa111": {"doc_hash": "fb1be9485063adb2856affdf0de54bfae58e71354da30c4124509a97ec0a9505", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "e1dc5dc3-da43-4f73-8f12-044bb62d00a7": {"doc_hash": "f5937bfebe680faaaba1f675eca2dd3e0e5ccfc7c4d806b43f22924ee724b857", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "9c4cf3a0-1dde-490c-85dd-8105a5c76b66": {"doc_hash": "6256ba08ccf37171abfb7812be6a7e4fdbd3cfe3717d81f3e781656f39241a3d", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "13e01cbf-00da-4a49-9b2e-bacefbcb330c": {"doc_hash": "9dba49e8010b0ee34b93bae3eb92d04febf197627b8c026ccab4768405c70526", "ref_doc_id": "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9"}, "ad4afe8b-fc81-4908-a259-54e898eff11c": {"doc_hash": "2b0788624c705bab5c2c68d885059756fd43edf278352e79c369545d5336321d", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "d5e4f0e9-d886-44af-b274-cab2f09f6b4a": {"doc_hash": "b6d6b080fc3d8afd022c25ab18bfcab73115d334aca554380ecbf0bb8a328ea2", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "f988bcb0-d57c-4b3f-ab4d-f1fac4a8150c": {"doc_hash": "c5c5eb1c62dea38ec44a7a0ff23b49fe804100926ec688a53bf6c54e2dd061ef", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "5a0c31ea-1608-4066-b33d-e6e290f0b14a": {"doc_hash": "4456771cb089a04e73723d75fb62e703459554fb8a4a51729e2e9c22e4b2c510", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "9f3b4804-c08e-4caf-807d-d89fa65ac418": {"doc_hash": "eeea325a6de03731823befcb2893a28d4f2a011669761251cc2f11adad50d8fc", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "2dcdf35b-8bd2-4d8a-953f-fc6a24f5ba35": {"doc_hash": "bdc236ded0628b2a052e5359acc444a960ecc35650483ff2257c195081daba9e", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "c4dc018a-4a52-44cc-90e4-7f3358b13224": {"doc_hash": "7cb3c4edb4c0f3705b025090494127a0b051a417c93ddf2835fd8204d4172fef", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "716c16c0-4f76-4b99-b4b5-2a9288fa738a": {"doc_hash": "86579fcf6efc39fa0a4827dd627f748b030cff14a947785094af2a10f00ef16b", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "bc8a51d1-77ce-47d8-bc1e-c96e094a8408": {"doc_hash": "5a1eee565720e4202d735762680b73879ab50b9b9fc6cd4ece1ed2ef0a7aa52a", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "95215568-0d20-4eab-8183-9cedaebe6ea0": {"doc_hash": "31a4110a99acd176aafc493b422d298c9ada710847e28f3c8211ccf3bf00026e", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "d39fde06-a319-41df-a697-e96f466ebf40": {"doc_hash": "3ecf332da01350728422fb4d7bb778253c8a604d389865131425990d82152d18", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "e12a19b4-b628-4c76-80e6-2aa8c7d7b318": {"doc_hash": "e3d35071d5ab995011132868264fccebe12be0dcfdc12e8a16d42a7236333bdf", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "0380933a-c072-4497-b842-3c69aa2904ec": {"doc_hash": "a07970a2f79e3f40d8160cf82eafc45f545bb5e8ef9af0359b49cbe59926a3c9", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "7be62860-c765-4554-90b8-80a9ffdc325b": {"doc_hash": "9ea90ae003c63365b55d4c0dd6156a11778d4f742494f63cc6941329746e48d2", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "9379087b-37b1-4c2a-a605-7af6cb38e11c": {"doc_hash": "e97d0820aaa1e3d75c92ec6afcb4a7c19319447b26a814e956646c929de9161e", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "8fc86513-8e91-47c3-8089-637ae98202b7": {"doc_hash": "24d85b03c43cd57ef6b20ec6227c54af873dc202630531679e253d88a63eab91", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "c578a7e8-f1bc-49e4-b45b-e37dea63f901": {"doc_hash": "cbd0787f9d455ab25883aba0d25f6b277b52fe7017f57a78fb612f022ed9eaed", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "7279f662-6d2c-400f-be00-00dc6f6b8656": {"doc_hash": "9e24b1e4858641034b40a127181c6dbbc5fdef8b694ba8c11524b1e417d604f4", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "62949e60-24e6-4a7a-bb03-3edb34c3634c": {"doc_hash": "850edec5d520fa8456857867bec810649d86fae9d9e0255b129aeee40102a2c1", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "98dff14b-4c0a-4971-a6ba-252f832d7663": {"doc_hash": "348705529971458e85930a869077a07d25f76f30a9fb0836ebf44dc1547ec7b8", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "3593808a-bf41-46db-bb7f-7aa50c3164f1": {"doc_hash": "cc67e197c87c5c349d40ed4d18954cd7b2fcd580762e9b7a401adf35026f2d12", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "56f4bb68-0e16-44f8-a25b-b85d22919a3d": {"doc_hash": "cd5cc28c2aefee11775e45f54131eb62908ff5be4b7763f57c4a683f882779d6", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "01b2cd11-dcc2-4418-b961-c4d29dfeb4ef": {"doc_hash": "681ba59a703fbea9934d5a03785b17fc4e44a7e45814c530b1962d8819c98f5f", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "294a8623-fd69-4b87-a01d-e7da861126a5": {"doc_hash": "e855023ae4e2726cf1ff6b055b16a84be0b78ceaa2be601de812b919b0984fce", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "56ffdfbb-d918-42f7-b9b5-d29b02ddc6a4": {"doc_hash": "0e914821432dc1c414d4d9da4a7dc03c50f008e8927a6e69a75ad1b580d96bf7", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "3056b351-137a-4cf8-adc5-e2787e26bf77": {"doc_hash": "7526b02f04393d9ae507b9a05884ae43d6b2778ccef0e82c8f6cd358ffdd1849", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "24a9bc83-b6ea-4313-ab25-b6141dee1f11": {"doc_hash": "4b40d6ceae063645599e05fbaf29bcb2f254bed8f1354cad0f513f3972a4b295", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "227b8164-6776-4c01-b43e-886ad9ae521c": {"doc_hash": "1aa83ef3480e6fa7139a1783f932651b0caa3acf10c8014376a8685393e1caca", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "f1c3a140-36e4-4382-a37c-76902a961bec": {"doc_hash": "d2014f7c5a0907e5666fc5f299721b52f3562a2dbc94205184e8f365be968a86", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "0d3691b3-27fd-4dc6-bcb6-c6fe13c11060": {"doc_hash": "7aa0ff1bb48e67c51195fac466bf1ce4de58300f7a7b7543eb3e1ea5b923690b", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "51282aaf-3053-46fb-9906-828663f1884c": {"doc_hash": "f8f58075544e58ab449aa3a92d039c324e89730c068e625bd9772949e3830c82", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "ba6366bd-82a6-4a31-b85b-e5a885c34228": {"doc_hash": "68e03e7ad292ff4742045d6d4bdca4e94104eeee51a6f4ee4febd3ee8812aba8", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "a3d67f08-3a7c-491d-87bd-98d6f17fcb79": {"doc_hash": "7de311fac0a021b542379b99e8ed003719ef5ed1187066cdd984287da87f75ff", "ref_doc_id": "9e39e9cf-e65d-4182-8f62-ba747bd24f55"}, "4f1ea861-abeb-4fcf-a99c-d749605e20cf": {"doc_hash": "6f0df2a3444a8cadc90620aeae7e5ce0183730d627abb2b7e040808409a0d400", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "94e42d7d-7741-4d1a-adce-8cdd13b94986": {"doc_hash": "9fa3ec98abc22c0cfc11f538bdc94890cfa62a0b3f637fab56040b891277131a", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "9084a20d-f4a7-4c33-9a90-579a4df55962": {"doc_hash": "0892e9919780f15bb3cf321bb79e4cb147f907d4d8eba8dc9e9743b1f5c8a142", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "fc0ae8f9-29a1-4a47-b6d4-953410a86d77": {"doc_hash": "a0fe4eb968b13c992108ff403d3530bb3d62a7e8628a6770c512316541857c70", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "16f04b7a-789c-4643-9a35-36f4eb0fe087": {"doc_hash": "a7fe42ae459e5791369690a8b748ac3b315ac7097d45d33541cbe74d4bd5597d", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "605faf57-dd2c-432c-8208-cf703c4a5404": {"doc_hash": "fff049f4e4a6cd28d101900f54da6e73a551e61ee5f95a0d3279be2aa0b74de5", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "0e405582-73c7-47d4-b0c9-754cfe3e7746": {"doc_hash": "cf59db16ab0580a9d8434d3189fe4776d94eac58ff275197cc6649002f8a201e", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "43753e7f-2442-47e5-b4ab-22c545f141f8": {"doc_hash": "d024b10cd89073fad5b2f7f4f78b94c7ad5d54849a8767ed2c09dcee8c2f6da0", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "7cbb097b-da73-4f60-9a60-055f99d7d06b": {"doc_hash": "921760613e41f31e7788870d27f38e1fe1e88d78659e21f7bdfd6faa4de6d6d3", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "1cc84ce7-3b3b-423a-86fe-007ca4010b47": {"doc_hash": "62c5f1d165ff25a0032a1671913cb5bb614dc443dba791233051b48348587194", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "ae2f9902-f2c0-4729-a882-927a9885f7e5": {"doc_hash": "b7206def7c3008f0808cc6dc81f931a27bc29596ecfeb434eae499a9987af4f8", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "98695a0a-47fb-44dc-86bd-f4abcf42301f": {"doc_hash": "7d63620127146bb37b1c00f7a66bc0eadd7f7b01c4817d7db9fcd5a0b8ca0cc0", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "afde9dcb-5727-4887-ba9c-b2a0670bb231": {"doc_hash": "9806384ad9d70f5f3467d9691dee6dcb21442f3b10306f2786297a1415da354f", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "3955dbe8-db0a-47e3-89cc-b076dd4a31cb": {"doc_hash": "1e64592d0f32e728ce7fb003558131bb2f59e5622a8f226f31fb0cf35f54c3af", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "7f6494e4-2fe1-416b-a11f-8b532515f4ca": {"doc_hash": "958c5e4eef3e27b527c507d25a4a77779d2b8f1fdf4b1eb5789d7dbf7ab1a0c3", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "28597111-3490-4744-b228-6164919b9fd6": {"doc_hash": "08d8ca7d7f7d2c3f88e992739c6c26f6a3bdc1fd95646f31ae281e4e3538b85f", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "5e9cf254-0a6c-4918-b4b6-096b768c98e7": {"doc_hash": "37ddeb13bb085d351816a05507dfe4767e772aad1373ff56f17e91a08443a979", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "a95f3b1f-b8a0-480d-b433-1061db96dd51": {"doc_hash": "c8a0de0d9ff1e1b7f8d349e65e96613031d84ee2a23e2f2cf018ec4792844185", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "5f1a83ba-4695-4139-8f2a-28402c61e49f": {"doc_hash": "8e2947260390575da07dce988e29c7754ecd816a81e6e32be8f6f1fb396aee69", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "c5abca40-5d9a-4c3d-a32a-7a234d90d64b": {"doc_hash": "579b47d707b39e01fb902f0c9d49aa1394550b2bfe2611414a9620503c614695", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "d5bb1c0d-c729-4dfe-b6dc-83dafcc884d4": {"doc_hash": "faf3687f14cb3292d86233c97dd16eefb611906aed7fed46c619b273e68d1958", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "6b709a58-7979-48f6-8143-41ba5716a601": {"doc_hash": "0e728ec14f5937770816d9b79830553151d39797d61ae1c476da135fdeef5f4c", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "2d425a5c-f80f-4152-a441-69b51f06121b": {"doc_hash": "4131559e5ccd169cac7e98ce1bd260a681d91d6840dc1589ebfad63dd0abd292", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "fa2c6242-a394-4f10-a467-d62e761e34e1": {"doc_hash": "701afcd45e93773ea562218d8375c9209382071b0674bc9bc31f03aade41cb8b", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "fda1fab6-b2b0-4ea4-bea5-920b167dfa04": {"doc_hash": "0745d84c54464b9a98435182a07ca60cb4cb159608a0a1305bcffae49fdf2ffb", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "530c5d5e-146b-4586-b53a-4c0cc1855a40": {"doc_hash": "059190611084473c98c0ddf62b6ad368cd18ab7994c1196dbee6b9fecb7f8684", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "9c9fa03b-5c3e-48ae-946a-cdfc71ce8905": {"doc_hash": "b27d06df6931b2c53ce588ee5c3ba091d009925399e2560fa9f5b422297e5250", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "bc7c5d09-ff17-4b60-b0cc-aef9e1c00818": {"doc_hash": "e9a976f2e157c42a75b7f994a231331a5b7e154e394efe4013d7ddbdc2657cb1", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "bee39490-2ee1-46cc-8d12-2252808ab394": {"doc_hash": "233eeb47d0efb864b51cfb979f4cfd84fc8eba98cfa9041dc10b5d0baac0d65a", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "e6ae0dda-7b39-4ece-9980-f74114eeba6a": {"doc_hash": "6631c3bb953877b583696f42ad624a222dbf8b41c8af86f4dd1b00d8e98d851d", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "75f7e881-c842-4bd0-b1fb-b55687f45aac": {"doc_hash": "c0dc76a5d9b8afb73dc834a27651d78095579e5a9fb174247d92e194ac8f7ca0", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "a4f8e8b3-7394-434b-bb61-87821bc5f49d": {"doc_hash": "1031e4e8ed79e18132e5db2f3514fe4f1d601d73b8bbff6b721144d872c8376d", "ref_doc_id": "70ecbaaa-669b-46fb-a85b-a8618284cc04"}, "2c058aaa-0508-4862-b229-e2352d0309c2": {"doc_hash": "480dbd3701d0a3c54c9aaf8943ceda9419a52139191006a57324dbcaf0f6f624", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "1fd54ac1-458d-4e89-b21e-6b6167dd1e33": {"doc_hash": "af3e939fd3c6a94148fc329daf1e8d7c5829b36a65858d5acf37a656bc68d1da", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "450b1fc0-1aa8-44b8-94ac-ca7dc4a63545": {"doc_hash": "6c972acb4a4d53b3252355064e5bac9f5affcfac462eb276da0a9cf862c7a176", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "0458fcbd-9f08-4fca-8ce6-634a14eb3cb3": {"doc_hash": "e6dded4fb8ffd7a5c9ef7db6fc5569088a49cf45bc8fd28d38e2294b15a1f965", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "bc28e6aa-0574-46c1-b841-e5c4a3512c9f": {"doc_hash": "9fee84d8cad0bf5aede040d6529871285135dcc49460b9e22b4f09a63a61bae8", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "5ec3e019-e43d-46e1-bc2f-15c7ce5354c7": {"doc_hash": "e00893784a15affa7d374fe13eb322d7b0379a4a94865bca8a19e2b77d51f76a", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "94435c02-42d6-4c36-9e99-5b8173a78567": {"doc_hash": "19821227d679c8fc6167ac07052b12c9f382bee136c9b29d16adc0b2b30d9fd0", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "32f6cf84-fb38-46bb-895e-20ea5d3a9d55": {"doc_hash": "d65af1023a326c9f34fc646bc1fc1ad451ebd06a9dcbeb331393b7242c672e5f", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "ab2cc8e7-86ae-411b-b762-0865567961c9": {"doc_hash": "650559f75595ba11e5e486563244c5740eff6d64e5bff5dbee22df59d6f132c0", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "06515981-4f39-4435-92ef-6f6fb0591d58": {"doc_hash": "fd7ad84d25b3ca30e18704b2d152cd6417dea806223198c3b17fa0cfb0452a93", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "89242551-9aa4-4863-80dc-bf6762ee53e7": {"doc_hash": "8282bf1800a51ea40e5a6a5c231c0acb07d1ccb09b437d29f70d8b7469db56eb", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "f602f917-b12c-4cde-a94c-d0cab57b9ba7": {"doc_hash": "57f66414f216d0c20821bf04c49a4467da15ae301ec2f7b7146c4cd7628ba8de", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "72fb3114-13a3-4b56-b8e2-726071e6dd14": {"doc_hash": "45e2e75c77aa13b562a80d88c8248c27495efed012d1cc0794b3e6cf4610d4eb", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "ed7c3e4e-8d3c-4c3b-bddc-474f911b9c7c": {"doc_hash": "f973f9a8440ad099d1495d872547849b7db794203ea2db8dad214b86228c33b7", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "f49bb022-5e8c-4737-9aba-b4f4cd2a2cf6": {"doc_hash": "92b2c60335638e48e0046a82176902bfcee0e11966e624f05c6c806e22110c51", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "36f14e96-8562-4c6e-90db-a482131832ff": {"doc_hash": "97fe3587dff5c4dab5419f137bbd92056c9b9088bfb26b4e8f8d2001d8e712d5", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "6f687cd8-e3b7-4238-b9ce-b17793a81630": {"doc_hash": "1219816e47e41a795c99ea289e8f10ff72d3e9b8148e9401db808667080e8b88", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "86c57975-019d-4d61-9b8f-d0177a659cbc": {"doc_hash": "4e32366e9cf09bc25dd457ac6b674c04a74385c6a6d261c11e3dbfe4fc6d4c0f", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "9ce5980d-f03f-4a60-b868-bb1f641ec756": {"doc_hash": "46c220045343c3a2f928f839049a6b15080b352c9ce28b14447041e3e0266726", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "64a132ed-cc12-493f-9f48-6db628da9cb2": {"doc_hash": "a745250416a063f65e84d214025b412a0dff86370b9f868ff3956725cec9cd93", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "7ff195d2-62c2-4258-89a5-5c7742c00888": {"doc_hash": "e3cb97827597ce621423baff0ee2fc3c1dee4b3edcd4184c8b690f9b2477dff9", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "8e3db2ae-dae8-4d17-8cfe-d3998f814b5c": {"doc_hash": "65e8e3c6c50c6d31ba16ab3870716a78c0df9a4cd92310d35183b92cf56811f9", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "33b04eb6-d3a8-404f-b6f2-231c8b10a1c7": {"doc_hash": "7fce7a8a7a21ca5667b2be578be356b23cf92c4f7d34301b74530be30e93176d", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "b384a697-0d52-4c59-b70f-2bd4986b6b0c": {"doc_hash": "29a4227c7558e7864cfce08bcbe4704b576b8ad5a14ed07b277db837f6344efe", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "45d5d2db-29fa-4ec5-95ff-1be6d9e01978": {"doc_hash": "5513b68ef85446ed82339128a51d82ba597478264e7379f0b7297d4f6e0ee73d", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "9be27e8d-d98a-4246-a8a4-b5d887b2009d": {"doc_hash": "650cab4f97877d82399e927b10f1e27aab7b578f881df6fd930cc762ad66518d", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "51e2d3e6-f708-4992-8175-f91a3be9c63b": {"doc_hash": "77a917980edbfad08ac20bd6d977d0b94127d7a884bb2fcec93473dd5fe8813d", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "04b6ea6a-b237-4fee-839a-8e81a583db9d": {"doc_hash": "dd1f1c4182c95a51bda1c47baad2eb37c092f263054151b6dd91364c371128a0", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "b211bf13-cdca-4a43-a669-3b6e30cec7e2": {"doc_hash": "49ebd84d2208d64116ac7828673c5e0bc9c8a961576f5bd5a2ce172b3e5d79f2", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "171281ce-85c8-4016-ab98-e0f53cf86e27": {"doc_hash": "79841c3d73b5202517aaa8a8685caed86a3f1f0280e68999720c6bb2c8853e34", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "76c55d98-800c-4d13-813f-c89a95147db3": {"doc_hash": "1ce36132ca4d090186079a831472f1216b43ffa0418fae8ebbf8c89e85033f71", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "5be0684f-738b-4b38-a5ed-ac78d8da85ee": {"doc_hash": "abe1c257c57c19d12ff39cf66dd50631ad3045479ff6836ceb73dc339c2b31e5", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "a7ac0e86-c81d-48e9-a467-553511426f17": {"doc_hash": "48b66f57f95da8b5a43b15f4b163ca07226c53a4a47f6bd362ebecb985f4450b", "ref_doc_id": "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7"}, "80b3bdfa-5925-43ec-94dd-6b08c128cc92": {"doc_hash": "cac17c57d4687ba8702a420063f3cf5e9b69dce3e02dc2a23a2d59c3cf94ca91", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "dc2205f9-6d2a-4668-bc77-5dd834c9bf8f": {"doc_hash": "b7b857a19cd910d7087fb97d9dd15966ed7adae439f1eb73724970b0adb2caec", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "660085e4-251c-4c20-8c98-cb66b56acc87": {"doc_hash": "d4f41a4e007e15dd0710d6d5b640971b605c466ea1185bd7a8eb6cabb0d09fbf", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "b9cbdabd-b7bc-4c82-adb1-dbb63a3ec278": {"doc_hash": "d0ce34b51453d58a1aeb65843568b82b0627033510541a52cf0c5de2d71052b1", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "a571d0d1-0afd-428d-bd02-3a4211777e7a": {"doc_hash": "1c0c7aab045642f4c322aeb16f7e4117e437740830897d50abc37ebf454f1b0f", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "bb45c661-ae1c-4b9d-9ff3-dbbd81e56357": {"doc_hash": "5acf769a85ee6d9a3d9e72235231215145772f1bc3ce1fcd9f27177541885e3e", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "99404296-f973-4ced-b138-cc86ccb0cc84": {"doc_hash": "2e334c274ce28c5752112329482334c14278d2c8b0b994e822b0fc520ed7736e", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "12fbf7d0-96f9-430e-9373-aebf19d0ce9a": {"doc_hash": "fe9a961b765151884bae239b6f8f3e84bddebe5941365f68b0934be69f756657", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "0335857e-4cc7-4337-9829-a7553ebff089": {"doc_hash": "9128e365d741dcbee668add56e4747e927db39ff2a190a58420e0c1fe92be427", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "dc103864-a474-4884-9bdf-1aa3d9c4bb3b": {"doc_hash": "b51aa8f0ee5d4a73cfdd9737340d26cd56fd1348ebf7d1eb0436544250146433", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "35ea8e6b-ad3f-4533-bc66-7b9143e64b90": {"doc_hash": "290f3f2b0c7e8dcddfedd9056f7963dc18d51b6d7d41db1df6c9151f44600544", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "e174487c-e0a5-4e14-bf9d-c22b0239c532": {"doc_hash": "a077f4f25d7c4d03d219665991cfdb841dd55cdb28743a5b837e00d45fe0313a", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "2ece0d10-f0d8-4bdc-aff1-829c72b796be": {"doc_hash": "8d7d7a97745af104905992a2e88849a145e45c83743317764dcd926474f82653", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "49abd47c-2ce9-4549-9ee6-7b116b995b93": {"doc_hash": "429f6dfbc6f1160505c70f08f2f4ceaf2f1509cce8fe4c32b847c275e2aa90b3", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "d88b006c-547b-4992-bee7-98df032d55bf": {"doc_hash": "12df810e8d2d48fbe4ea197bf2ac7ed929cc293d4946cf9b02271eb978f6a5d8", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "3a68ab75-e2e8-4c54-a432-0648c8d5446e": {"doc_hash": "bb213cc9219dcc7f798943b13cabf73bef5428fc58f1b52f0698d5d23a29baa8", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "e80cb903-c6f5-478b-98b3-d44f0923cd2d": {"doc_hash": "d6e1ce187b9eb3bfae9334c5f2369f4d17a326f26f4567ea418446e2e3e7d967", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "4fab3547-420b-426d-9e15-04af3bd2d367": {"doc_hash": "0fd08cc76b985ee17f163843ebbb2cd666710d2b1c2fb50504a67c71cf79ef6f", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "1e1a2d75-8fc9-45b1-bcc5-03a52be810d7": {"doc_hash": "c24877e38c9c9608778036bc5aaed0b1e7af78fcbbaf03927a3c79f54f9117bb", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "878db290-d9c0-4043-a166-9c2c9257f3bf": {"doc_hash": "82a698ba38c2fc9c4d84ce40a506d059a7c461fdea6bba5209286ae84eecfdd9", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "2c296e71-91ea-4706-86fe-190c0897ed1c": {"doc_hash": "6e35fec08a1d8cea091a95aa06185b87cb72ff4d1298bd76962d866d9c711f80", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "8c6fd982-5a52-44d3-b22f-8747f03a9200": {"doc_hash": "4a37d5ef888fa7e58af76376711a7d87a6a1e4b35278767a442ce41d37f0eef1", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "d903d5f0-9ba5-4d30-a0c1-44820c205984": {"doc_hash": "6e804bd4590096424dfcd7ab1ffd745056efbf3b0a1f062c703c73e3b61413a4", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "af1a3711-3f70-4c72-903c-fa699feaf582": {"doc_hash": "53f5a09d0d5709dededeb77a2b957c3002a04df0d157af7323059666a9b60c75", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "7e7e2dab-afed-4e05-89e3-37233b541f8a": {"doc_hash": "fafc76a984b578e64416071fec2590b1ccfb4593de899d6b25d561b10019d278", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "3925d66a-af3a-459c-a919-bad5c3e7f326": {"doc_hash": "1ed2a77977b7c09591f4677e0291abb505e319e3706961621ac96633495085f1", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "f090eb67-5903-4df3-979b-865db115f43c": {"doc_hash": "5adab6abe1b4c9063a8a1f3a7e8c8f7c2d5e90332f753206d1aaebf519bc1f49", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "98824340-c5dc-41bf-a871-786431248c36": {"doc_hash": "ee31627d7063a330cda8ae98cb2ce6f752fe058f38bc63ed9e353f4774d0620a", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "c51e29e9-2384-4834-bd1d-907d6e9d5790": {"doc_hash": "334d6fc8f2ca441f4c9932106d0d8a64c41e4e1f31da7776702859fc9cfb5ab4", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "e1014dd5-9840-46fb-959a-c00d6bcac39b": {"doc_hash": "079fc44b56ba1f66b88f58df7690241a29b54c00c575d9d5631bff4e44accf14", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "abac5b5c-bf25-425c-ac83-0e6fd736bc03": {"doc_hash": "0dcd2814540e6c18e64d06f327acaa70ecbe9ce014ed2d6558a446070b4ef64e", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "9b07cc9f-7c66-491c-aa01-b231caff88ed": {"doc_hash": "7d850c7642340e078e6b4f231a78434b10328baed24b55bca288764bce0aea5b", "ref_doc_id": "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67"}, "d07e96e6-73f3-41c6-8293-cdc90de7cdc4": {"doc_hash": "549183f947e99193e1661fee905864923b1b9e79a322b50f6639a39cd8f6d0b3", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "7d759623-5427-4e9b-a43a-8f59e6ccc511": {"doc_hash": "174ff7ee8dbf3202bb554b9cea851c67274f9eb7123ea5e10977fe5c186b68da", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "1e69b78e-8f2f-421c-83be-0ad66e048ebb": {"doc_hash": "a1e57da3713fbc67d9b8fb983583ed53764173ce2bd8fa5bc91a80e0f2f361f7", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "7035c024-c966-4cd1-945a-c71693f464d0": {"doc_hash": "c7ce1ce00e525fa33fb8d2e7eeea2dadec7fbde8c025cb8319f7814aca686797", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "dd207bef-0dc4-4e8f-8c2b-abe77a3a92ab": {"doc_hash": "f5bd7f513149248d117ef3eedef0147d2aea3ac377d87b0bc6f3eb2d060dddce", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "e49baafe-0007-4630-a628-919ea7146855": {"doc_hash": "f52550ff16d075527e8f2d97142960637b8da862185731ad2c9be4c2a881f099", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "6d1c8a1a-8323-4d21-b331-2a0b473b2cbe": {"doc_hash": "87196f4e0e505ebe04aadedbfafd6a92ad1e150ea91e3e7e504e33215b0f8fe2", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "55ec75bc-b632-4cfd-a6d8-92982f815aee": {"doc_hash": "d934350feee33dad5d32484f2b4bebe9df9930a6981226898afd390394da9946", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "7881a53e-6317-4318-8012-c29140dfb3ca": {"doc_hash": "ade8cc8850a8abd0b815cb9a74f8700f28dbfb517ba2516c5af043a2526faad7", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "817f10b8-aa45-41f5-b931-65be23ca7182": {"doc_hash": "8258af7c7371c382df89c5b3d08b22e7f534a3394e3dc3c3aa649908c4d87d55", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "bc0e3e10-c6e6-479b-9348-eeba3981ac39": {"doc_hash": "f0c6d9a90d18ff43c8a0bc5cc7836782724ea3998938f6c931c398d7beca9fd9", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "d687589c-b363-4993-92a6-e654691f2b09": {"doc_hash": "92f84f59bbb3284f4ebe4fb20eecf562e196a7cf9975344160e2cc6f3156a1c0", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "7ce6b6d2-11f8-4dc4-9651-58cfb11622ab": {"doc_hash": "4da64fdf9f14a4612ec1c849de5bb58a9ea43d14d9007b518eb8bc57ab8c30e5", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "0668c72a-0c2e-4c21-8f08-5f5284db3166": {"doc_hash": "e1aafc5f180ae788fed0848649f9ecc68b9c663da2715f6e148c18985528aa5c", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "e076b600-eba6-438b-ad98-6f3c6e2f907d": {"doc_hash": "c94392969e34565f0985f275b86681c877b7f24b8c7e2c5f25c522039f023af1", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "bcef4aa9-c7d0-4f0f-8dc7-97649c66aa5f": {"doc_hash": "644a4542b1c81ce755afe15a7ed723e4d0fb4f21fc29b83da900690cc92cac7a", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "70eb499d-de91-465f-968a-4ec5b8993a2d": {"doc_hash": "1be36190643ad0b1d616b99fae4d89589654667908365422249f4d7b395f428c", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "b6c455bd-ad96-4ccd-a3eb-66c0f52da9fe": {"doc_hash": "92875d1de0244d39c8e807ee5ed946909abfc52874023141cb904a00435dda55", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "da7cbef0-e495-4732-8566-127eb6031fa3": {"doc_hash": "0062b2dbd4d36e90cf38fe0c8baf9ddb3efc33c74a85cd312d4678e4ca48a57d", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "dbbbf0b1-b409-451d-887c-b82077213b60": {"doc_hash": "664c795028125432d0cb25522ade689016f4983329fad376d7b8c88bffa5a7b4", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "412f5a82-c0b0-4385-b1e9-105cff2478b7": {"doc_hash": "2dc474fb81416c0ecbe4da3d286755344656190c4d8a8a6d6aa6f9499ca2e511", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "458f65cc-f29b-4122-80f3-7945e3fa2677": {"doc_hash": "e3560310b8b59f71fcfa593616763da6c74a939c958656f10d734c6bc1cf28b7", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "381c6c28-3992-4096-8cab-c6dc96ac70df": {"doc_hash": "61091665b71ff6886b703bf032d6fb798a95e5b286343c90b390b237099ccacf", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "89e14d5a-da07-4024-b35b-abd44543e9de": {"doc_hash": "830792dc8df8742590b228d18ac137f4b364f5dda8d191b6467a4169566f4167", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "936a2467-0b8d-4272-8697-940e1c1e052b": {"doc_hash": "dd95c8721c3112cba60ed3935d121d2e8d95f56a985378a901880c6ca2d5ccc8", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "03ce3a2a-c056-4428-a01e-6bed0a9c9804": {"doc_hash": "12daaaf88a11227b72fd46d3e761c910094137ef07ae3eb6343d098f73fc74a3", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "5e489d9d-8328-4c4f-b35f-bfe9d217af96": {"doc_hash": "bde1818a67545164576b9bd5f145b8ca7577e4604e051478f8c18e4e38adacb9", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "3ee45df8-2fc9-45fb-b197-94a7c2f0df8e": {"doc_hash": "17628822d3dcd7ff6c289066d9e00c3dca64850aaab0d4442a0f284e40197f58", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "df38657f-e5fb-41a9-915c-db907065292f": {"doc_hash": "c6f04d1f5f5c9328841a1f021dbb50e90f9d6f35ce2887d4e20ba57a6586ef37", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "53e08043-fbb3-4e58-8531-1ae8fa27c209": {"doc_hash": "c41599b4ea33c2e95995abb1062fe7f3212eb49f05386664ca47ac163d351307", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "87562aea-b07f-4b80-be1b-bf63dc0929c6": {"doc_hash": "a169332ceed10735bf7c7d22c88539eb1ccee1243ed9cad9934fa356dd4799ff", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "377068da-4f45-4fcd-b127-212eedab42eb": {"doc_hash": "9d9b0a673c1038d2b8b1c41050bc071346cddf29a1a30f81cd9ef0d32e00b49e", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "dac9a7fd-35b0-4934-9153-b3724abe642a": {"doc_hash": "0a03d22a2630729a8a1ea579175858ef35d6464c3fa983c98cfd64479b279e23", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "50f23761-b43f-4469-ac31-a78bd79eb1fb": {"doc_hash": "03be2c2409a32108066e54c7cef817b69b2667df191336b75a781ae31eb6d710", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "33b24c1e-919f-4217-bf68-80939107e8f8": {"doc_hash": "1d0cc05670c4249c12fb0585ba0b3b57773a48a3a47f386c8282d08db67c406b", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "d4f788ee-0e3e-4087-b7b1-98c9eb01b76f": {"doc_hash": "8e890d43edc26f54c8030576fbb9fe4c521d61f3067d3981477fbdcf63594b5d", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "f4c27623-ede8-4dd4-aa0b-34e47f716fa4": {"doc_hash": "7c3c27beb725a960d44f83b0330b876b228ab4b8de551776c3a34b2c716668a5", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "d0660d59-10fe-4a3f-808b-d71b044f06e7": {"doc_hash": "5badba1e143f35d1e41340b5264a62d8dbf779a1171ef0195dbd37257f117a54", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "dd1e5588-ad1e-444b-9e28-67cefeffe05c": {"doc_hash": "cbb3408bff74e837f8cae612b18bf85b6921b089e4c8da2da401dff90b124945", "ref_doc_id": "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1"}, "dec30737-8d0d-4f18-a691-e2306a3a627f": {"doc_hash": "102892462f62de66c23d117aa51d39aba5e5cd734b12e3388ce28bc4a4f9ef45", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "698fd18d-e6ca-43df-8a17-bd9e8fbcb2bb": {"doc_hash": "3ca93e57dfb87fc488758c23537851d68e560ad09cb4ececd450333882f84938", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "c0aa4366-cb77-47c2-9025-eff96edbe85e": {"doc_hash": "cdc7246d8cb079b422e84e526f670b36eb8e628b93fd1fa3dec7f5b186916863", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "6300fd1e-fa1c-4087-8afa-2aaf255a515f": {"doc_hash": "ae457c1c4e2acacb0156abce6e350abea6b3ac2dfc43c7fd7cf4d92a7531becd", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "2198856d-05a1-4553-8764-ab47fe7e5613": {"doc_hash": "ae354f549989e9b5a01ec464e44c4a8e7f2506347a2e9ac07bdbbf771e1574be", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "580c8b78-4ed0-4966-8652-e383a6e0454c": {"doc_hash": "643a2b4273dd20e0707771ce951b2cd543b60b285668c345d36d76611f2c7cc1", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "bffc3de2-7435-42d6-aa2f-6e0efdec0540": {"doc_hash": "8ebf41cafb87ad8462754335f72bc234e09a2e953326681067ad03cbfbe340c1", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "21de8db9-90d6-49f1-babb-1343538eec73": {"doc_hash": "eedec1266364ddd3cd1f193343869bbad1c9fc2283b2eea66777b1d86e36e3e2", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "3c3c70b6-f328-48c5-a12e-5c6024dfd70e": {"doc_hash": "ca02018487e19ca396f430f97b3edb8c2cf9f82f4397d399782a39d5d949bb4e", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "5a485dfc-6682-4afc-8b2b-cf089cac0ab8": {"doc_hash": "564591b690a77694b39043ba8bbfc5b579ef7f1b9b442fa839260f8221fb4f11", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "7ae8d378-4070-45c1-8e1f-5c09cfd2ce26": {"doc_hash": "8d2ce14026be1ebb2f3e9626126b415b69e2c04067d9626bb015942c80933447", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "f9f4c34c-7882-4a8a-88c7-70e31ea195d0": {"doc_hash": "bda61f5650dc070b24f4adb2fda313d7352def345dc78385a5a2b5817d7cd52c", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "4f61d384-d4e7-4485-ab3e-b69d09bb2737": {"doc_hash": "646d7c43be0a4613d6e8a7d5e13c8c74fc25ec28974399d4de91d1d47db58615", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "4697386b-b340-43ad-92a6-3d7f64c681bb": {"doc_hash": "1a3c23429b187e9882f9fbc2de112eaa0349467bbec25ade1123f6642767d9bc", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "26f52930-103d-46a4-9f6b-54d012f7225f": {"doc_hash": "08819cfb66149e2a8195b498f72173171c307f9cb62c2801dd94769c13fe515b", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "6a2bcde0-a782-4f8f-b43a-7dcdf0b9c121": {"doc_hash": "e770ac3f47c6b5eaafccfe3c096a5e93dbf3039f2da570cbf1890e8416fdee25", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "5a098961-208e-4b11-ad0e-a2fe535e69c8": {"doc_hash": "ff6e3a077ebd2f789aa36111378bb6b09327f43b6357f79dc511e20107985196", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "7a324e5b-aeb7-4b22-9782-3774dd59453f": {"doc_hash": "7cf950b23420c0c27a3c554478e7813fb04f798b25e623c238628aa9230ca2dd", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "1465bbd2-1e43-4cfc-8bc2-02ce8ad6e8d5": {"doc_hash": "45de136588a5e6bbeb399fd0de07b3b0aa3cc532f59cbab9fcf8e33a356619ad", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "dbeeb12b-d218-4a2f-94c0-88ac8e69ba08": {"doc_hash": "3555faed7fe42540734d0b4fbbe8d63d779e056129ab18339eec6e25feadddc4", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "766755b9-b799-4ccc-a640-06e684aba9e6": {"doc_hash": "2c487c4c320a846afa8320a872b767cb3f2866a522d2ec02f6a1bdf49821229e", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "54bb171f-a584-48ce-bee9-25ab5a352be2": {"doc_hash": "9c7871f6877512bcaa332558867782a4a89e5621284cce3d80df45cccf77c88c", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "07f56dd0-da21-45f3-ad97-9c260bdba631": {"doc_hash": "7614d5be6516e3fdcedd2a15a38a5bb25e10a82cb0335547dd08e3fa34177ddc", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "625099d9-164c-4ed7-bb1a-5214660f5eca": {"doc_hash": "ab4789536c52434735c4bacd7fe73e8511563e6488a06b8cb98b7fb5eecaa52d", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "9bad1ec1-8b0f-43e6-ae23-c61c9f6780f6": {"doc_hash": "60bca08bdc9422188992bedbf959345eb527ce20e4b4b268329d858fa4e56ec4", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "fa00deb2-10ed-405a-b14e-d60f8fab5560": {"doc_hash": "d46d8628e5d381df4ab9fdf67ca147159c9218c27977983e3a8ccb83cae2f34c", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "a16b452a-ee00-4871-b978-7010d8b96129": {"doc_hash": "f6bca54ba9b17a938fd899b8d7b9aa13ed08e820bdc10d3c6bbf0852e392e411", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "fb15a653-0fc1-494d-8bd3-aa1c6424b664": {"doc_hash": "3890ff8eef694b5043cc97dce5938ac92623fe68cffb071b88871a6b9d5ce292", "ref_doc_id": "919db9c5-1077-4aa3-aaf5-7d111774b8be"}, "aa1a75ab-cd5f-4946-842f-f5ccb7771507": {"doc_hash": "a711240c0587cdd6f1ce808a307819eede73cf698797ee57854fc75222d9a213", "ref_doc_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7"}, "73196145-d83b-41da-a3ae-7b2095e8aa41": {"doc_hash": "f997e611ac3b4af04f9209764157c0dfc1adf2b7ce5c0976e073248b2d4fa9d4", "ref_doc_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7"}, "4b9f1ca9-95ce-4e2f-85c9-a47410c6f936": {"doc_hash": "51d46023585bae9b9093176b50c4fe3272e05eeca6d87c3242a006bd0dc4dd15", "ref_doc_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7"}, "fd21c577-1456-47a1-83e0-c9aacfc6e296": {"doc_hash": "816ed030f85d915737a166aad1d5d21f468bc55c21fd98f699432a74cf5c293b", "ref_doc_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7"}, "63e9c30e-52a6-45d0-a37a-915c0ab4af84": {"doc_hash": "2068c60f51179e0585cbb8db8453787736a26191a17539325e878df7d964a062", "ref_doc_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7"}, "cfecd884-cb70-41ad-b28d-ad535139e5b2": {"doc_hash": "4415e7bb234fb8c3ebb1e1a23b6d3ef0d5a120785a01fe2ed8c8ce09bdb0d149", "ref_doc_id": "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7"}}, "docstore/ref_doc_info": {"73e88ae9-dcc6-42f0-8a74-2da4c68ddfb4": {"node_ids": ["f8be2f47-1816-414e-ac75-f27d3d25d1d1", "3c057e0c-565a-40a8-b28b-c265be499c15", "6d56136e-972c-4797-975a-d7d13926d78f", "1b714e93-c618-4c48-b41e-9d1f90bdd661", "dcf02825-daab-41d5-9467-a086b729efcf", "18dc4bd9-473b-4549-9890-ff2ad3357164", "fec8e4ab-6ec3-4bbd-b1d6-9f7e2007e6ea", "bea57437-c45c-4873-af12-7b66f6a49ac8", "f8acd3d2-d179-48e6-9143-503f3ab1f628", "9917a0ac-b6fa-4d50-9f11-46e87be9e29c", "08f868bb-9703-4559-abc8-ed6d99d0280f", "8057e9b8-c2a9-4bdc-88a5-c71ec088357c", "004a8dcd-4ea3-4861-a921-fffbd5c0a6e7", "4e63949f-837a-44d7-95b7-9c008cceb30f", "0256b854-944a-4fe0-8080-30c74772e76c", "aa2dec6c-71a5-44d1-9819-e397a3af78b2", "a4df9469-c32f-4f7f-aa5f-58dc19346080", "6a15e290-f4fa-403d-9d6e-3460379ba45b", "027aedf3-8639-4ecb-b371-81c1f38342cd", "3892cc2e-2f79-4e4b-aba6-baac9be08de9", "767fdeec-9add-479b-9915-8cfd1792d121", "72843e07-db0d-452a-b172-fb81373ffcd2", "4719906b-7f3b-4c67-9319-dd44980388b8", "59cc4763-388f-470e-b970-19fc32c4bfa6", "8140f80e-c907-4bc7-8858-087e03997f7e", "269f6b2f-2d00-40c7-8eae-39e68962d863"], "metadata": {"window": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 9 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.   First Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded. ", "original_text": " \nPage 1 of 15 \n \nQ1 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "27bfb634-9113-41d0-a325-ee5b790158c9": {"node_ids": ["13649259-bad8-449e-a70d-16fcfbb5c752", "1c675f69-b3a7-400d-89c8-ec08747a4bf1", "1de9a6ce-0625-4ef9-bade-74134b68eb5d", "702a60a0-9a60-4006-a401-a9c74140ce9d", "09c50bd0-33c1-42a9-b110-4e6affa1cc0b", "1436fd30-a053-4b60-819f-134c3a61aa1d", "58d6d352-9e20-4770-8c55-025b734ffe4a", "5479f15b-470e-46d6-a189-2bae5bb97756", "bf308104-e1dd-4fba-8e83-998db2eb783c", "f7efd170-c39a-4f2d-bc4e-7aff97318a0e", "10f67a20-6d5e-44cf-b015-f85b4612d98f", "c9bb9024-0ba9-432d-a2ea-a5c55ce6ea33", "298e8675-67d0-4c8c-bbb9-b1a0e5d44b9a", "d19a3d0f-a70e-4a51-b509-c3a74d42b33c", "22b0dd39-84a4-4e22-8611-5e22f6b8ef8c", "957f0333-3f8f-4272-9512-ceb958c3d2e0", "ac6817cb-d000-4356-9663-c9daf4ec94b0", "d6f90ac5-509b-46b8-af0c-79ab171c396a", "b5212602-c134-4e74-99e9-ad61f5ce6a13", "0dbcf863-98e2-489a-84f9-f00745210599", "ddea68d1-430f-4189-95be-d57c12b6c79a", "f69b74ce-aa1a-4015-95c7-8769c1ad6c62"], "metadata": {"window": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday.  We are prioritizing investment in our strategic growth areas and in innovative solutions to meet \nour customers'  needs , today and tomorrow.   And with our improved balance sheet, commitment to our \ndividend , and now an additional $3 billion share repurchase authorization, we're  positioned to return \ncapital to shareholders.  Looking ahead, we remain confident in our strategy.  \n \n", "original_text": " \nPage 2 of 15 \n \nWe have been on a journey to simplify our portfolio and strengthen our core businesses so we are \npositioned for broad -based , sustainable growth,  as noted in  the long -term targets we're  announcing \ntoday. ", "page_label": "2", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "72a30e96-83fc-428c-b761-b15b1cddf892": {"node_ids": ["81ea7d56-20b8-4311-a134-59ab96dd5188", "41f00ef7-18ae-4b0a-ac7b-6c91669a5106", "c31bd46a-795e-449a-a013-d5b5a611bb74", "bd9ba67f-19e1-440a-a380-2e0e192af402", "a26959c7-62d6-4460-8fe5-1fe19b2278c0", "3045797a-7ab3-42c8-b926-cc389a00aa65", "13611a5b-da69-4eb2-bead-6794badb6c0a", "84a9366d-81ba-455e-a5ef-2f105506251e", "4a44daa4-1bbc-4b9f-aa70-23a633d14389", "0593d4e1-8f2f-465b-8afe-34dbdcb3002c", "b4500e4d-d33b-4db6-b73b-7d9293ae8342", "2b838084-5ac3-45a9-88f6-3cb495bfc4a3", "79789807-265b-4daf-b97d-cce98bed4437", "a73e1908-bb6e-4d64-8cdb-d97866c4e876", "7a92315d-a906-43a1-b499-c97a491d7609", "4303e111-f371-4573-83fc-ae525466ad7f", "a063a29b-71b2-4b0a-af93-f09c7f607f5d", "4286fe1f-6362-437e-91b8-3810b1dbd95d", "9bb8a1ae-00d3-4ec2-b486-23e2298effe7", "8ee3a7a6-ebe1-4123-9603-797583466df2"], "metadata": {"window": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit grew 1% to $406 million, which reflects an improvement in volumes compared to the \nprior year quarte r, which was adversely impacted by COVID -19.  This was largely offset by \ninvestments in information technology enhancements.  \n \n As a reminder, last quarter we began deploying new technology platforms across our Pharmaceutical \nDistribution business as a part o f a multi -year journey to enhance our IT infrastructure. ", "original_text": " \nPage 3 of 15 \n \nRevenue increased  13% to $40 billion, driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution and Specialty customers.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0ac2170e-3a4e-448d-b690-3779d62717e3": {"node_ids": ["a5bd8d41-4b90-40c0-b482-9c3c314dc1bd", "340747b2-4172-4ca5-95b7-ba208bc1591e", "bb78c482-5705-4608-a902-e0617c249182", "a3e5f663-5b59-4c35-9675-c0c4904a821b", "f8944b13-c93e-476b-802a-0e53fa2b1458", "d9b5fcc1-4257-4ceb-9ac7-68a460821e4f", "ea5a02c1-1565-4d68-84fc-3707d436dfa2", "bd1dbb2f-1fb7-4282-a100-6e8cea710d3a", "74cafe3f-d98f-4b4a-9b44-162c910f4503", "c50c3abc-ba87-4ce1-8ebc-0e2c408906b1", "78803784-4cad-4b9a-9c6d-6b8c03b8dc7a", "a874db74-d558-4a5e-befe-1d64fd2cbc4d", "dd2cab71-d2ea-4708-b044-33c36df4fc99", "d01e86d1-b298-4667-aac8-0b33bd88f8a6", "255d8878-820e-43dc-8df7-e877665b313d", "351369cf-c669-4500-9fdb-d71d5c5cdac5", "9a1d84a5-2c5a-4c43-8fae-823ec62a7ab0", "66b08f8a-19dc-4599-9363-c1da604c795e", "55f9e462-1005-4a70-8b8d-a8cd887f39da"], "metadata": {"window": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n We are reiterating our EPS guidance range of $5.60 to $5.90 per share.   \n \n This reflects updated expectations for the Medical segment , as well as lower ranges for our tax rate \nand share count.  We now expect our annual effective tax rate in the rang e of 23 % to 25%. ", "original_text": " \nPage 4 of 15 \n \nNext, on slide 8, a few updates to our fiscal '22 outlook.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7d8e6b24-d522-40a9-8411-7a6cd0e70190": {"node_ids": ["8cc2c8b7-b599-454a-92e0-b8667c83d6a2", "a9f2d87c-52f6-40d3-a982-1c64623d53b6", "a480df9c-cc8c-4f46-8331-e0c2f589c70b", "ab4ca7da-c1b9-4f16-a44e-e5c734860335", "e012d16f-4e6a-4f98-8e77-75174126e5dd", "ee1eeeb2-fd07-442b-83c7-4c3b93bcc6a8", "b684b163-579b-42e7-99df-2d645ce0d9a7", "8053db17-c266-47e2-8560-6f4389966deb", "d1c5ae66-8f30-4fe8-9741-dca1de98a62e", "7c814e47-5143-4e0f-b553-8437b1791db2", "6c3877a4-1554-4b89-98c4-9c8f4664c538", "2ebab35b-5b9f-4fbf-94aa-a190084665c1", "740a3194-bfec-4786-99f6-86eab90207de", "b11e6fc9-012b-43a4-8bc2-bff4125b33a4", "16f85ef1-2037-4416-9f31-c0dfd7da636d", "5f9cb17e-2a18-4583-835e-44a6c39fb36f", "7f432a4d-33f1-469d-91cc-f4b054f4fb9a", "694bbdc0-e424-4ecf-ae9e-162568a42059", "6df3bc89-0f8c-4041-9cde-12eefdd7c826", "3f22d055-e32e-4101-a09b-3ffa9719997f", "501635b6-7af0-43f5-b0f4-31f543ec217e", "bf625c55-8ebe-493b-88f7-3eb39cee431d"], "metadata": {"window": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason.  Throughout the pandemic we have responded to challenges with \nresilience and agility, approaching every situation with a focus of delivering for our customers , so they \ncan care for their p atients.  We are continually reviewing our business and seeking areas to improve \nas we navigate the dynamic macroeconomic environment.  \n \n We're  taking action to mitigate elevated costs and manage through temporary supply chain \ndisruptions in Medical. ", "original_text": " \nPage 5 of 15 \n \nMike Kaufmann:   Thanks, Jason. ", "page_label": "5", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f8fabbd3-2905-4e3a-94ee-316d3497adce": {"node_ids": ["08064886-17bd-4ae6-86d2-925ba7cae5ff", "499e4c14-c429-4cc7-b8d1-90628aed4aed", "95471064-3936-48d1-9e8c-94723ad765db", "d7ad6534-6cea-4631-8e64-3f3235999be4", "6e9056c9-248a-4508-b48e-5f5fa8882eb2", "5160b103-8fd6-4da9-96f9-6fc21f96efd9", "8d43cd42-2989-434c-bb6c-8a94f89a000a", "f60f2f42-cbf5-4c74-994b-4917add9dc2d", "cc818b24-f455-4b6c-b93c-265722789ffd", "e44ef599-e3ae-47e7-af91-c5e835a105a5", "b53e241e-77d1-4087-9852-54241f91287b", "0e76d7a1-956a-401c-b8cf-38ac4d8e3bad", "b42441e6-508b-4066-adfb-7577247ec2a2", "4a651dd4-7d71-4232-89a7-e86f54f2a6ba", "71160d8c-e606-42f9-a4f3-69e8c8b1c3f6", "311a3b80-ab37-4776-9351-54b1e66f9a1f", "bf6664df-de70-409e-87ea-90f552c132ea", "8d571119-97c2-450a-bea3-ce9222f847ce", "88064374-bb66-4f1e-844d-bcbd1828a2c6", "5a318eb6-36a3-4a0a-9567-54d1dd885904", "d4895ead-c3f8-4ed4-bd03-415c0b823c38"], "metadata": {"window": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home.  We are investing in new technologies to drive operational \nefficiencies and enhanced  data visibility.  \n \n Moving to Pharma .  We have 2 primary objectives to achieve our long -term guidance of low -to-mid-\nsingle  digit segment growth: continuing to strengthen our core Pharma Distribution business , and \nfueling our growth businesses : Specialty, Nuclear , and Outcomes.  \n \n", "original_text": " \nPage 6 of 15 \n \nAnd in at -Home Solutions, which is now a $2.2 billion business, we continue to see volume growth as \ncare is rapidly shifting to the home. ", "page_label": "6", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9f0d8936-98ed-4c2e-907b-d810ba967b41": {"node_ids": ["22274283-5acd-4d92-8322-5385a7302db3", "1af5a485-4139-4f3d-8143-675bb9fecf83", "7ec754da-e027-4986-ae22-0603ddef5de0", "131cda9b-0cc7-42f8-9832-a1f54c9ba956", "81cc33b6-6b6a-48a2-82f5-27e8bc977706", "f6cea530-0022-4849-a1a5-1463ca50ca4d", "6bdf0b2d-251d-4eab-8794-e1342cbb967f", "ef1bea6b-0eae-456f-8160-8cad49ef49e2", "fd05a63e-b5e7-4fb9-bb5e-92037b4e1cb7", "b2ca38fe-0bdb-4f15-9456-ffb1f6113f74", "496d52bf-863d-4b63-9e88-f8e40be32ed9", "56f78a6a-dfab-4451-a447-6fe93f69abd8", "a6de4c3a-a6ad-4465-9bc2-43b09c9c289f", "fc6bfb71-08d5-469a-aa59-ae8d0c13d361", "bd9e06ad-8466-4390-9344-5f07d5467096", "42e8a3d7-ce9a-41c1-888d-f49581beb2ec", "5e5adb93-f5a3-48f4-ba90-0d815dda40be", "1d1c5b50-a521-49e6-9b1e-f33c5f150331", "1fb09fc5-7b78-46c9-b3bb-7f0da8c41a0f", "a97d9e60-67fe-44c1-b823-713ad491fc9c", "17a03335-ce0c-4019-9255-e730141164d5", "275913b6-8fc0-4fb7-955b-943645742df5", "9b463bbd-40f1-48f3-b9d6-f618c4312ae4", "ab361b74-a015-4269-81ca-94b93e0db030", "9d9ac62e-3396-4232-95db-f2b3822e0887"], "metadata": {"window": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.   We continue to build out our multimillion -dollar Center  for Theranostics \nAdvancement  in Indianapolis and are investing to expand our PET capabilities.  We\u2019re  partnering with \nseveral companies to grow the pipeline of novel theranostics.  \n \n For example, through our agreement with TerraPower, we will produce and distribute Actinium -225, a \nradio nuclide involved in creating targeted therapies for several cancer types.  \n \n", "original_text": " \nPage 7 of 15 \n \nIn Nuclear, we are expecting co ntinued double  digit profit growth , resulting in a doubling of our profits \nin this business by FY \u201926.  ", "page_label": "7", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "edbbd509-3f7c-4e90-bfd3-8261f5ff62c9": {"node_ids": ["0c26ed8b-f540-4491-9f5a-7a93d65f437f", "c9af985a-c095-4182-a657-7cb4376e0f08", "1dbe70e7-f3cb-429e-8f57-d8871651f4f4", "a8ad445f-e58d-450f-88a8-632dc924672b", "26c03fb6-47c6-44cb-a1fd-3e461126907c", "4d4d473a-72de-46f6-86ac-7e2035c5005b", "c78066fd-875d-496d-bd45-bd033d157b8a", "5d93670d-8f11-48f7-89da-3cdecb2e71b4", "543ca4e0-8fd2-484d-901b-e6e7bc4c4ad9", "4020eae1-f668-4012-af07-26973372b537", "1d7650f5-cb12-4935-8db3-5759d0232bde", "9dc4557e-966f-4076-ac17-75b4a3068b5f", "8b17af86-c972-4e29-a6c6-20741cdeb85f", "d86720fd-86e1-47e3-864d-0c468785be03", "49ce993a-1f01-4413-ba4f-b4ce2047430d", "aea051ea-9d43-48a4-ba00-2c586f46c36d", "5fc86186-1479-459f-b950-0176efa2e2fd", "96bcdc03-a91d-410f-841a-1139ea35d397", "83ac524e-2962-492a-8181-18fd09325223", "50871397-4c29-4151-a2bf-01986e4bb0a0", "e7998afb-2b1e-4625-a2c5-765308cc75e3", "9e72fdb1-e486-443a-8d3c-717def42dd3e", "7085d3c9-79df-43ee-8fe8-1bfd001f9796", "99215f82-70ac-450e-a6da-7977d3c65c4e", "7001605f-fc0d-4ff4-8897-3dbdbfaf134e", "c9d61bee-d129-4a7f-bbe9-7f7c77602c02", "c5a0886c-8cef-438c-8051-34e87e63a70c", "e8dc2f95-fb54-4c7f-9cca-fbd426ec8ead", "213980cf-3827-4ca3-a492-1318fc26fb15", "a2c41cae-d574-479a-80ae-96644f4201cd", "570a0a0e-6924-44f0-866f-a6cf2917159c", "2cab207c-e86d-4bbd-bc17-d95e033fa111", "e1dc5dc3-da43-4f73-8f12-044bb62d00a7", "9c4cf3a0-1dde-490c-85dd-8105a5c76b66", "13e01cbf-00da-4a49-9b2e-bacefbcb330c"], "metadata": {"window": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.   Once again, everyone, to a sk a question, \npress \u201cstar,\u201d \u201c1\u201d on your telephone keypad.  We\u2019ll pause for a moment to assemble the queue.  \n \n And our first question will come from Lisa Gill with J.P. ", "original_text": " \nPage 8 of 15 \n \nturned off to allow your signal to reach our equipment.  ", "page_label": "8", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9e39e9cf-e65d-4182-8f62-ba747bd24f55": {"node_ids": ["ad4afe8b-fc81-4908-a259-54e898eff11c", "d5e4f0e9-d886-44af-b274-cab2f09f6b4a", "f988bcb0-d57c-4b3f-ab4d-f1fac4a8150c", "5a0c31ea-1608-4066-b33d-e6e290f0b14a", "9f3b4804-c08e-4caf-807d-d89fa65ac418", "2dcdf35b-8bd2-4d8a-953f-fc6a24f5ba35", "c4dc018a-4a52-44cc-90e4-7f3358b13224", "716c16c0-4f76-4b99-b4b5-2a9288fa738a", "bc8a51d1-77ce-47d8-bc1e-c96e094a8408", "95215568-0d20-4eab-8183-9cedaebe6ea0", "d39fde06-a319-41df-a697-e96f466ebf40", "e12a19b4-b628-4c76-80e6-2aa8c7d7b318", "0380933a-c072-4497-b842-3c69aa2904ec", "7be62860-c765-4554-90b8-80a9ffdc325b", "9379087b-37b1-4c2a-a605-7af6cb38e11c", "8fc86513-8e91-47c3-8089-637ae98202b7", "c578a7e8-f1bc-49e4-b45b-e37dea63f901", "7279f662-6d2c-400f-be00-00dc6f6b8656", "62949e60-24e6-4a7a-bb03-3edb34c3634c", "98dff14b-4c0a-4971-a6ba-252f832d7663", "3593808a-bf41-46db-bb7f-7aa50c3164f1", "56f4bb68-0e16-44f8-a25b-b85d22919a3d", "01b2cd11-dcc2-4418-b961-c4d29dfeb4ef", "294a8623-fd69-4b87-a01d-e7da861126a5", "56ffdfbb-d918-42f7-b9b5-d29b02ddc6a4", "3056b351-137a-4cf8-adc5-e2787e26bf77", "24a9bc83-b6ea-4313-ab25-b6141dee1f11", "227b8164-6776-4c01-b43e-886ad9ae521c", "f1c3a140-36e4-4382-a37c-76902a961bec", "0d3691b3-27fd-4dc6-bcb6-c6fe13c11060", "51282aaf-3053-46fb-9906-828663f1884c", "ba6366bd-82a6-4a31-b85b-e5a885c34228", "a3d67f08-3a7c-491d-87bd-98d6f17fcb79"], "metadata": {"window": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets?  Thanks.  \n \n Jason Hollar:  Okay, hi .  Good morning.  ", "original_text": " \nPage 9 of 15 \n \ncosts, do you assume those go away after this year as we think about it in relation to the long -term \ntargets? ", "page_label": "9", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "70ecbaaa-669b-46fb-a85b-a8618284cc04": {"node_ids": ["4f1ea861-abeb-4fcf-a99c-d749605e20cf", "94e42d7d-7741-4d1a-adce-8cdd13b94986", "9084a20d-f4a7-4c33-9a90-579a4df55962", "fc0ae8f9-29a1-4a47-b6d4-953410a86d77", "16f04b7a-789c-4643-9a35-36f4eb0fe087", "605faf57-dd2c-432c-8208-cf703c4a5404", "0e405582-73c7-47d4-b0c9-754cfe3e7746", "43753e7f-2442-47e5-b4ab-22c545f141f8", "7cbb097b-da73-4f60-9a60-055f99d7d06b", "1cc84ce7-3b3b-423a-86fe-007ca4010b47", "ae2f9902-f2c0-4729-a882-927a9885f7e5", "98695a0a-47fb-44dc-86bd-f4abcf42301f", "afde9dcb-5727-4887-ba9c-b2a0670bb231", "3955dbe8-db0a-47e3-89cc-b076dd4a31cb", "7f6494e4-2fe1-416b-a11f-8b532515f4ca", "28597111-3490-4744-b228-6164919b9fd6", "5e9cf254-0a6c-4918-b4b6-096b768c98e7", "a95f3b1f-b8a0-480d-b433-1061db96dd51", "5f1a83ba-4695-4139-8f2a-28402c61e49f", "c5abca40-5d9a-4c3d-a32a-7a234d90d64b", "d5bb1c0d-c729-4dfe-b6dc-83dafcc884d4", "6b709a58-7979-48f6-8143-41ba5716a601", "2d425a5c-f80f-4152-a441-69b51f06121b", "fa2c6242-a394-4f10-a467-d62e761e34e1", "fda1fab6-b2b0-4ea4-bea5-920b167dfa04", "530c5d5e-146b-4586-b53a-4c0cc1855a40", "9c9fa03b-5c3e-48ae-946a-cdfc71ce8905", "bc7c5d09-ff17-4b60-b0cc-aef9e1c00818", "bee39490-2ee1-46cc-8d12-2252808ab394", "e6ae0dda-7b39-4ece-9980-f74114eeba6a", "75f7e881-c842-4bd0-b1fb-b55687f45aac", "a4f8e8b3-7394-434b-bb61-87821bc5f49d"], "metadata": {"window": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year.  Next question.  \n \n Operator:  The  next question will come from Eric Percher with Nephron Research.  \n \n Eric Percher:  Thank you. ", "original_text": " \nPage 10 of 15 \n \ncontributions from our growth businesses as we see the effects of various initiatives and investments \nthat have been put in place over the course of last year. ", "page_label": "10", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3ffbdff9-3a18-4911-a4dd-9dd07b96f0f7": {"node_ids": ["2c058aaa-0508-4862-b229-e2352d0309c2", "1fd54ac1-458d-4e89-b21e-6b6167dd1e33", "450b1fc0-1aa8-44b8-94ac-ca7dc4a63545", "0458fcbd-9f08-4fca-8ce6-634a14eb3cb3", "bc28e6aa-0574-46c1-b841-e5c4a3512c9f", "5ec3e019-e43d-46e1-bc2f-15c7ce5354c7", "94435c02-42d6-4c36-9e99-5b8173a78567", "32f6cf84-fb38-46bb-895e-20ea5d3a9d55", "ab2cc8e7-86ae-411b-b762-0865567961c9", "06515981-4f39-4435-92ef-6f6fb0591d58", "89242551-9aa4-4863-80dc-bf6762ee53e7", "f602f917-b12c-4cde-a94c-d0cab57b9ba7", "72fb3114-13a3-4b56-b8e2-726071e6dd14", "ed7c3e4e-8d3c-4c3b-bddc-474f911b9c7c", "f49bb022-5e8c-4737-9aba-b4f4cd2a2cf6", "36f14e96-8562-4c6e-90db-a482131832ff", "6f687cd8-e3b7-4238-b9ce-b17793a81630", "86c57975-019d-4d61-9b8f-d0177a659cbc", "9ce5980d-f03f-4a60-b868-bb1f641ec756", "64a132ed-cc12-493f-9f48-6db628da9cb2", "7ff195d2-62c2-4258-89a5-5c7742c00888", "8e3db2ae-dae8-4d17-8cfe-d3998f814b5c", "33b04eb6-d3a8-404f-b6f2-231c8b10a1c7", "b384a697-0d52-4c59-b70f-2bd4986b6b0c", "45d5d2db-29fa-4ec5-95ff-1be6d9e01978", "9be27e8d-d98a-4246-a8a4-b5d887b2009d", "51e2d3e6-f708-4992-8175-f91a3be9c63b", "04b6ea6a-b237-4fee-839a-8e81a583db9d", "b211bf13-cdca-4a43-a669-3b6e30cec7e2", "171281ce-85c8-4016-ab98-e0f53cf86e27", "76c55d98-800c-4d13-813f-c89a95147db3", "5be0684f-738b-4b38-a5ed-ac78d8da85ee", "a7ac0e86-c81d-48e9-a467-553511426f17"], "metadata": {"window": " \nPage 11 of 15 \n \nexpected duration.  We had anticipated that they would come back to more normalized levels a bit \nearlier,  so we saw a higher spike and a longer duration.  \n \n And in terms of just how you model it through on revenue, I'd like to just draw a little bit of distinction. \n With PPE, we saw many, many times higher total impact on that product cost. ", "original_text": " \nPage 11 of 15 \n \nexpected duration. ", "page_label": "11", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9ed6f12b-d4e1-4c44-b102-ecedbc27fa67": {"node_ids": ["80b3bdfa-5925-43ec-94dd-6b08c128cc92", "dc2205f9-6d2a-4668-bc77-5dd834c9bf8f", "660085e4-251c-4c20-8c98-cb66b56acc87", "b9cbdabd-b7bc-4c82-adb1-dbb63a3ec278", "a571d0d1-0afd-428d-bd02-3a4211777e7a", "bb45c661-ae1c-4b9d-9ff3-dbbd81e56357", "99404296-f973-4ced-b138-cc86ccb0cc84", "12fbf7d0-96f9-430e-9373-aebf19d0ce9a", "0335857e-4cc7-4337-9829-a7553ebff089", "dc103864-a474-4884-9bdf-1aa3d9c4bb3b", "35ea8e6b-ad3f-4533-bc66-7b9143e64b90", "e174487c-e0a5-4e14-bf9d-c22b0239c532", "2ece0d10-f0d8-4bdc-aff1-829c72b796be", "49abd47c-2ce9-4549-9ee6-7b116b995b93", "d88b006c-547b-4992-bee7-98df032d55bf", "3a68ab75-e2e8-4c54-a432-0648c8d5446e", "e80cb903-c6f5-478b-98b3-d44f0923cd2d", "4fab3547-420b-426d-9e15-04af3bd2d367", "1e1a2d75-8fc9-45b1-bcc5-03a52be810d7", "878db290-d9c0-4043-a166-9c2c9257f3bf", "2c296e71-91ea-4706-86fe-190c0897ed1c", "8c6fd982-5a52-44d3-b22f-8747f03a9200", "d903d5f0-9ba5-4d30-a0c1-44820c205984", "af1a3711-3f70-4c72-903c-fa699feaf582", "7e7e2dab-afed-4e05-89e3-37233b541f8a", "3925d66a-af3a-459c-a919-bad5c3e7f326", "f090eb67-5903-4df3-979b-865db115f43c", "98824340-c5dc-41bf-a871-786431248c36", "c51e29e9-2384-4834-bd1d-907d6e9d5790", "e1014dd5-9840-46fb-959a-c00d6bcac39b", "abac5b5c-bf25-425c-ac83-0e6fd736bc03", "9b07cc9f-7c66-491c-aa01-b231caff88ed"], "metadata": {"window": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model.  And \nso our goal of low single -digit to mid -single -digit growth in Pharma is really focused on strengthening \nthat core PD balance.  Getting that right mix of generics, making sure we're managing the balancing \nthrough our margin initiative and all th at as well as then driving our growth businesses, especially \nNuclear and Outcomes, and we gave some color on those that hopefully you found helpful and \nexciting.  For instance, Nuclear doubling in the next 5 years, Specialty continuing, and Outcomes \ncontinu ing with double -digit growth. ", "original_text": " \nPage 12 of 15 \n \nIn Pharma, the \u2013 to your point, we don't really see those fluctuations in commodities and costs \naffecting that business generally because if it does, it generally happens in the form of the drugs \nhaving increases, which in that model, are able to be passed on and worked through th e model. ", "page_label": "12", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "93f6fe4c-70ee-44fe-b1f9-73a27c6598e1": {"node_ids": ["d07e96e6-73f3-41c6-8293-cdc90de7cdc4", "7d759623-5427-4e9b-a43a-8f59e6ccc511", "1e69b78e-8f2f-421c-83be-0ad66e048ebb", "7035c024-c966-4cd1-945a-c71693f464d0", "dd207bef-0dc4-4e8f-8c2b-abe77a3a92ab", "e49baafe-0007-4630-a628-919ea7146855", "6d1c8a1a-8323-4d21-b331-2a0b473b2cbe", "55ec75bc-b632-4cfd-a6d8-92982f815aee", "7881a53e-6317-4318-8012-c29140dfb3ca", "817f10b8-aa45-41f5-b931-65be23ca7182", "bc0e3e10-c6e6-479b-9348-eeba3981ac39", "d687589c-b363-4993-92a6-e654691f2b09", "7ce6b6d2-11f8-4dc4-9651-58cfb11622ab", "0668c72a-0c2e-4c21-8f08-5f5284db3166", "e076b600-eba6-438b-ad98-6f3c6e2f907d", "bcef4aa9-c7d0-4f0f-8dc7-97649c66aa5f", "70eb499d-de91-465f-968a-4ec5b8993a2d", "b6c455bd-ad96-4ccd-a3eb-66c0f52da9fe", "da7cbef0-e495-4732-8566-127eb6031fa3", "dbbbf0b1-b409-451d-887c-b82077213b60", "412f5a82-c0b0-4385-b1e9-105cff2478b7", "458f65cc-f29b-4122-80f3-7945e3fa2677", "381c6c28-3992-4096-8cab-c6dc96ac70df", "89e14d5a-da07-4024-b35b-abd44543e9de", "936a2467-0b8d-4272-8697-940e1c1e052b", "03ce3a2a-c056-4428-a01e-6bed0a9c9804", "5e489d9d-8328-4c4f-b35f-bfe9d217af96", "3ee45df8-2fc9-45fb-b197-94a7c2f0df8e", "df38657f-e5fb-41a9-915c-db907065292f", "53e08043-fbb3-4e58-8531-1ae8fa27c209", "87562aea-b07f-4b80-be1b-bf63dc0929c6", "377068da-4f45-4fcd-b127-212eedab42eb", "dac9a7fd-35b0-4934-9153-b3724abe642a", "50f23761-b43f-4469-ac31-a78bd79eb1fb", "33b24c1e-919f-4217-bf68-80939107e8f8", "d4f788ee-0e3e-4087-b7b1-98c9eb01b76f", "f4c27623-ede8-4dd4-aa0b-34e47f716fa4", "d0660d59-10fe-4a3f-808b-d71b044f06e7", "dd1e5588-ad1e-444b-9e28-67cefeffe05c"], "metadata": {"window": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays.  Please go ahead.  \n \n Steven Valiquette:  Hi, thanks.  Good morning everybody. ", "original_text": " \nPage 13 of 15 \n \nOperator:  And up next, we'll take a question from Steven Valiquette with Barclays. ", "page_label": "13", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "919db9c5-1077-4aa3-aaf5-7d111774b8be": {"node_ids": ["dec30737-8d0d-4f18-a691-e2306a3a627f", "698fd18d-e6ca-43df-8a17-bd9e8fbcb2bb", "c0aa4366-cb77-47c2-9025-eff96edbe85e", "6300fd1e-fa1c-4087-8afa-2aaf255a515f", "2198856d-05a1-4553-8764-ab47fe7e5613", "580c8b78-4ed0-4966-8652-e383a6e0454c", "bffc3de2-7435-42d6-aa2f-6e0efdec0540", "21de8db9-90d6-49f1-babb-1343538eec73", "3c3c70b6-f328-48c5-a12e-5c6024dfd70e", "5a485dfc-6682-4afc-8b2b-cf089cac0ab8", "7ae8d378-4070-45c1-8e1f-5c09cfd2ce26", "f9f4c34c-7882-4a8a-88c7-70e31ea195d0", "4f61d384-d4e7-4485-ab3e-b69d09bb2737", "4697386b-b340-43ad-92a6-3d7f64c681bb", "26f52930-103d-46a4-9f6b-54d012f7225f", "6a2bcde0-a782-4f8f-b43a-7dcdf0b9c121", "5a098961-208e-4b11-ad0e-a2fe535e69c8", "7a324e5b-aeb7-4b22-9782-3774dd59453f", "1465bbd2-1e43-4cfc-8bc2-02ce8ad6e8d5", "dbeeb12b-d218-4a2f-94c0-88ac8e69ba08", "766755b9-b799-4ccc-a640-06e684aba9e6", "54bb171f-a584-48ce-bee9-25ab5a352be2", "07f56dd0-da21-45f3-ad97-9c260bdba631", "625099d9-164c-4ed7-bb1a-5214660f5eca", "9bad1ec1-8b0f-43e6-ae23-c61c9f6780f6", "fa00deb2-10ed-405a-b14e-d60f8fab5560", "a16b452a-ee00-4871-b978-7010d8b96129", "fb15a653-0fc1-494d-8bd3-aa1c6424b664"], "metadata": {"window": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain.  What's the contribution of labor cost to that \nheadwind?  Because when we think about labor costs, we think about it as potentially more structural \nbecause once you raised someone's salaries, it's difficult to bring it back down.  S o how should we \nthink about that component within the additional cost?  \n \n", "original_text": " \nPage 14 of 15 \n \nAnd then secondly, as we think about these sort of transitory costs in nature, you talk about $100 \nmillion to $125 million costs re lated to the supply chain. ", "page_label": "14", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e4f9f608-cd18-429b-8c41-fb6bb2b4afb7": {"node_ids": ["aa1a75ab-cd5f-4946-842f-f5ccb7771507", "73196145-d83b-41da-a3ae-7b2095e8aa41", "4b9f1ca9-95ce-4e2f-85c9-a47410c6f936", "fd21c577-1456-47a1-83e0-c9aacfc6e296", "63e9c30e-52a6-45d0-a37a-915c0ab4af84", "cfecd884-cb70-41ad-b28d-ad535139e5b2"], "metadata": {"window": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided.  With that, th ank you again.  We hope you all have a good day.  \n \n Operator:  And this concludes today's call. ", "original_text": " \nPage 15 of 15 \n \nAnd together, this gives us confidence in achieving the new long -term growth targets that we \nprovided. ", "page_label": "15", "file_name": "CAH-Q1-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 185582, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}